US20070293540A1 - Novel hydroxamates as therapeutic agents - Google Patents
Novel hydroxamates as therapeutic agents Download PDFInfo
- Publication number
- US20070293540A1 US20070293540A1 US11/830,686 US83068607A US2007293540A1 US 20070293540 A1 US20070293540 A1 US 20070293540A1 US 83068607 A US83068607 A US 83068607A US 2007293540 A1 US2007293540 A1 US 2007293540A1
- Authority
- US
- United States
- Prior art keywords
- optionally substituted
- hydroxy
- benzamide
- ethoxy
- ylcarbonylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title description 14
- 229940124597 therapeutic agent Drugs 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 196
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- -1 hydroxyalkoxyalkyl Chemical group 0.000 claims description 544
- 125000000217 alkyl group Chemical group 0.000 claims description 103
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 85
- 125000001072 heteroaryl group Chemical group 0.000 claims description 73
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 51
- 125000001424 substituent group Chemical group 0.000 claims description 49
- 125000003545 alkoxy group Chemical group 0.000 claims description 42
- 125000001188 haloalkyl group Chemical group 0.000 claims description 41
- 239000001257 hydrogen Substances 0.000 claims description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims description 39
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 31
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 31
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000002253 acid Substances 0.000 claims description 24
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 24
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 23
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 20
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 19
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 claims description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 125000002431 aminoalkoxy group Chemical group 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000004414 alkyl thio group Chemical group 0.000 claims description 14
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000004660 phenylalkylthio group Chemical group 0.000 claims description 12
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 5
- 125000006345 2,2,2-trifluoroethoxymethyl group Chemical group [H]C([H])(*)OC([H])([H])C(F)(F)F 0.000 claims description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 28
- 201000010099 disease Diseases 0.000 abstract description 24
- 239000003112 inhibitor Substances 0.000 abstract description 22
- 102000003964 Histone deacetylase Human genes 0.000 abstract description 17
- 108090000353 Histone deacetylase Proteins 0.000 abstract description 17
- 208000005176 Hepatitis C Diseases 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 414
- 238000005160 1H NMR spectroscopy Methods 0.000 description 208
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 148
- 239000000243 solution Substances 0.000 description 65
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 46
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 42
- 150000003254 radicals Chemical class 0.000 description 41
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 239000011541 reaction mixture Substances 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 36
- 125000005843 halogen group Chemical group 0.000 description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 33
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 29
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 29
- 239000000203 mixture Substances 0.000 description 29
- 125000004663 dialkyl amino group Chemical group 0.000 description 26
- 125000003282 alkyl amino group Chemical group 0.000 description 25
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 25
- 125000004475 heteroaralkyl group Chemical group 0.000 description 25
- 239000007787 solid Substances 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 24
- 125000006413 ring segment Chemical group 0.000 description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 23
- 125000003118 aryl group Chemical group 0.000 description 21
- 125000001153 fluoro group Chemical group F* 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 239000004215 Carbon black (E152) Substances 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 229930195733 hydrocarbon Natural products 0.000 description 16
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 14
- 150000001204 N-oxides Chemical class 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 14
- 125000000842 isoxazolyl group Chemical group 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 14
- 125000006239 protecting group Chemical group 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 125000001309 chloro group Chemical group Cl* 0.000 description 13
- 125000005549 heteroarylene group Chemical group 0.000 description 13
- 125000005842 heteroatom Chemical group 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 0 [51*]C(=O)CC[Y]CC Chemical compound [51*]C(=O)CC[Y]CC 0.000 description 12
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 12
- 239000012267 brine Substances 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 235000011121 sodium hydroxide Nutrition 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 10
- 125000004465 cycloalkenyloxy group Chemical group 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 108010044426 integrins Proteins 0.000 description 10
- 102000006495 integrins Human genes 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 9
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 125000000000 cycloalkoxy group Chemical group 0.000 description 9
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- OFFSPAZVIVZPHU-UHFFFAOYSA-N 1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)=CC2=C1 OFFSPAZVIVZPHU-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 8
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 8
- YKKLMHVRCUIUIT-UHFFFAOYSA-N methyl 4-(2-aminoethoxy)benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=C(OCCN)C=C1 YKKLMHVRCUIUIT-UHFFFAOYSA-N 0.000 description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 7
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 7
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 7
- 239000004037 angiogenesis inhibitor Substances 0.000 description 7
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 125000002541 furyl group Chemical group 0.000 description 7
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 6
- 239000005977 Ethylene Substances 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 102000004357 Transferases Human genes 0.000 description 6
- 108090000992 Transferases Proteins 0.000 description 6
- 229940034982 antineoplastic agent Drugs 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 6
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 5
- YMZTUCZCQMQFMK-UHFFFAOYSA-N 3-methyl-1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2C(C)=C(C(O)=O)OC2=C1 YMZTUCZCQMQFMK-UHFFFAOYSA-N 0.000 description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 5
- PCRRIQADJRPUSM-UHFFFAOYSA-L CC(=O)N[Y]OC1=CC=C(C(=O)NO)C=C1 Chemical compound CC(=O)N[Y]OC1=CC=C(C(=O)NO)C=C1 PCRRIQADJRPUSM-UHFFFAOYSA-L 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 239000002254 cytotoxic agent Substances 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000002834 estrogen receptor modulator Substances 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 5
- 125000004254 isoquinolin-1-yl group Chemical group [H]C1=C([H])C2=C([H])C([H])=C([H])C([H])=C2C(*)=N1 0.000 description 5
- 125000004551 isoquinolin-3-yl group Chemical group C1=NC(=CC2=CC=CC=C12)* 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 5
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 5
- 125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 239000003558 transferase inhibitor Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 4
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- GXOFMHYSDHBUFQ-UHFFFAOYSA-N 4-(2-benzamidoethoxy)-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC=C1 GXOFMHYSDHBUFQ-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 4
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 4
- 108010079944 Interferon-alpha2b Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 description 4
- 239000004030 hiv protease inhibitor Substances 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
- 125000005493 quinolyl group Chemical group 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 102000027483 retinoid hormone receptors Human genes 0.000 description 4
- 108091008679 retinoid hormone receptors Proteins 0.000 description 4
- 229960000329 ribavirin Drugs 0.000 description 4
- 239000000849 selective androgen receptor modulator Substances 0.000 description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- 125000005505 thiomorpholino group Chemical group 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 description 3
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 3
- ZELNMYNSHZMHSH-UHFFFAOYSA-N CC[Y]CCC(C)=O Chemical compound CC[Y]CCC(C)=O ZELNMYNSHZMHSH-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100040018 Interferon alpha-2 Human genes 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 3
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940123468 Transferase inhibitor Drugs 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
- 229960000975 daunorubicin Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- DUXQSFDZZHXQGM-UHFFFAOYSA-N methyl 3-(bromomethyl)-1-benzofuran-2-carboxylate Chemical compound C1=CC=C2C(CBr)=C(C(=O)OC)OC2=C1 DUXQSFDZZHXQGM-UHFFFAOYSA-N 0.000 description 3
- RBUBVOPMBWDQKS-UHFFFAOYSA-N methyl 4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylsulfanyl]benzoate Chemical compound COC(=O)C1=CC=C(SCCNC(=O)OC(C)(C)C)C=C1 RBUBVOPMBWDQKS-UHFFFAOYSA-N 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- GUYCSHUDCXKIOO-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC=CC=C2O1 GUYCSHUDCXKIOO-UHFFFAOYSA-N 0.000 description 3
- CNSOVOBKISGHJM-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzothiophene-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC=CC=C2S1 CNSOVOBKISGHJM-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- 229950001248 squalamine Drugs 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- DSIBSRXKQRYPJP-UHFFFAOYSA-N 1,2-oxazole-5-carboxamide Chemical compound NC(=O)C1=CC=NO1 DSIBSRXKQRYPJP-UHFFFAOYSA-N 0.000 description 2
- OPCMVVKRCLOEDQ-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(methylamino)pentan-1-one Chemical compound ClC1=CC=C(C=C1)C(C(CCC)NC)=O OPCMVVKRCLOEDQ-UHFFFAOYSA-N 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- BKMMTJMQCTUHRP-UHFFFAOYSA-N 2-aminopropan-1-ol Chemical compound CC(N)CO BKMMTJMQCTUHRP-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- YTMBMUCAPYTRDI-UHFFFAOYSA-N 3-(2,2,2-trifluoroethoxymethyl)-1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2C(COCC(F)(F)F)=C(C(=O)O)OC2=C1 YTMBMUCAPYTRDI-UHFFFAOYSA-N 0.000 description 2
- PZPRKRAWDGRNCX-UHFFFAOYSA-N 3-(dimethylamino)-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide Chemical compound O1C2=CC=CC=C2C(N(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 PZPRKRAWDGRNCX-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 2
- PLHJCIYEEKOWNM-UHFFFAOYSA-N 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound CN1C=NC=C1C(N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Porfiromycine Chemical compound O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 2
- 102000051792 Promyelocytic Leukemia Zinc Finger Human genes 0.000 description 2
- 108700003766 Promyelocytic Leukemia Zinc Finger Proteins 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 125000004533 benzofuran-5-yl group Chemical group O1C=CC2=C1C=CC(=C2)* 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- JXHYCCGOZUGBFD-UHFFFAOYSA-N benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1 JXHYCCGOZUGBFD-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004534 benzothien-2-yl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004238 benzotriazol-4-yl group Chemical group [H]N1N=NC2=C(*)C([H])=C([H])C([H])=C12 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- WNRZHQBJSXRYJK-UHFFFAOYSA-N carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 229960005110 cerivastatin Drugs 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960005537 combretastatin A-4 Drugs 0.000 description 2
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- 229960001842 estramustine Drugs 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 125000005241 heteroarylamino group Chemical group 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 125000004245 indazol-3-yl group Chemical group [H]N1N=C(*)C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 2
- 229960001936 indinavir Drugs 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- HVUOTQOUAMXGLR-UHFFFAOYSA-N methyl 3-methyl-1-benzofuran-2-carboxylate Chemical compound C1=CC=C2C(C)=C(C(=O)OC)OC2=C1 HVUOTQOUAMXGLR-UHFFFAOYSA-N 0.000 description 2
- TZGMFJXZODBLIF-UHFFFAOYSA-N methyl 4-(2-aminoethylsulfanyl)benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=C(SCCN)C=C1 TZGMFJXZODBLIF-UHFFFAOYSA-N 0.000 description 2
- BDIZHGWECDDQCW-UHFFFAOYSA-N methyl 4-(2-benzamidoethoxy)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OCCNC(=O)C1=CC=CC=C1 BDIZHGWECDDQCW-UHFFFAOYSA-N 0.000 description 2
- HNWSDWJGIRPPHP-UHFFFAOYSA-N methyl 4-[2-(1-benzofuran-2-carbonylamino)ethylsulfanyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1SCCNC(=O)C1=CC2=CC=CC=C2O1 HNWSDWJGIRPPHP-UHFFFAOYSA-N 0.000 description 2
- YSAVBWUIPPZPLQ-UHFFFAOYSA-N methyl 4-[2-[(3-methyl-1-benzofuran-2-carbonyl)amino]ethoxy]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OCCNC(=O)C1=C(C)C2=CC=CC=C2O1 YSAVBWUIPPZPLQ-UHFFFAOYSA-N 0.000 description 2
- JDAFFSLECFMWSP-UHFFFAOYSA-N methyl 4-[2-[[3-(dimethylamino)-1-benzofuran-2-carbonyl]amino]ethoxy]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OCCNC(=O)C1=C(N(C)C)C2=CC=CC=C2O1 JDAFFSLECFMWSP-UHFFFAOYSA-N 0.000 description 2
- WDKCWMBQEATPDZ-UHFFFAOYSA-N methyl 4-[2-[[5-(2-pyrrolidin-1-ylethoxy)-1-benzofuran-2-carbonyl]amino]ethoxy]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OCCNC(=O)C1=CC2=CC(OCCN3CCCC3)=CC=C2O1 WDKCWMBQEATPDZ-UHFFFAOYSA-N 0.000 description 2
- BTZOMWXSWVOOHG-UHFFFAOYSA-N methyl 4-sulfanylbenzoate Chemical compound COC(=O)C1=CC=C(S)C=C1 BTZOMWXSWVOOHG-UHFFFAOYSA-N 0.000 description 2
- KUDQUOBMXQWDCZ-UHFFFAOYSA-N methyl 5-(2-pyrrolidin-1-ylethoxy)-1-benzofuran-2-carboxylate Chemical compound C=1C=C2OC(C(=O)OC)=CC2=CC=1OCCN1CCCC1 KUDQUOBMXQWDCZ-UHFFFAOYSA-N 0.000 description 2
- KPSJSEXMKPMEAM-UHFFFAOYSA-N methyl 5-hydroxy-1-benzofuran-2-carboxylate Chemical compound OC1=CC=C2OC(C(=O)OC)=CC2=C1 KPSJSEXMKPMEAM-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- XFLNIKFMSAZGRS-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-(2,2,2-trifluoroethoxymethyl)-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=C(COCC(F)(F)F)C2=CC=CC=C2O1 XFLNIKFMSAZGRS-UHFFFAOYSA-N 0.000 description 2
- RVUPSYZQQBAERY-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-(2-pyrrolidin-1-ylethoxy)-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC(OCCN3CCCC3)=CC=C2O1 RVUPSYZQQBAERY-UHFFFAOYSA-N 0.000 description 2
- PAUWNAFITJKJLL-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenyl]sulfanylethyl]-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1SCCNC(=O)C1=CC2=CC=CC=C2O1 PAUWNAFITJKJLL-UHFFFAOYSA-N 0.000 description 2
- UCCWTBVXKJXGNY-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenyl]sulfonylethyl]-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1S(=O)(=O)CCNC(=O)C1=CC2=CC=CC=C2O1 UCCWTBVXKJXGNY-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- RPZXKDRIDTWUKH-DHZHZOJOSA-N n-hydroxy-4-[2-[[(e)-3-(2-methylphenyl)prop-2-enoyl]amino]ethoxy]benzamide Chemical compound CC1=CC=CC=C1\C=C\C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 RPZXKDRIDTWUKH-DHZHZOJOSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229940043138 pentosan polysulfate Drugs 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
- 239000003600 podophyllotoxin derivative Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- CGVIVKXBBJJGJS-UHFFFAOYSA-M potassium;4-[2-[[3-[(dimethylamino)methyl]-1-benzofuran-2-carbonyl]amino]ethoxy]benzoate Chemical compound [K+].O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C([O-])=O)C=C1 CGVIVKXBBJJGJS-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 108010006693 promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein Proteins 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229960001852 saquinavir Drugs 0.000 description 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 229960001099 trimetrexate Drugs 0.000 description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- JKFZMIQMKFWJAY-RQJQXFIZSA-N (1r,3s,5z)-5-[(2e)-2-[(3as,7as)-1-[(2r)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC=C([C@]2(CCC1)C)[C@@H](CC#CC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C JKFZMIQMKFWJAY-RQJQXFIZSA-N 0.000 description 1
- USYHIIHUJPBCQG-UHFFFAOYSA-N (2-chloroacetyl)-[5-methoxy-4-[2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl]carbamic acid Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(N(C(O)=O)C(=O)CCl)CCC21CO2 USYHIIHUJPBCQG-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- SCVZUBLUQMMQED-BYPYZUCNSA-N (2s)-2-[(2-acetamidoacetyl)amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)CNC(C)=O SCVZUBLUQMMQED-BYPYZUCNSA-N 0.000 description 1
- MCEHFIXEKNKSRW-LBPRGKRZSA-N (2s)-2-[[3,5-dichloro-4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=C(Cl)C=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1Cl MCEHFIXEKNKSRW-LBPRGKRZSA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- JCBPETKZIGVZRE-BYPYZUCNSA-N (2s)-2-aminobutan-1-ol Chemical compound CC[C@H](N)CO JCBPETKZIGVZRE-BYPYZUCNSA-N 0.000 description 1
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2s)-n-benzyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 description 1
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2s,3r,4s,5s,6r)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- CVYSHGQXOVPJDD-LLVKDONJSA-N (3r)-3-hydroxy-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]pyrrolidine-1-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)N1C[C@H](O)CC1 CVYSHGQXOVPJDD-LLVKDONJSA-N 0.000 description 1
- CUFQBQOBLVLKRF-RZDMPUFOSA-N (4r)-3-[(2s,3s)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-5,5-dimethyl-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=CC=CC=C1CNC(=O)[C@@H]1C(C)(C)SCN1C(=O)[C@@H](O)[C@@H](NC(=O)C=1C(=C(O)C=CC=1)C)CC1=CC=CC=C1 CUFQBQOBLVLKRF-RZDMPUFOSA-N 0.000 description 1
- ZKSNZYLCOXUJIR-VOKUKXJJSA-N (5s,5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7-(dimethylamino)-8-hydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)N(C)C)[C@@H]3[C@@H]2C(OC3)=O)=C1 ZKSNZYLCOXUJIR-VOKUKXJJSA-N 0.000 description 1
- DLROLUIVVKTFPW-LVEBQJTPSA-N (5s,5as,8ar,9r)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5-(4-nitroanilino)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](NC=3C=CC(=CC=3)[N+]([O-])=O)[C@@H]3[C@@H]2C(OC3)=O)=C1 DLROLUIVVKTFPW-LVEBQJTPSA-N 0.000 description 1
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
- RGVRUQHYQSORBY-JIGXQNLBSA-N (7s,9r)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyethyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O([C@H]1C[C@](O)(CCO)CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 RGVRUQHYQSORBY-JIGXQNLBSA-N 0.000 description 1
- BSRQHWFOFMAZRL-BODGVHBXSA-N (7s,9s)-7-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@@H](O)C[C@H](O[C@@H]2C3=C(O)C=4C(=O)C5=CC=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)O[C@H]1C BSRQHWFOFMAZRL-BODGVHBXSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZGNLFUXWZJGETL-YUSKDDKASA-N (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium Chemical compound N[C@@H](C\[N+]([O-])=N\O)C(O)=O ZGNLFUXWZJGETL-YUSKDDKASA-N 0.000 description 1
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- KODLUXHSIZOKTG-UHFFFAOYSA-N 1-aminobutan-2-ol Chemical compound CCC(O)CN KODLUXHSIZOKTG-UHFFFAOYSA-N 0.000 description 1
- DNGLRCHMGDDHNC-UHFFFAOYSA-N 1-benzothiophene-2-carbonyl chloride Chemical compound C1=CC=C2SC(C(=O)Cl)=CC2=C1 DNGLRCHMGDDHNC-UHFFFAOYSA-N 0.000 description 1
- 125000000980 1H-indol-3-ylmethyl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[*])C2=C1[H] 0.000 description 1
- SXFWKZNLYYRHMK-UHFFFAOYSA-N 1h-indolo[7,6-f]quinoline Chemical class C1=CC=C2C3=C(NC=C4)C4=CC=C3C=CC2=N1 SXFWKZNLYYRHMK-UHFFFAOYSA-N 0.000 description 1
- ROZCIVXTLACYNY-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-(3-fluoro-4-methoxyphenyl)benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ROZCIVXTLACYNY-UHFFFAOYSA-N 0.000 description 1
- LWCYLAVASFVIEH-UHFFFAOYSA-N 2,3-dichloro-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC(Cl)=C1Cl LWCYLAVASFVIEH-UHFFFAOYSA-N 0.000 description 1
- XESIWSIINJHDIV-UHFFFAOYSA-N 2,4-difluoro-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(F)C=C1F XESIWSIINJHDIV-UHFFFAOYSA-N 0.000 description 1
- 125000003870 2-(1-piperidinyl)ethoxy group Chemical group [*]OC([H])([H])C([H])([H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- XWNJMSJGJFSGRY-UHFFFAOYSA-N 2-(benzylamino)-3,7-dihydropurin-6-one Chemical compound N1C=2N=CNC=2C(=O)N=C1NCC1=CC=CC=C1 XWNJMSJGJFSGRY-UHFFFAOYSA-N 0.000 description 1
- DPUAPTNHFHSWHO-UHFFFAOYSA-N 2-(bromomethyl)-3h-1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)(CBr)CC2=C1 DPUAPTNHFHSWHO-UHFFFAOYSA-N 0.000 description 1
- PYZOVVQJTLOHDG-FQEVSTJZSA-N 2-[(2s)-4-methyl-3-oxo-7-(4-piperidin-4-ylpiperidine-1-carbonyl)-2,5-dihydro-1h-1,4-benzodiazepin-2-yl]acetic acid Chemical compound O=C([C@H](CC(O)=O)NC1=CC=2)N(C)CC1=CC=2C(=O)N(CC1)CCC1C1CCNCC1 PYZOVVQJTLOHDG-FQEVSTJZSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- QUNOQBDEVTWCTA-UHFFFAOYSA-N 2-[2-[3-[2-(1,3-dioxobenzo[de]isoquinolin-2-yl)ethylamino]propylamino]ethyl]benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)N(CCNCCCNCCN2C(C=3C=CC=C4C=CC=C(C=34)C2=O)=O)C2=O)=C3C2=CC=CC3=C1 QUNOQBDEVTWCTA-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- CBIAKDAYHRWZCU-UHFFFAOYSA-N 2-bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C(Br)=C1 CBIAKDAYHRWZCU-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- FFRFGVHNKJYNOV-DOVUUNBWSA-N 3',4'-Anhydrovinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C=C(C2)CC)N2CCC2=C1NC1=CC=CC=C21 FFRFGVHNKJYNOV-DOVUUNBWSA-N 0.000 description 1
- QDJHIPZZZHXEJS-UHFFFAOYSA-N 3,4-difluoro-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(F)C(F)=C1 QDJHIPZZZHXEJS-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- WQNMNXAAZGGIHS-UHFFFAOYSA-N 3-(diethylaminomethyl)-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide Chemical compound O1C2=CC=CC=C2C(CN(CC)CC)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 WQNMNXAAZGGIHS-UHFFFAOYSA-N 0.000 description 1
- METCFWWPKBZBRE-UHFFFAOYSA-N 3-(dimethylamino)-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide;hydrochloride Chemical compound Cl.O1C2=CC=CC=C2C(N(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 METCFWWPKBZBRE-UHFFFAOYSA-N 0.000 description 1
- SPCMUBFTADOPCN-UHFFFAOYSA-N 3-[(2-fluorophenoxy)methyl]-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=C(COC=2C(=CC=CC=2)F)C2=CC=CC=C2O1 SPCMUBFTADOPCN-UHFFFAOYSA-N 0.000 description 1
- WUWDLXZGHZSWQZ-UHFFFAOYSA-N 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one Chemical compound N1C(C)=CC(C)=C1C=C1C2=CC=CC=C2NC1=O WUWDLXZGHZSWQZ-UHFFFAOYSA-N 0.000 description 1
- CBBDSQMDJTUDIZ-UHFFFAOYSA-N 3-[(4-fluorophenoxy)methyl]-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=C(COC=2C=CC(F)=CC=2)C2=CC=CC=C2O1 CBBDSQMDJTUDIZ-UHFFFAOYSA-N 0.000 description 1
- JDDNYNXNIMWSAC-UHFFFAOYSA-N 3-[(dimethylazaniumyl)methyl]-1-benzofuran-2-carboxylate Chemical compound C1=CC=C2C(CN(C)C)=C(C(O)=O)OC2=C1 JDDNYNXNIMWSAC-UHFFFAOYSA-N 0.000 description 1
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
- VHUXMDZZRCHQSS-UHFFFAOYSA-N 3-[2-(1-benzofuran-2-carbonylamino)ethoxy]-n-hydroxy-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCNC(=O)C=2OC3=CC=CC=C3C=2)=N1 VHUXMDZZRCHQSS-UHFFFAOYSA-N 0.000 description 1
- FDEUSPHZNMLSNO-UHFFFAOYSA-N 3-[3-(1-benzofuran-2-carbonylamino)propoxy]-n-hydroxy-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCCNC(=O)C=2OC3=CC=CC=C3C=2)=N1 FDEUSPHZNMLSNO-UHFFFAOYSA-N 0.000 description 1
- LEEXPLSIPDZRNT-UHFFFAOYSA-N 3-[[[2-(hydroxyamino)-2-oxoethyl]amino]methyl]-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide Chemical compound O1C2=CC=CC=C2C(CNCC(=O)NO)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 LEEXPLSIPDZRNT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CURYRIVJTBNEGU-UHFFFAOYSA-L 3-bromo-1-[12-(3-bromopropanoyl)-3,12-diaza-6,9-diazoniadispiro[5.2.5^{9}.2^{6}]hexadecan-3-yl]propan-1-one;dichloride Chemical compound [Cl-].[Cl-].C1CN(C(=O)CCBr)CC[N+]21CC[N+]1(CCN(CC1)C(=O)CCBr)CC2 CURYRIVJTBNEGU-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- LHTGSOKWKKDJTK-UHFFFAOYSA-N 3-chloro-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzothiophene-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=C(Cl)C2=CC=CC=C2S1 LHTGSOKWKKDJTK-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- CTEKFMDNNUZLAZ-UHFFFAOYSA-N 3-ethoxy-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]benzamide Chemical compound CCOC1=CC=CC(C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)=C1 CTEKFMDNNUZLAZ-UHFFFAOYSA-N 0.000 description 1
- QKJUPULAJQGBPV-UHFFFAOYSA-N 3-ethyl-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide Chemical compound O1C2=CC=CC=C2C(CC)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 QKJUPULAJQGBPV-UHFFFAOYSA-N 0.000 description 1
- MHBCKTUZMLPZPL-UHFFFAOYSA-N 3-fluoro-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-methoxybenzamide Chemical compound C1=C(F)C(OC)=CC=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MHBCKTUZMLPZPL-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- SLSBYHLKDYHTEG-UHFFFAOYSA-N 3-hydroxy-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]pyridine-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=NC=CC=C1O SLSBYHLKDYHTEG-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WIYNWLBOSGNXEH-UHFFFAOYSA-N 4-(2-amino-6,7-dimethoxyquinazolin-4-yl)phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC(N)=NC=1C1=CC=C(O)C=C1 WIYNWLBOSGNXEH-UHFFFAOYSA-N 0.000 description 1
- VEFAEYCHGVFLFO-UUFSLDAJSA-N 4-[(2r)-3-benzylsulfanyl-2-[[(e)-3-phenylprop-2-enoyl]amino]propoxy]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OC[C@@H](NC(=O)\C=C\C=1C=CC=CC=1)CSCC1=CC=CC=C1 VEFAEYCHGVFLFO-UUFSLDAJSA-N 0.000 description 1
- DUFWHDWPJFQMTA-UUFSLDAJSA-N 4-[(2r)-3-benzylsulfonyl-2-[[(e)-3-phenylprop-2-enoyl]amino]propoxy]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OC[C@@H](NC(=O)\C=C\C=1C=CC=CC=1)CS(=O)(=O)CC1=CC=CC=C1 DUFWHDWPJFQMTA-UUFSLDAJSA-N 0.000 description 1
- HYOSAZXBQWATFJ-UHFFFAOYSA-N 4-[2-(1-benzofuran-2-carbonylamino)ethoxy]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1OCCNC(=O)C1=CC2=CC=CC=C2O1 HYOSAZXBQWATFJ-UHFFFAOYSA-N 0.000 description 1
- XJFDTZOBHUGCRD-UHFFFAOYSA-N 4-[2-[(4-cyclohex-2-en-1-yloxybenzoyl)amino]ethoxy]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C(C=C1)=CC=C1OC1C=CCCC1 XJFDTZOBHUGCRD-UHFFFAOYSA-N 0.000 description 1
- PTKSTRZNKHJPAB-SOFGYWHQSA-N 4-[2-[[(e)-3-(5-bromothiophen-2-yl)prop-2-enoyl]amino]ethoxy]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)\C=C\C1=CC=C(Br)S1 PTKSTRZNKHJPAB-SOFGYWHQSA-N 0.000 description 1
- JEILZXMBYAPZON-BQYQJAHWSA-N 4-[2-[[(e)-3-(furan-2-yl)prop-2-enoyl]amino]ethoxy]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)\C=C\C1=CC=CO1 JEILZXMBYAPZON-BQYQJAHWSA-N 0.000 description 1
- YNQJOABAMZEMPG-LZCJLJQNSA-N 4-[2-[[(e)-3-(furan-3-yl)prop-2-enoyl]amino]ethoxy]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)\C=C\C1=COC=C1 YNQJOABAMZEMPG-LZCJLJQNSA-N 0.000 description 1
- KRHVWKSRJDXZIF-LFYBBSHMSA-N 4-[2-[[(e)-3-[4-(dimethylamino)phenyl]prop-2-enoyl]amino]ethoxy]-n-hydroxybenzamide Chemical compound C1=CC(N(C)C)=CC=C1\C=C\C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 KRHVWKSRJDXZIF-LFYBBSHMSA-N 0.000 description 1
- RHAAIIJTUNUHCW-UHFFFAOYSA-N 4-[2-[[2-(3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinolin-2-yl)acetyl]amino]ethoxy]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)CN1CC2CCCCC2CC1 RHAAIIJTUNUHCW-UHFFFAOYSA-N 0.000 description 1
- OZBUFFXESDBEHG-FXILSDISSA-N 4-[[(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OZBUFFXESDBEHG-FXILSDISSA-N 0.000 description 1
- WLVHBBPXDUBYFM-UHFFFAOYSA-N 4-[[3-[[4-(2-oxopyridin-1-yl)phenyl]methyl]imidazol-4-yl]methyl]benzonitrile Chemical compound O=C1C=CC=CN1C(C=C1)=CC=C1CN1C(CC=2C=CC(=CC=2)C#N)=CN=C1 WLVHBBPXDUBYFM-UHFFFAOYSA-N 0.000 description 1
- GHMGFTZBWQOPRO-UHFFFAOYSA-N 4-[[5-[[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl]-2-methylimidazol-1-yl]methyl]benzonitrile Chemical compound C=1C=C(C#N)C=CC=1CN1C(C)=NC=C1CN(CC1=O)CCN1C1=CC=CC(Cl)=C1 GHMGFTZBWQOPRO-UHFFFAOYSA-N 0.000 description 1
- NPKDCCRVSJRVIZ-UHFFFAOYSA-N 4-[[5-[[4-[(3-chlorophenyl)methyl]-4-(hydroxymethyl)piperidin-1-yl]methyl]-2-methylimidazol-1-yl]methyl]benzonitrile Chemical compound C=1C=C(C#N)C=CC=1CN1C(C)=NC=C1CN(CC1)CCC1(CO)CC1=CC=CC(Cl)=C1 NPKDCCRVSJRVIZ-UHFFFAOYSA-N 0.000 description 1
- OAIUDXOPIYIFPT-UHFFFAOYSA-N 4-[[5-[[4-[(4-chloropyridin-2-yl)methyl]-4-(hydroxymethyl)piperidin-1-yl]methyl]-2-methylimidazol-1-yl]methyl]benzonitrile Chemical compound C=1C=C(C#N)C=CC=1CN1C(C)=NC=C1CN(CC1)CCC1(CO)CC1=CC(Cl)=CC=N1 OAIUDXOPIYIFPT-UHFFFAOYSA-N 0.000 description 1
- GFFXZLZWLOBBLO-BWVDBABLSA-N 4-amino-1-[(2r,4s,5r)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=CF)[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-BWVDBABLSA-N 0.000 description 1
- PULHLIOPJXPGJN-BWVDBABLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methylideneoxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C)[C@H](O)[C@@H](CO)O1 PULHLIOPJXPGJN-BWVDBABLSA-N 0.000 description 1
- NAXUFNXWXFZVSI-UHFFFAOYSA-N 4-aminobutan-2-ol Chemical compound CC(O)CCN NAXUFNXWXFZVSI-UHFFFAOYSA-N 0.000 description 1
- MKAZJOLBHCXTKM-UHFFFAOYSA-N 4-benzamido-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1 MKAZJOLBHCXTKM-UHFFFAOYSA-N 0.000 description 1
- DPFJBMIUUVCKRD-UHFFFAOYSA-N 4-benzyl-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]piperazine-1-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)N1CCN(CC=2C=CC=CC=2)CC1 DPFJBMIUUVCKRD-UHFFFAOYSA-N 0.000 description 1
- AXBKVPQCKRCGNX-UHFFFAOYSA-N 4-chloro-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-2-methoxybenzamide Chemical compound COC1=CC(Cl)=CC=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 AXBKVPQCKRCGNX-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- AZEIRPAUJXANCS-UHFFFAOYSA-N 4-ethoxybenzamide Chemical compound CCOC1=CC=C(C(N)=O)C=C1 AZEIRPAUJXANCS-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- RYHMGIBBLWZTHR-UHFFFAOYSA-N 4-hydroxy-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=C(O)C=CC=C2O1 RYHMGIBBLWZTHR-UHFFFAOYSA-N 0.000 description 1
- 125000000439 4-methylpentoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- KEPFALMJXBYEOQ-UHFFFAOYSA-N 4-tert-butyl-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 KEPFALMJXBYEOQ-UHFFFAOYSA-N 0.000 description 1
- QAFMAXQEHBFSHQ-QGZVFWFLSA-N 5-(1-cyclopropylpiperidin-4-yl)oxy-n-[(2r)-2-[4-(hydroxycarbamoyl)phenoxy]propyl]-1-benzofuran-2-carboxamide Chemical compound C([C@@H](C)OC=1C=CC(=CC=1)C(=O)NO)NC(=O)C(OC1=CC=2)=CC1=CC=2OC(CC1)CCN1C1CC1 QAFMAXQEHBFSHQ-QGZVFWFLSA-N 0.000 description 1
- LRZXSHJICUSCIN-UHFFFAOYSA-N 5-(1-cyclopropylpiperidin-4-yl)oxy-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC(OC3CCN(CC3)C3CC3)=CC=C2O1 LRZXSHJICUSCIN-UHFFFAOYSA-N 0.000 description 1
- UTKAPAFUQBYNLU-UHFFFAOYSA-N 5-(2-pyrrolidin-1-ylethoxy)-1-benzofuran-2-carboxylic acid Chemical compound C=1C=C2OC(C(=O)O)=CC2=CC=1OCCN1CCCC1 UTKAPAFUQBYNLU-UHFFFAOYSA-N 0.000 description 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
- DISACWVFSPDPOV-UHFFFAOYSA-N 5-[4-(dimethylamino)phenyl]-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]pyridine-3-carboxamide Chemical compound C1=CC(N(C)C)=CC=C1C1=CN=CC(C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)=C1 DISACWVFSPDPOV-UHFFFAOYSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- MFEFTTYGMZOIKO-UHFFFAOYSA-N 5-azacytosine Chemical compound NC1=NC=NC(=O)N1 MFEFTTYGMZOIKO-UHFFFAOYSA-N 0.000 description 1
- SRYRVEZRFXDKML-UHFFFAOYSA-N 5-bromo-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]pyridine-3-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CN=CC(Br)=C1 SRYRVEZRFXDKML-UHFFFAOYSA-N 0.000 description 1
- UZVIOYRAHHQIIX-UHFFFAOYSA-N 5-chloro-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC(Cl)=CC=C2O1 UZVIOYRAHHQIIX-UHFFFAOYSA-N 0.000 description 1
- SGIBRTOPUZCDIT-UHFFFAOYSA-N 5-fluoro-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzothiophene-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC(F)=CC=C2S1 SGIBRTOPUZCDIT-UHFFFAOYSA-N 0.000 description 1
- IGDCPMOWUIGWMK-UHFFFAOYSA-N 5-fluoro-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1h-indole-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC(F)=CC=C2N1 IGDCPMOWUIGWMK-UHFFFAOYSA-N 0.000 description 1
- XZELWEMGWISCTP-UHFFFAOYSA-N 5-methoxy-1-benzofuran-2-carboxylic acid Chemical compound COC1=CC=C2OC(C(O)=O)=CC2=C1 XZELWEMGWISCTP-UHFFFAOYSA-N 0.000 description 1
- GBOQUHPYCRYKGV-UHFFFAOYSA-N 5-nitro-2-(2-pyrrolidin-1-ylethyl)benzo[de]isoquinoline-1,3-dione Chemical compound O=C1C(C=23)=CC=CC3=CC([N+](=O)[O-])=CC=2C(=O)N1CCN1CCCC1 GBOQUHPYCRYKGV-UHFFFAOYSA-N 0.000 description 1
- KJVCSKFLSHMYRN-UHFFFAOYSA-N 6-(4-acetamidophenoxy)-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]pyridine-2-carboxamide Chemical compound C1=CC(NC(=O)C)=CC=C1OC1=CC=CC(C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)=N1 KJVCSKFLSHMYRN-UHFFFAOYSA-N 0.000 description 1
- YJOVEZVOSFPCSC-UHFFFAOYSA-N 6-(4-aminophenoxy)-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]pyridine-2-carboxamide Chemical compound C1=CC(N)=CC=C1OC1=CC=CC(C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)=N1 YJOVEZVOSFPCSC-UHFFFAOYSA-N 0.000 description 1
- BLDODJFXPHMOQZ-UHFFFAOYSA-N 6-bromo-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]pyridine-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC(Br)=N1 BLDODJFXPHMOQZ-UHFFFAOYSA-N 0.000 description 1
- ARGQVIRZWCBQDN-UHFFFAOYSA-N 6-fluoro-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-2-methyl-3,4-dihydro-2h-quinoline-1-carboxamide Chemical compound CC1CCC2=CC(F)=CC=C2N1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 ARGQVIRZWCBQDN-UHFFFAOYSA-N 0.000 description 1
- KAEVHZSIYLATMK-UHFFFAOYSA-N 6-n-[bis(aziridin-1-yl)phosphoryl]-2-n,2-n,7-trimethylpurine-2,6-diamine Chemical compound C=12N(C)C=NC2=NC(N(C)C)=NC=1NP(=O)(N1CC1)N1CC1 KAEVHZSIYLATMK-UHFFFAOYSA-N 0.000 description 1
- RFGQHRWJEYIGQL-UHFFFAOYSA-N 7-[(dimethylamino)methyl]-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide Chemical compound O1C=2C(CN(C)C)=CC=CC=2C=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 RFGQHRWJEYIGQL-UHFFFAOYSA-N 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- YSMXHWKTLPPEQL-UHFFFAOYSA-N 7-chloro-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-methyl-1-benzofuran-2-carboxamide Chemical compound C=1C=2C(C)=CC=C(Cl)C=2OC=1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 YSMXHWKTLPPEQL-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- YPLKQCZEGUQWAJ-MXDQRGINSA-N C/C=C/C(C)(C)C.CC(C)=CC(C)(C)C Chemical compound C/C=C/C(C)(C)C.CC(C)=CC(C)(C)C YPLKQCZEGUQWAJ-MXDQRGINSA-N 0.000 description 1
- NEVUVBSHHIMLEC-UHFFFAOYSA-L CC(=O)N[Y]OC1=NOC(C(=O)NO)=C1 Chemical compound CC(=O)N[Y]OC1=NOC(C(=O)NO)=C1 NEVUVBSHHIMLEC-UHFFFAOYSA-L 0.000 description 1
- YOILZFHHYTYUJE-UHFFFAOYSA-N CC.CC(C)=O.CC(C)=O.CC(C)=O.CC(C)=O.CCC.CCCC.CCCC.CC[Y]N.CNC(C)=O.CO.I Chemical compound CC.CC(C)=O.CC(C)=O.CC(C)=O.CC(C)=O.CCC.CCCC.CCCC.CC[Y]N.CNC(C)=O.CO.I YOILZFHHYTYUJE-UHFFFAOYSA-N 0.000 description 1
- AFHBOWPEWHBNDB-UHFFFAOYSA-N CC1=C(C2=CC=C(SOON)C=C2)C(C2=CC=CC=C2)=NO1.CC1=CC=C(C2=CC(C(F)(F)F)=NN2C2=CC=C(S(N)(=O)=O)C=C2)C=C1.CCC(=O)NS(=O)(=O)C1=CC=C(C2=C(C)ON=C2C2=CC=CC=C2)C=C1 Chemical compound CC1=C(C2=CC=C(SOON)C=C2)C(C2=CC=CC=C2)=NO1.CC1=CC=C(C2=CC(C(F)(F)F)=NN2C2=CC=C(S(N)(=O)=O)C=C2)C=C1.CCC(=O)NS(=O)(=O)C1=CC=C(C2=C(C)ON=C2C2=CC=CC=C2)C=C1 AFHBOWPEWHBNDB-UHFFFAOYSA-N 0.000 description 1
- LKTALRNGXHECTO-UHFFFAOYSA-N CC1=CC=C(OCCNC(=O)C2=C(CN(C)C)C3=CC=CC=C3O2)C=C1 Chemical compound CC1=CC=C(OCCNC(=O)C2=C(CN(C)C)C3=CC=CC=C3O2)C=C1 LKTALRNGXHECTO-UHFFFAOYSA-N 0.000 description 1
- XVHJGKOHAIGIJP-UHFFFAOYSA-N CC[Y]CC.CNC(C)=O Chemical compound CC[Y]CC.CNC(C)=O XVHJGKOHAIGIJP-UHFFFAOYSA-N 0.000 description 1
- 108010082830 CEP 2563 Proteins 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- RSCIYYHIBVZXDI-UHFFFAOYSA-O Fagaridine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(O)=C4C=[N+](C)C3=C21 RSCIYYHIBVZXDI-UHFFFAOYSA-O 0.000 description 1
- 108010012088 Fibrinogen Receptors Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229940124683 HCV polymerase inhibitor Drugs 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940122440 HIV protease inhibitor Drugs 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- MLFKVJCWGUZWNV-UHFFFAOYSA-N L-alanosine Natural products OC(=O)C(N)CN(O)N=O MLFKVJCWGUZWNV-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- JXLYSJRDGCGARV-PJXZDTQASA-N Leurosidine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-PJXZDTQASA-N 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- OVBUTJZNWMLHTQ-OAHLLOKOSA-N N-[(2R)-1-[4-(hydroxycarbamoyl)phenoxy]-3-methylsulfanylpropan-2-yl]-1-benzofuran-2-carboxamide Chemical compound ONC(C1=CC=C(C=C1)OC[C@H](CSC)NC(=O)C=1OC2=C(C=1)C=CC=C2)=O OVBUTJZNWMLHTQ-OAHLLOKOSA-N 0.000 description 1
- PITUCQRFWLECTN-OAHLLOKOSA-N N-[(2R)-1-[4-(hydroxycarbamoyl)phenoxy]-3-methylsulfonylpropan-2-yl]-1-benzofuran-2-carboxamide Chemical compound ONC(C1=CC=C(C=C1)OC[C@H](CS(=O)(=O)C)NC(=O)C=1OC2=C(C=1)C=CC=C2)=O PITUCQRFWLECTN-OAHLLOKOSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- KISATBPQLWOMTN-UHFFFAOYSA-N N-hydroxy-3-[2-[(2-methyl-4-phenylbenzoyl)amino]ethoxy]-1,2-oxazole-5-carboxamide Chemical compound ONC(=O)C1=CC(=NO1)OCCNC(=O)C1=CC=C(C=C1C)C1=CC=CC=C1 KISATBPQLWOMTN-UHFFFAOYSA-N 0.000 description 1
- FTFRZXFNZVCRSK-UHFFFAOYSA-N N4-(3-chloro-4-fluorophenyl)-N6-(1-methyl-4-piperidinyl)pyrimido[5,4-d]pyrimidine-4,6-diamine Chemical compound C1CN(C)CCC1NC1=NC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=N1 FTFRZXFNZVCRSK-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 229920000305 Nylon 6,10 Polymers 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- WBNUCLPUOSXSNJ-ZDUSSCGKSA-N Sibrafiban Chemical compound C1CC(OCC(=O)OCC)CCN1C(=O)[C@H](C)NC(=O)C1=CC=C(C(=N)NO)C=C1 WBNUCLPUOSXSNJ-ZDUSSCGKSA-N 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XMYKNCNAZKMVQN-NYYWCZLTSA-N [(e)-(3-aminopyridin-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=NC=CC=C1N XMYKNCNAZKMVQN-NYYWCZLTSA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- CKXIPXAIFMTQCS-LRDUUELOSA-N [2-[(2s,4s)-4-[(2r,3r,4r,5s,6s)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 3-aminopropanoate Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)COC(=O)CCN)[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@H]1F CKXIPXAIFMTQCS-LRDUUELOSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- DJSLOQFVVUBAKG-UHFFFAOYSA-N [4-(3-chloroanilino)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]methanesulfonic acid Chemical compound C=12C(C)=C(C)NC2=NC(CS(O)(=O)=O)=NC=1NC1=CC=CC(Cl)=C1 DJSLOQFVVUBAKG-UHFFFAOYSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 1
- 229960004103 abiraterone acetate Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- JXLYSJRDGCGARV-KSNABSRWSA-N ac1l29ym Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-KSNABSRWSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229950005033 alanosine Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229950001104 anhydrovinblastine Drugs 0.000 description 1
- CIDNKDMVSINJCG-GKXONYSUSA-N annamycin Chemical compound I[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(=O)CO)C1 CIDNKDMVSINJCG-GKXONYSUSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- TWHSQQYCDVSBRK-UHFFFAOYSA-N asulacrine Chemical compound C12=CC=CC(C)=C2N=C2C(C(=O)NC)=CC=CC2=C1NC1=CC=C(NS(C)(=O)=O)C=C1OC TWHSQQYCDVSBRK-UHFFFAOYSA-N 0.000 description 1
- 229950011088 asulacrine Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- UBJAHGAUPNGZFF-XOVTVWCYSA-N bms-184476 Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC(C)=O)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OCSC)C(=O)C1=CC=CC=C1 UBJAHGAUPNGZFF-XOVTVWCYSA-N 0.000 description 1
- GMJWGJSDPOAZTP-MIDYMNAOSA-N bms-188797 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=4C=CC=CC=4)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)OC)C(=O)C1=CC=CC=C1 GMJWGJSDPOAZTP-MIDYMNAOSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 108010046713 cemadotin Proteins 0.000 description 1
- 229950009017 cemadotin Drugs 0.000 description 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
- IQCIQDNWBGEGRL-UHFFFAOYSA-N chembl1614651 Chemical compound O=C1C2=C(O)C=CC(O)=C2N2N=C(CNCCO)C3=CC=C(NCCCN)C1=C32 IQCIQDNWBGEGRL-UHFFFAOYSA-N 0.000 description 1
- YOQPCWIXYUNEET-UHFFFAOYSA-N chembl307697 Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O YOQPCWIXYUNEET-UHFFFAOYSA-N 0.000 description 1
- ROWSTIYZUWEOMM-UHFFFAOYSA-N chembl488755 Chemical compound C12=CC=CC=C2C(=O)C2=C1C1=CC=C(O)C=C1N=C2NCCN(C)C ROWSTIYZUWEOMM-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- 229950009003 cilengitide Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- POADTFBBIXOWFJ-VWLOTQADSA-N cositecan Chemical compound C1=CC=C2C(CC[Si](C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 POADTFBBIXOWFJ-VWLOTQADSA-N 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine mesylate Natural products CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 1
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229950007457 dibrospidium chloride Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229950009278 dimesna Drugs 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 229950004438 elinafide Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229950005450 emitefur Drugs 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- JEFPWOBULVSOTM-PPHPATTJSA-N ethyl n-[(2s)-5-amino-2-methyl-3-phenyl-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]carbamate;2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.C=1([C@H](C)NC=2C=C(N=C(N)C=2N=1)NC(=O)OCC)C1=CC=CC=C1 JEFPWOBULVSOTM-PPHPATTJSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229950011325 galarubicin Drugs 0.000 description 1
- 229950004410 galocitabine Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229950011595 glufosfamide Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229950002248 idoxifene Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229950005254 irofulven Drugs 0.000 description 1
- NICJCIQSJJKZAH-AWEZNQCLSA-N irofulven Chemical compound O=C([C@@]1(O)C)C2=CC(C)=C(CO)C2=C(C)C21CC2 NICJCIQSJJKZAH-AWEZNQCLSA-N 0.000 description 1
- 125000006316 iso-butyl amino group Chemical group [H]N(*)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- FPKOGTAFKSLZLD-FQEVSTJZSA-N lamifiban Chemical compound C1=CC(C(=N)N)=CC=C1C(=O)N[C@H](C(=O)N1CCC(CC1)OCC(O)=O)CC1=CC=C(O)C=C1 FPKOGTAFKSLZLD-FQEVSTJZSA-N 0.000 description 1
- 229950003178 lamifiban Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 229950000909 lometrexol Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- 229950010501 lotrafiban Drugs 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 lurtotecan Drugs 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- BWJBKTJZIZKKQO-UHFFFAOYSA-N methyl 3-[(dimethylamino)methyl]-1-benzofuran-2-carboxylate Chemical compound C1=CC=C2C(CN(C)C)=C(C(=O)OC)OC2=C1 BWJBKTJZIZKKQO-UHFFFAOYSA-N 0.000 description 1
- BBFWUUBQSXVHHZ-UHFFFAOYSA-N methyl 3-oxo-1,2-oxazole-5-carboxylate Chemical compound COC(=O)C1=CC(=O)NO1 BBFWUUBQSXVHHZ-UHFFFAOYSA-N 0.000 description 1
- WNNHCBVRAWPLKQ-UHFFFAOYSA-N methyl 4-(2-aminoethylsulfonyl)benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=C(S(=O)(=O)CCN)C=C1 WNNHCBVRAWPLKQ-UHFFFAOYSA-N 0.000 description 1
- FAOXDJNSGDRMER-UHFFFAOYSA-N methyl 4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylsulfonyl]benzoate Chemical compound COC(=O)C1=CC=C(S(=O)(=O)CCNC(=O)OC(C)(C)C)C=C1 FAOXDJNSGDRMER-UHFFFAOYSA-N 0.000 description 1
- ZSVJWYHFIAIXIQ-UHFFFAOYSA-N methyl 4-[2-[[3-(2,2,2-trifluoroethoxymethyl)-1-benzofuran-2-carbonyl]amino]ethoxy]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OCCNC(=O)C1=C(COCC(F)(F)F)C2=CC=CC=C2O1 ZSVJWYHFIAIXIQ-UHFFFAOYSA-N 0.000 description 1
- ICVJERAGLOTYPB-UHFFFAOYSA-N methyl 4-[2-[[3-(bromomethyl)-1-benzofuran-2-carbonyl]amino]ethoxy]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OCCNC(=O)C1=C(CBr)C2=CC=CC=C2O1 ICVJERAGLOTYPB-UHFFFAOYSA-N 0.000 description 1
- TWOPFTLUZFITDD-UHFFFAOYSA-N methyl 4-[2-[[3-[(dimethylamino)methyl]-1-benzofuran-2-carbonyl]amino]ethoxy]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OCCNC(=O)C1=C(CN(C)C)C2=CC=CC=C2O1 TWOPFTLUZFITDD-UHFFFAOYSA-N 0.000 description 1
- IIYBASHGWDCRPV-UHFFFAOYSA-N methyl 5-methoxy-1-benzofuran-2-carboxylate Chemical compound COC1=CC=C2OC(C(=O)OC)=CC2=C1 IIYBASHGWDCRPV-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- DMEKUKDWAIXWSL-UHFFFAOYSA-N n,n-dimethyl-7-nitro-9h-fluoren-2-amine Chemical compound [O-][N+](=O)C1=CC=C2C3=CC=C(N(C)C)C=C3CC2=C1 DMEKUKDWAIXWSL-UHFFFAOYSA-N 0.000 description 1
- IKNRXNNRYAUAPH-GFCCVEGCSA-N n-[(2r)-1-[4-(hydroxycarbamoyl)phenoxy]propan-2-yl]-1-benzothiophene-2-carboxamide Chemical compound C([C@@H](C)NC(=O)C=1SC2=CC=CC=C2C=1)OC1=CC=C(C(=O)NO)C=C1 IKNRXNNRYAUAPH-GFCCVEGCSA-N 0.000 description 1
- RIUWBZVEFYNMPZ-OAQYLSRUSA-N n-[(2r)-1-benzylsulfonyl-3-[4-(hydroxycarbamoyl)phenoxy]propan-2-yl]-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OC[C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)CS(=O)(=O)CC1=CC=CC=C1 RIUWBZVEFYNMPZ-OAQYLSRUSA-N 0.000 description 1
- GNYSGYIKVGOQKB-GFCCVEGCSA-N n-[(2r)-2-[4-(hydroxycarbamoyl)phenoxy]propyl]-1-benzothiophene-2-carboxamide Chemical compound O([C@@H](CNC(=O)C=1SC2=CC=CC=C2C=1)C)C1=CC=C(C(=O)NO)C=C1 GNYSGYIKVGOQKB-GFCCVEGCSA-N 0.000 description 1
- DRXGRXCEMDMHFX-CQSZACIVSA-N n-[(2r)-2-[4-(hydroxycarbamoyl)phenoxy]propyl]-4-(3,3,3-trifluoropropoxy)quinoline-2-carboxamide Chemical compound O([C@@H](CNC(=O)C=1N=C2C=CC=CC2=C(OCCC(F)(F)F)C=1)C)C1=CC=C(C(=O)NO)C=C1 DRXGRXCEMDMHFX-CQSZACIVSA-N 0.000 description 1
- BHPSDRHMIKSJMV-CYBMUJFWSA-N n-[(2r)-2-[4-(hydroxycarbamoyl)phenoxy]propyl]-4-methoxyquinoline-2-carboxamide Chemical compound O([C@H](C)CNC(=O)C=1C=C(C2=CC=CC=C2N=1)OC)C1=CC=C(C(=O)NO)C=C1 BHPSDRHMIKSJMV-CYBMUJFWSA-N 0.000 description 1
- HCJSEZFJFCSAKG-CYBMUJFWSA-N n-[(2r)-2-[4-(hydroxycarbamoyl)phenoxy]propyl]-4-phenyl-1,3-thiazole-2-carboxamide Chemical compound C([C@@H](C)OC=1C=CC(=CC=1)C(=O)NO)NC(=O)C(SC=1)=NC=1C1=CC=CC=C1 HCJSEZFJFCSAKG-CYBMUJFWSA-N 0.000 description 1
- VNQCLGBRDMIEEG-MRXNPFEDSA-N n-[(2r)-2-[4-(hydroxycarbamoyl)phenoxy]propyl]-4-phenylbenzamide Chemical compound C([C@@H](C)OC=1C=CC(=CC=1)C(=O)NO)NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 VNQCLGBRDMIEEG-MRXNPFEDSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- TVYPSLDUBVTDIS-FUOMVGGVSA-N n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CN(C(=O)N=2)[C@H]2[C@@H]([C@H](O)[C@@H](C)O2)O)F)=C1 TVYPSLDUBVTDIS-FUOMVGGVSA-N 0.000 description 1
- VPBOCHFZXIZNQW-UHFFFAOYSA-N n-[2-(2-carbamoyl-4-hydroxyphenoxy)ethyl]-3-[(dimethylamino)methyl]-1-benzofuran-2-carboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(O)C=C1C(N)=O VPBOCHFZXIZNQW-UHFFFAOYSA-N 0.000 description 1
- ZDUZYDDAHVZGCI-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethylpyrido[4,3-b]carbazole-1-carboxamide Chemical compound CN1C2=CC=C(O)C=C2C2=C1C(C)=C1C=CN=C(C(=O)NCCN(C)C)C1=C2 ZDUZYDDAHVZGCI-UHFFFAOYSA-N 0.000 description 1
- XBGNERSKEKDZDS-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]acridine-4-carboxamide Chemical compound C1=CC=C2N=C3C(C(=O)NCCN(C)C)=CC=CC3=CC2=C1 XBGNERSKEKDZDS-UHFFFAOYSA-N 0.000 description 1
- LSXCYTXSLQOPKR-UHFFFAOYSA-N n-[2-[3-[(4-cyanophenyl)methyl]imidazol-4-yl]ethyl]-1-(2,2-diphenylethyl)piperidine-3-carboxamide Chemical compound C1CCN(CC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1C(=O)NCCC1=CN=CN1CC1=CC=C(C#N)C=C1 LSXCYTXSLQOPKR-UHFFFAOYSA-N 0.000 description 1
- SZLWUGAPGROVDF-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1,3-benzodioxole-5-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(OCO2)C2=C1 SZLWUGAPGROVDF-UHFFFAOYSA-N 0.000 description 1
- QTDVHOZNZYMWCN-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1,3-benzothiazole-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=NC2=CC=CC=C2S1 QTDVHOZNZYMWCN-UHFFFAOYSA-N 0.000 description 1
- RYCCCUXRKBPVMY-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1,3-benzoxazole-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=NC2=CC=CC=C2O1 RYCCCUXRKBPVMY-UHFFFAOYSA-N 0.000 description 1
- WTFJXXHTKKNDNE-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1,3-dihydroisoindole-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)N1CC2=CC=CC=C2C1 WTFJXXHTKKNDNE-UHFFFAOYSA-N 0.000 description 1
- XVEFGRJMVFZJFO-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-methoxynaphthalene-2-carboxamide Chemical compound C1=CC2=CC=CC=C2C(OC)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 XVEFGRJMVFZJFO-UHFFFAOYSA-N 0.000 description 1
- YKTPNMTYLBLHDF-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-methylindole-2-carboxamide Chemical compound C=1C2=CC=CC=C2N(C)C=1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 YKTPNMTYLBLHDF-UHFFFAOYSA-N 0.000 description 1
- OYFXBHSLUKBJDP-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-methylindole-3-carboxamide Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 OYFXBHSLUKBJDP-UHFFFAOYSA-N 0.000 description 1
- FLCACKUGYDIHGZ-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1h-benzimidazole-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=NC2=CC=CC=C2N1 FLCACKUGYDIHGZ-UHFFFAOYSA-N 0.000 description 1
- LBQAEFSQFVTLPT-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1h-indazole-3-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=NNC2=CC=CC=C12 LBQAEFSQFVTLPT-UHFFFAOYSA-N 0.000 description 1
- QIAJBUWBUHPYNI-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1h-indole-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC=CC=C2N1 QIAJBUWBUHPYNI-UHFFFAOYSA-N 0.000 description 1
- NJRCBPSTFLVXJQ-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1h-indole-3-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CNC2=CC=CC=C12 NJRCBPSTFLVXJQ-UHFFFAOYSA-N 0.000 description 1
- YSQQWJKVWPBUHM-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1h-indole-5-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(NC=C2)C2=C1 YSQQWJKVWPBUHM-UHFFFAOYSA-N 0.000 description 1
- RTTGRJCRSSAYHE-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-2,3-dihydroindole-1-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)N1C2=CC=CC=C2CC1 RTTGRJCRSSAYHE-UHFFFAOYSA-N 0.000 description 1
- FOKHWUFEZFERTF-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-2,3-dimethylbenzamide Chemical compound CC1=CC=CC(C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)=C1C FOKHWUFEZFERTF-UHFFFAOYSA-N 0.000 description 1
- IRGKHARWUYPFTC-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-2,5-dimethylbenzamide Chemical compound CC1=CC=C(C)C(C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)=C1 IRGKHARWUYPFTC-UHFFFAOYSA-N 0.000 description 1
- DWIUFGMXFGSEKO-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-2-(thiophen-2-ylmethoxy)benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC=C1OCC1=CC=CS1 DWIUFGMXFGSEKO-UHFFFAOYSA-N 0.000 description 1
- VSXTVMCRTOHQPR-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-2-methyl-2,3-dihydroindole-1-carboxamide Chemical compound CC1CC2=CC=CC=C2N1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 VSXTVMCRTOHQPR-UHFFFAOYSA-N 0.000 description 1
- OKAUZDBFVMIEGD-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-2-phenylbenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC=C1C1=CC=CC=C1 OKAUZDBFVMIEGD-UHFFFAOYSA-N 0.000 description 1
- GGLGTBFCFOSCOF-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-2-pyrrol-1-ylbenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC=C1N1C=CC=C1 GGLGTBFCFOSCOF-UHFFFAOYSA-N 0.000 description 1
- JNZGWESHFUEKRN-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-2h-benzotriazole-5-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(NN=N2)C2=C1 JNZGWESHFUEKRN-UHFFFAOYSA-N 0.000 description 1
- WICONBVKKGBHRD-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3,4-dihydro-1h-isoquinoline-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)N1CC2=CC=CC=C2CC1 WICONBVKKGBHRD-UHFFFAOYSA-N 0.000 description 1
- CEBMMBJXVCHPHI-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3,4-dihydro-2h-quinoline-1-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)N1C2=CC=CC=C2CCC1 CEBMMBJXVCHPHI-UHFFFAOYSA-N 0.000 description 1
- GXTHVYPTZHKSNA-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 GXTHVYPTZHKSNA-UHFFFAOYSA-N 0.000 description 1
- BIQDGQTWPYIISV-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-(2-methoxyethoxymethyl)-1-benzofuran-2-carboxamide Chemical compound O1C2=CC=CC=C2C(COCCOC)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 BIQDGQTWPYIISV-UHFFFAOYSA-N 0.000 description 1
- DIJOTPKYAZPMPH-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-(3-hydroxypropylsulfanylmethyl)-1-benzofuran-2-carboxamide Chemical compound O1C2=CC=CC=C2C(CSCCCO)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 DIJOTPKYAZPMPH-UHFFFAOYSA-N 0.000 description 1
- SOMXJEHSHQZKMC-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-(3-hydroxypropylsulfinylmethyl)-1-benzofuran-2-carboxamide Chemical compound O1C2=CC=CC=C2C(CS(=O)CCCO)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 SOMXJEHSHQZKMC-UHFFFAOYSA-N 0.000 description 1
- KCJKDLBQJSTDBC-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-(3-hydroxypropylsulfonylmethyl)-1-benzofuran-2-carboxamide Chemical compound O1C2=CC=CC=C2C(CS(=O)(=O)CCCO)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 KCJKDLBQJSTDBC-UHFFFAOYSA-N 0.000 description 1
- KBFQJMGDVQMTTC-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-(methoxymethyl)-1-benzofuran-2-carboxamide Chemical compound O1C2=CC=CC=C2C(COC)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 KBFQJMGDVQMTTC-UHFFFAOYSA-N 0.000 description 1
- BKDJDHWZBARZMO-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-(phenoxymethyl)-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=C(COC=2C=CC=CC=2)C2=CC=CC=C2O1 BKDJDHWZBARZMO-UHFFFAOYSA-N 0.000 description 1
- KEFHYTUUBDLMLM-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-(propoxymethyl)-1-benzofuran-2-carboxamide Chemical compound O1C2=CC=CC=C2C(COCCC)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 KEFHYTUUBDLMLM-UHFFFAOYSA-N 0.000 description 1
- YNYRFHRGWUGTIU-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-(pyridin-4-yloxymethyl)-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=C(COC=2C=CN=CC=2)C2=CC=CC=C2O1 YNYRFHRGWUGTIU-UHFFFAOYSA-N 0.000 description 1
- BEXWSUXJRSGRJN-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-[(2-oxopyridin-1-yl)methyl]-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=C(CN2C(C=CC=C2)=O)C2=CC=CC=C2O1 BEXWSUXJRSGRJN-UHFFFAOYSA-N 0.000 description 1
- KAZYIGKQYQSYIZ-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-[2-(2-hydroxyethyl)phenyl]benzamide Chemical compound OCCC1=CC=CC=C1C1=CC=CC(C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)=C1 KAZYIGKQYQSYIZ-UHFFFAOYSA-N 0.000 description 1
- JOYSLIIZHGORFG-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-[2-[3-(trifluoromethoxy)phenyl]ethyl]-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=C(CCC=2C=C(OC(F)(F)F)C=CC=2)C2=CC=CC=C2O1 JOYSLIIZHGORFG-UHFFFAOYSA-N 0.000 description 1
- NZPWNHSFGVXMKV-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-[2-[3-(trifluoromethyl)phenyl]ethyl]-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=C(CCC=2C=C(C=CC=2)C(F)(F)F)C2=CC=CC=C2O1 NZPWNHSFGVXMKV-UHFFFAOYSA-N 0.000 description 1
- WVCZWLNNMKPKFE-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-[[2-(1h-indol-3-yl)ethyl-methylamino]methyl]-1-benzofuran-2-carboxamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(C)CC(C1=CC=CC=C1O1)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 WVCZWLNNMKPKFE-UHFFFAOYSA-N 0.000 description 1
- QGWRXFKSRBXFDE-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-methyl-1-benzofuran-2-carboxamide Chemical compound O1C2=CC=CC=C2C(C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 QGWRXFKSRBXFDE-UHFFFAOYSA-N 0.000 description 1
- AFYNUTNBQQXGOK-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-methyl-1-benzothiophene-2-carboxamide Chemical compound S1C2=CC=CC=C2C(C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 AFYNUTNBQQXGOK-UHFFFAOYSA-N 0.000 description 1
- VVDGDUPVQQRPFK-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3-phenylbenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1 VVDGDUPVQQRPFK-UHFFFAOYSA-N 0.000 description 1
- JQVVQGXZQRHVFA-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-3h-benzimidazole-5-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(NC=N2)C2=C1 JQVVQGXZQRHVFA-UHFFFAOYSA-N 0.000 description 1
- MODQGAFJNXPXJQ-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-(2-methoxyethoxy)quinoline-2-carboxamide Chemical compound N=1C2=CC=CC=C2C(OCCOC)=CC=1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MODQGAFJNXPXJQ-UHFFFAOYSA-N 0.000 description 1
- DVYIBMXYLLIQFP-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-(2-pyridin-2-yl-1,3-thiazol-5-yl)benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(C=2SC(=NC=2)C=2N=CC=CC=2)C=C1 DVYIBMXYLLIQFP-UHFFFAOYSA-N 0.000 description 1
- NNKZKTSMGBWMKU-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-(4-hydroxypiperidin-1-yl)benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(N2CCC(O)CC2)C=C1 NNKZKTSMGBWMKU-UHFFFAOYSA-N 0.000 description 1
- QHSRPYNUHCBAII-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-(4-methylpiperazin-1-yl)benzamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)C=C1 QHSRPYNUHCBAII-UHFFFAOYSA-N 0.000 description 1
- NMSQFUBLLJTBBR-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-(pyridin-3-ylmethoxy)-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C(OC1=CC=C2)=CC1=C2OCC1=CC=CN=C1 NMSQFUBLLJTBBR-UHFFFAOYSA-N 0.000 description 1
- OVNPHDQHHWAYEZ-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-(trifluoromethyl)-1-benzothiophene-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=C(C(F)(F)F)C=CC=C2S1 OVNPHDQHHWAYEZ-UHFFFAOYSA-N 0.000 description 1
- NBIDEDQYPJCKHE-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-[2-(4-methylpiperazin-1-yl)-1,3-thiazol-5-yl]benzamide Chemical compound C1CN(C)CCN1C1=NC=C(C=2C=CC(=CC=2)C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)S1 NBIDEDQYPJCKHE-UHFFFAOYSA-N 0.000 description 1
- XENSCEKVLVTGFX-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-[2-(pyridin-4-ylamino)-1,3-thiazol-5-yl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(C=2SC(NC=3C=CN=CC=3)=NC=2)C=C1 XENSCEKVLVTGFX-UHFFFAOYSA-N 0.000 description 1
- HMLFUWJBNTYPBV-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-[2-[(4-methylpiperazin-1-yl)methyl]-1,3-thiazol-5-yl]benzamide Chemical compound C1CN(C)CCN1CC1=NC=C(C=2C=CC(=CC=2)C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)S1 HMLFUWJBNTYPBV-UHFFFAOYSA-N 0.000 description 1
- QRXGMYQGYWLBMO-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-[3-(2-hydroxyethyl)phenyl]benzamide Chemical compound OCCC1=CC=CC(C=2C=CC(=CC=2)C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)=C1 QRXGMYQGYWLBMO-UHFFFAOYSA-N 0.000 description 1
- ACOBUCWRXTXLMO-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-[4-(2-morpholin-4-ylethyl)-1,3-thiazol-2-yl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(C=2SC=C(CCN3CCOCC3)N=2)C=C1 ACOBUCWRXTXLMO-UHFFFAOYSA-N 0.000 description 1
- XABGSWLFDQCEED-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-[4-(morpholin-4-ylmethyl)-1,3-thiazol-5-yl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(C2=C(N=CS2)CN2CCOCC2)C=C1 XABGSWLFDQCEED-UHFFFAOYSA-N 0.000 description 1
- UBBBCDNVHMYRMY-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-methoxy-1-benzofuran-2-carboxamide Chemical compound C=1C=2C(OC)=CC=CC=2OC=1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 UBBBCDNVHMYRMY-UHFFFAOYSA-N 0.000 description 1
- XHGLIOHZXQIQBW-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-methoxy-1h-indole-2-carboxamide Chemical compound C=1C=2C(OC)=CC=CC=2NC=1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 XHGLIOHZXQIQBW-UHFFFAOYSA-N 0.000 description 1
- CWOVVUPBANGQNQ-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-methoxy-2-methylbenzamide Chemical compound CC1=CC(OC)=CC=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 CWOVVUPBANGQNQ-UHFFFAOYSA-N 0.000 description 1
- ONVRDFZZIJYYPT-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-methoxyquinoline-2-carboxamide Chemical compound N=1C2=CC=CC=C2C(OC)=CC=1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 ONVRDFZZIJYYPT-UHFFFAOYSA-N 0.000 description 1
- IGUWGIQCWIVRDT-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-methyl-1-benzofuran-2-carboxamide Chemical compound C=1C=2C(C)=CC=CC=2OC=1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 IGUWGIQCWIVRDT-UHFFFAOYSA-N 0.000 description 1
- OGLNSZMXVCNMLD-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-oxo-1h-quinoline-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC(O)=C(C=CC=C2)C2=N1 OGLNSZMXVCNMLD-UHFFFAOYSA-N 0.000 description 1
- BXYTWTPTPNNCHZ-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-phenyl-1,3-thiazole-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=NC(C=2C=CC=CC=2)=CS1 BXYTWTPTPNNCHZ-UHFFFAOYSA-N 0.000 description 1
- XPUOZJHAXLVRBN-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-phenylbenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(C=2C=CC=CC=2)C=C1 XPUOZJHAXLVRBN-UHFFFAOYSA-N 0.000 description 1
- GSJZYVYQKLVZSG-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-pyridin-2-ylbenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(C=2N=CC=CC=2)C=C1 GSJZYVYQKLVZSG-UHFFFAOYSA-N 0.000 description 1
- CTLBQMCTYDGDKX-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-pyridin-3-ylbenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(C=2C=NC=CC=2)C=C1 CTLBQMCTYDGDKX-UHFFFAOYSA-N 0.000 description 1
- HBZHLRDQNQPENC-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-4-pyrrol-1-ylbenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(N2C=CC=C2)C=C1 HBZHLRDQNQPENC-UHFFFAOYSA-N 0.000 description 1
- ZBNQLIAVQGXXKM-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5,6-dimethoxy-1h-indole-2-carboxamide Chemical compound N1C=2C=C(OC)C(OC)=CC=2C=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 ZBNQLIAVQGXXKM-UHFFFAOYSA-N 0.000 description 1
- AJQXZWBVDWICFR-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-(2,2,2-trifluoroethoxy)-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC(OCC(F)(F)F)=CC=C2O1 AJQXZWBVDWICFR-UHFFFAOYSA-N 0.000 description 1
- WEBRHBRCEHNMPS-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-(2-hydroxyethoxy)-1-benzofuran-2-carboxamide Chemical compound C=1C2=CC(OCCO)=CC=C2OC=1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 WEBRHBRCEHNMPS-UHFFFAOYSA-N 0.000 description 1
- QVLAIXIUJXAFAP-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-(2-morpholin-4-ylethoxy)-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC(OCCN3CCOCC3)=CC=C2O1 QVLAIXIUJXAFAP-UHFFFAOYSA-N 0.000 description 1
- VMHAHWMKQDRASA-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-(oxan-4-yloxy)-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC(OC3CCOCC3)=CC=C2O1 VMHAHWMKQDRASA-UHFFFAOYSA-N 0.000 description 1
- HSDJRSDTOVISHL-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-(pyridin-3-ylmethoxy)-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC(OCC=3C=NC=CC=3)=CC=C2O1 HSDJRSDTOVISHL-UHFFFAOYSA-N 0.000 description 1
- LUQULKOGXFUUKL-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-methoxy-1-benzofuran-2-carboxamide Chemical compound C=1C2=CC(OC)=CC=C2OC=1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 LUQULKOGXFUUKL-UHFFFAOYSA-N 0.000 description 1
- WRIKQNZZNFHGNM-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-methoxy-1-benzothiophene-2-carboxamide Chemical compound C=1C2=CC(OC)=CC=C2SC=1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 WRIKQNZZNFHGNM-UHFFFAOYSA-N 0.000 description 1
- AJKLQZFBULFAIG-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-methoxy-1h-indole-2-carboxamide Chemical compound C=1C2=CC(OC)=CC=C2NC=1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 AJKLQZFBULFAIG-UHFFFAOYSA-N 0.000 description 1
- OIRUXNYCKRTXQK-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-methyl-1-benzofuran-2-carboxamide Chemical compound C=1C2=CC(C)=CC=C2OC=1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 OIRUXNYCKRTXQK-UHFFFAOYSA-N 0.000 description 1
- HBNDSYLZWKDTCY-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-methyl-1-benzothiophene-2-carboxamide Chemical compound C=1C2=CC(C)=CC=C2SC=1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 HBNDSYLZWKDTCY-UHFFFAOYSA-N 0.000 description 1
- FHSBENCNHKCJSV-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-phenylpyridine-3-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CN=CC(C=2C=CC=CC=2)=C1 FHSBENCNHKCJSV-UHFFFAOYSA-N 0.000 description 1
- JRIGNSIQQKUANG-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-phenylthiophene-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(C=2C=CC=CC=2)S1 JRIGNSIQQKUANG-UHFFFAOYSA-N 0.000 description 1
- WXPYVXKQABNJSE-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-thiophen-3-ylpyridine-3-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CN=CC(C2=CSC=C2)=C1 WXPYVXKQABNJSE-UHFFFAOYSA-N 0.000 description 1
- IGPXMNQDPDTXGC-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-6-(2-methylpropoxy)pyridine-2-carboxamide Chemical compound CC(C)COC1=CC=CC(C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)=N1 IGPXMNQDPDTXGC-UHFFFAOYSA-N 0.000 description 1
- WGSNVUMKGRBAHY-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-6-(2-morpholin-4-ylethoxy)-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C(OC1=C2)=CC1=CC=C2OCCN1CCOCC1 WGSNVUMKGRBAHY-UHFFFAOYSA-N 0.000 description 1
- AHCKVUJBBQWDAD-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-6-(2-phenylethoxy)pyridine-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC(OCCC=2C=CC=CC=2)=N1 AHCKVUJBBQWDAD-UHFFFAOYSA-N 0.000 description 1
- BEMPIJUOULYHKO-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-6-(4-nitrophenoxy)pyridine-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC(OC=2C=CC(=CC=2)[N+]([O-])=O)=N1 BEMPIJUOULYHKO-UHFFFAOYSA-N 0.000 description 1
- LZZBEXUGNYWARJ-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-6-methoxy-1-benzothiophene-2-carboxamide Chemical compound S1C2=CC(OC)=CC=C2C=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 LZZBEXUGNYWARJ-UHFFFAOYSA-N 0.000 description 1
- ZNCYBUROZKKQNS-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-6-methyl-1-benzofuran-2-carboxamide Chemical compound O1C2=CC(C)=CC=C2C=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 ZNCYBUROZKKQNS-UHFFFAOYSA-N 0.000 description 1
- JGLLBLHNIPYTET-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-6-methyl-3,4-dihydro-2h-quinoline-1-carboxamide Chemical compound C1CCC2=CC(C)=CC=C2N1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 JGLLBLHNIPYTET-UHFFFAOYSA-N 0.000 description 1
- VDZLXHIUPJSXBU-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-6-oxo-1h-pyridine-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC(O)=N1 VDZLXHIUPJSXBU-UHFFFAOYSA-N 0.000 description 1
- AEFRNIGRESRTQV-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-6-phenylmethoxypyridine-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC(OCC=2C=CC=CC=2)=N1 AEFRNIGRESRTQV-UHFFFAOYSA-N 0.000 description 1
- KLFGTYMILHUSHO-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-7-(methoxymethyl)-1-benzofuran-2-carboxamide Chemical compound O1C=2C(COC)=CC=CC=2C=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 KLFGTYMILHUSHO-UHFFFAOYSA-N 0.000 description 1
- IDDNDHHRWSTENO-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-7-(morpholin-4-ylmethyl)-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC=CC(CN3CCOCC3)=C2O1 IDDNDHHRWSTENO-UHFFFAOYSA-N 0.000 description 1
- NIMCVBWKOWFYTF-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-7-(phenoxymethyl)-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC=CC(COC=3C=CC=CC=3)=C2O1 NIMCVBWKOWFYTF-UHFFFAOYSA-N 0.000 description 1
- ROULYISZYUUDRL-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-7-methoxy-1-benzofuran-2-carboxamide Chemical compound O1C=2C(OC)=CC=CC=2C=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 ROULYISZYUUDRL-UHFFFAOYSA-N 0.000 description 1
- TZCIECHOOVXVLZ-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]furan-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CO1 TZCIECHOOVXVLZ-UHFFFAOYSA-N 0.000 description 1
- JEHPPLVLBSCHEQ-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]isoquinoline-1-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=NC=CC2=CC=CC=C12 JEHPPLVLBSCHEQ-UHFFFAOYSA-N 0.000 description 1
- BUKBTSZBDXYUTQ-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]isoquinoline-3-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC2=CC=CC=C2C=N1 BUKBTSZBDXYUTQ-UHFFFAOYSA-N 0.000 description 1
- OPLVVRWFUQXEMS-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]morpholine-4-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)N1CCOCC1 OPLVVRWFUQXEMS-UHFFFAOYSA-N 0.000 description 1
- MDSIGQCXHPZMQO-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]naphthalene-1-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC2=CC=CC=C12 MDSIGQCXHPZMQO-UHFFFAOYSA-N 0.000 description 1
- ZYVUYRKCHDGTET-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]piperidine-1-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)N1CCCCC1 ZYVUYRKCHDGTET-UHFFFAOYSA-N 0.000 description 1
- SJAGABCRANFIEJ-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]pyridine-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC=N1 SJAGABCRANFIEJ-UHFFFAOYSA-N 0.000 description 1
- RBSWWUDUXPAICR-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]pyridine-3-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CN=C1 RBSWWUDUXPAICR-UHFFFAOYSA-N 0.000 description 1
- IHZFYYFEOHRXEK-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]quinoline-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(C=CC=C2)C2=N1 IHZFYYFEOHRXEK-UHFFFAOYSA-N 0.000 description 1
- VLYYCJJGRXTMHP-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]quinoline-3-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CN=C(C=CC=C2)C2=C1 VLYYCJJGRXTMHP-UHFFFAOYSA-N 0.000 description 1
- IKOJWHBGSKECLI-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]quinoline-4-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=NC2=CC=CC=C12 IKOJWHBGSKECLI-UHFFFAOYSA-N 0.000 description 1
- FEYHPUUXHKSGPU-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]quinoline-6-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=C(N=CC=C2)C2=C1 FEYHPUUXHKSGPU-UHFFFAOYSA-N 0.000 description 1
- SQLBPLFPJINSAH-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]quinoline-8-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CC2=CC=CN=C12 SQLBPLFPJINSAH-UHFFFAOYSA-N 0.000 description 1
- PMLXGKMIRAWFPF-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]quinoxaline-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CN=C(C=CC=C2)C2=N1 PMLXGKMIRAWFPF-UHFFFAOYSA-N 0.000 description 1
- LLDZTGJWTSXAIA-UHFFFAOYSA-N n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]thiophene-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)C1=CC=CS1 LLDZTGJWTSXAIA-UHFFFAOYSA-N 0.000 description 1
- FBVVIOAKCVUDAH-UHFFFAOYSA-N n-[3-[4-(hydroxycarbamoyl)phenoxy]propyl]-1-benzothiophene-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCCNC(=O)C1=CC2=CC=CC=C2S1 FBVVIOAKCVUDAH-UHFFFAOYSA-N 0.000 description 1
- PACLSVAXAHSCPO-UHFFFAOYSA-N n-[3-[4-(hydroxycarbamoyl)phenoxy]propyl]-4-phenyl-1,3-thiazole-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCCNC(=O)C1=NC(C=2C=CC=CC=2)=CS1 PACLSVAXAHSCPO-UHFFFAOYSA-N 0.000 description 1
- FUICEJKDHGEMEM-UHFFFAOYSA-N n-[3-[4-(hydroxycarbamoyl)phenoxy]propyl]-5-methyl-1-benzothiophene-2-carboxamide Chemical compound C=1C2=CC(C)=CC=C2SC=1C(=O)NCCCOC1=CC=C(C(=O)NO)C=C1 FUICEJKDHGEMEM-UHFFFAOYSA-N 0.000 description 1
- CAWWEBXCHMZQRN-UHFFFAOYSA-N n-[3-[4-(hydroxycarbamoyl)phenoxy]propyl]-6-methoxy-1-benzothiophene-2-carboxamide Chemical compound S1C2=CC(OC)=CC=C2C=C1C(=O)NCCCOC1=CC=C(C(=O)NO)C=C1 CAWWEBXCHMZQRN-UHFFFAOYSA-N 0.000 description 1
- XOHIGJQRZIOPSO-UHFFFAOYSA-N n-[3-[4-(hydroxycarbamoyl)phenoxy]propyl]-7-(methoxymethyl)-1-benzofuran-2-carboxamide Chemical compound O1C=2C(COC)=CC=CC=2C=C1C(=O)NCCCOC1=CC=C(C(=O)NO)C=C1 XOHIGJQRZIOPSO-UHFFFAOYSA-N 0.000 description 1
- TZXQQKXUXMKFTK-UHFFFAOYSA-N n-[3-[4-(hydroxycarbamoyl)phenoxy]propyl]-7-(phenoxymethyl)-1-benzofuran-2-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCCNC(=O)C1=CC2=CC=CC(COC=3C=CC=CC=3)=C2O1 TZXQQKXUXMKFTK-UHFFFAOYSA-N 0.000 description 1
- GWLFIMOOGVXSMZ-UHFFFAOYSA-N n-[[1-[2-(diethylamino)ethylamino]-7-methoxy-9-oxothioxanthen-4-yl]methyl]formamide Chemical compound S1C2=CC=C(OC)C=C2C(=O)C2=C1C(CNC=O)=CC=C2NCCN(CC)CC GWLFIMOOGVXSMZ-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002004 n-butylamino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PPRVLEZWKXVATQ-LLVKDONJSA-N n-hydroxy-3-[(2r)-1-(naphthalene-1-carbonylamino)propan-2-yl]oxy-1,2-oxazole-5-carboxamide Chemical compound O([C@@H](CNC(=O)C=1C2=CC=CC=C2C=CC=1)C)C=1C=C(C(=O)NO)ON=1 PPRVLEZWKXVATQ-LLVKDONJSA-N 0.000 description 1
- AIBRCLBHFNIVFN-CYBMUJFWSA-N n-hydroxy-3-[(2r)-1-[(3-phenylbenzoyl)amino]propan-2-yl]oxy-1,2-oxazole-5-carboxamide Chemical compound C([C@@H](C)OC1=NOC(=C1)C(=O)NO)NC(=O)C(C=1)=CC=CC=1C1=CC=CC=C1 AIBRCLBHFNIVFN-CYBMUJFWSA-N 0.000 description 1
- JTMKHIDIDQDVOL-CYBMUJFWSA-N n-hydroxy-3-[(2r)-1-[(4-phenylbenzoyl)amino]propan-2-yl]oxy-1,2-oxazole-5-carboxamide Chemical compound C([C@@H](C)OC1=NOC(=C1)C(=O)NO)NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 JTMKHIDIDQDVOL-CYBMUJFWSA-N 0.000 description 1
- GFHCRJMTSNXQOY-UHFFFAOYSA-N n-hydroxy-3-[2-(naphthalene-1-carbonylamino)ethoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCNC(=O)C=2C3=CC=CC=C3C=CC=2)=N1 GFHCRJMTSNXQOY-UHFFFAOYSA-N 0.000 description 1
- ZKKCBJFHKHJNQK-UHFFFAOYSA-N n-hydroxy-3-[2-[(2-phenylbenzoyl)amino]ethoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCNC(=O)C=2C(=CC=CC=2)C=2C=CC=CC=2)=N1 ZKKCBJFHKHJNQK-UHFFFAOYSA-N 0.000 description 1
- JWRQYONCQGWIMI-UHFFFAOYSA-N n-hydroxy-3-[2-[(3-phenylbenzoyl)amino]ethoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCNC(=O)C=2C=C(C=CC=2)C=2C=CC=CC=2)=N1 JWRQYONCQGWIMI-UHFFFAOYSA-N 0.000 description 1
- OTNPURLGPHNEQL-UHFFFAOYSA-N n-hydroxy-3-[2-[(4-phenyl-1,3-thiazole-2-carbonyl)amino]ethoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCNC(=O)C=2SC=C(N=2)C=2C=CC=CC=2)=N1 OTNPURLGPHNEQL-UHFFFAOYSA-N 0.000 description 1
- ULCRHERDFPYFLT-UHFFFAOYSA-N n-hydroxy-3-[2-[(4-phenylbenzoyl)amino]ethoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCNC(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=N1 ULCRHERDFPYFLT-UHFFFAOYSA-N 0.000 description 1
- JKNNRCBHEYLGJV-VOTSOKGWSA-N n-hydroxy-3-[2-[[(e)-3-phenylprop-2-enoyl]amino]ethoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCNC(=O)\C=C\C=2C=CC=CC=2)=N1 JKNNRCBHEYLGJV-VOTSOKGWSA-N 0.000 description 1
- KSISWUZQSBGDLC-UHFFFAOYSA-N n-hydroxy-3-[2-[[3-(phenoxymethyl)-1-benzofuran-2-carbonyl]amino]ethoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCNC(=O)C2=C(C3=CC=CC=C3O2)COC=2C=CC=CC=2)=N1 KSISWUZQSBGDLC-UHFFFAOYSA-N 0.000 description 1
- ZUIDNKGRNKGAAD-UHFFFAOYSA-N n-hydroxy-3-[3-(naphthalene-1-carbonylamino)propoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCCNC(=O)C=2C3=CC=CC=C3C=CC=2)=N1 ZUIDNKGRNKGAAD-UHFFFAOYSA-N 0.000 description 1
- UZJMPEOSIJEBJY-UHFFFAOYSA-N n-hydroxy-3-[3-[(2-phenylbenzoyl)amino]propoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCCNC(=O)C=2C(=CC=CC=2)C=2C=CC=CC=2)=N1 UZJMPEOSIJEBJY-UHFFFAOYSA-N 0.000 description 1
- VOKPKHMFSLFNDS-UHFFFAOYSA-N n-hydroxy-3-[3-[(3-phenylbenzoyl)amino]propoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCCNC(=O)C=2C=C(C=CC=2)C=2C=CC=CC=2)=N1 VOKPKHMFSLFNDS-UHFFFAOYSA-N 0.000 description 1
- HPXPTGRKFBOTMV-UHFFFAOYSA-N n-hydroxy-3-[3-[(4-phenyl-1,3-thiazole-2-carbonyl)amino]propoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCCNC(=O)C=2SC=C(N=2)C=2C=CC=CC=2)=N1 HPXPTGRKFBOTMV-UHFFFAOYSA-N 0.000 description 1
- QVKFFNZTSNXHNR-UHFFFAOYSA-N n-hydroxy-3-[3-[(4-phenylbenzoyl)amino]propoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCCNC(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=N1 QVKFFNZTSNXHNR-UHFFFAOYSA-N 0.000 description 1
- UKGBEGMVXLVIAG-BQYQJAHWSA-N n-hydroxy-3-[3-[[(e)-3-phenylprop-2-enoyl]amino]propoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCCNC(=O)\C=C\C=2C=CC=CC=2)=N1 UKGBEGMVXLVIAG-BQYQJAHWSA-N 0.000 description 1
- CYEGARXHHUMYHB-UHFFFAOYSA-N n-hydroxy-3-[3-[[2-(2-phenylethyl)benzoyl]amino]propoxy]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)NO)=CC(OCCCNC(=O)C=2C(=CC=CC=2)CCC=2C=CC=CC=2)=N1 CYEGARXHHUMYHB-UHFFFAOYSA-N 0.000 description 1
- YWRZEPALANKSJH-FMQWLBJXSA-N n-hydroxy-4-[(2r)-2-[[(e)-3-(7-methoxy-1-benzofuran-2-yl)prop-2-enoyl]amino]butoxy]benzamide Chemical compound C([C@@H](CC)NC(=O)\C=C\C=1OC2=C(OC)C=CC=C2C=1)OC1=CC=C(C(=O)NO)C=C1 YWRZEPALANKSJH-FMQWLBJXSA-N 0.000 description 1
- XQFBSKHFPDSTRJ-MSGBMKDASA-N n-hydroxy-4-[(2r)-2-[[(e)-3-phenylprop-2-enoyl]amino]butoxy]benzamide Chemical compound C([C@@H](CC)NC(=O)\C=C\C=1C=CC=CC=1)OC1=CC=C(C(=O)NO)C=C1 XQFBSKHFPDSTRJ-MSGBMKDASA-N 0.000 description 1
- JHWUHZMZMVLSAE-WEKMIXOTSA-N n-hydroxy-4-[(2r)-2-[[(e)-3-phenylprop-2-enoyl]amino]propoxy]benzamide Chemical compound C([C@@H](C)NC(=O)\C=C\C=1C=CC=CC=1)OC1=CC=C(C(=O)NO)C=C1 JHWUHZMZMVLSAE-WEKMIXOTSA-N 0.000 description 1
- XAESBWRXFOXXMJ-CWRQFWGNSA-N n-hydroxy-4-[(2r)-3-methyl-2-[[(e)-3-phenylprop-2-enoyl]amino]butoxy]benzamide Chemical compound C([C@@H](C(C)C)NC(=O)\C=C\C=1C=CC=CC=1)OC1=CC=C(C(=O)NO)C=C1 XAESBWRXFOXXMJ-CWRQFWGNSA-N 0.000 description 1
- WJLXGQNDTIJVIN-UPMCQBDUSA-N n-hydroxy-4-[(2r)-3-phenyl-2-[[(e)-3-phenylprop-2-enoyl]amino]propoxy]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OC[C@H](NC(=O)\C=C\C=1C=CC=CC=1)CC1=CC=CC=C1 WJLXGQNDTIJVIN-UPMCQBDUSA-N 0.000 description 1
- IOUSOGFKIWBVQI-BNOPAZPUSA-N n-hydroxy-4-[(2r)-4-methyl-2-[[(e)-3-phenylprop-2-enoyl]amino]pentoxy]benzamide Chemical compound C([C@@H](CC(C)C)NC(=O)\C=C\C=1C=CC=CC=1)OC1=CC=C(C(=O)NO)C=C1 IOUSOGFKIWBVQI-BNOPAZPUSA-N 0.000 description 1
- FYJRCIFDFCJFSG-VWGXWWAPSA-N n-hydroxy-4-[(2r)-4-methylsulfanyl-2-[[(e)-3-phenylprop-2-enoyl]amino]butoxy]benzamide Chemical compound C([C@@H](CCSC)NC(=O)\C=C\C=1C=CC=CC=1)OC1=CC=C(C(=O)NO)C=C1 FYJRCIFDFCJFSG-VWGXWWAPSA-N 0.000 description 1
- INUZJPRBDCQIBC-VWGXWWAPSA-N n-hydroxy-4-[(2r)-4-methylsulfonyl-2-[[(e)-3-phenylprop-2-enoyl]amino]butoxy]benzamide Chemical compound C([C@@H](CCS(=O)(=O)C)NC(=O)\C=C\C=1C=CC=CC=1)OC1=CC=C(C(=O)NO)C=C1 INUZJPRBDCQIBC-VWGXWWAPSA-N 0.000 description 1
- KIZGTPOZPHJQBF-UHFFFAOYSA-N n-hydroxy-4-[2-(3-phenylpropanoylamino)ethoxy]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)CCC1=CC=CC=C1 KIZGTPOZPHJQBF-UHFFFAOYSA-N 0.000 description 1
- BLQBYQHRXFQFHZ-UHFFFAOYSA-N n-hydroxy-4-[2-[(2-thiophen-2-ylacetyl)amino]ethoxy]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)CC1=CC=CS1 BLQBYQHRXFQFHZ-UHFFFAOYSA-N 0.000 description 1
- JRSDPTOEGOYJBX-JXMROGBWSA-N n-hydroxy-4-[2-[[(e)-3-(1h-indol-3-yl)prop-2-enoyl]amino]ethoxy]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)\C=C\C1=CNC2=CC=CC=C12 JRSDPTOEGOYJBX-JXMROGBWSA-N 0.000 description 1
- BXPAJELCROVQMS-JXMROGBWSA-N n-hydroxy-4-[2-[[(e)-3-(2-hydroxyphenyl)prop-2-enoyl]amino]ethoxy]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)\C=C\C1=CC=CC=C1O BXPAJELCROVQMS-JXMROGBWSA-N 0.000 description 1
- UFAHQVFFKZRTIV-DHZHZOJOSA-N n-hydroxy-4-[2-[[(e)-3-(2-methoxyphenyl)prop-2-enoyl]amino]ethoxy]benzamide Chemical compound COC1=CC=CC=C1\C=C\C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 UFAHQVFFKZRTIV-DHZHZOJOSA-N 0.000 description 1
- GFTHTKFZLQIOHG-RUDMXATFSA-N n-hydroxy-4-[2-[[(e)-3-(3-hydroxyphenyl)prop-2-enoyl]amino]ethoxy]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)\C=C\C1=CC=CC(O)=C1 GFTHTKFZLQIOHG-RUDMXATFSA-N 0.000 description 1
- XWLPHESOSBBJOP-BJMVGYQFSA-N n-hydroxy-4-[2-[[(e)-3-(3-methoxyphenyl)prop-2-enoyl]amino]ethoxy]benzamide Chemical compound COC1=CC=CC(\C=C\C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)=C1 XWLPHESOSBBJOP-BJMVGYQFSA-N 0.000 description 1
- ZTLWFYVXNAKEGT-BJMVGYQFSA-N n-hydroxy-4-[2-[[(e)-3-(3-methylphenyl)prop-2-enoyl]amino]ethoxy]benzamide Chemical compound CC1=CC=CC(\C=C\C(=O)NCCOC=2C=CC(=CC=2)C(=O)NO)=C1 ZTLWFYVXNAKEGT-BJMVGYQFSA-N 0.000 description 1
- GDVOOIZYEKHSJG-XCVCLJGOSA-N n-hydroxy-4-[2-[[(e)-3-(4-hydroxyphenyl)prop-2-enoyl]amino]ethoxy]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)\C=C\C1=CC=C(O)C=C1 GDVOOIZYEKHSJG-XCVCLJGOSA-N 0.000 description 1
- CYZUYWWYNBEFQM-IZZDOVSWSA-N n-hydroxy-4-[2-[[(e)-3-(4-methylphenyl)prop-2-enoyl]amino]ethoxy]benzamide Chemical compound C1=CC(C)=CC=C1\C=C\C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 CYZUYWWYNBEFQM-IZZDOVSWSA-N 0.000 description 1
- XDLLRJKPYYPENV-MDZDMXLPSA-N n-hydroxy-4-[2-[[(e)-3-(7-methoxy-1-benzofuran-2-yl)prop-2-enoyl]amino]ethoxy]benzamide Chemical compound O1C=2C(OC)=CC=CC=2C=C1\C=C\C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 XDLLRJKPYYPENV-MDZDMXLPSA-N 0.000 description 1
- JQWQQGMAQSTBFZ-FPYGCLRLSA-N n-hydroxy-4-[2-[[(e)-3-pyridin-3-ylprop-2-enoyl]amino]ethoxy]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)\C=C\C1=CC=CN=C1 JQWQQGMAQSTBFZ-FPYGCLRLSA-N 0.000 description 1
- CHMZSRNWPDWFOM-BQYQJAHWSA-N n-hydroxy-4-[2-[[(e)-3-thiophen-2-ylprop-2-enoyl]amino]ethoxy]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)\C=C\C1=CC=CS1 CHMZSRNWPDWFOM-BQYQJAHWSA-N 0.000 description 1
- LNBCAMBREPRYEC-LZCJLJQNSA-N n-hydroxy-4-[2-[[(e)-3-thiophen-3-ylprop-2-enoyl]amino]ethoxy]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)\C=C\C1=CSC=C1 LNBCAMBREPRYEC-LZCJLJQNSA-N 0.000 description 1
- RMYKQGVOWUQRAO-UHFFFAOYSA-N n-hydroxy-4-[2-[[2-(1h-indol-3-yl)acetyl]amino]ethoxy]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)CC1=CNC2=CC=CC=C12 RMYKQGVOWUQRAO-UHFFFAOYSA-N 0.000 description 1
- LHQAYKHJCAVZFW-UHFFFAOYSA-N n-hydroxy-4-[2-[[2-(4-pyridin-4-ylpiperazin-1-yl)acetyl]amino]ethoxy]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1OCCNC(=O)CN1CCN(C=2C=CN=CC=2)CC1 LHQAYKHJCAVZFW-UHFFFAOYSA-N 0.000 description 1
- PYUKROIOVNLUHG-LFYBBSHMSA-N n-hydroxy-4-[3-[[(e)-3-(4-methoxyphenyl)prop-2-enoyl]amino]propoxy]benzamide Chemical compound C1=CC(OC)=CC=C1\C=C\C(=O)NCCCOC1=CC=C(C(=O)NO)C=C1 PYUKROIOVNLUHG-LFYBBSHMSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- XHWRWCSCBDLOLM-UHFFFAOYSA-N nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
- 229950000891 nolatrexed Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000005359 phenoxyalkyl group Chemical group 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950004317 pinafide Drugs 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 229950008499 plitidepsin Drugs 0.000 description 1
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229940089484 pravachol Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 229950007401 pumitepa Drugs 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229940100552 retinamide Drugs 0.000 description 1
- 108091008726 retinoic acid receptors α Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229950005747 sibrafiban Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- NSFFYSQTVOCNLX-JKIHJDPOSA-M sodium;[(2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl octadecyl phosphate;hydrate Chemical compound O.[Na+].O[C@H]1[C@H](O)[C@@H](COP([O-])(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 NSFFYSQTVOCNLX-JKIHJDPOSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Chemical group 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960005566 swainsonine Drugs 0.000 description 1
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003102 tasonermin Drugs 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IYRULVWLVRRRIS-UHFFFAOYSA-N tert-butyl 3-amino-2-hydroxypropanoate Chemical compound CC(C)(C)OC(=O)C(O)CN IYRULVWLVRRRIS-UHFFFAOYSA-N 0.000 description 1
- GPTXCAZYUMDUMN-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCO GPTXCAZYUMDUMN-UHFFFAOYSA-N 0.000 description 1
- BEUUJDAEPJZWHM-COROXYKFSA-N tert-butyl n-[(2s,3s,5r)-3-hydroxy-6-[[(2s)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate Chemical compound C([C@@H]([C@@H](O)C[C@H](C(=O)N[C@H](C(=O)NCCOC)C(C)C)CC=1C(=C(OC)C(OC)=CC=1)OC)NC(=O)OC(C)(C)C)C1=CC=CC=C1 BEUUJDAEPJZWHM-COROXYKFSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960005526 triapine Drugs 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229950010147 troxacitabine Drugs 0.000 description 1
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000009265 virologic response Effects 0.000 description 1
- RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229940072168 zocor Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Definitions
- the present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
- Chronic hepatitis C is a slowly progressive disease having a significant impact on morbidity and mortality. While many patients who contract hepatitis C will have sub clinical or mild disease, at least 80% of the individuals who contract HCV develop chronic infection and hepatitis. Twenty to fifty percent of these eventually progress to cirrhosis and 1-2% develop liver cancer (Hoofnagle, J. H.; 1997; Hepatology 26: 15S-20S). There are an estimated 170 million HCV carriers world-wide, and HCV-associated end-stage liver disease is now one of the leading cause of liver transplantation. In the United States alone, hepatitis C is responsible for 8,000 to 10,000 deaths annually.
- interferon- ⁇ 2b/ribavirin combination therapy is the only available treatment. Sustained virologic response to IFN- ⁇ 2b -ribavirin combination therapy occurs in about 40-45% of those treated. For those patients who fail interferon- ⁇ 2b/ribavirin combination therapy, there is currently no alternative to prevent the progression of liver disease. Thus, a need exists for alternative therapies for the treatment of chronic HCV infection. The present invention fulfills this need.
- HDACs histone deacetylase enzymes
- HDAC inhibitors can lead to growth inhibition, growth arrest, terminal differentiation and/or apoptosis.
- In vivo studies have demonstrated growth inhibition of tumors and a reduction in tumor metastasis as a result of treatment with HDAC inhibitors.
- the PLZF-RAR ⁇ form of the disease is treatable with retinoic acid
- the PLZF-RAR ⁇ form is resistant to this treatment.
- HDAC inhibitor sodium butyrate to the dosing regimen led to complete clinical and cytogenic remission (Warrell et al., 1998, J. Natl. Cancer. Inst. 90:1621-1625).
- HDACs have also been associated with Huntington's disease (Steffan, et al., Nature 413:739-744, “Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila”).
- an increase in HDAC activity contributes to the pathology and/or symptomatology of a number of diseases. Accordingly, molecules that inhibit the activity of HDAC are useful as therapeutic agents in the treatment of such diseases.
- this invention provides a compound of Formula (1): wherein:
- R 1 is hydrogen or alkyl
- X is —O—, —NR 2 —, or —S(O) n where n is 0-2 and R 2 is hydrogen or alkyl;
- Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkylsulfinyl, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy;
- Ar 1 is optionally substituted with one or two groups independently selected from alkyl, halo, hydroxy, alkoxy, haloalkoxy, or haloalkyl;
- R 3 is hydrogen, alkyl, hydroxyalkyl, or optionally substituted phenyl
- Ar is aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl; or a pharmaceutically acceptable salt thereof.
- this invention is directed to a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient.
- this invention is directed to a method for treating a disease in an animal mediated by HDAC which method comprises administering to the animal a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
- the disease is a proliferative disorder such as cancer and bipolar disorders and the animal is a human.
- the cancer is prostate cancer, breast cancer, lung melanoma, stomach cancer, neuroblastoma, colon cancer, pancreatic cancer, ovarian cancer, T-cell lymphoma, or leukemia such as myelogenous leukemia (MM) and acute myelogenous leukemia (AML).
- this invention is directed to a method for treating cancer in an animal which method comprises administering to the animal a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient in combination with radiation therapy and optionally in combination with one or more compound(s) independently selected from an estrogen receptor modulator, an androgen receptor modulator, a retinoid receptor modulator, a cytotoxic agent, another antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor, an angiogenesis inhibitor, or a DNA methyl transferase inhibitor.
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient in combination with radiation therapy and optionally in combination with one or more compound(s) independently selected from an estrogen receptor modulator, an androgen receptor
- this invention is directed to a method of treating hepatitis C in an animal comprising administering the animal a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient optionally in combination with one or more other hepatitis C agent.
- the hepatitis C agents are interferon- ⁇ 2b, ribavirin, and hcv polymerase inhibitors.
- this invention is direct to an intermediate of Formula (II):
- R 50 is hydrogen or alkyl and Ar 1 , Ar 2 , R 3 , X and Y are as defined for compounds of Formula (1) above; or a salt thereof.
- Ar 1 , Ar 2 , R 3 , X and Y are as defined in Preferred embodiments below.
- this invention is directed to a process of preparing a compound of Formula (I) comprising: (i) reacting a compound of Formula (III):
- R 51 is hydroxy, alkoxy, halo, or succinimido ester with a hydroxylamine of formula NH 2 OR′′ where R′′ is hydrogen, alkyl, or an oxygen protecting group; or (ii) treating a compound of Formula (IV):
- M + is an alkali metal with an acid; followed by treatment with NH 2 OR′′ where R′′ is hydrogen, alkyl, or an oxygen protecting group; to give a compound of Formula (V): (iii) optionally removing R′′ group in compound (V) to give a compound of Formula (I) where R 1 is hydrogen; (iv) optionally forming an acid addition salt of the product formed in Step (i), (ii), or (iii) above; (v) optionally forming free base of the product formed in Step (i), (ii), (iii), or (iv) above; or (vi) optionally modifying any of the X, Y, R 1 , R 2 , R 3 , Ar 1 and Ar 2 groups in the product formed in Step (i), (ii), (ii), (iv), or (v) above.
- this invention is directed to the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.
- this invention is directed to the use of a compound of Formula (I) or (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of hepatitis C.
- Alkyl means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl (including all isomeric forms), pentyl (including all isomeric forms), and the like.
- Alkylene means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms unless otherwise stated e.g., methylene, ethylene, propylene, I-methylpropylene, 2-methylpropylene, butylene, pentylene, and the like.
- Alkenylene means a linear divalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms containing one or two double bonds, e.g., ethenylene, propenylene, 2-propenylene, butenylene (including all isomeric forms), and the like.
- Alkylthio means a —SR radical where R is alkyl as defined above, e.g., methylthio, ethylthio, propylthio (including all isomeric forms), butylthio (including all isomeric forms), and the like.
- Alkylsulfinyl means a —S(O)R radical where R is alkyl as defined above, e.g., methylsulfinyl, ethylsulfinyl, propylsulfinyl (including all isomeric forms), and the like.
- Alkylsulfonyl means a —SO 2 R radical where R is alkyl as defined above, e.g., methylsulfonyl, ethylsulfonyl, and the like.
- Amino means a —NH 2 ; or an Noxide derivative or a protected derivative thereof e.g., —NH ⁇ O, —NHBoc, —NHCbz, and the like. Preferably, —NH 2 .
- Alkylamino means a —NHR radical where R is alkyl as defined above; or an N-oxide derivative, or a protected derivative thereof, e.g., methylamino, ethylamino, n-, iso-propylamino, n-, iso-, tert-butylamino, methylamino-N-oxide, —N(Boc)CH 3 , and the like.
- Alkoxy means a -OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or tert-butoxy, and the like.
- Alkoxycarbonyl means a —C(O)OR radical where R is alkyl as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, and the like.
- Alkoxyalkyl means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one alkoxy group, preferably one or two alkoxy groups, as defined above, e.g., 2-methoxyethyl, 1-, 2-, or 3-methoxypropyl, 2-ethoxyethyl, and the like,
- Alkoxyalkyloxy means a —OR radical where R is alkoxyalkyl as defined above, e.g., methoxyethoxy, 2-ethoxyethoxy, and the like.
- Alkoxyalkyloxyalkyl means a -alkylene)-R radical where R is alkoxyalkyloxy as defined above, e.g., methoxyethoxymethyl, 2-ethoxyethoxymethyl, and the like.
- Aminoalkyl means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one, preferably one or two, —NRR′ where R is hydrogen, alkyl, or —COR′ where R a is alkyl, and R′ is selected from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or haloalkyl; or an N-oxide derivative or a protected derivative thereof.
- R and R′ are independently selected from hydrogen, alkyl, or —COR a where R a is alkyl; or an N-oxide derivative, or a protected derivative e.g., aminomethyl, methylaminoethyl, 2-ethylamino-2-methylethyl, 1,3-diaminopropyl, dimethylaminomethyl, diethylaminoethyl, acetylaminopropyl, aminomethyl-N-oxide, and the like.
- Aminoalkoxy means a —OR radical where R is aminoalkyl as defined above, e.g., 2-aminoethoxy, 2-dimethylaminopropoxy, and the like.
- Aminocarbonyl means a —CONRR radical where each R is independently hydrogen or alkyl as defined above, e.g., —CONH 2 , methylaminocarbonyl, 2-dimethylaminocarbonyl, and the like.
- “Acylamino” means a —NHCOR radical where R is alkyl as defined above, e.g., acetylamino, propionylamino, and the like.
- Aryl means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical of 6 to 12 ring atoms e.g., phenyl, naphthyl or anthracenyl. Unless stated otherwise, the aryl ring is optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, hydroxyalkoxyalkyl, alkoxyalkyloxyalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryloxy, optionally substituted beteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl
- the substituents are independently methoxy, methyl, ethyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-(morpholin-4-yl)ethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-(N,N-dimethylamino)-ethoxy, methoxymethyl, phenoxymethyl, 2-morpholino-4-ylethyl, morpholino4-ylmethyl, N,N-dimethylaminomethyl, i-propoxymethyl, or phenoxymethyl.
- Alkyl means a -alkylene)-R radical where R is aryl as defined above.
- Alkenyl means a -alkenylene)-R radical where R is aryl as defined above.
- Cycloalkyl means a cyclic saturated monovalent hydrocarbon radical of three to ten carbon atoms, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or adamantyl.
- the cycloalkyl is optionally substituted with optionally substituted phenyl.
- “Cycloalkenyl” means a cyclic unsaturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., cyclopropenyl, cyclobutenyl, cyclohexenyl, and the like.
- Cycloalkylalkyl means a -(alkylene)-R radical where R is cycloalkyl as defined above; e.g., cyclopropylmethyl, cyclobutytmethyl, cyclopentylethyl, or cyclohexylmethyl, and the like.
- Cycloalkyloxy means a —OR radical where R is cycloalkyl as defined above, e.g., cyclopropyloxy, cyclohexyloxy, and the like.
- Cycloalkenyloxy means a —OR radical where R is cycloalkenyl as defined above, e.g., cyclopropenyloxy, cyclohexenyloxy, and the like.
- Dialkylamino means a —NRR′ radical where R and R′ are independently alkyl as defined above, e.g., dimethylamino, diethylamino, methylpropylamino, methylethylamino, n-, iso-, or tert-butylamino, and the like.
- Halo means fluoro, chloro, bromo, and iodo, preferably fluoro or chloro.
- Haloalkyl means alkyl substituted with one or more halogen atoms, preferably one to five halogen atoms, preferably fluorine or chlorine, including those substituted with different halogens, e.g., —CH 2 Cl, —CF 3 , —CHF 2 , —CF 2 CF 3 , —CF(CH 3 ) 3 , and the like.
- Haloalkoxy means a —R radical where R is haloalkyl as defined above e.g., —OCF 3 , —OCHF 2 , and the like.
- Haloalkoxyalkyl means a -(alkylene)—OR radical where R is haloalkyl as defined above e.g., trifluoromethyloxymethyl, 2,2,2-trifluoroethyloxymethyl, 2-trifluoromethoxyethyl, and the like.
- Hydroalkyl means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with one or two hydroxy groups, provided that if two hydroxy groups are present they are not both on the same carbon atom.
- Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-di hydroxypropyl, and 1-(hydroxymethyl)-2-hydroxyethyl.
- Haldroxyalkoxy or “hydroxyalkyloxy” means a OR radical where R is hydroxyalkyl as defined above.
- “Hydroxyalkoxyalkyl” or “hydroxyalkyloxyalkyl” means a -(alkylene)—OR radical where R is hydroxyalkyl as defined above e.g., hydroxymethyloxymethyl, hydroxyethyloxymethyl, and the like.
- Heterocycloalkyl means a saturated or unsaturated monovalent cyclic group of 3 to 8 ring atoms in which one or two ring atoms are heteroatom selected from N, O, or S(O) n , where n is an integer from 0 to 2, the remaining ring atoms being C.
- One or two ring carbon atoms can optionally be replaced by a —CO— group.
- heterocycloalkyl includes, but is not limited to, pyrrolidino, piperidino, morpholino, piperazino, tetrahydropyranyl, tetrahydroquinolinyl and thiomorpholino, and the derivatives thereof (formed when the heterocyloalkyl ring is substituted with a substituent listed below); and an N-oxide or a protected derivative thereof.
- the heterocycloalkyl is optionally fused to aryl.
- the heterocyloalkyl ring is optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, hydroxyalkoxyalkyl, alkoxyalkyloxyalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, haloalkoxyalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkyl, optional
- the substituents are independently methoxy, methyl, ethyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-(morpholin4-yl)ethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-(N,N-dimethylamino)ethoxy, methoxymethyl, phenoxymethyl, 2-morpholino-4-ylethyl, morpholino-4-ylmethyl, N,N-dimethylaminomethyl, i-propoxymethyl, or phenoxymethyl.
- Heterocycloalkylalkyl means a -(alkylene)-R radical where R is heterocycloalkyl ring as defined above e.g., furanylmethyl, piperazinylmethyl, morpholinylethyl, and the like.
- Heteroaryl means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms where one or more, preferably one, two, or three, ring atoms are heteroatom selected from N, O, or S, the remaining ring atoms being carbon.
- heteroaryl includes, but is not limited to, pyridyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, benzoxazolyl, benzothiophenyl, benzthiazolyl, quinolinyl, isoquinolinyl, benzofuranyl, benzopyranyl, and thiazolyl, and the derivatives thereof (formed when the heterocyloalkyl ring is substituted with a substituent listed below); or an N-oxide or a protected derivative thereof.
- the heteroaryl ring is optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, hydroxyalkoxyalkyl, alkoxyalkyloxyalkyl, optionally substituted phenyl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, haloalkoxyalkyl, optionally substituted phenylalkyl, optionally substituted phenyloxy, optionally substituted phenylalkyloxy, optionally substituted phenylalky
- the substituents are independently methoxy, miethyl, ethyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-(morpholin-4-yl)ethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-(N,N-dimethylamino)ethoxy, methoxymethyl, phenoxymethyl, 2-morpholino4-ylethyl, morpholino4-ylmethyl, N,N-dimethylamino-methyl, i-propoxymethyl, or phenoxymethyl.
- heteroaryl ring When the heteroaryl ring is divalent it has been referred to as heteroarylene in this application.
- Heteroarylamino means a NHR radical where R is heteroaryl as defined above.
- Heteroaralkyl means a -(alkylene)-R radical where R is heteroaryl as defined above.
- Heteroaralkenyl means a -(alkenylene)-R radical where R is heteroaryl as defined above.
- the present invention also includes the prodrugs of compounds of Formula (I).
- prodrug is intended to represent covalently bonded carriers, which are capable of releasing the active ingredient of Formula (I) when the prodrug is administered to a mammalian subject. Release of the active ingredient occurs in vivo.
- Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups however regenerate original functional groups by routine manipulation or in vivo.
- Prodrugs of compounds of Formula (I) include compounds wherein a hydroxy, amino, carboxylic, or a similar group is modified.
- prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy or amino functional groups in compounds of Formula (I)), amides (e.g., trifluoroacetylamino, acetylamino, and the like), and the like.
- esters e.g., acetate, formate, and benzoate derivatives
- carbamates e.g., N,N-dimethylaminocarbonyl
- amides e.g., trifluoroacetylamino, acetylamino, and the like
- Prodrugs of compounds of Formula (I) are also within the scope of this invention.
- the present invention also includes N-oxide derivatives and protected derivatives of compounds of Formula (I).
- compounds of Formula (I) when compounds of Formula (I) contain an oxidizable nitrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known in the art.
- compounds of Formula (I) when compounds of Formula (I) contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable protecting groups.
- a comprehensive list of suitable protective groups can be found in T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc. 1981, the disclosure of which is incorporated herein by reference in its entirety.
- the protected derivatives of compounds of Formula (I) can be prepared by methods well known in the art.
- Phenylene means a divalent phenyl radical.
- a “pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
- Such salts include:
- acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid,
- a metal ion e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion
- organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
- the compounds of the present invention may have asymmetric centers.
- Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of materials. All chiral, diastereomeric, racemic forms are within the scope of this invention, unless the specific stereochemistry or isomeric form is specifically indicated.
- Certain compounds of Formula (I) can exist as tautomers and/or geometric isomers. All possible tautomers and cis and trans isomers, individual and mixtures thereof are within the scope of this invention.
- alkyl includes all the possible isomeric forms of said alkyl group albeit only a few examples are set forth.
- cyclic groups such as aryl, heteroaryl, heterocycloalkyl are substituted, they include all the positional isomers albeit only a few examples are set forth.
- all polymorphic forms and hydrates of a compound of Formula (I) are within the scope of this invention.
- Optionally substituted phenyl means a phenyl ring optionally substituted with one, two, or three substituents independently selected from alkyl, halo, alkoxy, alkylthio, haloalkyl, haloalkoxy, heteroaryl (that is optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxy, alkoxy, carboxy, amino, alkylamino, or dialkylamino), heterocycloalkyl (that is optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxy, alkoxy, carboxy, amino, alkylamino, or dialkylamino), amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, methylenedioxy, aminocarbonyl, acylamino, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, or carboxy or optionally substituted with five fluorine atoms.
- Optionally substituted phenyloxy or phenoxy means a —OR radical where R is optionally substituted phenyl as defined above e.g., phenoxy, chlorophenoxy, and the like.
- Optionally substituted phenylcarbonylamino means a —NHCOR radical where R is optionally substituted phenyl as defined above e.g., benzoylamino, and the like.
- Optionally substituted phenylalkyl means a -(alkylene)-R radical where R is optionally substituted phenyl as defined above e.g., benzyl, phenylethyl, and the like.
- Optionally substituted phenylalkyloxy means a —R radical where R is optionally substituted phenylalkyl as defined above e.g., benzyloxy, phenylethyloxy, and the like.
- Optionally substituted phenylalkylthio means a —S-(alkylene)-R radical where R is optionally substituted phenyl as defined above e.g., benzylthio, phenylethylthio, and the like.
- Optionally substituted phenylalkylsulfonyl means a —SO 2 -(alkylene)-R radical where R is optionally substituted phenyl as defined above e.g., benzylsulfonyl, phenylethylsulfonyl, and the like.
- Optionally substituted phenylalkenyl means a -(alkenylene)-R radical where R is optionally substituted as defined above e.g., phenylethenyl, phenylpropenyl, and the like.
- Optionally substituted phenoxyalkyl means a -(alkylene)-OR radical where R is optionally substituted phenyl as defined above e.g., phenoxymethyl, phenoxyethyl, and the like.
- Optionally substituted heteroaryl means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms where one or more, preferably one, two, or three, ring atoms are heteroatoms selected from N, O, or S, the remaining ring atoms being carbon that is optionally substituted with one, two, or three substituents independently selected from alkyl, halo, alkoxy, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, aminocarbonyl, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, optionally substituted phenyl, optionally substituted phenoxy, carboxy, or heteroaryl that is optionally substituted with alkyl, halo, hydroxy, alkoxy, carboxy, amino, alkylamino, or dialkylamino, heterocycloalkyl optionally substituted with one or two substituents independently selected from alkyl,
- the tern optionally substituted heteroaryl includes, but is not limited to, pyridyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzopyranyl, and thiazolyl, and the derivatives thereof (formed when the heteroaryl ring is substituted with a substituent listed above); or an N-oxide or a protected derivative thereof.
- Optionally substituted heteroaryloxy means a —OR radical where R is optionally substituted heteroaryl as defined above e.g., furanyloxy, pyridinyloxy, and the like.
- Optionally substituted heteroaralkyloxy means a —OR radical where R is optionally substituted heteroaralkyl ring as defined below.
- Optionally substituted heteroaryloxyalkyl means a dalkylene)-OR radical where R is optionally substituted heteroaryl ring as defined above.
- Optionally substituted heteroaralkyl means a -alkylene)-R radical where R is optionally substituted heteroaryl ring as defined above.
- Optionally substituted heterocycloalkyl means a saturated or unsaturated monovalent cyclic group of 3 to 8 ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or S(O) n , where n is an integer from 0 to 2, the remaining ring atoms being C.
- One or two ring carbon atoms can optionally be replaced by a —CO— group.
- heterocycloalkyl includes, but is not limited to, pyrrolidino, piperidino, morpholino, piperazino, tetrahydropyranyl, and thiomorpholino and the derivatives thereof (formed when the heterocycloalkyl ring is substituted with a substituent listed below); or an N-oxide or a protected derivative thereof.
- the heterocycloalkyl is optionally fused to aryl and is optionally substituted with one, two, or three substituents independently selected from alkyl, cycloalkyl, halo, alkoxy, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, optionally substituted phenylalkyl, optionally substituted heteroaralkyl aminocarbonyl, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, or carboxy.
- Optionally substituted heterocycloalkyloxy means a —OR radical where R is optionally substituted heterocycloalkyl ring as defined above.
- Optionally substituted heterocycloalkylalkyl means a -(alkylene)-R radical where R is optionally substituted heterocycloalkyl ring as defined above.
- Optionally substituted heterocycloalkylalkyloxy means a —OR radical where R is optionally substituted heterocycloalkylalkyl ring as defined above.
- Optionally substituted heterocycloalkyloxyalkyl means a -(alkylene)-OR radical where R is optionally substituted heterocycloalkyl as defined above e.g., piperidinyloxymethyl, pyrrolidinyloxyethyl, and the like.
- heterocycloalkyl group optionally mono- or di-substituted with an alkyl group means that the alkyl may but need not be present, and the description includes situations where the heterocycloalkyl group is mono- or disubstituted with an alkyl group and situations where the heterocycloalkyl group is not substituted with the alkyl group.
- a “pharmaceutically acceptable carrier or excipient” means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for veterinary use as well as human pharmaceutical use. “A pharmaceutically acceptable carrier/excipient” as used in the specification and claims includes both one and more than one such excipient.
- Treating” or “treatment” of a disease includes:
- treating cancer refers to administration to a mammal afflicted with a cancerous condition and refers to an effect that alleviates the cancerous condition by killing the cancerous cells, but also to an effect that results in the inhibition of growth and/or metastasis of the cancer.
- a “therapeutically effective amount” means the amount of a compound of Formula (I) that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease.
- the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
- a preferred group of compounds of Formula (I) is that wherein:
- R 1 is hydrogen or alkyl
- X is —O—, —NR 2 —, or —S(O) n where n is 0-2 and R 2 is hydrogen or alkyl;
- Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, or hydroxy;
- Ar 1 is phenylene or heteroarylene wherein said Ar 1 is optionally substituted with one or two groups independently selected from alkyl, halo, hydroxy, alkoxy, haloalkoxy, or haloalkyl;
- R 3 is hydrogen, alkyl, hydroxyalkyl, or optionally substituted phenyl
- Ar 2 is aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl;
- aryl means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical of 6 to 12 ring atoms e.g., phenyl, naphthyl or anthracenyl optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, hydroxyalkoxyalkyl, alkoxyalkyloxyalkyl, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryloxy, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, haloalkoxyalkyl, optional
- the aryl ring is optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkyloxy, optionally substituted heterocycloalkyl
- the substituents are independently methoxy, methyl, ethyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-(morpholin-4-yl)ethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-(N,N-dimethylamino)ethoxy, methoxymethyl, phenoxymethyl, 2-morpholino-4-ylethyl, morpholino-4-ylmethyl, N,N-dimethylaminomethyl, i-propoxymethyl, or phenoxymethyl;
- heterocycloalkyl means a saturated monovalent cyclic group of 3 to 8 ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or S(O) n , where n is an integer from 0 to 2, the remaining ring atoms being C. More specifically the term heterocycloalkyl includes, but is not limited to, pyrrolidino, piperidino, morpholino, piperazino, tetrahydropyranyl, and thiomorpholino, and the derivatives thereof (formed when the heterocycloalkyl ring is substituted with a substituent listed below); or an N-oxide or a protected derivative thereof.
- the heterocycloalkyl is optionally fused to aryl and is optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkyloxy, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, optionally substituted phenyloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkyloxy, or optionally substituted heterocycloalkyloxy.
- the substituents are independently methoxy, methyl, ethyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-(morpholin-4-yl)ethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-(N,-dimethylamino)ethoxy, methoxymethyl, phenoxymethyl, 2-morpholino-4-ylethyl, morpholino4-ylmethyl, N,N-dimethylaminomethyl, i-propoxymethyl, or phenoxymethyl;
- heteroaryl means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms containing one or more, preferably one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being carbon.
- heteroaryl includes, but is not limited to, pyridyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, benzoxazolyl, benzothiophenyl, benzthiazolyl, quinolinyl, isoquinolinyl, benzopyranyl, and thiazolyl, and the derivatives thereof (formed when the heteroaryl ring is substituted with a substituent listed below), or an N-oxide or a protected derivative thereof.
- the heteroaryl ring is optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, hydroxyalkoxyalkyl, alkoxyalkyloxyalkyl, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, haloalkoxyalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkyloxyalkyl, optionally substituted heterocycl
- the substituents are independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkyloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkyloxy, or optionally substituted heterocycloal
- the substituents are independently methoxy, methyl, ethyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-(morpholin4-yl)ethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-(N,N-dimethylamino)ethoxy, methoxymethyl, phenoxymethyl, 2-morpholino-4-ylethyl, morpholino-4-ylmethyl, N,N-dimethylaminomethyl, i-propoxymethyl, or phenoxymethyl;
- “optionally substituted phenyl” means a phenyl ring optionally substituted with one, two, or three substituents independently selected from alkyl, halo, alkoxy, alkylthio, haloalkyl, haloalkoxy, heteroaryl (that is optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxy, alkoxy, carboxy, amino, alkylamino, or dialkylamino), heterocycloalkyl (that is optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxy, alkoxy, carboxy, amino, alkylamino, or dialkylamino), amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, methylenedioxy, aminocarbonyl, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, or carboxy or optionally substituted with five fluorine atoms.
- the substituents are independently selected from alkyl, halo, alkoxy, alkylthio, trifluoromethyl, trifluoromethoxy, amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, methylenedioxy, aminocarbonyl, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, or carboxy or optionally substituted with five fluorine atoms;
- “optionally substituted heteroaryl” means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms containing one or more, preferably one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being carbon which is optionally substituted with one, two, or three substituents independently selected from alkyl, halo, alkoxy, trifluoromethyl, trifluoromethoxy, amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, aminocarbonyl, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, optionally substituted phenyl, optionally substituted phenoxy, carboxy, or heteroaryl that is optionally substituted with alkyl, halo, hydroxy, alkoxy, carboxy, amino, alkylamino, or dialkylamino.
- optionally substituted heteroaryl includes, but is not limited to, pyridyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzopyranyl, and thiazolyl, and the derivatives thereof (formed when the heteroaryl ring is substituted with a substituent listed below), or an N-oxide or a protected derivative thereof;
- “optionally substituted heterocycloalkyl” a saturated monovalent cyclic group of 3 to 8 ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or S(O) n , where n is an integer from 0 to 2, the remaining ring atoms being C.
- the heterocycloalkyl is optionally fused to aryl and is optionally substituted with one, two, or three substituents independently selected from alkyl, halo, alkoxy, trifluoromethyl, trifluoromethoxy, amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, optionally substituted phenylalkyl, optionally substituted heteroaralkyl, aminocarbonyl, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, or carboxy.
- heterocycloalkyl includes, but is not limited to, pyrrolidino, piperidino, morpholino, piperazino, tetrahydropyranyl, and thiomorpholino, and the derivatives thereof (formed when the heterocycloalkyl ring is substituted with a substituent listed below); or an N-oxide or a protected derivative thereof; and
- aminoalkyl means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one, preferably one or two, —NRR′ where R and R′ are independently selected from hydrogen, alkyl, or —COR a where R a is alkyl, or an N-oxide derivative, or a protected derivative e.g., aminomethyl, methylaminoethyl, 2-ethylamino-2-methylethyl, 1,3-diaminopropyl, dimethylaminomethyl, diethylaminoethyl, acetylaminopropyl, and the like; and
- a preferred group of compounds is that wherein R 1 and R 3 are hydrogen, X is —O— and Y is ethylene or n-propylene, preferably ethylene.
- R 1 and R 3 are hydrogen, X is —O— and Y is —CH(C 2 H 5 )CH 2 —, —CH(i-C 3 H 7 )CH 2 —, or CH(CH 3 )CH 2 — and the stereochemistry at the chiral carbon is (S). More preferably, Y is —CH(C 2 H 5 )CH 2 —.
- a more preferred group of compounds is that wherein Ar 1 is phenylene in which the hydroxamate and the X group are para to each other and Ar 2 is aryl.
- Ar 2 is phenyl and is optionally substituted with one or two substituents independently selected from methoxy, ethoxy, phenyl, methyl, tert-butyl, pyrrol-1-yl, cyclohexene-3-oxy, pyridin-3-yl, pyridin-2-yl, benzoylamino, fluoro, chloro, or thiophen-2-ylmethoxy.
- Ar 2 is phenyl, 4-biphenyl, 3-biphenyl, 4-tert-butylphenyl, 4-pyrrol-1-ylphenyl, 4-(cyclohexene-3-oxy)phenyl, 4-(pyridin-2-yl)phenyl, 4-(pyridin-3-yl)-phenyl, 2,4-difluorophenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3,4-difluorophenyl, 2,5-dimethylphenyl, 2,3-dichlorophenyl, 2,3-dimethylphenyl, 4-chloro-2-methoxyphenyl, 3-ethoxyphenyl, 4-methoxy-2-methylphenyl, 3-fluoro4-methoxyphenyl, 2-thiophen-2-ylmethoxyphenyl, 3-thiophen-2-ylmethoxyphenyl, 2-biphenyl, or 2-pyrrol-1-y
- Ar 1 is phenylene in which the hydroxamate and the X group are para to each other and Ar 2 is trans aryl-CH ⁇ CH—.
- Ar 2 is trans phenyl-CH ⁇ CH— and is optionally substituted with alkoxy, preferably methoxy.
- Ar 2 is trans phenyl-CH ⁇ CH—.
- Ar 1 is phenylene in which the hydroxamate and the X group are para to each other and Ar 2 is heteroaryl-CH ⁇ CH—.
- Ar 2 is pyridinyl-CH ⁇ CH—.
- Ar 2 is trans 5-bromothiophen-2-yl-CH ⁇ CH— or trans indol-3-yl-CH ⁇ CH—.
- Ar 1 is phenylene in which the hydroxamate and the X group are para to each other and Ar 2 is heteroaryl.
- Ar 2 is pyridin-3-yl, thiophen-2-yl, quinolin-6-yl, thiazol-2-yl, benzthiazol-2-yl, benzoxazol-2-yl, furanyl, pyrrol-2-yl, indol-5-yl, indol-3-yl, indazol-3-yl, quinolin-3-yl, quinolin-1-yl, quinolin-8-yl, benzotriazol4-yl, benzofuran-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, quinoxalin-2-yl, quinolin-2-yl, or benzimidazol-5-yl wherein said rings are optionally substitute
- Ar 1 is phenylene in which the hydroxamate and the X group are para to each other and Ar 2 is indol-2-yl, benzofuran-2-yl or benzothiophen-2-yl which are optionally substituted with alkyl, alkoxy, halo, haloalkyl, alkoxyalkyloxy, optionally substituted heterocycloalkylalkyloxy, optionally substituted heteroaralkyloxy, hydroxyalkoxy, aminoalkyl, aminoalkyloxy, alkoxyalkyloxy, alkoxyalkyl, optionally substituted phenyloxyalkyl, or optionally substituted heterocycloalkylalkyl.
- Ar 2 is benzofuran-2-yl or benzothiophen-2-yl wherein benzofuran-2-yl or benzothiophen-2-yl is optionally substituted with methoxy, methyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-morpholin-4-ylethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-N,N-dimethylaminoethoxy, ethyl, methoxymethyl, 2-propyloxymethyl, phenoxymethyl, morpholin4-ylmethyl, or N,N-dimethylaminomethyl which is located at the 3-position or 5-position, preferably 3-position of the benzothiophen-2-yl or benzofuran-2-yl ring. Even more preferably, Ar 2 is benzofuran-2-yl, 3-N,N-dimethylaminomethylbenzofuran-2-yl, or 3-phenoxymethylbenzofuran-2-yl
- Ar 1 is phenylene in which the hydroxamate and the X group are para to each other and Ar 2 is indol-2-yl, benzofuran-2-yl or benzothiophen-2-yl and is substituted with phenyloxyalkyl, substituted heteroaryloxyalkyl, substituted heterocycloalkyloxyalkyl, or haloalkoxyalkyl which are located at the 3-position of the benzothiophen-2-yl and benzofuran-2-yl rings.
- Ar 2 is 3-(2,2,2-trifluoroethyloxymethyl)benzofuran-2-yl.
- Ar 1 is heteroarylene and Ar 2 is aryl.
- Ar 1 is five membered heteroarylene ring containing one, two, or three heteroatoms independently selected from N, 0 or S, more preferably Ar 1 is isoxazolyl where the hydroxamate and the X groups are located at the 5- and 3-position of the isoxazolyl ring, the oxygen atom in the ring being position 1 and Ar 2 is aryl.
- Ar 1 is phenyl that is optionally substituted with one or two substituents independently selected from methoxy, ethoxy, phenyl optionally substituted with ethoxy or methyl, methyl, tert-butyl, pyrrol-1-yl, cyclohexene-3-oxy, pyridin-3-yl, pyridin-2-yl, benzoylamino, fluoro, chloro, or thiophen-2-ylmethoxy.
- Ar 2 is phenyl, 4-biphenyl, 3-biphenyl, 2-(2-ethoxyphenyl)phenyl, 3-methylbiphen-4-yl, 4-tert-butylphenyl, 4-pyrrol-1-ylphenyl, 4-(cyclohexene-3-oxy)phenyl, 4-(pyridin-2-yl)phenyl, 4-(pyridin-3-yl)-phenyl, 2,4-difluorophenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3,4-difluorophenyl, 2,5-dimethylphenyl, 2,3-dichlorophenyl, 2,3-dimethylphenyl, 4-chloro-2-methoxyphenyl, 3-ethoxyphenyl, 4-methoxy-2-methylphenyl, 3-fluoro-4-methoxyphenyl, 2-thiophen-2-ylmethoxyphenyl, 3-thiophen-2
- Ar 1 is heteroarylene and Ar 2 is aryl-CH ⁇ CH—.
- Ar 1 is five membered heteroarylene ring containing one, two, or three heteroatoms independently selected from N, O or S, more preferably Ar 1 is isoxazolyl where the hydroxamate and the X groups are located at the 5- and 3-position of the isoxazolyl ring, the oxygen atom in the ring being position I and Ar 2 is phenyl-CH ⁇ CH— and is optionally substituted with alkoxy.
- Ar 1 is heteroarylene and Ar 2 is heteroaryl-CH ⁇ CH—.
- Ar 1 is five membered heteroarylene ring containing one, two, or three heteroatoms independently selected from N, O or S, more preferably Ar 1 is isoxazolyl where the hydroxamate and the X groups are located at the 5- and 3-position of the isoxazolyl ring, the oxygen atom in the ring being position I and Ar 2 is pyridinyl-CH ⁇ CH—.
- Ar 1 is heteroarylene and Ar 2 is heteroaryl.
- Ar 1 is five membered heteroarylene ring containing one, two, or three heteroatoms independently selected from N, O or S, more preferably Ar 1 is isoxazolyl where the hydroxamate and the X groups are located at the 5- and 3-position of the isoxazolyl ring, the oxygen atom in the ring being position 1 and Ar 2 is pyridin-3-yl, thiophen-2-yl, quinolin-6-yl, thiazol-2-yl, benzthiazol-2-yl, benzoxazol-2-yl, furanyl, pyrrol-2-yl, indol-5-yl, indol-3-yl, indazol-3-yl, quinolin-3-yl, quinolin-8-yl, benzotriazol-4-yl, isoquinolin-1
- Ar 1 is heteroarylene and Ar 2 is indol-2-yl, benzofuran-2-yl or benzothiophen-2-yl which are optionally substituted with alkyl, alkoxy, halo, haloalkyl, alkoxyalkyloxy, optionally substituted heterocycloalkylalkyloxy, optionally substituted heteroaralkyloxy, hydroxyalkoxy, aminoalkyloxy, alkoxyalkyloxy, alkoxyalkyl, optionally substituted phenyloxyalkyl, or optionally substituted heterocycloalkylalkyl.
- Ar 1 is a five membered heteroarylene ring containing one, two, or three heteroatoms independently selected from N, O or S, more preferably Ar 1 is isoxazolyl where the hydroxamate and the X groups are located at the 5- and 3-position of the isoxazolyl ring, the oxygen atom in the ring being position 1 and Ar 2 is benzofuran-2-yl and benzothiophen-2-yl which are optionally substituted with methoxy, methyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-morpholin-4-ylethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-N,N-dimethylaminoethoxy, ethyl, methoxymethyl, phenoxymethyl, morpholin-4-ylmethyl, or dimethylaminomethyl and are located at the 3-position of the benzothiophen-2-yl and benzofuran-2-yl rings. Even more preferably
- Another preferred group of compounds of Formula (I) is that wherein X is —O—, R 1 is hydrogen, Ar 1 is phenylene and Ar 2 is heteroaryl; where the scope of the terms contained within preferred Group II are as defined in the definition section of the Application.
- the compound is represented by Formula (Ia):
- Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy;
- Ar 2 is heteroaryl
- Ar 2 is heteroaryl optionally substituted with one or two substituent(s) independently selected from alkyl, halo, haloalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, hydroxyalkoxyalkyl, alkoxyalkyloxy, alkoxyalkyloxyalkyl, aminoalkyl, aminoalkoxy, haloalkoxy, haloalkoxyalkyl, optionally substituted phenyl, optionally substituted phenoxy, optionally substituted phenylalkyloxy, optionally substituted phenylalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkyloxy, optionally substituted heterocycloalkylalkyloxy, optionally substituted heterocycloalkylalkyloxy, -al
- Ar 2 is thiophen-2-yl, pyridin-3-yl, quinolin-6-yl, benzothiazol-2-yl, benzoxazol-2-yl, benzofuran-2-yl, benzofuran-5-yl, benzothien-2-yl, furan-2-yl, 1H-benzimidazol-2-yl, 1H-pyrrol-2-yl, thiazol-2-yl, 1H-indol-2-yl, 1H-indol-5-yl, 1H-indol-3-yl, quinolin-3-yl, quinolin-8-yl, 1H-indazol-3-yl, 1H-benzotriazol-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, quinoxalin-2-yl, quinolin-2-yl, 1H-benzimidazol-5-yl, quinolin-1-yl,
- Ar 2 is benzofuran-2-yl and is mono-substituted at the 3-, 4- or 5-position or disubstituted at the 4 and 7 positions, preferably the benzofuran-2-yl is monosubstituted at the 3 or 5 position with a substituent described in the paragraph immediately above.
- the substituents are independently selected from chloro, fluoro, trifluoromethyl, methyl, ethyl, methoxy, 1-cyclopropylpiperidin-4-yloxy, 1-(2,2,2-trifluoroethyl)piperidin-4-yloxy, N,N-dimethylaminomethyl, N,N-diethylaminomethyl, 2-methoxyethoxymethyl, phenoxymethyl, 2-methoxyethoxy, 2-morpholin-4-ylethoxy, pyridin-3-yl-methoxy, 2-hydroxyethoxy, 2-N,N-dimethylaminoethoxy, methoxymethyl, 3-i-propoxymethyl, morpholin-4-ylmethyl, 3-hydroxypropyloxymethyl, 2-fluorophenoxymethyl, 3-fluorophenoxymethyl, 4-fluorophenoxy-methyl, 3-methoxypropyloxymethyl, pyridin4-yloxymethyl, 2,4,6-trifluorophenoxymethyl, 2-o
- Ar 2 is benzofuran-2-yl that is substituted at the 3-position with N,N-dimethylaminomethyl, N,N-diethylaminomethyl, 2-fluorophenoxymethyl, 3-fluorophenoxymethyl, 4-fluorophenoxymethyl, pyridin4-yloxymethyl, 2,4,6-trifluorophenoxy-methyl, 2-oxopyridin-1-ylmethyl, 2,2,2-trifluoroethoxy-methyl, 4-imidazol-1-ylphenoxy-methyl, 4-[1.2.4]-triazin-1-yl-phenoxymethyl, 2-phenylethyl, 3-hydroxypropyloxymethyl, 2-methoxyethyloxymethyl, pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl, 4-trifluoromethyl-piperidin-1-ylmethyl, 4-methylpiperazin-1-ylmethyl, 3,3,3-trifluoropropyloxymethyl, 4-fluorophenylthiomethyl, 4-
- Ar 2 is benzofuran-2-yl that is substituted at the 5-position with 1-cyclopropylpiperidin4-yloxy, piperidin-4-yloxy, tetrahydropyran4-yloxy, 2,2,2-trifluoroethoxy, 2-pyrrolidin-1-ylethyloxy, or 1-(2,2,2-trifluoroethyl)piperidin4-yloxy.
- Ar 2 is 7-chloro-4-methylbenzofuran-2-yl, 4-methylbenzofuran-2-yl, 7-fluoro-4-methylbenzofuran-2-yl, or 7-fluoro-4-phenoxymethylbenzofuran-2-yl.
- Ar 2 is thiophen-2-yl, pyridin-3-yl, 5-phenylthiophen-2-yl, quinolin-6-yl, 4-phenylthiazol-2-yl, benzothiazol-2-yl, benzoxazol-2-yl, furan-2-yl, 1H-benzimidazol-2-yl, 1H-pyrrol-2-yl, 4-(pyridin-4-yl)-thiazol-2-yl, 1H-indol-5-yl, 1H-indol-3-yl, quinolin-3-yl, quinolin-8-yl, 1H-indazol-3-yl, 1H-benzotriazol-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, quinoxalin-2-yl, quinolin-2-yl, 1H-benzimidazol-5-yl, 1-methyl-indol-3-yl, 4-phenylthi
- a more preferred group of compounds is that wherein Y is straight alkylene, preferably ethylene or n-propylene, preferably ethylene.
- (E) Another more preferred group of compounds is that wherein Y is branched alkylene, preferably CH(C 2 H 5 )CH 2 —, —CH(i-C 3 H 7 )CH 2 —, or —CH(CH 3 )CH 2 — and the stereochemistry at the chiral carbon is (S). More preferably, Y is —H(C 2 H 5 )CH 2 —.
- Another preferred group of compounds of Formula (I) is that wherein X is —O—, R 1 is hydrogen, Ar 1 is phenylene and Ar 2 is aralkenyl; where the scope of the terms contained within preferred Group III are as defined in the definition section of the Application.
- the compound is represented by Formula (Ib):
- Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy;
- Ar 2 is aryl(C 2-3 )alkenyl.
- Ar 2 represented by the formulae:
- phenyl is optionally substituted with one or two substituents independently selected from alkyl, alkoxy, methylenedioxy, dialkylamino, or hydroxy.
- Ar 2 is trans phenyl-CH ⁇ CH—, trans 4-MeO-phenyl-CH ⁇ CH—, trans 3,4-methylenedioxyphenyl-CH ⁇ CH—, trans 3-hydroxyphenyl-CH ⁇ CH—, trans 4-hydroxyphenyl-CH ⁇ CH—, trans 2-methoxyphenyl-CH ⁇ CH—, trans 3-methoxyphenyl-CH ⁇ CH—, trans 3-tolyl-CH ⁇ CH—, trans 4-tolyl-CH ⁇ CH—, trans 4-dimethylaminophenyl-CH ⁇ CH—, trans 2-tolyl-CH ⁇ CH—, or trans 2-hydroxyphenyl-CH ⁇ CH—.
- Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy;
- Ar 2 is heteroaryl(C 2-3 )alkenyl; where the scope of the terms contained within preferred Group IV are as defined in the definition section of the Application.
- Ar is trans heteroaryl-CH ⁇ CH— or trans heteroaryl-C(CH 3 ) ⁇ CH—, preferably heteroaryl ring is pyridinyl, benzofuranyl, thienyl (thiophene), furanyl, or indolyl optionally substituted with one or two substituents selected from hydroxyl, alkoxy, halo, or optionally substituted heterocycloalkoxy.
- Another preferred group of compounds of Formula (I) is that wherein X is —O—, R 1 is hydrogen, Ar 1 is phenylene and Ar 2 is aryl; where the scope of the terms contained within preferred Group V are as defined in the definition section of the Application.
- the compound is represented by Formula (Id):
- Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy;
- Ar 2 is aryl
- the substituents on the aryl ring are independently selected from optionally substituted phenyl, alkyl, alkoxy, halo, optionally substituted heteroaryl, optionally substituted cycloalkenyloxy, optionally substituted heteroaralkyloxy, optionally substituted hetercycloalkyl, optionally substituted phenylcarbonylamino, or methylenedioxy.
- Ar 2 is phenyl, 4-biphenyl, 3-biphenyl, 4-tert-butylphenyl, 4-pyrrol-1-ylphenyl, 4-(pyridin-3-yl)phenyl, 4-(pyridin-2-yl)phenyl, 4-benzoylamino)phenyl, 2,4-difluorophenyl, 3,4-methylenedioxyphenyl, 3,4-dimethoxyphenyl, 3 ,5-dimethoxyphenyl, 3,4-difluorophenyl, 2,5-dimethylphenyl, 2,3-dichlorophenyl, 2,3-dimethylphenyl, 4-chloro-2-methoxyphenyl, 3-ethoxyphenyl, 4-methoxy-2-methylphenyl, 3-fluoro-4-methoxyphenyl, 2-(thiophen-2-ylmethoxy)phenyl, 3-(thiophen-2-ylmethoxy)-phenyl,
- the starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Bachem (Torrance, Calif.), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 140 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
- the reactions described herein take place at atmospheric pressure over a temperature range from about ⁇ 78° C. to about 150° C., more preferably from about 0° C. to about 125° C. and most preferably at about room (or ambient) temperature, e.g., about 20° C.
- the reaction is carried out in the presence of triphenylphosphine and diisopropyl azodicarboxylate in a suitable organic solvent such as tetrahydrofuran, and the like.
- Compounds of formula I such as methyl 4-hydroxybenzoate, methyl 4-mercaptobenzoate, and methyl 3-hydroxyisoxazole-5-carboxylate are commercially available.
- Compounds of formula 2 can be prepared from commercially available aminoalcohols by reacting the amine with a suitable amino protecting group such as benzyloxycarbonyl, tert-butoxycarbonyl and the like under reaction conditions well known in the art. A detailed description of suitable amino protecting groups and reaction conditions for their preparation can be found in T. W. Greene, Protecting Groups in Organic Synthesis, John Wiley & Sons, Inc. 1981 the teaching of which is incorporated herein by reference in its entirety.
- Aminoalcohols such as 2-ethanolamine, 2-amino-1-propanol, 2-methylaminoethanol, 2-amino-2-methyl-1-propanol, 2-amino-1-propanol, 4-amino-2-butanol, and 1-amino-2-butanol are commercially available.
- compounds of formula 2 can be prepared from commercially available aminoacids by protecting the amino group with a suitable protecting group followed by reduction of the acid group to the hydroxy group with a suitable reducing agent under conditions well known in the art.
- Removal of the amino protecting group in 3 provides a compound of formula 4.
- the reaction conditions employed for removal of the amino protecting group depend on the nature of the protecting group. For example, if the protecting group is tert-butoxycarbonyl, it is removed under acid reaction conditions. Suitable acids are trifluoroacetic acid, hydrochloric acid, and the like in a suitable organic solvent such as methanol, dioxane, tetrahydrofuran, and the like. If the protecting group is benzyl or benzyloxycarbonyl, it is removed under catalytic hydrogenation reaction conditions. Suitable catalyst are palladium based catalysts and others known in the art. Other suitable reaction conditions for their removal can be found in T. W. Greene, Protecting Groups in Organic Synthesis, John Wiley & Sons, Inc. 1981. The reaction is carried out in an inert organic solvent methylene chloride, tetrahydrofuran, dioxane, and the like.
- Reaction of 4 with an acid or acid derivative (e.g., acid halide) of formula Ar 2 -COZ where Z is hydroxy or halo provides a compound of formula 5.
- the reaction conditions employed depend on the nature of the Z group. If Z is hydroxy, the reaction is typically carried out in the presence of a suitable coupling agent e.g., benzdtriazole-1-yloxy-trispyrrolidino-phosphonium hexafluorophosphate (PyBOP®), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyl-uronium hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.
- a suitable coupling agent
- HCl 1,3-dicyclohexylcarbodiimide
- DCC 1,3-dicyclohexylcarbodiimide
- HOBT. H 2 O 1-hydroxybenzotriazole hydrate
- base such as N,N-diisopropylethylamine, triethylamine, N-methylmorpholine, and the like.
- the reaction is typically carried out at 20 to 30° C., preferably at about 25° C., and requires 2 to 24 hours to complete.
- Suitable reaction solvents are inert organic solvents such as halogenated organic solvents (e.g., methylene chloride, chloroform, and the like), acetonitrile, N,N-dimethylformamide, ethereal solvents such as tetrahydrofuran, dioxane, and the like.
- halogenated organic solvents e.g., methylene chloride, chloroform, and the like
- acetonitrile e.g., methylene chloride, chloroform, and the like
- N,N-dimethylformamide ethereal solvents
- the reaction is carried out with HOBt. H 2 O, EDC.HCl in dichloromethane or N,N-dimethylformamide.
- Ar 2 COZ is an acid halide
- the reaction is carried out in the presence of a suitable base (e.g. triethylamine, diisopropylethylamine, pyridine, and the like).
- Suitable reaction solvents are polar organic solvents such as tetrahydrofuran, acetonitrile, N,N-dimethylfornamide (DMF), dichloromethane, or any suitable mixtures thereof.
- the acid halide such as acid chloride can be prepared by reacting the corresponding acids with a halogenating agent such as oxalyl chloride, thionyl chloride, phosphorus oxychloride, and the like.
- Acids of formula Ar 2 COZ are either commercially available or they can be prepared from commercially available starting materials by methods known in the art.
- benzoic acid, cinnamic acid, phenylacetic acid, nicotinic acid, isonicotinic acid, 3-methylbenzofuran-2-carboxylic acid, and benzofuran-2-carboxylic acid are commercially available.
- Others such as 3-phenoxymethylbenzofluran-2-carboxylic acid can be readily prepared from commercially available 3-methylbenzofuran-2-carboxylic acid by first converting it to 2-bromomethylbenzofuran-2-carboxylic acid (brominating it with N-bromosuccinimide under conditions well known in the art) followed by reacting with phenol.
- Compound 5 where R 3 is hydrogen can optionally be converted to a corresponding compound of formula 5 where R 3 is other than hydrogen by reacting it with an alkylating agent under conditions well known in the art.
- Compound 5 is then converted to a compound of Formula (I) by reacting it with aqueous hydroxylamine in the presence of a base such as sodium hydroxide and a mixture of organic solvents such as tetrahydrofuran and methanol.
- a base such as sodium hydroxide and a mixture of organic solvents such as tetrahydrofuran and methanol.
- the acid group in 5 is first activated with a suitable coupling agent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC. HCl), or 1,3-dicyclohexylcarbodiimide (DCC), optionally in the presence of 1-hydroxybenzotriazole hydrate (HOBT.
- EDC. HCl 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
- DCC 1,3-dicyclohexylcarbodiimide
- a compound of Formula (I) where Ar 1 is phenylene, X is —O—, Y is ethylene, Ar 2 is 3-dimethylaminomethylbenzofuran-2-yl, R 1 and R 3 are hydrogen can be prepared by reacting a compound of formula 4 where Ar 1 is phenylene, X is —O—, Y is ethylene, and R is alkyl with 3-methylbenzofuran-2-carboxylic acid as described above to give a compound of formula 5 where Ar 2 is 3-methylbenzofuran-2-yl.
- the compounds of this invention are inhibitors of histone deacetylase enzymes and are therefore useful in the treatment of proliferative diseases such as cancer such as lung, colon, AML, MML, skin, breast, ovarian, prostate, liver, brain and skin, psoriasis, fibroproliferative disorder such as liver fibrosis, smooth muscle proliferative disorder such as atherosclerosis and restenosis, inflammatory diseases such as arthritis, diseases involving angiogenesis such as cancer, diabetic retinopathy, haematopoietic disorder such as anaemia, fungal, parasitic and bacterial infections, viral infection, autoimmune diseases such as arthritis, multiple sclerosis, lupus, allergies, asthma, allergic rhinitis, and organ transplant, and bipolar disorders. Additionally, the compounds of the present invention are useful in the treatment of hepatitis C infection.
- proliferative diseases such as cancer such as lung, colon, AML, MML, skin, breast, ovarian, prostate, liver, brain and skin
- the ability of the compounds of this invention to inhibit histone deacetylase enzymes can be tested in vitro and in vivo assays described in biological assays Example 1 and 2 below.
- the hcv activity of the compounds of this invention was tested in a hcv replicon assay at Georgetown University.
- the compounds can also be tested for hcv activity utilizing the replicon assay described in Komer, V. L. et al., Science 1999 Jul 2:285 (5424):110-3.
- the compounds of this invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities.
- the actual amount of the compound of this invention, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors.
- Therapeutically effective amounts of compounds of Formula (I) may range from approximately 0.1-50 mg per kilogram body weight of the recipient per day; preferably about 0.5-20 mg/kg/day. Thus, for administration to a 70 kg person, the dosage range would most preferably be about 35 mg to 1.4 g per day.
- compounds of this invention will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
- routes e.g., oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
- parenteral e.g., intramuscular, intravenous or subcutaneous
- the preferred manner of administration is oral or parenteral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction.
- Oral compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
- formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance.
- pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size.
- U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules.
- 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
- compositions are comprised of in general, a compound of Formula (I) in combination with at least one pharmaceutically acceptable excipient.
- Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of Formula (1).
- excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
- Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like.
- Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
- Preferred liquid carriers, particularly for injectable solutions include water, saline, aqueous dextrose, and glycols.
- Compressed gases may be used to disperse a compound of this invention in aerosol form.
- Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.
- the amount of the compound in a formulation can vary within the full range employed by those skilled in the art.
- the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound of Formula (I) based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.
- the compound is present at a level of about 1-80 wt %. Representative pharmaceutical formulations containing a compound of Formula (I) are described below.
- the compounds of this invention can be administered in combination with known anti-cancer agents.
- known anti-cancer agents include the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-CoA reductase inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors, DNA methyl tranferase inhibitors, and other angiogenesis inhibitors.
- the compound of the present invention compounds are particularly useful when administered in combination with radiation therapy.
- Preferred angiogenesis inhibitors are selected from the group consisting of a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP (matrix metalloprotease) inhibitor, an integrin blocker, interferon-a, interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine, 6-Q-chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin, troponin-i, and an antibody to VEGF.
- a tyrosine kinase inhibitor an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP (matrix metalloprotease) inhibitor, an integrin block
- Preferred estrogen receptor modulators are tamoxifen and raloxifene.
- Estrogen receptor modulators refers to compounds that interfere or inhibit the binding of estrogen to the receptor, regardless of mechanism.
- Examples of estrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LY11708 1, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl-2,2-dimethylpropanoate, 4,4′-dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone, and SH646.
- Androgen receptor modulators refers to compounds which interfere or inhibit the binding of androgens to the receptor, regardless of mechanism.
- Examples of androgen receptor modulators include finasteride and other 5 ⁇ -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole, and abiraterone acetate.
- Retinoid receptor modulators refers to compounds which interfere or inhibit the binding of retinoids to the receptor, regardless of mechanism. Examples of such retinoid receptor modulators include bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, ⁇ -difluoromethylomithine, ILX23-7553, trans-N-(4′-hydroxyphenyl) retinamide, and N-4-carboxyphenyl retinamide.
- Cytotoxic agents refer to compounds which cause cell death primarily by interfering directly with the cell's functioning or inhibit or interfere with cell myosis, including alkylating agents, tumor necrosis factors, intercalators, microtubulin inhibitors, and topoisomerase inhibitors.
- cytotoxic agents include, but are not limited to, tirapazimine, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosilate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-aminedichloro(2-methyl-pyridine) platinum, benzylguanine, glufosfamide, GPX 100, (trans, trans, trans)-bis-mu-(hexane-1,6-diamine,
- microtubulin inhibitors include paclitaxel, vindesine sulfate, 3′,4′-didehydro-4′-deoxy-8′-norvincaleukoblastine, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzene sulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258, and BMS188797.
- topoisomerase inhibitors are topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3′,4′-O-exo-benzylidene-chartreusin, 9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2-(6H)propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3′,4′:b,7]-indolizino[1,2b]quinoline-10,13(9H,15H)dione, lurtotecan, 7-[2-(N-isopropylamino)-ethyl]-(20S)camptothecin, BNP1350, BNPI1100, BN80915, BN80942, etoposide phosphate
- Antiproliferative agents includes antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231, and INX3001, and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine oefosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2′-deoxy-2′-methylidenecytidine, 2′-fluoromethylene-2′-deoxycytidine, N-[5-(2,3-dihydro-benzofiryl)sulfonyl]-N′-(3,4-dichlorophenyl)ure
- Antiproliferative agents also includes monoclonal antibodies to growth factors, other than those listed under “angiogenesis inhibitors”, such as trastuzumab, and tumor suppressor genes, such as p53, which can be delivered via recombinant virus-mediated gene transfer (see U.S. Pat. No. 6,069,134, for example).
- angiogenesis inhibitors such as trastuzumab
- tumor suppressor genes such as p53
- HMG-CoA reductase inhibitors refers to inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase.
- Compounds which have inhibitory activity for HMG-CoA reductase can be readily identified by using assays well-known in the art. For example, see the assays described or cited in U.S. Pat. No. 4,231,938 at col. 6, and WO 84/02131 at pp. 30-33.
- the terms “HMG-CoA reductase inhibitor” and “inhibitor of HMG-CoA reductase” have the same meaning when used herein. It has been reported that ( Int. J.
- HMG-CoA reductase inhibitors examples include but are not limited to lovastatin (MEVACOR.; see U.S. Pat. Nos. 4,231,938; 4,294,926; 4,319,039), simvastatin (ZOCOR®; see U.S. Pat. Nos. 4,444,784; 4,820,850; 4,916,239), pravastatin (PRAVACHOL’; see U.S. Pat. Nos. 4,346,227; 4,537,859; 4,410,629; 5,030,447 and 5,180,589), fluvastatin (LESCOLO; see U.S. Pat. Nos.
- HMG-CoA reductase inhibitor as used herein includes all pharmaceutically acceptable lactone and open-acid forms (i.e., where the lactone ring is opened to form the free acid) as well as salt and ester forms of compounds which have HMG-CoA reductase inhibitory activity, and [Oolchicin the use of such salts, esters, open-acid and lactone forms is included within the scope of this invention.
- HMG-CoA reductase inhibitors where an open-acid form can exist
- salt and ester forms may preferably be formed from the open-acid, and all such forms are included within the meaning of the term “HMG-CoA reductase inhibitor” as used herein.
- the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin, and most preferably simvastatin.
- the term “pharmaceutically acceptable salts” with respect to the HMG-CoA reductase inhibitor shall mean non-toxic salts of the compounds employed in this invention which are generally prepared by reacting the free acid with a suitable organic or inorganic base, particularly those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc and tetramethylammonium, as well as those salts formed from amines such as ammonia, ethylenediamine, N-methylglucamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylenediamine, cbloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, 1-p-chlorobenzyl-2-pyrrolidine-1′-yl-methylbenzimidazole, diethylamine, piperazine, and tris(hydroxymethyl) aminomethane.
- a suitable organic or inorganic base particularly those formed from cations such as
- salt forms of HMG-CoA reductase inhibitors may include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium hydroxyl, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, hydroxyl, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamaote
- Ester derivatives of the described HMG-CoA reductase inhibitor compounds may act as prodrugs which, when absorbed into the bloodstream of a warm-blooded animal, may cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.
- Prenyl-protein transferase inhibitor refers to a compound which inhibits any one or any combination of the prenyl-protein transferase enzymes, including farnesyl-protein transferase (FPase), geranylgeranyl-protein transferase type I (GGPTase-1), and geranylgeranyl-protein transferase type-II (GGPTase-II, also called Rab GGPTase).
- FPase farnesyl-protein transferase
- GGPTase-1 geranylgeranyl-protein transferase type I
- GGPTase-II also called Rab GGPTase
- prenyl-protein transferase inhibiting compounds examples include (U)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]4-(3-chlorophenyl)-1-methyl-2(1H)quinolinone, ( ⁇ )-6-[amino(4-chlorophenyl)( 1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chloro phenyl)-1-methyl-2(1H)-quinolinone, (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chloro phenyl)-1-methyl-2(1H)-quinolinone, 5(S)-n-butyl-1-(2,3-dimethylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazin
- prenyl-protein transferase inhibitors can be found in the following publications and patents: WO 96/30343, WO 97/18813, WO 97/21701, WO 97/23478, WO 97/38665, WO 98/28980, WO 98/29119, WO 95/32987, U.S. Pat. Nos. 5,420,245, 5,523,430, 5,532,359, 5,510,510, 5,589,485, 5,602,098, European Patent Pub]. 0 618 221, European Patent Publ. 0 675 112, European Patent Pub]. 0 604 181, European Patent Publ.
- HIV protease inhibitors examples include amprenavir, abacavir, CGP-73547, CGP-61755, DMP450, indinavir, nelfinavir, tipranavir, ritonavir, saquinavir, ABT-378, AG 1776, and BMS-232, 632.
- reverse transcriptase inhibitors examples include delaviridine, efavirenz, GS-840, HB Y097, lamivudine, nevirapine, AZT, 3TC, ddC, and ddl. It has been reported ( Nat. Med.; 8(3):225-32, 2002) that HIV protease inhibitors, such as indinavir or saquinavir, have potent anti-angiogenic activities and promote regression of Kaposi sarcoma
- Angiogenesis inhibitors refers to compounds that inhibit the formation of new blood vessels, regardless of mechanism.
- angiogenesis inhibitors include, but are not limited to, tyrosine kinase inhibitors, such as inhibitors of the tyrosine kinase receptors Flt-1 (VEGFRI) and Flk-1/KDR (VEGFR20), inhibitors of epidermal-derived, fibroblast-derived, or platelet derived growth factors, MMP (matrix metal loprotease) inhibitors, integrin blockers, interferon, interleukin-12, pentosan polysulfate, cyclooxygenase inhibitors, including nonsteroidal anti-inflammatories (NSAIDs) like aspirin and ibuprofen as well as selective cyclooxygenase-2 inhibitors like celecoxib, valecoxib, and rofecoxib (PNAS, Vol.
- NSAIDs nonsteroidal anti-inflammatories
- NSAIDs
- NSAID's which are potent COX-2 inhibiting agents.
- an NSAID is potent if it possess an IC 50 for the inhibition of COX-2 of 1 ⁇ M or less as measured by the cell or microsomal assay known in the art.
- NSAID's which are selective COX-2 inhibitors are defined as those which possess a specificity for inhibiting COX-2 over COX-1 of at least 100 fold as measured by the ratio of IC 50 for COX-2 over IC 50 for COX-1 evaluated by the cell or microsomal assay disclosed hereinunder.
- Such compounds include, but are not limited to those disclosed in U.S. Pat. No. 5,474,995, issued Dec. 12, 1995, U.S. Pat. No. 5,861,419, issued Jan. 19, 1999, U.S. Pat. No. 6,001,843, issued Dec. 14, 1999, U.S. Pat. No. 6,020,343, issued Feb.
- angiogenesis inhibitors include, but are not limited to, endostatin, ukrain, ranpimase, IM862, 5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2,5]oct-6-yl(chloroacetyl)carbamate, acetyldinanaline, 5-amino-1-[[3,5-dichloro4-(4-chlorobenzoyl)phenyl]-methyl]-1H-1,2,3-triazo le-4-carboxamide, CM101, squalamine, combretastatin, RP14610, NX31838, sulfated mannopentose phosphate, 7,7-(carbonyl-bis[imino-N-methyl4,2-pyrrolocarbonyi-imino[N-methyl4,2-pyrrole]-carbonylimino]-bis-(1,3-naphthalene
- integrated circuit blockers refers to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the ⁇ v ⁇ 3 integrin, to compounds which selectively antagonize, inhibit or counter-act binding of a physiological ligand to the ⁇ v ⁇ 5 integrin, to compounds which antagonize, inhibit or counteract binding of a physiological ligand to both the ⁇ v ⁇ 3 integrin and the ⁇ v ⁇ 5 integrin, and to compounds which antagonize, inhibit or counteract the activity of the particular integrin(s) expressed on capillary endothelial cells.
- the term also refers to antagonists of the ⁇ v ⁇ 6 ; ⁇ v ⁇ 8 , ⁇ 1 ⁇ 1 , ⁇ 5 ⁇ 1 , ⁇ 6 ⁇ 1 and ⁇ 6 ⁇ 4 integrins.
- the term also refers to antagonists of any combination of ⁇ v ⁇ 3 , ⁇ v ⁇ 5 , ⁇ v ⁇ 6 , ⁇ v ⁇ 8 , ⁇ 1 ⁇ 1 , ⁇ 2 ⁇ 1 , ⁇ 5 ⁇ 1 , ⁇ 6 ⁇ 1 and ⁇ 5 ⁇ 4 integrins.
- tyrosine kinase inhibitors include N-(trifluoromethylphenyl)-5-methylisoxazol4-carboxamide, 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl)indolin-2-one, 17-(allylamino)-17-demethoxygeldanamycin, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxyl]quinazoline, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine, BIBX1382, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-hydroxy-9-methyl-9,12-epoxy -1H-diindolo[1,2,3-fg:3′,2′,1′-k1]pyrrolo[3,4-1,6]
- the instant compounds are also useful, alone or in combination with platelet fibrinogen receptor (GP Iib/IIIa) antagonists, such as tirofiban, to inhibit metastasis of cancerous cells.
- Tumor cells can activate platelets largely via thrombin generation. This activation is associated with the release of VEGF.
- the release of VEGF enhances metastasis by increasing extravasation at points of adhesion to vascular endothelium (Amirkhosravi, Platelets 10, 285-292, 1999). Therefore, the present compounds can serve to inhibit metastasis, alone or in combination with GP Iib/IIIa) antagonists.
- fibrinogen receptor antagonists include abciximab, eptifibatide, sibrafiban, lamifiban, lotrafiban, cromofiban, and CT50352.
- DNA methyltransferase inhibitor refers to compounds which inhibit the methylation of the DNA base cytosine at the C-5 position of that base by the DNA methyltransferase enzyme. Examples of such DNA methyltransferase inhibitor include compounds disclosed in U.S. Pat. Nos. 6,329,412 and 6,268,137. Specific DNA methyltransferase inhibitors include 5-azacytosine and zebularine®.
- Such combination products employ the compounds of this invention within the dosage range described above and the other pharmaceutically active agent(s) within its approved dosage range.
- Compounds of the instant invention may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when a combination formulation is inappropriate.
- administration and variants thereof in reference to a compound of the invention means introducing the compound or a prodrug of the compound into the system of the animal in need of treatment.
- a compound of the invention or prodrug thereof is provided in combination with one or more other active agents (e.g., a cytotoxic agent, etc.)
- administration and its variants are each understood to include concurrent and sequential introduction of the compound or prodrug thereof and other agents.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- the compounds of the instant invention may also be co-administered with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated.
- the compounds of the instant invention may also be co-administered with other well known cancer therapeutic agents that are selected for their particular usefulness against the condition that is being treated. Included in such combinations of therapeutic agents are combinations of the farnesyl-protein transferase inhibitors disclosed in U.S. Pat. No. 6,313,138 and an antineoplastic agent. It is also understood that such a combination of antineoplastic agent and inhibitor of farnesyl-protein transferase may be used in conjunction with other methods of treating cancer and/or tumors, including radiation therapy and surgery.
- antineoplastic agent examples include, in general, microtubule-stabilizing agents (such as paclitaxel (also known as Taxol®, docetaxel (also known as Taxotere®, epothilone A, epothilone B, desoxyepothilone A, desoxyepothilone B or their derivatives); microtubule-disruptor agents; alkylating agents, anti-metabolites; epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes; biological response modifiers and growth inhibitors; hormonal/anti-hormonal therapeutic agents and haematopoietic growth factors.
- microtubule-stabilizing agents such as paclitaxel (also known as Taxol®, docetaxel (also known as Taxotere®, epothilone A, epothilone B, desoxyepothilone A, desoxyepothil
- Example classes of antineoplastic agents include, for example, the anthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, the taxanes, the epothilones, discodermolide, the pteridine family of drugs, diynenes and the podophyllotoxins.
- Particularly useful members of those classes include, for example, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloro-methotrexate, mitomycin C, porfiromycin, Herceptin®, Rituxan®, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin or podo-phyllotoxin derivatives such as colchicines, etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosidine, vindesine, leurosine, paclitaxel and the like.
- antineoplastic agents include estramustine, cisplatin, carboplatin, cyclophosphamide, bleomycin, tamoxifen, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT-11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons and interleukins.
- the preferred class of antineoplastic agents is the taxanes and the preferred antineoplastic agent is paclitaxel.
- Radiation therapy including x-rays or gamma rays that are delivered from either an externally applied beam or by implantation of tiny radioactive sources, may also be used in combination with the compounds of this invention alone to treat cancer.
- 3-Bromomethylbenzofuran-2-carboxylic acid methyl ester (269 mg, 1 mmol) was dissolved in anhydrous DMF and added 2M dimethylamine/THF solution (1.5 ml, 3 mmol). After 1-2 h, the reaction was diluted with EtOAc and washed twice with saturated NaHCO 3 (aq.) and brine. The organic extract over was dried over Na 2 SO 4 and then concentrated in vacua. The crude was purified on a silica gel column (5% MeOH in dichloromethane) to give 3-dimethylaminomethylbenzofuran-2-carboxylic acid methyl ester (131 mg).
- the product was extracted into 1.0 M hydrochloric acid and the combined acid extracts were washed with Et 2 O. The extracts were cooled and the pH of the extracts was adjusted to pH 12 with 50% aqueous NaOH. The basic solution was extracted with CH 2 Cl 2 and the organic layer was dried over anhydrous MgSO 4 , and concentrated to give 5-(2-pyrrolidin-1-yl-ethoxy)benzofuran-2-carboxylic acid methyl ester (0.96 g) as an amber colored solid.
- N-hydroxy-4-[2-(3-dimethylaminobenzofuran-2-ylcarbonylamino)ethoxy]-benzamide (22.7 g, 0.057 mol) was suspended in 2-propanol (220 ml). 12 M HCl (5.2 ml, 0.063 mol) was added in one portion and the resulting mixture was heated to reflux. Water (44 ml) was added dropwise until a homogenous solution was obtained. The reaction mixture was allowed to cool and crystallize overnight. After cooling below 5° C. for one h, the crystals were filtered and washed with 2-propanol before being dried in vacuo to to give the title compound (22.0 g) as a white solid.
- Methyl 4-(2-aminoethylsulfanyl)benzoate hydrochloride (0.248 g, 1.00 mmol), was combined with benzofuran-2-carboxylic acid (0.162 g, 1.00 mmol) and HBTU (0.379 g, 1.00 mmol) in DMF (5 ml) at room temperature.
- Triethylamine (0.307 ml, 2.2 mmol) was added and the reaction mixture was stirred at room temperature overnight.
- Saturated aqueous NaHCO 3 (15 ml) was added to give precipitates which was broken up by the addition of water (20 ml). The solid was filtered and the cake was dissolved in ethyl acetate.
- tert-Boc N-Acetyl-Lys)-AMC (445 mg, 1mmol, purchased from Bachem) was dissolved in 4 M HCL in dioxane to provide H-(N-acetyl-Lys)-AMC as a white solid.
- the reaction mixture was stirred for 1 h and monitored by MS/LC for the presence of H-(N-acetyl-Lys)-AMC. Additional amounts of PyBOP (260 mg, 0.5 mmol), HOBt (70 mg, 0.5 mmol), and NMM (0.146 ml, 1 mmol) was added and the stirring was continued for additional 4 h after which the product was isolated in quantitative yield.
- the HDAC inhibitory activity of the compounds of this invention in vitro was determined as follows.
- HDAC-1 200 pM final concentration
- reaction buffer 50 mM HEPES, 100 mM KCl, 0.001% Tween-20, 5% DMSO, pH 7.4
- trypsin and acetyl-Gly-Ala-(N-acetyl-Lys)-AMC were added to final concentrations of 50 nM and 25 ⁇ M, respectively, to initiate the reaction.
- Negative control reactions were performed in the absence of inhibitor in replicates of eight.
- the reactions were monitored in a fluorescence plate reader. After a 30 minute lag time, the fluorescence was measured over a 30 minute time frame using an excitation wavelength of 355 nm and a detection wavelength of 460 nm. The increase in fluorescence with time was used as the measure of the reaction rate. Inhibition constants were obtained using the program BatchKi (Kuzmic et al. Anal. Biochem. 2000, 286, 45-50). Most of the compounds of this invention had a Ki of ⁇ 40 nm.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
- This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Applications Ser. Nos. 60/461,286 and 60/464,448, filed on Apr. 7, 2003, and Apr. 21, 2003, respectively. The disclosures of these applications are incorporated herein by reference in their entirety.
- 1. Field of the Invention
- The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
- 2. State of the Art
- Hepatitis C:
- Chronic hepatitis C is a slowly progressive disease having a significant impact on morbidity and mortality. While many patients who contract hepatitis C will have sub clinical or mild disease, at least 80% of the individuals who contract HCV develop chronic infection and hepatitis. Twenty to fifty percent of these eventually progress to cirrhosis and 1-2% develop liver cancer (Hoofnagle, J. H.; 1997; Hepatology 26: 15S-20S). There are an estimated 170 million HCV carriers world-wide, and HCV-associated end-stage liver disease is now one of the leading cause of liver transplantation. In the United States alone, hepatitis C is responsible for 8,000 to 10,000 deaths annually.
- At the present time, interferon-α2b/ribavirin combination therapy is the only available treatment. Sustained virologic response to IFN-α2b -ribavirin combination therapy occurs in about 40-45% of those treated. For those patients who fail interferon-α2b/ribavirin combination therapy, there is currently no alternative to prevent the progression of liver disease. Thus, a need exists for alternative therapies for the treatment of chronic HCV infection. The present invention fulfills this need.
- Histone Deacetylases:
- Interest in histone deacetylase enzymes (HDACs) as targets for pharmaceutical development has centered on the role of HDACs in regulating genes associated with cell-cycle progression and the development and progression of cancer (reviewed in Kramer et. al. 2001. Trends Endocrinol. Metab. 12:294-300). Several studies have shown that treatment of various cell lines with HDAC inhibitors leads to hyper acetylation of histone proteins and cell-cycle arrest in late G1 phase or at the G2/M transition. Genes involved in the cell cycle that have been shown to be up regulated by HDAC inhibitors include p21, p27, p53 and cyclin E. Cyclin A and cyclin D have been reported to be down regulated by HDAC inhibitors. In tumor cell lines, several studies have shown that treatment with HDAC inhibitors can lead to growth inhibition, growth arrest, terminal differentiation and/or apoptosis. In vivo studies have demonstrated growth inhibition of tumors and a reduction in tumor metastasis as a result of treatment with HDAC inhibitors.
- The clearest link between abnormal HDAC activity and cancer occurs in acute promyelocytic leukemia. In this condition, a chromosomal translocation leads to the fusion of the retinoic acid receptor RARα with the promyelocytic leukemia (PML) or promyelocytic leukemia zinc-finger (PLZF) proteins. Both PML-RARα and PLZF-RARα promote the progression of leukemia by repressing retinoic acid-regulated genes through the abnormal recruitment of SMRT-mSin3-HDAC complex (Lin et. al., 1998, Nature 391:811-814; Grignani et al., 1998, Nature 391:815-818). Whereas the PML-RARα form of the disease is treatable with retinoic acid, the PLZF-RARα form is resistant to this treatment. For a patient with the retinoic acid-resistant form of the disease, the addition of the HDAC inhibitor sodium butyrate to the dosing regimen led to complete clinical and cytogenic remission (Warrell et al., 1998, J. Natl. Cancer. Inst. 90:1621-1625). HDACs have also been associated with Huntington's disease (Steffan, et al., Nature 413:739-744, “Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila”).
- In summary, an increase in HDAC activity contributes to the pathology and/or symptomatology of a number of diseases. Accordingly, molecules that inhibit the activity of HDAC are useful as therapeutic agents in the treatment of such diseases.
-
- R1 is hydrogen or alkyl;
- X is —O—, —NR2—, or —S(O)n where n is 0-2 and R2 is hydrogen or alkyl;
- Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkylsulfinyl, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy;
- Art is phenylene or heteroarylene wherein said Ar1 is optionally substituted with one or two groups independently selected from alkyl, halo, hydroxy, alkoxy, haloalkoxy, or haloalkyl;
- R3 is hydrogen, alkyl, hydroxyalkyl, or optionally substituted phenyl; and
- Ar is aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl; or a pharmaceutically acceptable salt thereof.
- In a second aspect, this invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient.
- In a third aspect, this invention is directed to a method for treating a disease in an animal mediated by HDAC which method comprises administering to the animal a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. Preferably, the disease is a proliferative disorder such as cancer and bipolar disorders and the animal is a human. Preferably, the cancer is prostate cancer, breast cancer, lung melanoma, stomach cancer, neuroblastoma, colon cancer, pancreatic cancer, ovarian cancer, T-cell lymphoma, or leukemia such as myelogenous leukemia (MM) and acute myelogenous leukemia (AML).
- In a fourth aspect, this invention is directed to a method for treating cancer in an animal which method comprises administering to the animal a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient in combination with radiation therapy and optionally in combination with one or more compound(s) independently selected from an estrogen receptor modulator, an androgen receptor modulator, a retinoid receptor modulator, a cytotoxic agent, another antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor, an angiogenesis inhibitor, or a DNA methyl transferase inhibitor.
- Applicants have also discovered that the compounds of the present invention are useful in the treatment of hepatitis C. Accordingly, in a fifth aspect, this invention is directed to a method of treating hepatitis C in an animal comprising administering the animal a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient optionally in combination with one or more other hepatitis C agent. Preferably, the hepatitis C agents are interferon-α2b, ribavirin, and hcv polymerase inhibitors.
-
- where R50 is hydrogen or alkyl and Ar1, Ar2, R3, X and Y are as defined for compounds of Formula (1) above; or a salt thereof. Preferably, Ar1, Ar2, R3, X and Y are as defined in Preferred embodiments below.
-
-
- where M+ is an alkali metal with an acid; followed by treatment with NH2OR″ where R″ is hydrogen, alkyl, or an oxygen protecting group;
to give a compound of Formula (V):
(iii) optionally removing R″ group in compound (V) to give a compound of Formula (I) where R1 is hydrogen;
(iv) optionally forming an acid addition salt of the product formed in Step (i), (ii), or (iii) above;
(v) optionally forming free base of the product formed in Step (i), (ii), (iii), or (iv) above; or
(vi) optionally modifying any of the X, Y, R1, R2, R3, Ar1 and Ar2 groups in the product formed in Step (i), (ii), (iii), (iv), or (v) above. - In a eighth aspect, this invention is directed to the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.
- In a ninth aspect, this invention is directed to the use of a compound of Formula (I) or (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of hepatitis C.
- Definitions:
- Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this Application and have the following meaning:
- “Alkyl” means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl (including all isomeric forms), pentyl (including all isomeric forms), and the like.
- “Alkylene” means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms unless otherwise stated e.g., methylene, ethylene, propylene, I-methylpropylene, 2-methylpropylene, butylene, pentylene, and the like.
- “Alkenylene” means a linear divalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms containing one or two double bonds, e.g., ethenylene, propenylene, 2-propenylene, butenylene (including all isomeric forms), and the like.
- “Alkylthio” means a —SR radical where R is alkyl as defined above, e.g., methylthio, ethylthio, propylthio (including all isomeric forms), butylthio (including all isomeric forms), and the like.
- “Alkylsulfinyl” means a —S(O)R radical where R is alkyl as defined above, e.g., methylsulfinyl, ethylsulfinyl, propylsulfinyl (including all isomeric forms), and the like.
- “Alkylsulfonyl” means a —SO2R radical where R is alkyl as defined above, e.g., methylsulfonyl, ethylsulfonyl, and the like.
- “Amino” means a —NH2; or an Noxide derivative or a protected derivative thereof e.g., —NH→O, —NHBoc, —NHCbz, and the like. Preferably, —NH2.
- “Alkylamino” means a —NHR radical where R is alkyl as defined above; or an N-oxide derivative, or a protected derivative thereof, e.g., methylamino, ethylamino, n-, iso-propylamino, n-, iso-, tert-butylamino, methylamino-N-oxide, —N(Boc)CH3, and the like.
- “Alkoxy” means a -OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or tert-butoxy, and the like.
- “Alkoxycarbonyl” means a —C(O)OR radical where R is alkyl as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, and the like.
- “Alkoxyalkyl” means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one alkoxy group, preferably one or two alkoxy groups, as defined above, e.g., 2-methoxyethyl, 1-, 2-, or 3-methoxypropyl, 2-ethoxyethyl, and the like,
- “Alkoxyalkyloxy” means a —OR radical where R is alkoxyalkyl as defined above, e.g., methoxyethoxy, 2-ethoxyethoxy, and the like.
- “Alkoxyalkyloxyalkyl” means a -alkylene)-R radical where R is alkoxyalkyloxy as defined above, e.g., methoxyethoxymethyl, 2-ethoxyethoxymethyl, and the like.
- “Aminoalkyl” means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one, preferably one or two, —NRR′ where R is hydrogen, alkyl, or —COR′ where Ra is alkyl, and R′ is selected from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or haloalkyl; or an N-oxide derivative or a protected derivative thereof. Preferably, R and R′ are independently selected from hydrogen, alkyl, or —CORa where Ra is alkyl; or an N-oxide derivative, or a protected derivative e.g., aminomethyl, methylaminoethyl, 2-ethylamino-2-methylethyl, 1,3-diaminopropyl, dimethylaminomethyl, diethylaminoethyl, acetylaminopropyl, aminomethyl-N-oxide, and the like.
- “Aminoalkoxy” means a —OR radical where R is aminoalkyl as defined above, e.g., 2-aminoethoxy, 2-dimethylaminopropoxy, and the like.
- “Aminocarbonyl” means a —CONRR radical where each R is independently hydrogen or alkyl as defined above, e.g., —CONH2, methylaminocarbonyl, 2-dimethylaminocarbonyl, and the like.
- “Acylamino” means a —NHCOR radical where R is alkyl as defined above, e.g., acetylamino, propionylamino, and the like.
- “Aryl” means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical of 6 to 12 ring atoms e.g., phenyl, naphthyl or anthracenyl. Unless stated otherwise, the aryl ring is optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, hydroxyalkoxyalkyl, alkoxyalkyloxyalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryloxy, optionally substituted beteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, haloalkoxyalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkyloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkyloxy, optionally substituted heterocycloalkyloxy, -alkylene-S(O)n—Ra (where n is 0 to 2 and Ra is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl), -alkylene-NHSO2-Rb (where Rb is alkyl, haloalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or optionally substituted heterocycloalkyl), -alkylene-NHCO—Rc (where Rc is alkyl, haloalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or optionally substituted heterocycloalkyl), or -alkylene)n1—CONRdRc (where n1 is 0 or 1, Rd and Re are independently, hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or optionally substituted heterocycloalkylalkyl, or Rd and Re together with the nitrogen atom to which they are attached form heterocycloalkyl) wherein the alkyl chain in haloalkoxyalkli, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, or aminoalkyl is optionally substituted with one or two fluoro. Preferably, the substituents are independently methoxy, methyl, ethyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-(morpholin-4-yl)ethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-(N,N-dimethylamino)-ethoxy, methoxymethyl, phenoxymethyl, 2-morpholino-4-ylethyl, morpholino4-ylmethyl, N,N-dimethylaminomethyl, i-propoxymethyl, or phenoxymethyl.
- “Aralkyl” means a -alkylene)-R radical where R is aryl as defined above.
- “Aralkenyl” means a -alkenylene)-R radical where R is aryl as defined above.
- “Cycloalkyl” means a cyclic saturated monovalent hydrocarbon radical of three to ten carbon atoms, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or adamantyl. The cycloalkyl is optionally substituted with optionally substituted phenyl.
- “Cycloalkenyl” means a cyclic unsaturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., cyclopropenyl, cyclobutenyl, cyclohexenyl, and the like.
- “Cycloalkylalkyl” means a -(alkylene)-R radical where R is cycloalkyl as defined above; e.g., cyclopropylmethyl, cyclobutytmethyl, cyclopentylethyl, or cyclohexylmethyl, and the like.
- “Cycloalkyloxy” means a —OR radical where R is cycloalkyl as defined above, e.g., cyclopropyloxy, cyclohexyloxy, and the like.
- “Cycloalkenyloxy” means a —OR radical where R is cycloalkenyl as defined above, e.g., cyclopropenyloxy, cyclohexenyloxy, and the like.
- “Dialkylamino” means a —NRR′ radical where R and R′ are independently alkyl as defined above, e.g., dimethylamino, diethylamino, methylpropylamino, methylethylamino, n-, iso-, or tert-butylamino, and the like.
- “Halo” means fluoro, chloro, bromo, and iodo, preferably fluoro or chloro.
- “Haloalkyl” means alkyl substituted with one or more halogen atoms, preferably one to five halogen atoms, preferably fluorine or chlorine, including those substituted with different halogens, e.g., —CH2Cl, —CF3, —CHF2, —CF2CF3, —CF(CH3)3, and the like.
- “Haloalkoxy” means a —R radical where R is haloalkyl as defined above e.g., —OCF3, —OCHF2, and the like.
- “Haloalkoxyalkyl” means a -(alkylene)—OR radical where R is haloalkyl as defined above e.g., trifluoromethyloxymethyl, 2,2,2-trifluoroethyloxymethyl, 2-trifluoromethoxyethyl, and the like.
- “Hydroxyalkyl” means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with one or two hydroxy groups, provided that if two hydroxy groups are present they are not both on the same carbon atom. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-di hydroxypropyl, and 1-(hydroxymethyl)-2-hydroxyethyl.
- “Hydroxyalkoxy” or “hydroxyalkyloxy” means a OR radical where R is hydroxyalkyl as defined above.
- “Hydroxyalkoxyalkyl” or “hydroxyalkyloxyalkyl” means a -(alkylene)—OR radical where R is hydroxyalkyl as defined above e.g., hydroxymethyloxymethyl, hydroxyethyloxymethyl, and the like.
- “Heterocycloalkyl” means a saturated or unsaturated monovalent cyclic group of 3 to 8 ring atoms in which one or two ring atoms are heteroatom selected from N, O, or S(O)n, where n is an integer from 0 to 2, the remaining ring atoms being C. One or two ring carbon atoms can optionally be replaced by a —CO— group. More specifically the term heterocycloalkyl includes, but is not limited to, pyrrolidino, piperidino, morpholino, piperazino, tetrahydropyranyl, tetrahydroquinolinyl and thiomorpholino, and the derivatives thereof (formed when the heterocyloalkyl ring is substituted with a substituent listed below); and an N-oxide or a protected derivative thereof. The heterocycloalkyl is optionally fused to aryl. Unless stated otherwise, the heterocyloalkyl ring is optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, hydroxyalkoxyalkyl, alkoxyalkyloxyalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, haloalkoxyalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkyloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkyloxy, optionally substituted heterocycloalkyloxy, -alkylene-S(O)n—Ra (where n is 0 to 2 and Ra is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl), -alkylene-NHSO2—Rb (where Rb is alkyl, haloalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl), -alkylene-NHCO—Rc (where Rc is alkyl, haloalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl), or -(alkylene)n1—CONRdRc (where n1 is 0 or 1, Rd and Rc are independently, hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or optionally substituted heterocycloalkylalkyl, or Rd and Re together with the nitrogen atom to which they are attached form heterocycloalkyl) wherein the alkyl chain in haloalkoxyalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, or aminoalkyl is optionally substituted with one or two fluoro. Preferably, the substituents are independently methoxy, methyl, ethyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-(morpholin4-yl)ethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-(N,N-dimethylamino)ethoxy, methoxymethyl, phenoxymethyl, 2-morpholino-4-ylethyl, morpholino-4-ylmethyl, N,N-dimethylaminomethyl, i-propoxymethyl, or phenoxymethyl.
- “Heterocycloalkylalkyl” means a -(alkylene)-R radical where R is heterocycloalkyl ring as defined above e.g., furanylmethyl, piperazinylmethyl, morpholinylethyl, and the like.
- “Heteroaryl” means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms where one or more, preferably one, two, or three, ring atoms are heteroatom selected from N, O, or S, the remaining ring atoms being carbon. More specifically the term heteroaryl includes, but is not limited to, pyridyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, benzoxazolyl, benzothiophenyl, benzthiazolyl, quinolinyl, isoquinolinyl, benzofuranyl, benzopyranyl, and thiazolyl, and the derivatives thereof (formed when the heterocyloalkyl ring is substituted with a substituent listed below); or an N-oxide or a protected derivative thereof. Unless stated otherwise, the heteroaryl ring is optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, hydroxyalkoxyalkyl, alkoxyalkyloxyalkyl, optionally substituted phenyl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, haloalkoxyalkyl, optionally substituted phenylalkyl, optionally substituted phenyloxy, optionally substituted phenylalkyloxy, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkyloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkyloxy, optionally substituted heterocycloalkyloxy, -alkylene-S(O)n—Ra (where n is 0 to 2 and Ra is alkyl, hydroxyalkyl, haloalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl), -alkylene-NHSO2—Rb (where Rb is alkyl, haloalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or optionally substituted heterocycloalkyl), -alkylene-NHCO—Rc (where Rc is alkyl, haloalkyl, hydroxyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or optionally substituted heterocycloalkyl), -(alkylene)n1—CONRdRf (where n1 is 0 or 1, Rd is hydrogen or alkyl, and Rf is hydrogen, alkyl, hydroxylalkyl, alkoxyalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or optionally substituted heterocycloalkylalkyl, or Rd and Rf together with the nitrogen atom to which they are attached form heterocycloalkyl), -alkylene-NRe-alkyleneCONRcRd (where Rc is as defined above and Rd and Re are independently hydrogen or alkyl), or carboxyalkylaminoalkyl wherein the alkyl chain in haloalkoxyalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, or aminoalkyl is optionally substituted with one or two fluoro. Preferably, the substituents are independently methoxy, miethyl, ethyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-(morpholin-4-yl)ethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-(N,N-dimethylamino)ethoxy, methoxymethyl, phenoxymethyl, 2-morpholino4-ylethyl, morpholino4-ylmethyl, N,N-dimethylamino-methyl, i-propoxymethyl, or phenoxymethyl.
- When the heteroaryl ring is divalent it has been referred to as heteroarylene in this application.
- “Heteroarylamino” means a NHR radical where R is heteroaryl as defined above.
- “Heteroaralkyl” means a -(alkylene)-R radical where R is heteroaryl as defined above.
- “Heteroaralkenyl” means a -(alkenylene)-R radical where R is heteroaryl as defined above.
- “Methylenedioxy” means —O—CH2—O—.
- The present invention also includes the prodrugs of compounds of Formula (I). The term prodrug is intended to represent covalently bonded carriers, which are capable of releasing the active ingredient of Formula (I) when the prodrug is administered to a mammalian subject. Release of the active ingredient occurs in vivo. Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups however regenerate original functional groups by routine manipulation or in vivo. Prodrugs of compounds of Formula (I) include compounds wherein a hydroxy, amino, carboxylic, or a similar group is modified. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy or amino functional groups in compounds of Formula (I)), amides (e.g., trifluoroacetylamino, acetylamino, and the like), and the like. Prodrugs of compounds of Formula (I) are also within the scope of this invention.
- The present invention also includes N-oxide derivatives and protected derivatives of compounds of Formula (I). For example, when compounds of Formula (I) contain an oxidizable nitrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known in the art. When compounds of Formula (I) contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable protecting groups. A comprehensive list of suitable protective groups can be found in T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc. 1981, the disclosure of which is incorporated herein by reference in its entirety. The protected derivatives of compounds of Formula (I) can be prepared by methods well known in the art.
- “Phenylene” means a divalent phenyl radical.
- A “pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include:
- acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4′-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or
- salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference.
- The compounds of the present invention may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of materials. All chiral, diastereomeric, racemic forms are within the scope of this invention, unless the specific stereochemistry or isomeric form is specifically indicated.
- Certain compounds of Formula (I) can exist as tautomers and/or geometric isomers. All possible tautomers and cis and trans isomers, individual and mixtures thereof are within the scope of this invention. Additionally, as used herein the terms alkyl includes all the possible isomeric forms of said alkyl group albeit only a few examples are set forth. Furthermore, when the cyclic groups such as aryl, heteroaryl, heterocycloalkyl are substituted, they include all the positional isomers albeit only a few examples are set forth. Furthermore, all polymorphic forms and hydrates of a compound of Formula (I) are within the scope of this invention.
- “Optionally substituted phenyl” means a phenyl ring optionally substituted with one, two, or three substituents independently selected from alkyl, halo, alkoxy, alkylthio, haloalkyl, haloalkoxy, heteroaryl (that is optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxy, alkoxy, carboxy, amino, alkylamino, or dialkylamino), heterocycloalkyl (that is optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxy, alkoxy, carboxy, amino, alkylamino, or dialkylamino), amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, methylenedioxy, aminocarbonyl, acylamino, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, or carboxy or optionally substituted with five fluorine atoms. When the phenyl is substituted it is referred herein as “substituted phenyl”.
- “Optionally substituted phenyloxy or phenoxy” means a —OR radical where R is optionally substituted phenyl as defined above e.g., phenoxy, chlorophenoxy, and the like.
- “Optionally substituted phenylcarbonylamino” means a —NHCOR radical where R is optionally substituted phenyl as defined above e.g., benzoylamino, and the like.
- “Optionally substituted phenylalkyl” means a -(alkylene)-R radical where R is optionally substituted phenyl as defined above e.g., benzyl, phenylethyl, and the like.
- “Optionally substituted phenylalkyloxy” means a —R radical where R is optionally substituted phenylalkyl as defined above e.g., benzyloxy, phenylethyloxy, and the like.
- “Optionally substituted phenylalkylthio” means a —S-(alkylene)-R radical where R is optionally substituted phenyl as defined above e.g., benzylthio, phenylethylthio, and the like.
- “Optionally substituted phenylalkylsulfonyl” means a —SO2-(alkylene)-R radical where R is optionally substituted phenyl as defined above e.g., benzylsulfonyl, phenylethylsulfonyl, and the like.
- “Optionally substituted phenylalkenyl” means a -(alkenylene)-R radical where R is optionally substituted as defined above e.g., phenylethenyl, phenylpropenyl, and the like.
- “Optionally substituted phenoxyalkyl” means a -(alkylene)-OR radical where R is optionally substituted phenyl as defined above e.g., phenoxymethyl, phenoxyethyl, and the like.
- “Optionally substituted heteroaryl” means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms where one or more, preferably one, two, or three, ring atoms are heteroatoms selected from N, O, or S, the remaining ring atoms being carbon that is optionally substituted with one, two, or three substituents independently selected from alkyl, halo, alkoxy, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, aminocarbonyl, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, optionally substituted phenyl, optionally substituted phenoxy, carboxy, or heteroaryl that is optionally substituted with alkyl, halo, hydroxy, alkoxy, carboxy, amino, alkylamino, or dialkylamino, heterocycloalkyl optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxy, alkoxy, amino, alkylamino or dialkylamino, heterocycloalkylalkyl optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxy, alkoxy, amino, alkylamino or dialkylamino, or heteroarylamino optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxy, alkoxy, amino, alkylamino or dialkylamino. More specifically the tern optionally substituted heteroaryl includes, but is not limited to, pyridyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzopyranyl, and thiazolyl, and the derivatives thereof (formed when the heteroaryl ring is substituted with a substituent listed above); or an N-oxide or a protected derivative thereof.
- “Optionally substituted heteroaryloxy” means a —OR radical where R is optionally substituted heteroaryl as defined above e.g., furanyloxy, pyridinyloxy, and the like.
- “Optionally substituted heteroaralkyloxy” means a —OR radical where R is optionally substituted heteroaralkyl ring as defined below.
- “Optionally substituted heteroaryloxyalkyl” means a dalkylene)-OR radical where R is optionally substituted heteroaryl ring as defined above.
- “Optionally substituted heteroaralkyl” means a -alkylene)-R radical where R is optionally substituted heteroaryl ring as defined above.
- “Optionally substituted heterocycloalkyl” means a saturated or unsaturated monovalent cyclic group of 3 to 8 ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or S(O)n, where n is an integer from 0 to 2, the remaining ring atoms being C. One or two ring carbon atoms can optionally be replaced by a —CO— group. More specifically the term heterocycloalkyl includes, but is not limited to, pyrrolidino, piperidino, morpholino, piperazino, tetrahydropyranyl, and thiomorpholino and the derivatives thereof (formed when the heterocycloalkyl ring is substituted with a substituent listed below); or an N-oxide or a protected derivative thereof. The heterocycloalkyl is optionally fused to aryl and is optionally substituted with one, two, or three substituents independently selected from alkyl, cycloalkyl, halo, alkoxy, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, optionally substituted phenylalkyl, optionally substituted heteroaralkyl aminocarbonyl, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, or carboxy.
- “Optionally substituted heterocycloalkyloxy” means a —OR radical where R is optionally substituted heterocycloalkyl ring as defined above.
- “Optionally substituted heterocycloalkylalkyl” means a -(alkylene)-R radical where R is optionally substituted heterocycloalkyl ring as defined above.
- “Optionally substituted heterocycloalkylalkyloxy” means a —OR radical where R is optionally substituted heterocycloalkylalkyl ring as defined above.
- “Optionally substituted heterocycloalkyloxyalkyl” means a -(alkylene)-OR radical where R is optionally substituted heterocycloalkyl as defined above e.g., piperidinyloxymethyl, pyrrolidinyloxyethyl, and the like.
- “Optional” or “optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “heterocycloalkyl group optionally mono- or di-substituted with an alkyl group” means that the alkyl may but need not be present, and the description includes situations where the heterocycloalkyl group is mono- or disubstituted with an alkyl group and situations where the heterocycloalkyl group is not substituted with the alkyl group.
- A “pharmaceutically acceptable carrier or excipient” means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for veterinary use as well as human pharmaceutical use. “A pharmaceutically acceptable carrier/excipient” as used in the specification and claims includes both one and more than one such excipient.
- “Treating” or “treatment” of a disease includes:
- (i) preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease;
- (ii) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or
- (iii) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.
- The term “treating cancer” or “treatment of cancer” refers to administration to a mammal afflicted with a cancerous condition and refers to an effect that alleviates the cancerous condition by killing the cancerous cells, but also to an effect that results in the inhibition of growth and/or metastasis of the cancer.
- A “therapeutically effective amount” means the amount of a compound of Formula (I) that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
- Representative compounds of Formula (I) are disclosed in Table I-IV below.
- Compounds of Formula (I) where R1 and R3 are hydrogen, Ar1 is phenyl and Ar2 and Y are as defined in Table I below are:
TABLE I Cpd # Ar2 Y 1 phenyl —CH2—CH2— 2 trans phenyl-CH═CH— —CH2—CH2— 3 trans phenylcyclopropyl —CH2—CH2— 4 trans 4-MeO-phenyl-CH═CH— —CH2—CH2— 5 2-phenylethyl —CH2—CH2— 6 1H-indol-3-ylmethyl —CH2—CH2— 7 thiophen-2-yl —CH2—CH2— 8 pyridin-3-yl —CH2—CH2— 9 4-biphenyl —CH2—CH2— 10 3-biphenyl —CH2—CH2— 11 5-phenylthiophen-2-yl —CH2—CH2— 12 thiophen-2-ylmethyl —CH2—CH2— 13 naphth-2-yl —CH2—CH2— 14 quinolin-6-yl —CH2—CH2— 15 4-phenylthiazol-2-yl —CH2—CH2— 16 4-tert-butylphenyl —CH2—CH2— 17 trans pyridin-3-yl-CH═CH— —CH2—CH2— 18 4-pyrrol-1-ylphenyl —CH2—CH2— 19 4-(cyclohexene-3-oxy)-phenyl —CH2—CH2— 20 benzothiazol-2-yl —CH2—CH2— 21 benzoxazol-2-yl —CH2—CH2— 22 octahydroisoquinolin-2-ylmethyl —CH2—CH2— 23 4-pyridin-4-yl-piperazin-1-ylmethyl —CH2—CH2— 24 furan-2-yl —CH2—CH2— 25 4-(pyridin-3-yl)-phenyl —CH2—CH2— 26 4-(pyridin-2-yl)-phenyl —CH2—CH2— 27 1H-benzimidazol-2-yl —CH2—CH2— 28 1H-pyrrol-2-yl —CH2—CH2— 29 4-(benzoylamino)-phenyl —CH2—CH2— 30 4-(pyridin-4-yl)-thiazol-2-yl —CH2—CH2— 31 adamantan-1-yl —CH2—CH2— 32 2,4-difluorophenyl —CH2—CH2— 33 trans 3,4-methylenedioxyphenylCH═CH— —CH2—CH2— 34 3,4-methylenedioxyphenyl —CH2—CH2— 35 3,4-dimethoxyphenyl —CH2—CH2— 36 3,5-dimethoxyphenyl —CH2—CH2— 37 3,4-difluorophenyl —CH2—CH2— 38 2,5-dimethylphenyl —CH2—CH2— 39 2,3-dichlorophenyl —CH2—CH2— 40 2,3-dimethylphenyl —CH2—CH2— 41 4-chloro-2-methoxyphenyl —CH2—CH2— 42 3-ethoxyphenyl —CH2—CH2— 43 4-methoxy-2-methylphenyl —CH2—CH2— 44 3-fluoro-4-methoxyphenyl —CH2—CH2— 45 2-(thiophen-2-ylmethoxy)phenyl —CH2—CH2— 46 3-(thiophen-2-ylmethoxy)-phenyl —CH2—CH2— 47 2-phenylphenyl —CH2—CH2— 48 1H-indol-5-yl —CH2—CH2— 49 1H-indol-3-yl —CH2—CH2— 50 quinolin-3-yl —CH2—CH2— 51 quinolin-8-yl —CH2—CH2— 52 1H-indazol-3-yl —CH2—CH2— 53 1H-benzotriazol-5-yl —CH2—CH2— 54 isoquinolin-1-yl —CH2—CH2— 55 isoquinolin-3-yl —CH2—CH2— 56 quinoxalin-2-yl —CH2—CH2— 57 naphth-1-yl —CH2—CH2— 58 quinolin-2-yl —CH2—CH2— 59 2-pyrrol-1-yl-phenyl —CH2—CH2— 60 4-fluoronaphth-1-yl —CH2—CH2— 61 1H-benzimidazol-5-yl —CH2—CH2— 62 1-methyl-indol-3-yl —CH2—CH2— 63 4-MeO-quinolin-2-yl —CH2—CH2— 64 3-MeO-naphth-2-yl —CH2—CH2— 65 2-MeO-naphth-1-yl —CH2—CH2— 66 quinolin-4-yl —CH2—CH2— 67 trans phenyl-CH═C(CH3)— —CH2—CH2— 68 2-N,N-dimethylaminomethylbenzofuran-5-yl —CH2—CH2— 69 indolin-1-yl —CH2—CH2— 70 1,2,3,4-tetrahydroquinolin-1-yl —CH2—CH2— 71 trans 5-hydroxybenzofuran-2-yl —C(CH3)═CH— -(S)-CH(CH2CH3)—CH2— 72 trans 5-(1-cyclopropylpiperidin-4- -(S)-CH(CH2CH3)—CH2— yloxy)benzofuran-2-yl —C(CH3)═CH— 73 benzofuran-2-yl -(S)-CH(2-phenylethyl)-CH2— 74 5-(1-cyclopropylpiperidin-4-yloxy)benzofuran- —CH2—CH2— 2-yl 75 5-(1-cyclopropylpiperidin-4-yloxy)benzofuran- -(S)-CH(CH2CH3)—CH2— 2-yl 76 5-(1-cyclopropylpiperidin-4-yloxy)benzofuran- -(R)-CH2—CH(CH3)— 2-yl 77 5-[1-(2,2,2-trifluoroethyl)piperidin-4- —CH2—CH2— yloxy]benzofuran-2-yl 78 benzofuran-2-yl -(R)-CH(benzylSO2-methyl)- CH2— 79 benzofuran-2-yl -(R)-CH(benzylS-methyl)- CH2— 80 trans 5-methoxybenzofuran-2-yl —C(CH3)═CH— —CH2—CH2— 81 1,2,3,4-tetrahydroisoquinolin-2-yl —CH2—CH2— 82 isoindolin-2-yl —CH2—CH2— 83 morpholin-4-yl —CH2—CH2— 84 4-benzyl-piperazin-1-yl —CH2—CH2— 85 (R)-3-HO-pyrrolidin-1-yl —CH2—CH2— 86 piperidin-1-yl —CH2—CH2— 87 6-CH3-1,2,3,4-tetrahydroquinolin-1-yl —CH2—CH2— 88 2-CH3-indolin-1-yl —CH2—CH2— 89 6-F-2-CH3-1,2,3,4-tetrahydroquinolin-1-yl —CH2—CH2— 90 isoindolin-1-yl -(S)-CH(CH2CH3)—CH2— 91 trans phenyl-CH═CH— —CH2—CH2—CH2— 92 trans 4-CH3O-phenyl-CH═CH— —CH2—CH2—CH2— 93 4-phenylthiazol-2-yl —CH2—CH2—CH2— 94 trans phenyl-CH═CH— -(S)-CH(methyl)-CH2— 95 trans phenyl-CH═CH— -(R)-CH(methyl)-CH2— 96 trans phenyl-CH═CH— -(S)-CH(i-butyl)-CH2— 97 trans phenyl-CH═CH— -(S)-CH(cyclohexyl- methyl)-CH2— 98 trans phenyl-CH═CH— -(S)-CH(i-propyl)-CH2— 99 trans phenyl-CH═CH— -(S)-CH(benzyl)-CH2— 100 trans phenyl-CH═CH— -(R)-CH(benzyl)-CH2— 101 trans phenyl-CH═CH— -(R)-CH(i-butyl)-CH2— 102 trans phenyl-CH═CH— -(R)-CH(i-propyl)-CH2— 103 trans phenyl-CH═CH— -(RS)-CH(n-butyl)-CH2— 104 trans phenyl-CH═CH— -(RS)-CH(4-Cl-benzyl)-CH2— 105 trans phenyl-CH═CH— -(S)-CH(CH2CH3)—CH2— 106 trans phenyl-CH═CH— -(R)-CH(CH2CH3)—CH2— 107 trans phenyl-CH═CH— -(S)-CH(2-MeS-ethyl)-CH2— 108 trans phenyl-CH═CH— -(R)-CH(2-MeS-ethyl)-CH2— 109 trans phenyl-CH═CH— -(S)-CH(phenyl)-CH2— 110 trans phenyl-CH═CH— -(R)-CH(phenyl)-CH2— 111 trans phenyl-CH═CH— -(S)-CH(2-MeSO2-ethyl)- CH2— 112 trans phenyl-CH═CH— -(R)-CH(2-MeSO2-ethyl)- CH2— 113 trans phenyl-CH═CH— -(R)-CH(benzylSO2-methyl)- CH2— 114 thiophen-2-yl -(S)-CH(CH2CH3)—CH2— 115 4-biphenyl -(S)-CH(CH2CH3)—CH2— 116 naphth-2-yl -(S)-CH(CH2CH3)—CH2— 117 trans phenyl-CH═CH— -(R)-CH(benzyl-S-methyl) CH2— 118 phenyl -(S)-CH(CH2CH3)—CH2— 119 benzyl -(S)-CH(CH2CH3)—CH2— 120 2-phenylethyl -(S)-CH(CH2CH3)—CH2— 121 trans phenyl-CH═CH— -(S)-CH(hydroxy-methyl)- CH2— 122 4-phenylthiazol-2-yl -(S)-CH(CH2CH3)—CH2— 123 trans 4-CH3O-phenyl-CH═CH— -(S)-CH(CH2CH3)—CH2— 124 2-N,N-dimethylaminomethyl-benzofuran-5-yl- -(S)-CH(CH2CH3)—CH2— 125 trans phenyl-CH═CH— -(R)-CH2—CH(CH3)— 126 trans phenyl-CH═CH— -(S)-CH2—CH(CH3)— 127 4-phenyl-thiazol-2-yl -(R)-CH2—CH(CH3)— 128 4-phenyl-thiazol-2-yl 129 4-biphenyl -(R)-CH2—CH(CH3)— 130 trans 4-CH3O-phenyl-CH═CH— -(R)-CH2—CH(CH3)— 131 4-(2-pyridin-4-ylthiazol-5-yl)phenyl —CH2—CH2— 132 7-chloro-4-methylbenzofuran-2-yl —CH2—CH2— 133 4-[2-(4-methylpiperazin-1-yl)thiazol-5-yl]- —CH2—CH2— phenyl 134 4-(2-pyridin-4-ylaminothiazol-5-yl)phenyl —CH2—CH2— 135 4-(4-methylpiperazin-1-yl)phenyl —CH2—CH2— 136 4-(4-hydroxypiperidin-1-yl)phenyl —CH2—CH2— 137 4-(4-morpholin-4-ylmethylthiazol-2-yl)phenyl —CH2—CH2— 138 7-fluoro-4-methylbenzofuran-2-yl —CH2—CH2— 139 7-fluoro-4-(2-methoxyethoxymethyl)- —CH2—CH2— benzofuran-2-yl 140 4-hydroxyquinolin-2-yl —CH2—CH2— 141 7-fluoro-4-phenoxymethylbenzofuran-2-yl —CH2—CH2— 143 4-[2-(4-methylpiperazin-1-ylmethyl)thiazol-5- —CH2—CH2— yl]phenyl 144 pyridin-2-yl —CH2—CH2— 145 3-hydroxypyridin-2-yl —CH2—CH2— 146 6-hydroxypyridin-2-yl —CH2—CH2— 147 6-(4-nitrophenoxy)pyridin-2-yl —CH2—CH2— 148 4-(2-methoxyethoxy)quinolin-2-yl —CH2—CH2— 149 4-(2-dimethylaminoethoxy)quinolin-2-yl —CH2—CH2— 150 6-bromopyridin-2-yl —CH2—CH2— 151 5-bromopyridin-3-yl —CH2—CH2— 152 4-methoxyquinolin-2-yl -(S)-CH(CH2CH3)—CH2— 153 1-methoxynaphth-2-yl —CH2—CH2— 154 4-methoxyquinolin-2-yl -(R)-CH2—CH(CH3)— 155 5-phenylpyridin-3-yl —CH2—CH2— 156 6-benzyloxypyridin-2-yl —CH2—CH2— 157 6-(2-methylpropyloxy)pyridin-2-yl —CH2—CH2— 158 6-(2-phenylethyloxy)pyridin-2-yl —CH2—CH2— 159 4-(3,3,3-trifluoropropyloxy)quinolin-2-yl —CH2—CH2— 160 4-(3,3,3-trifluoropropyloxy)quinolin-2-yl -(S)-CH(CH2CH3)—CH2— 161 4-(3,3,3-trifluoropropyloxy)quinolin-2-yl -(R)-CH2—CH(CH3)— 162 trans 3-hydroxyphenyl-CH═CH— —CH2—CH2— 163 trans 4-hydroxyphenyl-CH═CH— —CH2—CH2— 164 3′-(2-hydroxyethyl)biphen-4-yl —CH2—CH2— 165 3′-(2-hydroxyethyl)biphen-3-yl —CH2—CH2— 166 2′-(2-hydroxyethyl)biphen-4-yl —CH2—CH2— 167 trans benzofuran-2-yl-CH═CH— —CH2—CH2— 168 2′-(2-hydroxyethyl)biphen-3-yl —CH2—CH2— 169 5-thiophen-3-ylpyridin-3-yl —CH2—CH2— 170 6-(4-acetylaminophenoxy)pyridin-2-yl —CH2—CH2— 171 6-(4-aminophenoxy)pyridin-2-yl —CH2—CH2— 172 trans 2-methoxyphenyl-CH═CH— —CH2—CH2— 173 trans 3-methoxyphenyl-CH═CH— —CH2—CH2— 174 5-(4-dimethylaminophenyl)pyridin-3-yl —CH2—CH2— 175 trans 5-bromothiophen-2-yl-CH═CH— —CH2—CH2— 176 trans furan-3-yl-CH═CH— —CH2—CH2— 177 trans thiophen-3-yl-CH═CH— —CH2—CH2— 178 trans thiophen-2-yl-CH═CH— —CH2—CH2— 179 trans 3-tolyl-CH═CH— —CH2—CH2— 180 trans 4-tolyl-CH═CH— —CH2—CH2— 181 trans benzofuran-2-yl —C(CH3)═CH— —CH2—CH2— 182 cis benzofuran-2-yl —C(CH3)═CH— —CH2—CH2— 183 trans 4-dimethylaminophenyl-CH═CH— —CH2—CH2— 184 trans indol-3-yl —CH═CH— —CH2—CH2— 185 trans 2-tolyl-CH═CH— —CH2—CH2— 186 trans 2-hydroxyphenyl-CH═CH— —CH2—CH2— 187 trans 7-methoxybenzofuran-2-yl —CH═CH— —CH2—CH2— 188 trans 7-methoxybenzofuran-2-yl —CH═CH— -(R)-CH(CH2CH3)—CH2— 189 trans 5-methoxybenzofuran-2-yl —C(CH3)═CH— -(S)-CH(CH2CH3)—CH2— 190 trans furan-2-yl-CH═CH— —CH2—CH2— 191 4-[4-(2-morpholin-4-ylethyl)thiazol-2-yl]phenyl —CH2—CH2—
and are named as: - N-hydroxy-4-(2-benzenecarbonylamino-ethoxy)benzamide;
- N-hydroxy-4-(2-trans-cinnamoylaminoethoxy)benzamide;
- N-hydroxy-4-(2-trans-2-phenylcyclopropylcarbonylaminoethoxy)benzamide;
- N-hydroxy-4-(2-trans-4-methoxycinnamoylaminoethoxy)benzamide;
- N-hydroxy-4-[2-(2-phenylethylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(1H-indol-3-ylmethylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-(2-thiophen-2-ylcarbonylaminoethoxy)benzamide;
- N-hydroxy-4-(2-pyridin-3-ylcarbonylaminoethoxy)benzamide;
- N-hydroxy-4-(2-biphen-4-ylcarbonylaminoethoxy)benzamide;
- N-hydroxy-4-(2-biphen-3-ylcarbonylaminoethoxy)benzamide;
- N-hydroxy-4-[2-(5-phenylthiophen-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(thiophen-2-ylmethylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(napth-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(quinolin-6-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-phenylthiazol-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-tert-butylphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(trans-3-pyridin-3-ylacryloylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-pyrrol-1-ylphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-cyclohexene-3-oxyphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(benzthiazol-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(benzoxazol-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(octahydroisoquinolin-2-ylmethylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-pyridin4-ylpiperazin-1-ylmethylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(furan-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-pyridin-3-ylphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-pyridin-2-ylphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(benzimidazol-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-( )H-pyrrol-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-benzoylaminophenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-pyridin4-ylthiazol-20ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(admantan-1-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(2,4-difluorophenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(3-trans-3′4-methylenedioxyphenylacryloylaminonethoxy]-benzamide;
- N-hydroxy-4-[2-(3,4-methylenedioxyphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(3,4-dimethoxyphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(3,5-dimetboxyphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(3,4-difluorophenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(2,5-dimethylphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(2,3-dichlorophenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(2,3-dimethylphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-chloro-2-methoxyphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(3-ethoxyphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-methoxy-2-methylphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(3-fluoro-4-methoxyphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(2-thiophen-2-ylmethoxyphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(3-thiophen-2-ylmethoxyphenylarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(biphen-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(1H-indol-5-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(1H-indol-3-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(quinolin-3-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(quinolin-8-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(1H-indazol-3-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(1H-benzotriazol-5-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(isoquinolin- 1-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(isoquinolin-3-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(quinoxalin-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(naphth-1-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(quinolin-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(2-pyrrol-1-ylphenylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-fluoronapth-1-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-( 1H-benzimidazol-5-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(1-methylindol-3-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-methoxyquinolin-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(3- methoxynapth-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(2-methoxynapth-1-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(quinolin4-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(trans-2-methylcinnamoylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(2-N,N-dimethylaminomethylbenzofuran-5-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-(2-indolin-1-ylcarbonylaminoethoxy)benzamide;
- N-hydroxy-4-[2-(1 ,2,3,4-tetrahydroquinolin-1-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-{2S-[trans-3-(5-hydroxybenzofuran-2-yl)but-2-enoylamino]butoxy}benzamide;
- N-hydroxy-4-{2S-[trans-3-(5-(1-cyclopropylpiperidin-4-yloxy)benzofuran-2-yl)but-2-enoyl-amino]butoxy}benzamide;
- N-hydroxy-4-[2S-(benzofuran-2-ylcarbonylamino)-4-phenylbutoxy]benzamide;
- N-hydroxy-4-{2-[5-(1-cyclopropylpiperidin-4-yloxy)benzofuran-2-ylcarbonylamino]-ethoxy}benzamide;
- N-hydroxy-4-{2S-[5-(1-cyclopropylpiperidin-4-yloxy)benzofuran-2-ylcarbonylamino]-butoxy}benzamide;
- N-hydroxy-4-{2-[5-(1-cyclopropylpiperidin-4-yloxy)benzofuran-2-ylcarbonylamino]-1R-methylethoxy}benzamide;
- N-hydroxy-4-{2-[5-(1-(2,2,2-trifluoroethyl)piperidin-4-yloxy)benzofiuran-2-ylcarbonyl-amino]-ethoxy}benzamide;
- N-hydroxy-4-[2R-(benzofuran-2-ylcarbonylamino)-3-benzylsulfonylpropoxy]-benzamide;
- N-hydroxy-4-[2R-(benzofuran-2-ylcarbonylamino)-3-benylthiopropoxy]benzamide;
- N-hydroxy-4-[2-(trans-3-(5-methoxybenzofuran-2-yl)but-2-enoylcarbonylamino)-ethoxy]benzamide;
- N-hydroxy-4-[2-( 1 ,2,3,4-tetrahydroisoquinolin-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(isoindolin-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(morpholin-4-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-benzylpiperazin-1-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(3(R)-hydroxypyrrolidin-1-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(piperidin- 1-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(6-methyl-1,2,3,4-tetrahydroquinolin-1-ylcarbonylamino) ethoxy]-benzamide;
- N-hydroxy-4-[2-(2-methylindolin-1-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(6-fluoro-2-methyl-1,2,3,4-tetrahydroquinolin-1-ylcarbonylamino)-ethoxy]benzamide;
- N-hydroxy-4-[2S-(isoindolin-1-ylcarbonylamino)butoxy]benzamide;
- N-hydroxy-4-[3-(traw-cinnamoylamino)propoxy]benzamide;
- N-hydroxy-4-[3-(trans-4-methoxycinnamoylamino)propoxy]benzamide;
- N-hydroxy-4-[3-(4-phenylthiazol-2-ylcarbonylamino)propoxy]benzamide;
- N-hydroxy-4-[2S -trans-cinnamoylamino)propoxy]benzamide;
- N-hydroxy-4-[2R-(trans-cinnamoylamino)propoxy]benzamide;
- N-hydroxy-4-[2S-trans-cinnamoylamino)4-methylpentoxy]benzamide;
- N-hydroxy-4-[2S-trans-cinnamoylamino)-3-cyclohexylpropoxy]benzamide;
- N-hydroxy-4-[2S-(trans-cinnamoylamino)-3-methylbutoxy]benzamide;
- N-hydroxy-4-[2S-(trans-cinnamoylamino)-3-phenylpropoxy]benzamide;
- N-hydroxy-4-[2R-(trans-cinnamoylamino)-3-phenylpropoxy]benzamide;
- N-hydroxy-4-[2R-(trans-cinnamoylamino)4-methylpentoxy]benzamide;
- N-hydroxy-4-[2R-(trans-cinnamoylamino)-3-methylbutoxy]benzamide;
- N-hydroxy-4-[2RS-(trans-cinnamoylamino)hexyloxy]benzamide;
- N-hydroxy-4-[2RS-(trans-cinnamoylamino)-3-(4chlorophenyl]propoxy)benzamide;
- N-hydroxy-4-[2S-(trans-cinnamoyl amino)butoxy]benzamide;
- N-hydroxy-4-[2R-(trans-cinnamoylamino)butoxy]benzamide;
- N-hydroxy-4-[2S-(trans-innamoylamino)4-methylthiobutoxy)benzamide;
- N-hydroxy-4-[2R-(trans-cinnamoylamino)4-methylthiobutoxy]benzamide;
- N-hydroxy-4-[2S-(trans-cinnamoylamino)-2-phenylethoxy]benzamide;
- N-hydroxy-4-[2R-(trans-innamoylamino)-2-phenylethoxy]benzamide;
- N-hydroxy-4-[2S-(trans-cinnamoylamino)-4-methylsulfonylbutoxy]benzamide;
- N-hydroxy-4-[2R-(trans-cinnamoylamino)- 4-methylsulfonylbutoxy]benzamide;
- N-hydroxy-4-[2R-(trans-cinnamoylamino)-3-benzylsulfonylpropoxy]benzamide;
- N-hydroxy-4-[2S-(thiophen-2-ylcarbonylamino)butoxy]benzamide;
- N-hydroxy-4-[2S-(biphen-4-ylcarbonylamino)butoxy]benzamide;
- N-hydroxy-4-[2S-(naphth-2-ylcarbonylamino)butoxy]benzamide;
- N-hydroxy-4-[2R-(trans-cinnamoylamino)-3-benzylthiopropoxy]benzamide;
- N-hydroxy-4-[2S-(benzenecarbonylamino)butoxy]benzamide;
- N-hydroxy-4-[2S-(benzylcarbonylamino)butoxy]benzamide;
- N-hydroxy-4-[2S-(2-phenylethylcarbonylamino)butoxy]benzamide;
- N-hydroxy-4-[2S-(trans-cinnamoylamino)-3-hydroxypropoxy]benzamide;
- N-hydroxy-4-[2S-(4-phenylthiazol-2-ylcarbonylamino)butoxy]benzamide;
- N-hydroxy-4-[2S-(trans-4-methoxycinnamoylamino)butoxy]benzamide;
- N-hydroxy-4-[2S-(2-N4N-dimethylaminomethylbenzofuran-5 -ylcarbonylamino)-butoxy]-benzamide;
- N-hydroxy-4-[2-(trans-cinnamoylarnino)-1R-methylethoxy]benzamide;
- N-hydroxy-4-[2-(trans-cinnamoylamino)-1S-methylethoxy]benzamide;
- N-hydroxy-4-[2-(4-phenylthiazol-2-ylcarbonylamino)-1R-methylethoxy]benzamide;
- N-hydroxy-4-[2-(4-phenylthiazol-2-ylcarbonylamino)-1S-methylethoxy]benzamide;
- N-hydroxy-4-[2-(biphen-4-ylcarbonylamino)-1R-methylethoxy]benzamide;
- N-hydroxy-4-[2-(trans-4-methoxycinnamoylamino)-4R-methylethoxy]benzamide;
- N-hydroxy-4-{2-[4-(2-pyridin-2-ylthiazol-5-yl)phenylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-[2-(7-chloro-4-methylbenzofuran-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-{2-[4-(2-(4-methylpiperazin-1-yl)thiazol-5-yl)phenylcarbonylamino]-ethoxy}benzamide;
- N-hydroxy-4-{2-[4-(2-pyridin4-ylaminothiazol-5-yl)phenylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[4-(4-methylpiperazin-1-yl)phenylcarbonylamino]ethoxy}benzamide;
- N-hydroxy-4-{2-[4-(4-hydroxypiperidin-1-yl)phenylcarbonylamino]ethoxy}benzamide;
- N-hydroxy-4-{2-[4-(4-morpholin-4-ylmethylthiazol-5-yl)phenylcarbonylamino]-ethoxy}-benzamide;
- N-hydroxy-4-[2-(7-fluoro4-methylbenzofuran-2-ylcarbonylaminonethoxy]benzamide;
- N-hydroxy-4-{2-[7-fluoro-4-(2-methoxyethoxymethylbenzofuran-2-ylcarbonylamino]-ethoxy}benzamide;
- N-hydroxy-4-[2-(4-hydroxyquinolin-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(7-fluoro-4-phenoxymethylbenzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[4-(2-(4-methylpiperazin-1-ylmethyl)thiazol-5-yl)phenylcarbonyl-amino]-ethoxy}benzamide;
- N-hydroxy-4-[2-(pyridin-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(3-hydroxypyridin-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(6-hydroxypyridin-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-{2-[6-(4-nitrophenoxy)pyridin-2-ylcarbonylamino]ethoxy}benzamide;
- N-hydroxy-4- {2-[4-(2-methoxyethoxy)quinolin-2-ylcarbonylamino]ethoxy}benzamide;
- N-hydroxy-4-[2-[4-(2-N,N-dimethylaminoethoxy)quinolin-2-ylcarbonylamino]-ethoxy]benzamide;
- N-hydroxy-4-[2-(6-bromopyridin-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(5-bromopyridin-3-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2S-(4-methoxyquinolin-2-ylcarbonylamino)butoxy]benzamide;
- N-hydroxy-4-[2-(1-methoxynaphth-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(4-methoxyquinolin-2-ylcarbonylamino)-1R-methylethoxy]benzamide;
- N-hydroxy-4-[2-(5-phenylpyridin-3-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(6-benzyloxypyridin-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4- {2-[6-(2-methylpropyloxy)pyridin-2-ylcarbonylamino]-ethoxy}benzamide;
- N-hydroxy-4-{2-[6-(2-phenylethyloxy)pyridin-2-ylcarbonylamino]ethoxy}benzamide;
- N-hydroxy-4-12-[4-(3,3,3-trifluoropropyloxy)quinolin-2-ylcarbonylamino]ethoxy)-benzamide;
- N-hydroxy-4-{2S-[4-(3,3,3-trifluoropropyloxy)quinolin-2-ylcarbonylamino]butoxy}-benzamide;
- N-hydroxy-4-{2-[4-(3,3,3-trifluoropropyloxy)quinolin-2-ylcarbonylamino]-1R-methylethoxy}benzamide;
- N-hydroxy-4-[2-(trans-3-hydroxycinnamoylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(trans-4-hydroxycinnamoylamino)ethoxy]benzamide;
- N-hydroxy-4-(2-[3′-(2-hydroxyethyl)biphen-4-ylcarbonylamino]ethoxy)benzamide;
- N-hydroxy-4-{2-[3′-(2-hydroxyethyl}biphen-3-ylcarbonylamino]ethoxy]benzamide;
- N-hydroxy-4-(2-[2′-(2-hydroxyethyl)biphen-4-ylcarbonylamino]ethoxy-8benzamide;
- N-hydroxy-4-[2-(trans-2-benzofuran-2-ylacryloylamino)ethoxy]benzamide;
- N-hydroxy-4-{2-[2′-(2-hydroxyethyl)biphen-3-ylcarbonylamino]ethoxy}benzamide;
- N-hydroxy-4-(2-[5-(thiophen-3-yl)pyridin-3-ylcarbonylamino]ethoxy)benzamide;
- N-hydroxy-4-(2-[6-(4-acetylaminophenoxy)pyridin-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[6-(4-aminophenoxy)pyridin-2-ylcarbonylamino]ethoxy}benzamide;
- N-hydroxy-4-[2-(trans-2-methoxycinnamoylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(trans-3-methoxycinnamoylamino)ethoxy]benzamide;
- N-hydroxy-4-{2-[5-(4-dimethylaminophenyl)pyridin-3-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[trans-3-(5-bromothiophen-2-yl)acryloylamino]ethoxy}benzamide;
- N-hydroxy-4-[2-(trans-3-furan-3-ylacryloylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(trans-3-thiophen-3-ylacryloylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(trans-thiophen-2-ylacryloylamino)ethoxy]benzamide;
- N-hydroxy-4-{2-[trans-3-methylcinnamoylamino]ethoxy}benzamide;
- N-hydroxy-4-{2-[trans-4-methylcinnamoylamino]ethoxy}benzamide;
- N-hydroxy-4-{2-[trans-3-(benzofuran-2-yl)but-2-enoylamino]ethoxy}benzamide;
- N-hydroxy-4-(2-[cis-3-(benzofuran-2-yl)but-2-enoylamino]ethoxy}benzamide;
- N-hydroxy-4-[2-(trans-4-dimethylaminocinnamoylamino)ethoxy]benzamide;
- N-hydroxy-4-[2-(trans-3-indol-3-ylacryloylamino)ethoxy]benzamide;
- N-hydroxy-4-(2-[trans-2-methylcinnamoyl amino]ethoxy)benzamide;
- N-hydroxy-4-[2-(trans-2-hydroxycinnamoylamino)ethoxy]benzamide;
- N-hydroxy-4-{2-[trans-3-(7-methoxybenzofuran-2-yl)acryloylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2R-[trans-3-(7-methoxybenzofuran-2-yl)acryloylamino]butoxy}-benzamide;
- N-hydroxy-4-{2S-[trans-3-(5-methoxybenzofuran-2-yl)but-2-enoylamino]butoxy}-benzamide;
- N-hydroxy-4-[2-(trans-3-furan-2-ylacryloylamino)ethoxy]benzamide; and
- N-hydroxy-4-{2-[4-(4-(2-morpholin-4-ylethyl)thiazol-2-yl)phenylcarbonylamino]-ethoxy}-benzamide.
- Compounds of Formula (I) where R1 is hydrogen, Ar1 is phenyl and R3, Ar2 and Y are as defined in Table II below are:
TABLE II Cpd # R3 Ar2 Y 1 2-HO-ethyl trans phenyl-CH═CH— —CH2—CH2— 2 phenyl trans phenyl-CH═CH— —CH2—CH2— 3 CH3 trans phenyl-CH═CH— —CH2—CH2— 4 i-propyl benzothiophen-2-yl —CH2—CH2— 5 i-propyl trans phenyl-CH═CH— —CH2—CH2— 6 CH3 trans phenyl-CH═CH— —CH2—CH2—CH2—
and are named as: - N-hydroxy-4-(2-N-trans-cinnamoyl-N-hydroxyethylaminoethoxy)benzamide;
- N-hydroxy-4-(2-N-trans-cinnamoyl-N-phenylaminoethoxy)benzamide;
- N-hydroxy-4-(2-N-trans-cinnamoyl-N-methylam inoethoxy)benzamide;
- N-hydroxy-4-(2-N-benzothiophen-2-yl-N-isopropylaminoethoxy)benzamide;
- N-hydroxy-4-(2-N-trans-cinnamoyl-N-isopropylaminoethoxy)benzamide; and
- N-hydroxy-4-(3-N-trans-cinnamoyl-N-methylaminopropoxy)benzamide.
- Compounds of Formula (I) where R1 and R3 are hydrogen, Ar1 is phenyl, Ar2 and Y are as defined in Table III below are:
TABLE III Cpd # Z R Y 1 S H —CH2—CH2— 2 O H —CH2—CH2— 3 NH H —CH2—CH2— 4 NMe H —CH2—CH2— 5 S H —CH2—CH2—CH2— 6 O H —CH2—CH2—CH2— 7 S H -(S)-CH(i-propyl)- CH2— 8 S H -(S)-CH(ethyl)-CH2— 9 S H -(S)-CH(methyl)-CH2— 10 S H -(R)-CH(methyl)-CH2— 11 O H -(S)-CH(ethyl)-CH2— 12 S H -(R)-CH2—CH(CH3)— 13 S H -(S)-CH2—CH(CH3)— 14 O H -(R)-CH2—CH(CH3)— 15 S 6-methoxy —CH2—CH2— 16 S 5-methyl —CH2—CH2— 17 S 3-chloro —CH2—CH2— 18 O 5-methyl —CH2—CH2— 19 O 6-methyl —CH2—CH2— 20 S 4-CF3 —CH2—CH2— 21 S 5-fluoro —CH2—CH2— 22 S 5-methoxy —CH2—CH2— 23 O 5-chloro —CH2—CH2— 24 O 7-methoxy —CH2—CH2— 25 O 5-methoxy —CH2—CH2— 26 O 5-(2-methoxyethoxy)- —CH2—CH2— 27 O 5-(2-morpholin-4-ylethoxy)- —CH2—CH2— 28 O 5-pyridin-3-ylmethoxy —CH2—CH2— 29 O 3-methyl —CH2—CH2— 30 S 3 methyl —CH2—CH2— 31 O 5-(2-hydroxyethoxy)- —CH2—CH2— 32 O 5-(2-N,N-dimethylaminoethoxy)- —CH2—CH2— 33 O 6-CH3OCH2CH2O —CH2—CH2— 34 O 6-(2-morpholin-4-ylethoxy)- —CH2—CH2— 35 O 6-pyridin-3ylmethoxy- —CH2—CH2— 36 O 3-ethyl —CH2—CH2— 37 NH 5-fluoro —CH2—CH2— 38 NH 5-methoxy —CH2—CH2— 39 O 3-CH3OCH2 —CH2—CH2— 40 O 3-phenoxymethyl —CH2—CH2— 41 NH 5,6-dimethoxy —CH2—CH2— 42 O 3-morpholino-4-ylmethyl —CH2—CH2— 43 O 3-N,N-dimethylaminomethyl —CH2—CH2— 44 O 3-i-propoxymethyl —CH2—CH2— 45 O 7-phenoxymethyl —CH2—CH2— 46 O 7-CH3OCH2 —CH2—CH2— 47 O 7-morpholino-4-ylmethyl —CH2—CH2— 48 O 7-N,N-dimethylaminomethyl —CH2—CH2— 49 S 5-methyl —CH2—CH2—CH2— 50 S 6-methoxy —CH2—CH2—CH2— 51 O 7-CH3OCH2 —CH2—CH2—CH2— 52 O 7-phenoxymethyl —CH2—CH2—CH2— 53 O 5-CH3OCH2CH2O -(R)-CH2—CH(CH3)— 54 O H (R)-CH(CH3Smethyl)- CH2— 55 O H (R)-CH(CH3SO2- methyl)-CH2— 56 O 3-(2-phenylethyl)- —CH2—CH2— 57 O 3-(N-methyl-N-benzylaminomethyl)- —CH2—CH2— 58 O 3-(N-methyl-N-2-phenylethylamino- —CH2—CH2— methyl)- 59 O 3-(3-hydroxypropylthiomethyl)- —CH2—CH2— 60 O 3-(3-hydroxypropylsulfinyl-methyl)- —CH2—CH2— 61 O 3-(3-hydroxypropylsulfonyl-methyl)- —CH2—CH2— 62 O 3-(N-methyl-N-2-indol-3-yl- —CH2—CH2— ethylaminomethyl)- 63 O 3-[2-(3-trifluoromethyl-phenyl)ethyl]- —CH2—CH2— 64 O 3-[2-(3-trifluoromethoxy-phenyl)ethyl]- —CH2—CH2— 65 O 3-(N-hydroxyaminocarbonyl- —CH2—CH2— methylaminomethyl)- 66 O 3-(2-carboxyethylamino-methyl)- —CH2—CH2— 67 O H (RS)-CH2CH- (phenoxymethyl)- 68 O 3-(3-hydroxypropyloxy-methyl)- —CH2—CH2— 69 O 3-(2-fluorophenoxymethyl)- —CH2—CH2— 70 O 3-(3-fluorophenoxymethyl)- —CH2—CH2— 71 O 3-(4-fluorophenoxymethyl)- —CH2—CH2— 72 O 3-(2-methoxyethyloxymethyl)- —CH2—CH2— 73 O 3-(pyridin-4-yloxymethyl)- —CH2—CH2— 74 O 3-(2,4,6-trifluorophenoxy-methyl)- —CH2—CH2— 75 O 3-(2-oxopyridin-1-ylmethyl)- —CH2—CH2— 76 O 3-(2,2,2-trifluoroethoxy-methyl)- —CH2—CH2— 77 O 3-(4-imidazol-1-ylphenoxy-methyl)- —CH2—CH2— 78 O 3-(4-[1.2.4]-triazin-1-yl-phenoxy- —CH2—CH2— methyl)- 79 O 3-(pyrrolidin-1-ylmethyl)- —CH2—CH2— 80 O 3-(piperidin-1-ylmethyl)- —CH2—CH2— 81 O 3-(4-trifluoromethylpiperidin-ylmethyl)- —CH2—CH2— 82 O 3-(4-methylpiperazin-1-yl-methyl)- —CH2—CH2— 83 O 3-(3,3,3-trifluoropropyloxy-methyl)- —CH2—CH2— 84 O 4-methyl —CH2—CH2— 85 O 3-(4-fluorophenylthiomethyl)- —CH2—CH2— 86 O 3-(4-fluorophenylsulfinyl-methyl)- —CH2—CH2— 87 O 3-(4-fluorophenylsulfonyl-methyl)- —CH2—CH2— 88 O 3-(2,2,2-trifluoroethoxy-methyl)- (S)-CH(ethyl)-CH2— 89 O 4-hydroxy —CH2—CH2— 90 O 5-chloro (S)-CH(ethyl)-CH2— 91 O 5-chloro (R)-CH2—CH(methyl)- 92 O 4-pyridin-3-ylmethyloxy-methyl —CH2—CH2— 93 O 4-methoxy —CH2—CH2— 94 O 4-(2-methoxyethyloxy)- —CH2—CH2— 95 O 4-pyridin-3-ylmethyloxy —CH2—CH2— 96 NH 4-methoxy —CH2—CH2— 97 O 3-(2-methoxyethyloxymethyl)- (S)-CH(ethyl)-CH2— 98 O 3-(2-methoxyethyloxymethyl)- (R)-CH2—CH(methyl)- 99 O 3-N,N-diethylaminomethyl —CH2—CH2— 100 O 5-(2-methoxyethyloxy)- (S)-CH(ethyl)-CH2— 101 O 5-tetrahydropyran-4-yloxy —CH2—CH2— 102 O 5-tetrahydropyran-4-yloxy (S)-CH(ethyl)-CH2— 103 O 5-tetrahydropyran-4-yloxy (R)-CH2—CH(methyl)- 104 O 5-(2,2,2-trifluoroethyloxy)- —CH2—CH2— 105 O 5-(2-pyrrolidin-1-ylethyloxy)- —CH2—CH2— 106 O 5-(2-pyrrolidin-1-ylethyloxy)- (S)-CH(ethyl)-CH2— 107 O 5-(2-pyrrolidin-1-ylethyloxy)- (R)-CH2—CH(methyl)- 108 O 5-(piperidin-4-yloxy)- —CH2—CH2— 109 O H (S)-CH(2-CH3Sethyl)- CH2— 110 O H (S)-CH(2-CH3SO2- ethyl)-CH2—
and are named as: - N-hydroxy-4-[2-(benzothiophen-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(benzofuran-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(1H-indol-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-( 1-methylindol-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[3-(benzothiophen-2-ylcarbonylamino)propoxy]-benzamide;
- N-hydroxy-4-[3-(benzofiuran-2-y]carbonylamino)propoxyl-benzamide;
- N-hydroxy-4-[2S-(benzothiophen-2-ylcarbonylamino)-3-methylbutoxy]-benzamide;
- N-hydroxy-4-[2S-(benzothiophen-2-ylcarbonylamino)butoxy]-benzamide;
- N-hydroxy-4-[2S-(benzothiophen-2-ylcarbonylamino)-propoxy]-benzamide;
- N-hydroxy-4-[2R-(benzothiophen-2-ylcarbonylamino)-propoxy]-benzamide;
- N-hydroxy-4-[2S-(benzofiuran-2-ylcarbonylamino)butoxy]-benzamide;
- N-hydroxy-4-[2-(benzothiophen-2-ylcarbonylamino)-1R-methylethoxy]-benzamide;
- N-hydroxy-4-[2-(benzothiophen-2-ylcarbonylamino)-1S-methylethoxy]-benzamide;
- N-hydroxy-4-[2-(benzofiuran-2-ylcarbonylamino)- 1 R-methylethoxy]-benzamide;
- N-hydroxy-4-[2-(6-methoxybenzothiophen-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(5-methylbenzothiophen-2-ylcarbonylamino)ethoxy]-benzamide,
- N-hydroxy-4-[2-(3-chlorobenzothiophen-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(5-methylbenzofuran-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(6-methylbenzofuran-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(4-trifluoromethylbenzothiophen-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(5-fluorobenzothiophen-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(5-methoxybenzothiophen-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(5-chlorobenzofuran-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(7-methoxybenzofuran-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(5-methoxybenzofuran-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-{2-[5-(2-methoxyethoxy)benzofuran-2-ylcarbonylamino]ethoxy]-benzamide;
- N-hydroxy-4-{2-[5-(2-morpholin-4-ylethoxy)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[5-(pyridin-3-ylmethoxy)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-[2-(3-methylbenzofuran-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(3-methylbenzothiophen-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-{2-[5-(2-hydroxyethoxy)benzofuran-2-ylcarbonylamino]ethoxy}benzamide;
- N-hydroxy-4-{2-[5-(2-N,N-dimethylaminoethoxy}benzofiuran-2-ylcarbonylamino]-ethoxy)-benzamide;
- N-hydroxy-4-{2-[6-(2-methoxyethoxy)benzofiuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[6-(2-morpholin-4-ylethoxy)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-f2-[6-(pyridin-3-ylmethoxy)benzofuran-2-ylcarbonylamino]ethoxy)-benzamide;
- N-hydroxy-4-[2-(3-ethylbenzofuran-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(5-fluoroindol-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-[2-(5-methoxyindol-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-{2-[3-(methoxymethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide;
- N-hydroxy-4-{2-[3-(phenoxymethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-[2-(5,6-dimethoxyindol-2-ylcarbonylamino)ethoxy]-benzamide;
- N-hydroxy-4-{2-[3-morpholin-4-ylmethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]-ethoxy}-benzamide;
- N-hydroxy-4-{2-[3-(i-propoxymethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[7-(phenoxymethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[7-(methoxymethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[7-(morpholin-4-ylmethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4- {2-[7-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]-ethoxy}-benzamide;
- N-hydroxy-4-{3-[5-(methyl)benzothiophen-2-ylcarbonylamino]propoxy}-benzamide;
- N-hydroxy-4-{3-[6-(methoxy)benzothiophen-2-ylcarbonylamino]propoxy}-benzamide;
- N-hydroxy-4-{3-[7-(methoxymethyl)benzofuran-2-ylcarbonylamino]propoxy}-benzamide;
- N-hydroxy-4-{3-[7-(phenoxymethyl)benzofuran-2-ylcarbonylamino]propoxy}-benzamide;
- N-hydroxy-4-{2-[5-(2-methoxyethoxy)benzofuran-2-ylcarbonylamino]-1R-methyl ethoxy} benzamide.
- N-hydroxy-4-(2R-benzofuran-2-ylcarbonylamino-3-methylthiopropoxy)benzamide;
- N-hydroxy-4-(2R-benzofuran-2-ylcarbonylamino-3-methylsulfonylpropoxy)benzamide;
- N-hydroxy-4-{2-[3-(2-phenylethyl)benzofuran-2-ylcarbonylamino]ethoxy]benzamide;
- N-hydroxy-4-{2-[3-(N-methyl-N-benzylaminomethyl)benzofiuran-2-ylcarbonylamino]-ethoxy}benzamide;
- N-hydroxy-4-{2-[3-(N-methyl-N-2-phenylethylaminomethyl) benzofiuran-2-ylcarbonyl-amino]-ethoxy}benzamide;
- N-hydroxy-4-{2-[3-(3-hydroxypropylthiomethyl)benzofuran-2-ylcarbonylamino]-ethoxy}benzamide;
- N-hydroxy-4-(2-[3-(3-hydroxypropylsulfinylmethyl)benzofuran-2-ylcarbonylamino]-ethoxy}benzamide;
- N-hydroxy-4-{2-[3-(3-hydroxypropylsulfonylmethyl)benzofuran-2-ylcarbonylamino]-ethoxy}benzamide;
- N-hydroxy-4-{2-[3-(N-methyl-N-2-indol-3-ylethylaminomethyl)benzofuran-2-yl-carbonylamino]-ethoxy}benzamide;
- N-hydroxy-4-{2-[3-(2-(3-trifluoromethylphenyl)ethyl)benzofuran-2-ylcarbonylamino]-ethoxy}benzamide;
- N-hydroxy-4-{2-[3-(2-(3-trifluoromethoxyphenyl)ethyl)benzofuran-2-ylcarbonyl-amino]-ethoxy}benzamide;
- N-hydroxy-4- {2-[3-(N-hydroxyaminocarbonylmethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide;
- N-hydroxy-4-{2-[3-(2-carboxyethylaminomethy)benzofuran-2-ylcarbonylamino]-ethoxy}benzamide; and
- N-hydroxy-4-[2-(benzofuran-2-ylcarbonylamino)-IRS-phenoxymethylethoxy}-benzamide.
- N-hydroxy-4-{2-[3-(3-hydroxypropoxymethyl)benzofiuran-2-ylcarbonylamino]-ethoxy}-benzamide;
- N-hydroxy-4-{2-[3-(2-fluorophenoxymethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[3-(3-fluorophenoxymethyl)benzofiuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[3-(4-fluorophenoxymethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[3-(2-methoxyethyloxymethyl)benzofuran-2-ylcarbonylamino]-ethoxy}-benzamide;
- N-hydroxy-4-{2-[3-(pyridin4-yloxymethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-f2-[3-(2,4,6-trifluorophenoxymethyl)benzofuran-2-ylcarbonylamino]-ethoxy) benzamide;
- N-hydroxy-4-{2-[3-(2-oxopyridin-1-ylmethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-f2-[3-(2,2,2-trifluoroethoxymethyl)benzofuran-2-ylcarbonylamino]-ethoxy benzamide;
- N-hydroxy-4-{2-[3-(4-imidazol-1-ylphenoxymethyl)benzofuran-2-ylcarbonylamino]-ethoxy) benzamide;
- N-hydroxy-4-{2-[3-(4-[1.2.4]-triazin-1-ylphenoxymethyl)benzofuran-2-ylcarbonyl-amino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[3-(pyrrolidin-1-methyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-{2-[3-(piperidin-1-methyl)benzofiuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-(2-[3-(4-trifluoromethylpiperidin-1-methyl)benzofuran-2-ylcarbonyl-amino]-ethoxy}benzamide;
- N-hydroxy-4-{2-[3-(4-methylpiperazin-1-methyl)benzofuran-2-ylcarbonylamino]-ethoxy) benzamide;
- N-hydroxy-4-12-[3-(3,3,3-trifluoropropyloxymethyl)benzofuran-2-ylcarbonylamino]-ethoxy) benzamide;
- N-hydroxy-4-[2-(4-methylbenzofuran-2-ylcarbonylamino)-ethoxy]benzamide;
- N-hydroxy-4-{2-[3-(4-fluorophenylthiomethyl)benzofuran-2-ylcarbonylaminol-ethoxy}-benzamide;
- N-hydroxy-4-f2-(3-(4-fluorophenylsulfinylmethyl)benzofuran-2-ylcarbonylamino-ethoxy}benzamide;
- N-hydroxy-4-{2-[3-(4-fluorophenylsulfonylmethyl)benzofuran-2-ylcarbonylamino]-ethoxy) benzamide;
- N-hydroxy-4-{2S-[3-(2,2,2-trifluoroethoxymethyl)benzofuran-2-ylcarbonylamino]-butoxy) benzamide;
- N-hydroxy-4-[2-(4-hydroxybenzofuran-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-[2S-(5-chlorobenzofuran-2-ylcarbonylamino)butoxy]benzamide;
- 4051 N-hydroxy-4-[2-(5-chlorobenzofuran-2-ylcarbonylamino]-1R-methylethoxy]-benzamide;
- N-hydroxy-4-[2-(4-pyridin-3-ylmethyloxymethylbenzofuran-2-ylcarbonyiamino)-ethoxy]benzamide;
- N-hydroxy-4-[2-(4-methoxybenzofuran-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4- (2-[4-(2-methoxyethyloxy)benzofuran-2-ylcarbonylamino)ethoxy}-benzamide;
- N-hydroxy-4-[2-(4-pyridin-3-ylmethyloxybenzofuran-2-ylcarbonylamino)-ethoxy]benzamide;
- N-hydroxy-4-[2-(4-methoxyindol-2-ylcarbonylamino)ethoxy]benzamide;
- N-hydroxy-4-{2S-[3-(2-methoxyethyloxymnethyl)benzofuran-2-ylcarbonylamino]-butoxy)-benzamide;
- N-hydroxy-4-(2-[3-(2-methoxyethyloxymethyl)benzofiuran-2-ylcarbonylamino]-1R-methyl-ethoxy) benzamide;
- N-hydroxy-4-{2-[3-(N,N-diethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy)-benzamide;
- N-hydroxy-4-(2S-[5-(2-methoxyethyloxy)benzofuran-2-ylcarbonylamino]butoxy}-benzamide;
- N-hydroxy-4-{2-[5-(tetrahydropyran-4-yloxy)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-(2S-[5-(tetrahydropyran-4-yloxy)benzofuran-2-ylcarbonylamino]-butoxy)-benzamide;
- N-hydroxy-4-(2-[5-(tetrahydropyran-4-yloxy)benzofiuran-2-ylcarbonylamino]-1R-methyl-ethoxy) benzamide;
- N-hydroxy-4-(2-[5-(2,2,2-trifluoroethyloxy)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide;
- N-hydroxy-4-(2-[5-(2-pyrrolidin-1-ylethyloxy)benzofuran-2-ylcarbonylamino]-ethoxy)-benzamide;
- N-hydroxy-4-{2S-[5-(2-pyrrolidin-1-ylethyloxy)benzofiuran-2-ylcarbonylamino]-butoxy}-benzamide;
- N-hydroxy-4-{2-[5-(2-pyrrolidin- 1-ylethyloxy)benzofiuran-2-ylcarbonylamino]-1R-methyl-ethoxy}benzamide;
- N-hydroxy-4-f2-[5-(piperidin-4-yloxy)benzofuran-2-ylcarbonylamino]ethoxy)-benzamide;
- N-hydroxy-4-[2S-(benzofuran-2-ylcarbonylamino)4-methylthiobutoxy]benzamide; and
- N-hydroxy-4-[2S-(benzofuran-2-ylcarbonylamino)4-methylsulfonylbutoxy]benzamide.
- Compounds of Formula (I) where R1 and R3 are hydrogen, Ar1 is isoxazol-5-yl and Ar2 and Y are as defined in Table IV below are:
TABLE IV Cpd # Ar2 Y 1 4-biphenyl (R)-CH2—CH(CH3)— 2 4-biphenyl (S)-CH(ethyl)-CH2— 3 benzofuran-2-yl —CH2—CH2— 4 trans phenyl-CH═CH— —CH2—CH2— 5 4-(2-ethoxyphenyl)phenyl —CH2—CH2—CH2— 6 3-biphenyl —CH2—CH2—CH2— 7 4-biphenyl —CH2—CH2—CH2— 8 naphth-2-yl —CH2—CH2— 9 3-methylbiphen-4-yl —CH2—CH2— 10 2′-ethoxybiphen-4-yl —CH2—CH2— 11 3-methylbiphen-4-yl —CH2—CH2—CH2— 12 4-phenylthiazol-2-yl —CH2—CH2—CH2— 13 naphth-2-yl —CH2—CH2—CH2— 14 naphth-1-yl —CH2—CH2—CH2— 15 2-(2-phenylethyl)phenyl —CH2—CH2—CH2— 16 naphth-1-yl —CH2—CH2— 17 benzofuran-2-yl (S)-CH(ethyl)-CH2— 18 3-biphenyl (S)-CH(ethyl)-CH2— 19 benzofuran-2-yl (R)-CH2—CH(methyl)- 20 3-biphenyl (R)-CH2—CH(methyl)- 21 3-biphenyl —CH2—CH2— 22 4-biphenyl —CH2—CH2— 23 4-phenylthiazol-2-yl —CH2—CH2— 24 2-(2-phenylethyl)phenyl —CH2—CH2— 25 2-biphenyl —CH2—CH2— 26 2-biphenyl —CH2—CH2—CH2— 27 naphth-2-yl (S)-CH(ethyl)-CH2— 28 naphth-1-yl (S)-CH(ethyl)-CH2— 29 naphth-2-yl (R)-CH2—CH(methyl)- 30 naphth-1-yl (R)-CH2—CH(methyl)- 31 benzofuran-2-yl —CH2—CH2—CH2— 32 trans phenylCH═CH— —CH2—CH2—CH2— 33 3-(phenoxymethyl)benzofuran-2-yl —CH2—CH2—
and are named as: - N-hydroxy-3-[2-(biphen-4-ylcarbonylamino)-1R-methylethoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[2S-(biphen-4-ylcarbonylamino)butoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy- 3-[2-(benzofuran-2-ylcarbonylamino)ethoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy- 3-[2-(trans-cinnamoylamino)ethoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy- 3-[3-(4-(2-ethoxyphenyl)phenylcarbonylamino)propoxylisoxazol-5-ylcarboxamide;
- N-hydroxy- 3-[3-(biphen-3-ylcarbonylamino)propoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy- 3-[3-(biphen-4-ylcarbonylamino)propoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy- 3-[2-(naphth-2-ylcarbonylamino)ethoxy] isoxazol-5-ylcarboxamide;
- N-hydroxy- 3-[2-(3-methylbiphen-4-ylcarbonylamino)ethoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy- 3-[2-(2′-thoxylbiphen-4-ylcarbonylamino)ethoxylisoxazol-5-ylcarboxamide;
- N-hydroxy- 3-[3-(3-methylbiphen4-ylcarbonylamino)propoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy- 3-[3-(4-phenylthiazol-2-ylcarbonylamino)propoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy- 3-[3-(naphth-2-ylcarbonylamino)propoxy]isoxazo-1-5-ylcarboxamide;
- N-hydroxy- 3-[3-(naphth-1-ylcarbonylamino)propoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy- 3-(3-[2-(2-phenylethyl)phenylcarbonylamino]propoxy}isoxazol-5-ylcarboxamide;
- N-hydroxy- 3-[2-(naphth-1-ylcarbonylamino)ethoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[2S-(benzofuran-2-ylcarbonylamino)butoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[2S-(biphen-3-ylcarbonylamino)butoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[2-(benzofiuran-2-ylcarbonylamino)-1R-methylethoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[2-(biphen-3-ylcarbonylamino)-1R-methylethoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[2-(biphen-3-ylcarbonylamino)ethoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[2-(biphen-4-ylcarbonylamino)ethoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[2-(4-phenylthiazol-2-ylcarbonylamino)ethoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-{2-[2-(2-phenylethyl)phenylcarbonylamino]ethoxy} isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[2-(biphen-2-ylcarbonylamino)ethoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[3-(biphen-2-ylcarbonylamino)propoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[2S-(naphth-2-ylcarbonylamino)butoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[2S-(naphth- I -ylcarbonylamino)butoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-12-(naphth-2-ylcarbonylamino)-1R-methylethoxy] isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[2-(naphth-1-ylcarbonylamino)-1R-methylethoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[3-(benzofuran-2-ylcarbonylamino)propoxy]isoxazol-5-ylcarboxamide;
- N-hydroxy-3-[3-(trans-cinnamoylamino)propoxy]isoxazol-5-ylcarboxamide; and
- N-hydroxy-3-[2-(3-phenoxymethylbenzofuran-2-ylcarbonylamino)ethoxy]isoxazol-5-yl-carboxamide.
- While the broadest definition of this invention is set forth in the Summary of the Invention, certain compounds of Formula (I) are preferred. For example:
- I. A preferred group of compounds of Formula (I) is that wherein:
- R1 is hydrogen or alkyl;
- X is —O—, —NR2—, or —S(O)n where n is 0-2 and R2 is hydrogen or alkyl;
- Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, or hydroxy;
- Ar1 is phenylene or heteroarylene wherein said Ar1 is optionally substituted with one or two groups independently selected from alkyl, halo, hydroxy, alkoxy, haloalkoxy, or haloalkyl;
- R3 is hydrogen, alkyl, hydroxyalkyl, or optionally substituted phenyl; and
- Ar2 is aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl;
- wherein the terms aryl, heteroaryl, heterocycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, and aminoalkyl either alone or as part of another term (e.g., aralkyl, optionally substituted phenylalkylthio, aminoalkoxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryl, etc) contained within the scope of preferred Group I above, have the meaning given below:
- “aryl” means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical of 6 to 12 ring atoms e.g., phenyl, naphthyl or anthracenyl optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, hydroxyalkoxyalkyl, alkoxyalkyloxyalkyl, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryloxy, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, haloalkoxyalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkyloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkyloxy, optionally substituted heterocycloalkyloxy, -alkylene-S(O)n—Ra (where n is 0 to 2 and Ra is alkyl, haloalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl), -alkylene-NHSO2—Rb (where Rb is alkyl, haloalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or optionally substituted heterocycloalkyl), or -alkylene-NHCO—Rc (where Rc is alkyl, haloalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or optionally substituted heterocycloalkyl) wherein the alkyl chain in haloalkoxyalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, or aminoalkyl is optionally substituted with one or two fluoro. More preferably, the aryl ring is optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkyloxy, optionally substituted heterocycloalkyloxyalkyl, or optionally substituted heterocycloalkyloxy. Preferably, the substituents are independently methoxy, methyl, ethyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-(morpholin-4-yl)ethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-(N,N-dimethylamino)ethoxy, methoxymethyl, phenoxymethyl, 2-morpholino-4-ylethyl, morpholino-4-ylmethyl, N,N-dimethylaminomethyl, i-propoxymethyl, or phenoxymethyl;
- “heterocycloalkyl” means a saturated monovalent cyclic group of 3 to 8 ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or S(O)n, where n is an integer from 0 to 2, the remaining ring atoms being C. More specifically the term heterocycloalkyl includes, but is not limited to, pyrrolidino, piperidino, morpholino, piperazino, tetrahydropyranyl, and thiomorpholino, and the derivatives thereof (formed when the heterocycloalkyl ring is substituted with a substituent listed below); or an N-oxide or a protected derivative thereof. The heterocycloalkyl is optionally fused to aryl and is optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkyloxy, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, optionally substituted phenyloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkyloxy, or optionally substituted heterocycloalkyloxy. Preferably, the substituents are independently methoxy, methyl, ethyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-(morpholin-4-yl)ethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-(N,-dimethylamino)ethoxy, methoxymethyl, phenoxymethyl, 2-morpholino-4-ylethyl, morpholino4-ylmethyl, N,N-dimethylaminomethyl, i-propoxymethyl, or phenoxymethyl;
- “heteroaryl” means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms containing one or more, preferably one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being carbon. More specifically the term heteroaryl includes, but is not limited to, pyridyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, benzoxazolyl, benzothiophenyl, benzthiazolyl, quinolinyl, isoquinolinyl, benzopyranyl, and thiazolyl, and the derivatives thereof (formed when the heteroaryl ring is substituted with a substituent listed below), or an N-oxide or a protected derivative thereof. The heteroaryl ring is optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, hydroxyalkoxyalkyl, alkoxyalkyloxyalkyl, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, haloalkoxyalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkyloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkyloxy, optionally substituted heterocycloalkyloxy, -alkylene-S(O)n—Ra (where n is 0 to 2 and Ra is alkyl, haloalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl), -alkylene-NHSO2—Rb (where Rb is alkyl, haloalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or optionally substituted heterocycloalkyl), or -alkylene-NHCO—Rc (where Rc is alkyl, haloalkyl, optionally substituted phenyl, optionally substituted phenylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or optionally substituted heterocycloalkyl) wherein the alkyl chain in haloalkoxyalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, or aminoalkyl is optionally substituted with one or two fluoro. More preferably, the substituents are independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyloxy, cycloalkenyloxy, optionally substituted phenylcarbonylamino, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyl, alkoxyalkyloxy, methylenedioxy, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkyloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkyloxy, or optionally substituted heterocycloalkyloxy. Preferably, the substituents are independently methoxy, methyl, ethyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-(morpholin4-yl)ethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-(N,N-dimethylamino)ethoxy, methoxymethyl, phenoxymethyl, 2-morpholino-4-ylethyl, morpholino-4-ylmethyl, N,N-dimethylaminomethyl, i-propoxymethyl, or phenoxymethyl;
- “optionally substituted phenyl” means a phenyl ring optionally substituted with one, two, or three substituents independently selected from alkyl, halo, alkoxy, alkylthio, haloalkyl, haloalkoxy, heteroaryl (that is optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxy, alkoxy, carboxy, amino, alkylamino, or dialkylamino), heterocycloalkyl (that is optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxy, alkoxy, carboxy, amino, alkylamino, or dialkylamino), amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, methylenedioxy, aminocarbonyl, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, or carboxy or optionally substituted with five fluorine atoms. More preferably, the substituents are independently selected from alkyl, halo, alkoxy, alkylthio, trifluoromethyl, trifluoromethoxy, amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, methylenedioxy, aminocarbonyl, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, or carboxy or optionally substituted with five fluorine atoms;
- “optionally substituted heteroaryl” means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms containing one or more, preferably one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being carbon which is optionally substituted with one, two, or three substituents independently selected from alkyl, halo, alkoxy, trifluoromethyl, trifluoromethoxy, amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, aminocarbonyl, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, optionally substituted phenyl, optionally substituted phenoxy, carboxy, or heteroaryl that is optionally substituted with alkyl, halo, hydroxy, alkoxy, carboxy, amino, alkylamino, or dialkylamino. More specifically the term optionally substituted heteroaryl includes, but is not limited to, pyridyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzopyranyl, and thiazolyl, and the derivatives thereof (formed when the heteroaryl ring is substituted with a substituent listed below), or an N-oxide or a protected derivative thereof;
- “optionally substituted heterocycloalkyl” a saturated monovalent cyclic group of 3 to 8 ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or S(O)n, where n is an integer from 0 to 2, the remaining ring atoms being C. The heterocycloalkyl is optionally fused to aryl and is optionally substituted with one, two, or three substituents independently selected from alkyl, halo, alkoxy, trifluoromethyl, trifluoromethoxy, amino, alkylamino, dialkylamino, hydroxy, cyano, nitro, optionally substituted phenylalkyl, optionally substituted heteroaralkyl, aminocarbonyl, hydroxyalkyl, alkoxycarbonyl, aminoalkyl, or carboxy. More specifically the term heterocycloalkyl includes, but is not limited to, pyrrolidino, piperidino, morpholino, piperazino, tetrahydropyranyl, and thiomorpholino, and the derivatives thereof (formed when the heterocycloalkyl ring is substituted with a substituent listed below); or an N-oxide or a protected derivative thereof; and
- “aminoalkyl” means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one, preferably one or two, —NRR′ where R and R′ are independently selected from hydrogen, alkyl, or —CORa where Ra is alkyl, or an N-oxide derivative, or a protected derivative e.g., aminomethyl, methylaminoethyl, 2-ethylamino-2-methylethyl, 1,3-diaminopropyl, dimethylaminomethyl, diethylaminoethyl, acetylaminopropyl, and the like; and
- the other terms contained within the scope of preferred Group I are as defined in the definition section of this Application.
- Within this group I:
- (A). A preferred group of compounds is that wherein R1 and R3 are hydrogen, X is —O— and Y is ethylene or n-propylene, preferably ethylene.
- (B). Another preferred group of compounds is that wherein R1 and R3 are hydrogen, X is —O— and Y is —CH(C2H5)CH2—, —CH(i-C3H7)CH2—, or CH(CH3)CH2— and the stereochemistry at the chiral carbon is (S). More preferably, Y is —CH(C2H5)CH2—.
- (C). Yet another preferred group of compounds is that wherein R1 and R3 are hydrogen, X is —O— and Y is CH2CH(CH3)— and the stereochemistry at the chiral carbon is (R).
- (i) Within the groups (A)-(C), a more preferred group of compounds is that wherein Ar1 is phenylene in which the hydroxamate and the X group are para to each other and Ar2 is aryl. Preferably Ar2 is phenyl and is optionally substituted with one or two substituents independently selected from methoxy, ethoxy, phenyl, methyl, tert-butyl, pyrrol-1-yl, cyclohexene-3-oxy, pyridin-3-yl, pyridin-2-yl, benzoylamino, fluoro, chloro, or thiophen-2-ylmethoxy. More preferably, Ar2 is phenyl, 4-biphenyl, 3-biphenyl, 4-tert-butylphenyl, 4-pyrrol-1-ylphenyl, 4-(cyclohexene-3-oxy)phenyl, 4-(pyridin-2-yl)phenyl, 4-(pyridin-3-yl)-phenyl, 2,4-difluorophenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3,4-difluorophenyl, 2,5-dimethylphenyl, 2,3-dichlorophenyl, 2,3-dimethylphenyl, 4-chloro-2-methoxyphenyl, 3-ethoxyphenyl, 4-methoxy-2-methylphenyl, 3-fluoro4-methoxyphenyl, 2-thiophen-2-ylmethoxyphenyl, 3-thiophen-2-ylmethoxyphenyl, 2-biphenyl, or 2-pyrrol- I -ylphenyl.
- (ii) Within the groups (A)-(C), another more preferred group of compounds is that wherein Ar1 is phenylene in which the hydroxamate and the X group are para to each other and Ar2 is trans aryl-CH═CH—. Preferably Ar2 is trans phenyl-CH═CH— and is optionally substituted with alkoxy, preferably methoxy. Preferably, Ar2 is trans phenyl-CH═CH—.
- (iii) Within the groups (A)-(C), another more preferred group of compounds is that wherein Ar1 is phenylene in which the hydroxamate and the X group are para to each other and Ar2 is heteroaryl-CH═CH—. Preferably Ar2 is pyridinyl-CH═CH—. Preferably, Ar2 is trans 5-bromothiophen-2-yl-CH═CH— or trans indol-3-yl-CH═CH—.
- (iv) Within the groups (A)-(C), another more preferred group of compounds is that wherein Ar1 is phenylene in which the hydroxamate and the X group are para to each other and Ar2 is heteroaryl. Preferably Ar2 is pyridin-3-yl, thiophen-2-yl, quinolin-6-yl, thiazol-2-yl, benzthiazol-2-yl, benzoxazol-2-yl, furanyl, pyrrol-2-yl, indol-5-yl, indol-3-yl, indazol-3-yl, quinolin-3-yl, quinolin-1-yl, quinolin-8-yl, benzotriazol4-yl, benzofuran-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, quinoxalin-2-yl, quinolin-2-yl, or benzimidazol-5-yl wherein said rings are optionally substituted with phenyl, pyridin4-yl, methyl, methoxy, or dimethylaminomethyl.
- (v) Within the groups (A)-(C), another more preferred group of compounds is that wherein Ar1 is phenylene in which the hydroxamate and the X group are para to each other and Ar2 is indol-2-yl, benzofuran-2-yl or benzothiophen-2-yl which are optionally substituted with alkyl, alkoxy, halo, haloalkyl, alkoxyalkyloxy, optionally substituted heterocycloalkylalkyloxy, optionally substituted heteroaralkyloxy, hydroxyalkoxy, aminoalkyl, aminoalkyloxy, alkoxyalkyloxy, alkoxyalkyl, optionally substituted phenyloxyalkyl, or optionally substituted heterocycloalkylalkyl. Preferably, Ar2 is benzofuran-2-yl or benzothiophen-2-yl wherein benzofuran-2-yl or benzothiophen-2-yl is optionally substituted with methoxy, methyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-morpholin-4-ylethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-N,N-dimethylaminoethoxy, ethyl, methoxymethyl, 2-propyloxymethyl, phenoxymethyl, morpholin4-ylmethyl, or N,N-dimethylaminomethyl which is located at the 3-position or 5-position, preferably 3-position of the benzothiophen-2-yl or benzofuran-2-yl ring. Even more preferably, Ar2 is benzofuran-2-yl, 3-N,N-dimethylaminomethylbenzofuran-2-yl, or 3-phenoxymethylbenzofuran-2-yl.
- (vi) Within the groups (A)-(C), another more preferred group of compounds is that wherein Ar1 is phenylene in which the hydroxamate and the X group are para to each other and Ar2 is indol-2-yl, benzofuran-2-yl or benzothiophen-2-yl and is substituted with phenyloxyalkyl, substituted heteroaryloxyalkyl, substituted heterocycloalkyloxyalkyl, or haloalkoxyalkyl which are located at the 3-position of the benzothiophen-2-yl and benzofuran-2-yl rings. Even more preferably, Ar2 is 3-(2,2,2-trifluoroethyloxymethyl)benzofuran-2-yl.
- (vii) Within the groups (A)-(C), another more preferred group of compounds is that wherein Ar1 is heteroarylene and Ar2 is aryl. Preferably Ar1 is five membered heteroarylene ring containing one, two, or three heteroatoms independently selected from N, 0 or S, more preferably Ar1 is isoxazolyl where the hydroxamate and the X groups are located at the 5- and 3-position of the isoxazolyl ring, the oxygen atom in the ring being position 1 and Ar2 is aryl. Preferably Ar1 is phenyl that is optionally substituted with one or two substituents independently selected from methoxy, ethoxy, phenyl optionally substituted with ethoxy or methyl, methyl, tert-butyl, pyrrol-1-yl, cyclohexene-3-oxy, pyridin-3-yl, pyridin-2-yl, benzoylamino, fluoro, chloro, or thiophen-2-ylmethoxy. More preferably, Ar2 is phenyl, 4-biphenyl, 3-biphenyl, 2-(2-ethoxyphenyl)phenyl, 3-methylbiphen-4-yl, 4-tert-butylphenyl, 4-pyrrol-1-ylphenyl, 4-(cyclohexene-3-oxy)phenyl, 4-(pyridin-2-yl)phenyl, 4-(pyridin-3-yl)-phenyl, 2,4-difluorophenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3,4-difluorophenyl, 2,5-dimethylphenyl, 2,3-dichlorophenyl, 2,3-dimethylphenyl, 4-chloro-2-methoxyphenyl, 3-ethoxyphenyl, 4-methoxy-2-methylphenyl, 3-fluoro-4-methoxyphenyl, 2-thiophen-2-ylmethoxyphenyl, 3-thiophen-2-ylmethoxyphenyl, 2-biphenyl, or 2-pyrrol-1-ylphenyl.
- (viii) Within the groups (A)-(C), another more preferred group of compounds is that wherein Ar1 is heteroarylene and Ar2 is aryl-CH═CH—. Preferably Ar1 is five membered heteroarylene ring containing one, two, or three heteroatoms independently selected from N, O or S, more preferably Ar1 is isoxazolyl where the hydroxamate and the X groups are located at the 5- and 3-position of the isoxazolyl ring, the oxygen atom in the ring being position I and Ar2 is phenyl-CH═CH— and is optionally substituted with alkoxy.
- (ix) Within the groups (A)-(C), another more preferred group of compounds is that wherein Ar1 is heteroarylene and Ar2 is heteroaryl-CH═CH—. Preferably Ar1 is five membered heteroarylene ring containing one, two, or three heteroatoms independently selected from N, O or S, more preferably Ar1 is isoxazolyl where the hydroxamate and the X groups are located at the 5- and 3-position of the isoxazolyl ring, the oxygen atom in the ring being position I and Ar2 is pyridinyl-CH═CH—.
- (x) Within the groups (A)-(C), another more preferred group of compounds is that wherein Ar1 is heteroarylene and Ar2 is heteroaryl. Preferably Ar1 is five membered heteroarylene ring containing one, two, or three heteroatoms independently selected from N, O or S, more preferably Ar1 is isoxazolyl where the hydroxamate and the X groups are located at the 5- and 3-position of the isoxazolyl ring, the oxygen atom in the ring being position 1 and Ar2 is pyridin-3-yl, thiophen-2-yl, quinolin-6-yl, thiazol-2-yl, benzthiazol-2-yl, benzoxazol-2-yl, furanyl, pyrrol-2-yl, indol-5-yl, indol-3-yl, indazol-3-yl, quinolin-3-yl, quinolin-8-yl, benzotriazol-4-yl, isoquinolin-1-yl, isoquinolin-3-yl, quinoxalin-2-yl, quinolin-2-yl, or benzimidazol-5-yl wherein said rings are optionally substituted with phenyl, pyridin-4-yl, methyl, methoxy, or dimethylaminomethyl.
- (xi) Within the groups (A)-(C), another more preferred group of compounds is that wherein Ar1 is heteroarylene and Ar2 is indol-2-yl, benzofuran-2-yl or benzothiophen-2-yl which are optionally substituted with alkyl, alkoxy, halo, haloalkyl, alkoxyalkyloxy, optionally substituted heterocycloalkylalkyloxy, optionally substituted heteroaralkyloxy, hydroxyalkoxy, aminoalkyloxy, alkoxyalkyloxy, alkoxyalkyl, optionally substituted phenyloxyalkyl, or optionally substituted heterocycloalkylalkyl. Preferably Ar1 is a five membered heteroarylene ring containing one, two, or three heteroatoms independently selected from N, O or S, more preferably Ar1 is isoxazolyl where the hydroxamate and the X groups are located at the 5- and 3-position of the isoxazolyl ring, the oxygen atom in the ring being position 1 and Ar2 is benzofuran-2-yl and benzothiophen-2-yl which are optionally substituted with methoxy, methyl, chloro, trifluoromethyl, fluoro, 2-methoxyethoxy, 2-morpholin-4-ylethoxy, pyridin-3-ylmethoxy, 2-hydroxyethoxy, 2-N,N-dimethylaminoethoxy, ethyl, methoxymethyl, phenoxymethyl, morpholin-4-ylmethyl, or dimethylaminomethyl and are located at the 3-position of the benzothiophen-2-yl and benzofuran-2-yl rings. Even more preferably, Ar2 is benzofuran-2-yl or 3-phenoxymethylbenzofuran-2-yl.
- (xii) Within the groups (A) and (B), another more preferred group of compounds is that wherein Ar2 is substituted with alkoxyalkyloxy, optionally substituted heterocycloalkylalkyloxy, hydroxyalkoxy, aminoalkyloxy, alkoxyalkyloxy, alkoxyalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryloxyalkyl, or optionally substituted heterocycloalkylalkyl. Within this group, a more preferred group of compounds is that wherein Ar1 and Ar2 are as described in preferred embodiments above.
- II. Another preferred group of compounds of Formula (I) is that wherein X is —O—, R1 is hydrogen, Ar1 is phenylene and Ar2 is heteroaryl; where the scope of the terms contained within preferred Group II are as defined in the definition section of the Application.
-
- wherein:
- Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy; and
- Ar2 is heteroaryl.
- Preferably, Ar2 is heteroaryl optionally substituted with one or two substituent(s) independently selected from alkyl, halo, haloalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, hydroxyalkoxyalkyl, alkoxyalkyloxy, alkoxyalkyloxyalkyl, aminoalkyl, aminoalkoxy, haloalkoxy, haloalkoxyalkyl, optionally substituted phenyl, optionally substituted phenoxy, optionally substituted phenylalkyloxy, optionally substituted phenylalkyl, optionally substituted phenyloxyalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyloxy, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkyloxy, optionally substituted heterocycloalkylalkyloxy, -alkylene-S(O)nRa (where n is 0 to 2 and Ra is hydroxyalkyl or optionally substituted phenyl), -alkylene-NRc-alkyleneCONRcRd (where Rc is hydroxyl and Rd and Re are independently hydrogen or alkyl), or carboxyalkylaminoalkyl.
- Preferably, Ar2 is thiophen-2-yl, pyridin-3-yl, quinolin-6-yl, benzothiazol-2-yl, benzoxazol-2-yl, benzofuran-2-yl, benzofuran-5-yl, benzothien-2-yl, furan-2-yl, 1H-benzimidazol-2-yl, 1H-pyrrol-2-yl, thiazol-2-yl, 1H-indol-2-yl, 1H-indol-5-yl, 1H-indol-3-yl, quinolin-3-yl, quinolin-8-yl, 1H-indazol-3-yl, 1H-benzotriazol-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, quinoxalin-2-yl, quinolin-2-yl, 1H-benzimidazol-5-yl, quinolin-1-yl, pyridin-2-yl, pyridine-2-yl, quinolin-2-yl, furan-3-yl, thiophen-2-yl, or thiophen-3-yl, more preferably benzofuran-2-yl, or benzothien-2-yl that is optionally substituted with one or two substituents described in the paragraph immediately above.
- Even more preferably Ar2 is benzofuran-2-yl and is mono-substituted at the 3-, 4- or 5-position or disubstituted at the 4 and 7 positions, preferably the benzofuran-2-yl is monosubstituted at the 3 or 5 position with a substituent described in the paragraph immediately above. More preferably, the substituents are independently selected from chloro, fluoro, trifluoromethyl, methyl, ethyl, methoxy, 1-cyclopropylpiperidin-4-yloxy, 1-(2,2,2-trifluoroethyl)piperidin-4-yloxy, N,N-dimethylaminomethyl, N,N-diethylaminomethyl, 2-methoxyethoxymethyl, phenoxymethyl, 2-methoxyethoxy, 2-morpholin-4-ylethoxy, pyridin-3-yl-methoxy, 2-hydroxyethoxy, 2-N,N-dimethylaminoethoxy, methoxymethyl, 3-i-propoxymethyl, morpholin-4-ylmethyl, 3-hydroxypropyloxymethyl, 2-fluorophenoxymethyl, 3-fluorophenoxymethyl, 4-fluorophenoxy-methyl, 3-methoxypropyloxymethyl, pyridin4-yloxymethyl, 2,4,6-trifluorophenoxymethyl, 2-oxopyridin-1-ylmethyl, 2,2,2-trifluoroethoxymethyl, 4-imidazol-1-ylphenoxymethyl, 4-[1.2.4-triazin-1-yl-phenoxymethyl, 2-phenylethyl, pyrrolidin- l-ylmethyl, piperidin-1-ylmethyl, 4-trifluoromethylpiperidin- 1-yl-methyl, 4-methylpiperazin-1-ylmethyl, 3,3,3-trifluoropropyloxymethyl, 4-fluorophenylthio-methyl, 4-fluorophenylsulfinylmethyl, 4-fluorophenylsulfonylmethyl, pyridin-3-yl-methyloxymethyl, tetrahydropyran4-yloxy, 2,2,2-trifluoroethyloxy, 2-pyrrolidin-1-ylethyloxy, piperidin-4-yloxy, N-methyl-N-benzylaminomethyl, N-methyl-N-2-phenylethylaminomethyl, 3-hydroxypropylthiomethyl, 3-hydroxypropylsulfinylmethyl, 3-hydroxypropylsulfonyl-methyl, N-methyl-N-2-indol-3-ylethylaminomethyl, 2-(4-trifluoromethylphenyl)ethyl, 2-(3-trifluoromethoxyphenyl)ethyl, N-hydroxyaminocarbonyl-methylaminomethyl, or 3-(2-carboxyethylaminomethyl.
- Even more preferably, Ar2 is benzofuran-2-yl that is substituted at the 3-position with N,N-dimethylaminomethyl, N,N-diethylaminomethyl, 2-fluorophenoxymethyl, 3-fluorophenoxymethyl, 4-fluorophenoxymethyl, pyridin4-yloxymethyl, 2,4,6-trifluorophenoxy-methyl, 2-oxopyridin-1-ylmethyl, 2,2,2-trifluoroethoxy-methyl, 4-imidazol-1-ylphenoxy-methyl, 4-[1.2.4]-triazin-1-yl-phenoxymethyl, 2-phenylethyl, 3-hydroxypropyloxymethyl, 2-methoxyethyloxymethyl, pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl, 4-trifluoromethyl-piperidin-1-ylmethyl, 4-methylpiperazin-1-ylmethyl, 3,3,3-trifluoropropyloxymethyl, 4-fluorophenylthiomethyl, 4-fluorophenylsulfinylmethyl, 4-fluorophenylsulfonylmethyl, 2-(3-trifluoromethoxyphenylethyl)-, N-methyl-N-benzylaminomethyl, N-methyl-N-2-phenylethylaminomethyl, 3-hydroxypropylthiomethyl, 3-hydroxypropylsulfinyl-methyl, 3-hydroxypropylsulfonylmethyl, N-methyl-N-2-indol-3-ylethylaminomethyl, 2-(4-trifluoromethylphenyl)ethyl, N-hydroxyaminocarbonyl-methylaminomethyl, or 2-carboxyethylamino-methyl.
- Even more preferably, Ar2 is benzofuran-2-yl that is substituted at the 5-position with 1-cyclopropylpiperidin4-yloxy, piperidin-4-yloxy, tetrahydropyran4-yloxy, 2,2,2-trifluoroethoxy, 2-pyrrolidin-1-ylethyloxy, or 1-(2,2,2-trifluoroethyl)piperidin4-yloxy.
- Even more preferably, Ar2 is 7-chloro-4-methylbenzofuran-2-yl, 4-methylbenzofuran-2-yl, 7-fluoro-4-methylbenzofuran-2-yl, or 7-fluoro-4-phenoxymethylbenzofuran-2-yl.
- Even more preferably, Ar2 is thiophen-2-yl, pyridin-3-yl, 5-phenylthiophen-2-yl, quinolin-6-yl, 4-phenylthiazol-2-yl, benzothiazol-2-yl, benzoxazol-2-yl, furan-2-yl, 1H-benzimidazol-2-yl, 1H-pyrrol-2-yl, 4-(pyridin-4-yl)-thiazol-2-yl, 1H-indol-5-yl, 1H-indol-3-yl, quinolin-3-yl, quinolin-8-yl, 1H-indazol-3-yl, 1H-benzotriazol-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, quinoxalin-2-yl, quinolin-2-yl, 1H-benzimidazol-5-yl, 1-methyl-indol-3-yl, 4-MeO-quinolin-2-yl, quinolin4-yl, 4-hydroxyquinolin-2-yl, pyridin-2-yl, 3-hydroxypyridin-2-yl, 6-hydroxypyridin-2-yl, 6-(4-nitrophenoxy)pyridin-2-yl, 4-(2-methoxyethoxy)quinolin-2-yl, 4-(2-dimethylaminoethoxy)quinolin-2-yl, 6-bromopyridin-2-yl, 5-bromopyridin-3-y], 4-methoxyquinolin-2-yl, 5-phenylpyridin-3-yl, 6-benzyloxypyridin-2-yl, 6-(2-methylpropyloxy)-pyridin-2-yl, 6-(2-phenylethyloxy)pyridin-2-yl, 4-(3,3,3-trifluoropropyloxy)quinolin-2-yl, 5-thiophen-3-ylpyridin-3-yl, 6-(4-acetylaminophenoxy)-pyridin-2-yl, 6-(4-aminophenoxy)-pyridin-2-yl, or 5-(4-dimethylaminophenyl)pyridin-3-yl.
- Within the preferred and more preferred embodiments in group (II):
- (D) A more preferred group of compounds is that wherein Y is straight alkylene, preferably ethylene or n-propylene, preferably ethylene.
- (E) Another more preferred group of compounds is that wherein Y is branched alkylene, preferably CH(C2H5)CH2—, —CH(i-C3H7)CH2—, or —CH(CH3)CH2— and the stereochemistry at the chiral carbon is (S). More preferably, Y is —H(C2H5)CH2—.
- (F) Yet another more preferred group of compounds is that wherein Y is —CH2CH(CH3)- and the stereochemistry at the chiral carbon is (R).
- (G) Yet another more preferred group of compounds is that wherein Y is —CH(CHR′)CH2-where R′ is alkylthio, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy.
- III. Another preferred group of compounds of Formula (I) is that wherein X is —O—, R1 is hydrogen, Ar1 is phenylene and Ar2 is aralkenyl; where the scope of the terms contained within preferred Group III are as defined in the definition section of the Application.
-
- wherein:
- Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy; and
- Ar2 is aryl(C2-3)alkenyl.
-
- where phenyl is optionally substituted with one or two substituents independently selected from alkyl, alkoxy, methylenedioxy, dialkylamino, or hydroxy.
- Preferably, Ar2 is trans phenyl-CH═CH—, trans 4-MeO-phenyl-CH═CH—, trans 3,4-methylenedioxyphenyl-CH═CH—, trans 3-hydroxyphenyl-CH═CH—, trans 4-hydroxyphenyl-CH═CH—, trans 2-methoxyphenyl-CH═CH—, trans 3-methoxyphenyl-CH═CH—, trans 3-tolyl-CH═CH—, trans 4-tolyl-CH═CH—, trans 4-dimethylaminophenyl-CH═CH—, trans 2-tolyl-CH═CH—, or trans 2-hydroxyphenyl-CH═CH—.
- Within this group of compounds, more preferred groups are where Y is as described in (II) D-G above.
-
- wherein:
- Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy; and
- Ar2 is heteroaryl(C2-3)alkenyl; where the scope of the terms contained within preferred Group IV are as defined in the definition section of the Application.
- Preferably, Ar is trans heteroaryl-CH═CH— or trans heteroaryl-C(CH3)═CH—, preferably heteroaryl ring is pyridinyl, benzofuranyl, thienyl (thiophene), furanyl, or indolyl optionally substituted with one or two substituents selected from hydroxyl, alkoxy, halo, or optionally substituted heterocycloalkoxy.
- Preferably, Ar2 is trans pyridin-3-yl-CH═CH—, trans 5-hydroxybenzofuran-2-yl —C(CH3)═CH—, trans 5-(1-cyclopropylpiperidin-4-yloxy)benzofuran-2-yl -C(CH3)═CH—, trans 5-methoxybenzofuran-2-yl {I(CH3)═CH—, trans benzofuran-2-yl-CH═CH—, trans 5-bromothiophen-2-yl-CH═CH—, trans furan-3-yl-CH═CH—, trans thiophen-3-yl-CH═CH—, trans thiophen-2-yl-CH═CH—, trans benzofuran-2-yl -C(CH3)=CH—, cis benzofuran-2-yl-C(CH3)=CH—, trans indol-3-yl CH═CH—, trans 7-methoxybenzofuran-2-yl -CH═CH—, trans 5-methoxybenzofuran-2-yl -C(CH3)=CH—, or trans furan-2-yl-CH═CH.
- Within this group of compounds, more preferred groups are where Y is as described in (II) D-G above.
- V. Another preferred group of compounds of Formula (I) is that wherein X is —O—, R1 is hydrogen, Ar1 is phenylene and Ar2 is aryl; where the scope of the terms contained within preferred Group V are as defined in the definition section of the Application.
-
- wherein:
- Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy; and
- Ar2 is aryl.
- Preferably, the substituents on the aryl ring are independently selected from optionally substituted phenyl, alkyl, alkoxy, halo, optionally substituted heteroaryl, optionally substituted cycloalkenyloxy, optionally substituted heteroaralkyloxy, optionally substituted hetercycloalkyl, optionally substituted phenylcarbonylamino, or methylenedioxy. More preferably, Ar2 is phenyl, 4-biphenyl, 3-biphenyl, 4-tert-butylphenyl, 4-pyrrol-1-ylphenyl, 4-(pyridin-3-yl)phenyl, 4-(pyridin-2-yl)phenyl, 4-benzoylamino)phenyl, 2,4-difluorophenyl, 3,4-methylenedioxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3,4-difluorophenyl, 2,5-dimethylphenyl, 2,3-dichlorophenyl, 2,3-dimethylphenyl, 4-chloro-2-methoxyphenyl, 3-ethoxyphenyl, 4-methoxy-2-methylphenyl, 3-fluoro-4-methoxyphenyl, 2-(thiophen-2-ylmethoxy)phenyl, 3-(thiophen-2-ylmethoxy)-phenyl, 2-biphenyl, naphth-l -yl, 2-pyrrol-l -yl-phenyl, 4-fluoronaphth-1-yl, 3-MeO-naphth-2-yl, 2-MeO-naphth-1-yl, naphth-2-yl, 4-(2-pyridin4-ylthiazol-5-yl)phenyl, 4-[2-(4-methylpiperazin-1-yl)thiazol-5-yl]-phenyl, 4-(2-pyridin4-ylaminothiazol-5-yl)phenyl, 4-(4-methylpiperazin-1-yl)phenyl, 4-(4-hydroxypiperidin-1-yl)phenyl, 4-(4-morpholin4-ylmethylthiazol-2-yl)phenyl, 4-[2-(4-methylpiperazin-1-ylmethyl)thiazol-5-yl]phenyl, 1-methoxynaphth-2-yl, 3 ‘-(2-hydroxyethyl)biphen-4-yl, 3′-(2-hydroxyethyl)biphen-3-yl, 2′-(2-hydroxyethyl)biphen-4-yl, 2′-(2-hydroxyethyl)biphen-3-yl or 4-[4-(2-morpholin-4-yl-ethyl)thiazol-2-yl]phenyl.
- Within this group of compounds, more preferred groups are where Y is as described in (II) D-G above.
- Reference to the preferred embodiments set forth above is meant to include all combinations of particular and preferred groups unless stated otherwise.
- Compounds of this invention can be made by the methods depicted in the reaction scheme shown below.
- The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Bachem (Torrance, Calif.), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 140 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some methods by which the compounds of this invention can be synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art having referred to this disclosure. The starting materials and the intermediates of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.
- Unless specified to the contrary, the reactions described herein take place at atmospheric pressure over a temperature range from about −78° C. to about 150° C., more preferably from about 0° C. to about 125° C. and most preferably at about room (or ambient) temperature, e.g., about 20° C.
-
- Reaction of a compound of formula I where R is alkyl, X is —O— or —S— and Ar1 is as defined in the Summary of the Invention with an aminoalcohol of formula 2 where PG is a suitable amino protecting group provides a compound of formula 3. The reaction is carried out in the presence of triphenylphosphine and diisopropyl azodicarboxylate in a suitable organic solvent such as tetrahydrofuran, and the like.
- Compounds of formula I such as methyl 4-hydroxybenzoate, methyl 4-mercaptobenzoate, and methyl 3-hydroxyisoxazole-5-carboxylate are commercially available. Compounds of formula 2 can be prepared from commercially available aminoalcohols by reacting the amine with a suitable amino protecting group such as benzyloxycarbonyl, tert-butoxycarbonyl and the like under reaction conditions well known in the art. A detailed description of suitable amino protecting groups and reaction conditions for their preparation can be found in T. W. Greene, Protecting Groups in Organic Synthesis, John Wiley & Sons, Inc. 1981 the teaching of which is incorporated herein by reference in its entirety. Aminoalcohols such as 2-ethanolamine, 2-amino-1-propanol, 2-methylaminoethanol, 2-amino-2-methyl-1-propanol, 2-amino-1-propanol, 4-amino-2-butanol, and 1-amino-2-butanol are commercially available. Alternatively, compounds of formula 2 can be prepared from commercially available aminoacids by protecting the amino group with a suitable protecting group followed by reduction of the acid group to the hydroxy group with a suitable reducing agent under conditions well known in the art. If compounds of Formula (1) where X is —SO2— are desired, the corresponding compound of formula 3 where X is —S— can be treated with an oxidizing agent such as OXONE®, m-chloroperbenzoic acid, and the like.
- Removal of the amino protecting group in 3 provides a compound of formula 4. The reaction conditions employed for removal of the amino protecting group depend on the nature of the protecting group. For example, if the protecting group is tert-butoxycarbonyl, it is removed under acid reaction conditions. Suitable acids are trifluoroacetic acid, hydrochloric acid, and the like in a suitable organic solvent such as methanol, dioxane, tetrahydrofuran, and the like. If the protecting group is benzyl or benzyloxycarbonyl, it is removed under catalytic hydrogenation reaction conditions. Suitable catalyst are palladium based catalysts and others known in the art. Other suitable reaction conditions for their removal can be found in T. W. Greene, Protecting Groups in Organic Synthesis, John Wiley & Sons, Inc. 1981. The reaction is carried out in an inert organic solvent methylene chloride, tetrahydrofuran, dioxane, and the like.
- Reaction of 4 with an acid or acid derivative (e.g., acid halide) of formula Ar2-COZ where Z is hydroxy or halo provides a compound of formula 5. Again, the reaction conditions employed depend on the nature of the Z group. If Z is hydroxy, the reaction is typically carried out in the presence of a suitable coupling agent e.g., benzdtriazole-1-yloxy-trispyrrolidino-phosphonium hexafluorophosphate (PyBOP®), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyl-uronium hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC. HCl), or 1,3-dicyclohexylcarbodiimide (DCC), optionally in the presence of 1-hydroxybenzotriazole hydrate (HOBT. H2O), and a base such as N,N-diisopropylethylamine, triethylamine, N-methylmorpholine, and the like. The reaction is typically carried out at 20 to 30° C., preferably at about 25° C., and requires 2 to 24 hours to complete. Suitable reaction solvents are inert organic solvents such as halogenated organic solvents (e.g., methylene chloride, chloroform, and the like), acetonitrile, N,N-dimethylformamide, ethereal solvents such as tetrahydrofuran, dioxane, and the like. Preferably, the reaction is carried out with HOBt. H2O, EDC.HCl in dichloromethane or N,N-dimethylformamide.
- When Ar2COZ is an acid halide, the reaction is carried out in the presence of a suitable base (e.g. triethylamine, diisopropylethylamine, pyridine, and the like). Suitable reaction solvents are polar organic solvents such as tetrahydrofuran, acetonitrile, N,N-dimethylfornamide (DMF), dichloromethane, or any suitable mixtures thereof. The acid halide such as acid chloride can be prepared by reacting the corresponding acids with a halogenating agent such as oxalyl chloride, thionyl chloride, phosphorus oxychloride, and the like. Acids of formula Ar2COZ are either commercially available or they can be prepared from commercially available starting materials by methods known in the art. For example, benzoic acid, cinnamic acid, phenylacetic acid, nicotinic acid, isonicotinic acid, 3-methylbenzofuran-2-carboxylic acid, and benzofuran-2-carboxylic acid are commercially available. Others such as 3-phenoxymethylbenzofluran-2-carboxylic acid can be readily prepared from commercially available 3-methylbenzofuran-2-carboxylic acid by first converting it to 2-bromomethylbenzofuran-2-carboxylic acid (brominating it with N-bromosuccinimide under conditions well known in the art) followed by reacting with phenol. Compound 5 where R3 is hydrogen can optionally be converted to a corresponding compound of formula 5 where R3 is other than hydrogen by reacting it with an alkylating agent under conditions well known in the art.
- Compound 5 is then converted to a compound of Formula (I) by reacting it with aqueous hydroxylamine in the presence of a base such as sodium hydroxide and a mixture of organic solvents such as tetrahydrofuran and methanol. Alternatively, the acid group in 5 is first activated with a suitable coupling agent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC. HCl), or 1,3-dicyclohexylcarbodiimide (DCC), optionally in the presence of 1-hydroxybenzotriazole hydrate (HOBT. H2O) in a suitable organic solvent such as dimethylformamide, and the like, and then reacted with hydroxylamine hydrochloride in the presence of a base such as N,N-diisopropylethylamine, triethylamine, N-methylmorpholine, and the like. Compounds of Formula (I) can also be prepared from compound 5 by the methods disclosed in U.S. Pat. No. 5,998,412, the disclosure of which is incorporated herein by reference in its entirety. 105431 A compound of Formula (I) can be converted to other compounds of Formula (1). For example, a compound of Formula (I) where Ar1 is phenylene, X is —O—, Y is ethylene, Ar2 is 3-dimethylaminomethylbenzofuran-2-yl, R1 and R3 are hydrogen can be prepared by reacting a compound of formula 4 where Ar1 is phenylene, X is —O—, Y is ethylene, and R is alkyl with 3-methylbenzofuran-2-carboxylic acid as described above to give a compound of formula 5 where Ar2 is 3-methylbenzofuran-2-yl. Bromination of the methyl group with a suitable brominating agent such as N-bromosuccinimide, followed by reaction with dimethylamine provides the corresponding 3-dimethylaminobenzofuran-2-yl compound which is then converted to the desired compound under the reaction conditions described above.
- The compounds of this invention are inhibitors of histone deacetylase enzymes and are therefore useful in the treatment of proliferative diseases such as cancer such as lung, colon, AML, MML, skin, breast, ovarian, prostate, liver, brain and skin, psoriasis, fibroproliferative disorder such as liver fibrosis, smooth muscle proliferative disorder such as atherosclerosis and restenosis, inflammatory diseases such as arthritis, diseases involving angiogenesis such as cancer, diabetic retinopathy, haematopoietic disorder such as anaemia, fungal, parasitic and bacterial infections, viral infection, autoimmune diseases such as arthritis, multiple sclerosis, lupus, allergies, asthma, allergic rhinitis, and organ transplant, and bipolar disorders. Additionally, the compounds of the present invention are useful in the treatment of hepatitis C infection.
- The ability of the compounds of this invention to inhibit histone deacetylase enzymes can be tested in vitro and in vivo assays described in biological assays Example 1 and 2 below. The hcv activity of the compounds of this invention was tested in a hcv replicon assay at Georgetown University. The compounds can also be tested for hcv activity utilizing the replicon assay described in Komer, V. L. et al., Science 1999 Jul 2:285 (5424):110-3.
- In general, the compounds of this invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. The actual amount of the compound of this invention, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors.
- Therapeutically effective amounts of compounds of Formula (I) may range from approximately 0.1-50 mg per kilogram body weight of the recipient per day; preferably about 0.5-20 mg/kg/day. Thus, for administration to a 70 kg person, the dosage range would most preferably be about 35 mg to 1.4 g per day.
- In general, compounds of this invention will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred manner of administration is oral or parenteral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Oral compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
- The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
- The compositions are comprised of in general, a compound of Formula (I) in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of Formula (1). Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
- Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.
- Compressed gases may be used to disperse a compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.
- Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).
- The amount of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound of Formula (I) based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 1-80 wt %. Representative pharmaceutical formulations containing a compound of Formula (I) are described below.
- As stated previously, the compounds of this invention can be administered in combination with known anti-cancer agents. Such known anti-cancer agents include the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-CoA reductase inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors, DNA methyl tranferase inhibitors, and other angiogenesis inhibitors. The compound of the present invention compounds are particularly useful when administered in combination with radiation therapy. Preferred angiogenesis inhibitors are selected from the group consisting of a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP (matrix metalloprotease) inhibitor, an integrin blocker, interferon-a, interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine, 6-Q-chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin, troponin-i, and an antibody to VEGF.
- Preferred estrogen receptor modulators are tamoxifen and raloxifene.
- “Estrogen receptor modulators” refers to compounds that interfere or inhibit the binding of estrogen to the receptor, regardless of mechanism. Examples of estrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LY11708 1, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl-2,2-dimethylpropanoate, 4,4′-dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone, and SH646.
- “Androgen receptor modulators” refers to compounds which interfere or inhibit the binding of androgens to the receptor, regardless of mechanism. Examples of androgen receptor modulators include finasteride and other 5α-reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole, and abiraterone acetate.
- “Retinoid receptor modulators” refers to compounds which interfere or inhibit the binding of retinoids to the receptor, regardless of mechanism. Examples of such retinoid receptor modulators include bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, α-difluoromethylomithine, ILX23-7553, trans-N-(4′-hydroxyphenyl) retinamide, and N-4-carboxyphenyl retinamide.
- “Cytotoxic agents” refer to compounds which cause cell death primarily by interfering directly with the cell's functioning or inhibit or interfere with cell myosis, including alkylating agents, tumor necrosis factors, intercalators, microtubulin inhibitors, and topoisomerase inhibitors.
- Examples of cytotoxic agents include, but are not limited to, tirapazimine, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosilate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-aminedichloro(2-methyl-pyridine) platinum, benzylguanine, glufosfamide, GPX 100, (trans, trans, trans)-bis-mu-(hexane-1,6-diamine)-mu-[diamine-platinum(II)]bis[diamine(chloro)platinum(II)]-tetrachloride, diarizidinyispermine, arsenic trioxide, I-(II-odecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin, pinafide, valrubicin, amrubicin, antineoplaston, 3′-deamino-3 ‘-morpholino-133-deoxo-10-hydroxycarminomycin, annamycin, galarubicin, elinafide, MEN10755, and 4-demethoxy-3-deamino-3-aziridinyl-4-methylsulphonyl-daunorubicin (see WO 00/50032).
- Examples of microtubulin inhibitors include paclitaxel, vindesine sulfate, 3′,4′-didehydro-4′-deoxy-8′-norvincaleukoblastine, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzene sulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258, and BMS188797.
- Some examples of topoisomerase inhibitors are topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3′,4′-O-exo-benzylidene-chartreusin, 9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2-(6H)propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3′,4′:b,7]-indolizino[1,2b]quinoline-10,13(9H,15H)dione, lurtotecan, 7-[2-(N-isopropylamino)-ethyl]-(20S)camptothecin, BNP1350, BNPI1100, BN80915, BN80942, etoposide phosphate, teniposide, sobuzoxane, 2′-dimethylamino-2′-deoxy-etoposide, GL331, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, asulacrine, (5a, 5aB, 8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N-methylamino]ethyl]-5-[4-hydroxy -3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexohydrofuro(3′,4′: 6,7)colchic(2,3-d)-1,3-dioxol-6-one, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]-phenanthridinium, 6,9-bis[(2-aminoethyl)-amino]benzo[g]isoguinoline-5,10-dione, 5-(3-aminopropylamino)-7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5,1- de]acridin-6-one, N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide, N-(2-(dimethylamino)ethyl)acridine4-carboxamide, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2, 1-c]quinolin-7-one, and dimesna.
- “Antiproliferative agents” includes antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231, and INX3001, and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine oefosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2′-deoxy-2′-methylidenecytidine, 2′-fluoromethylene-2′-deoxycytidine, N-[5-(2,3-dihydro-benzofiryl)sulfonyl]-N′-(3,4-dichlorophenyl)urea, N6-[4-deoxy-4-[N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-manno-heptopyranosyl]-adenine, aplidine, ecteinascidin, troxacitabine, 4-[2-amino4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b][1,4]thiazin-6-yl- (S)-ethyl]-2,5-thienoyl-L-glutamic acid, aminopterin, 5-flurouracil, alanosine, 11-acety]-8-(carbamoyloxymethyl)-4-formyl-6-methoxy- 14-oxa-1,11-diazatetra cyclo(7.4.1.0.0)-tetradeca-2,4,6-trien-9-yl acetic acid ester, swainsonine, lometrexol, dexrazoxane, methioninase, 2′-cyano-2′-deoxy-N4-palmitoyl-1-B-D-arabino furanosyl cytosine, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. “Antiproliferative agents” also includes monoclonal antibodies to growth factors, other than those listed under “angiogenesis inhibitors”, such as trastuzumab, and tumor suppressor genes, such as p53, which can be delivered via recombinant virus-mediated gene transfer (see U.S. Pat. No. 6,069,134, for example).
- “HMG-CoA reductase inhibitors” refers to inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase. Compounds which have inhibitory activity for HMG-CoA reductase can be readily identified by using assays well-known in the art. For example, see the assays described or cited in U.S. Pat. No. 4,231,938 at col. 6, and WO 84/02131 at pp. 30-33. The terms “HMG-CoA reductase inhibitor” and “inhibitor of HMG-CoA reductase” have the same meaning when used herein. It has been reported that (Int. J. Cancer, 20;97(6):746-50, 2002) combination therapy with lovastatin, a HMG-CoA reductase inhibitor, and butyrate, an inducer of apoptosis in the Lewis lung carcinoma model in mice showed potentiating antitumor effects
- Examples of HMG-CoA reductase inhibitors that may be used include but are not limited to lovastatin (MEVACOR.; see U.S. Pat. Nos. 4,231,938; 4,294,926; 4,319,039), simvastatin (ZOCOR®; see U.S. Pat. Nos. 4,444,784; 4,820,850; 4,916,239), pravastatin (PRAVACHOL’; see U.S. Pat. Nos. 4,346,227; 4,537,859; 4,410,629; 5,030,447 and 5,180,589), fluvastatin (LESCOLO; see U.S. Pat. Nos. 5,354,772; 4,911,165; 4,929,437; 5,189,164; 5,118,853; 5,290,946; 5,356,896), atorvastatin (LIPITORe; see U.S. Pat. Nos. 5,273,995; 4,681,893; 5,489,691; 5,342,952) and cerivastatin (also known as rivastatin and BAYCHOL®; see U.S. Pat. No. 5,177,080). The structural formulas of these and additional HMG-CoA reductase inhibitors that may be used in the instant methods are described at page 87 of M. Yalpani, “Cholesterol Lowering Drugs”, Chemistry & Industry, pp. 85-89 (Feb. 5, 1996) and U.S. Pat. Nos. 4,782,084 and 4,885,314. The term HMG-CoA reductase inhibitor as used herein includes all pharmaceutically acceptable lactone and open-acid forms (i.e., where the lactone ring is opened to form the free acid) as well as salt and ester forms of compounds which have HMG-CoA reductase inhibitory activity, and [Oolchicin the use of such salts, esters, open-acid and lactone forms is included within the scope of this invention.
- In HMG-CoA reductase inhibitors where an open-acid form can exist, salt and ester forms may preferably be formed from the open-acid, and all such forms are included within the meaning of the term “HMG-CoA reductase inhibitor” as used herein. Preferably, the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin, and most preferably simvastatin.
- Herein, the term “pharmaceutically acceptable salts” with respect to the HMG-CoA reductase inhibitor shall mean non-toxic salts of the compounds employed in this invention which are generally prepared by reacting the free acid with a suitable organic or inorganic base, particularly those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc and tetramethylammonium, as well as those salts formed from amines such as ammonia, ethylenediamine, N-methylglucamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylenediamine, cbloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, 1-p-chlorobenzyl-2-pyrrolidine-1′-yl-methylbenzimidazole, diethylamine, piperazine, and tris(hydroxymethyl) aminomethane. Further examples of salt forms of HMG-CoA reductase inhibitors may include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium hydroxyl, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, hydroxyl, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamaote, palmitate, panthothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate.
- Ester derivatives of the described HMG-CoA reductase inhibitor compounds may act as prodrugs which, when absorbed into the bloodstream of a warm-blooded animal, may cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.
- “Prenyl-protein transferase inhibitor” refers to a compound which inhibits any one or any combination of the prenyl-protein transferase enzymes, including farnesyl-protein transferase (FPase), geranylgeranyl-protein transferase type I (GGPTase-1), and geranylgeranyl-protein transferase type-II (GGPTase-II, also called Rab GGPTase). Examples of prenyl-protein transferase inhibiting compounds include (U)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]4-(3-chlorophenyl)-1-methyl-2(1H)quinolinone, (−)-6-[amino(4-chlorophenyl)( 1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chloro phenyl)-1-methyl-2(1H)-quinolinone, (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chloro phenyl)-1-methyl-2(1H)-quinolinone, 5(S)-n-butyl-1-(2,3-dimethylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone, (S)-1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-5-[2-(ethanesulfonyl)-methyl)-2-piperazinone, 5(S)-n-butyl-1-(2-methylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone, 1-(3-chlorophenyl) 4-[1-(4-cyanobenzyl)-2-methyl-5-imidazolylmethyl]-2-piperazinone, 1-(2,2-diphenylethyl)-3-[N-(1-(4-cyanobenzyl)- 1H-imidazol-5-ylethyl)carbamoyl]piperidine, 4-{5-[4-hydroxymethyl-4-(4-chloropyridin-2-ylmethyl)-piperidine-1-ylmethyl]-2-methylimidazol-1-ylmethyl}benzonitrile, 4-{5-[4-hydroxymethyl-4-(3-chlorobenzyl)-piperidine-1-ylmethyl]-2-methylimidazol- 1-ylmethyl } benzonitrile, 4- {3-[4-(2-oxo-2H-pyridin-1-yl)benzyl]-3H-imidazol-4-ylmethyl}benzonitrile, 4-{3-[4-(5-chloro-2-oxo-2H-[1,2′]bipyridin-5 ‘-ylmethyl]-3H-imidazol4-ylmethyl}benzonitrile, 4-{3-[4-(2-oxo-2H-[1,2 ‘]bipyridin-5 ‘-ylmethyl]-3H-imidazol-4-ylmethyl} benzonitrile, 4-[3-(2-oxo-1-phenyl-1,2-dihydropyridin4-ylmethyl)-3H-imidazol-4-ylmethyl}benzonitrile, 18,19-dihydro-19-oxo-5H,17H-6,10: 12,16-dimetheno-1H-imidazo[4,3-c][1,11,4]dioxa-azacyclononadecine-9-carbonitrile, (i )-19,20-dihydro-19-oxo-5H-18,21-ethano-12,14-etheno-6,10-metheno-22H-benzo[d]imidazo[4,3-! k][1,6,9,12]-oxatriaza-cyclooctadecine-9-carbonitrile, 19,20-dihydro-19-oxo-5H,17H-18,21-ethano-6,10: 12,16-dimetheno-22H-imidazo[3,4-h][1,8,11,14]oxatriazacyclo-eicosine-9-carbonitrile, and +)-19,20-dihydro-3-niethyl-19-oxo-5H-18,21-ethano-12,14-etheno-6,10-metheno-22H-benzo[d]imidazo[4,3-k][1,6,9,12]oxa-triazacyclooctadecine-9-carbonitrile.
- Other examples of prenyl-protein transferase inhibitors can be found in the following publications and patents: WO 96/30343, WO 97/18813, WO 97/21701, WO 97/23478, WO 97/38665, WO 98/28980, WO 98/29119, WO 95/32987, U.S. Pat. Nos. 5,420,245, 5,523,430, 5,532,359, 5,510,510, 5,589,485, 5,602,098, European Patent Pub]. 0 618 221, European Patent Publ. 0 675 112, European Patent Pub]. 0 604 181, European Patent Publ. 0 696 593, WO 94/19357, WO 95/08542, WO 95/11917, WO 95/12612, WO 95/12572, WO 95/10514, U.S. Pat. No. 5,661,152, WO 95/10515, WO 95/10516, WO 95/24612, WO 95/34535, WO 95/25086, WO 96/05529, WO 96/06138, WO 96/06193, WO 96/16443, WO 96/21701, WO 96/21456, WO 96/22278, WO 96/24611, WO 96/24612, WO 96/05168, WO 96/05169, WO 96/00736, U.S. Pat. No. 5,571,792, WO 96/17861, WO 96/33159, WO 96/34850, WO 96/34851, WO 96/30017, WO 96/30018, WO 96/30362, WO 96/30363, WO 96/31111, WO 96/31477, WO 96/31478, WO 96/31501, WO 97/00252, WO 97/03047, WO 97/03050, WO 97/04785, WO 97/02920, WO 97/17070, WO 97/23478, WO 97/26246, WO 97/30053, WO 97/44350, WO 98/02436, and U.S. Pat. No. 5,532,359. For an example of the role of a prenyl-protein transferase inhibitor on angiogenesis see J. Of Cancer, Vol. 35, No. 9, pp. 1394-1401 (1999).
- Examples of HIV protease inhibitors include amprenavir, abacavir, CGP-73547, CGP-61755, DMP450, indinavir, nelfinavir, tipranavir, ritonavir, saquinavir, ABT-378, AG 1776, and BMS-232, 632. Examples of reverse transcriptase inhibitors include delaviridine, efavirenz, GS-840, HB Y097, lamivudine, nevirapine, AZT, 3TC, ddC, and ddl. It has been reported (Nat. Med.;8(3):225-32, 2002) that HIV protease inhibitors, such as indinavir or saquinavir, have potent anti-angiogenic activities and promote regression of Kaposi sarcoma
- “Angiogenesis inhibitors” refers to compounds that inhibit the formation of new blood vessels, regardless of mechanism. Examples of angiogenesis inhibitors include, but are not limited to, tyrosine kinase inhibitors, such as inhibitors of the tyrosine kinase receptors Flt-1 (VEGFRI) and Flk-1/KDR (VEGFR20), inhibitors of epidermal-derived, fibroblast-derived, or platelet derived growth factors, MMP (matrix metal loprotease) inhibitors, integrin blockers, interferon, interleukin-12, pentosan polysulfate, cyclooxygenase inhibitors, including nonsteroidal anti-inflammatories (NSAIDs) like aspirin and ibuprofen as well as selective cyclooxygenase-2 inhibitors like celecoxib, valecoxib, and rofecoxib (PNAS, Vol. 89, p. 7384 (1992); JNCI, Vol. 69, p. 475 (1982); Arch. Opthalmol., Vol. 108, p. 573 (1990); Anat. Rec., Vol. 238, p. 68 (1994); FEBS Letters, Vol. 372, p. 83 (1995); Clin., Orthop. Vol. 313, p. 76 (1995); J. Mol. Endocrinol., Vol 16, p. 107 (1996); Jpn. J. Pharmacol., Vol. 75, p. 105 (1997); Cancer Res., Vol. 57, p. 1625 (1997); Cell, Vol. 93, p. 705 (1998); Intl. J Mol. Med., Vol. 2, p. 715 (1998); J. Biol. Chem., Vol. 274, p. 9116 (1999)), carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-chloroacetyl-carbonyl)-flumagillol, thalidomide, angiostatin, troponin-1, angiotensin II antagonists (see Fernandez et al., J. Lab. Clin. Med. 105:141-145 (1985)), and antibodies to VEGF (see, Nature Biotechnology, Vol. 17, pp. 963-968 (October 1999); Kim et al., Nature, 362, 841-844 (1993); WO 00/44777; and WO 00/61186).
- As described above, the combinations with NSAID's are directed to the use of NSAID's which are potent COX-2 inhibiting agents. For purposes of this specification an NSAID is potent if it possess an IC50 for the inhibition of COX-2 of 1 μM or less as measured by the cell or microsomal assay known in the art.
- The invention also encompasses combinations with NSAID's which are selective COX-2 inhibitors. For purposes of this specification NSAID's which are selective inhibitors of COX-2 are defined as those which possess a specificity for inhibiting COX-2 over COX-1 of at least 100 fold as measured by the ratio of IC50 for COX-2 over IC50 for COX-1 evaluated by the cell or microsomal assay disclosed hereinunder. Such compounds include, but are not limited to those disclosed in U.S. Pat. No. 5,474,995, issued Dec. 12, 1995, U.S. Pat. No. 5,861,419, issued Jan. 19, 1999, U.S. Pat. No. 6,001,843, issued Dec. 14, 1999, U.S. Pat. No. 6,020,343, issued Feb. 1, 2000, U.S. Pat. No.5,409,944, issued Apr. 25, 1995, U.S. Pat. No. 5,436,265, issued Jul.25, 1995, U.S. Pat. No. 5,536,752, issued Jul. 16, 1996, U.S. Pat. No. 5,550,142, issued Aug. 27, 1996, U.S. Pat. No. 5,604,260, issued Feb. 18, 1997, U.S. Pat. No. 5,698,584, issued Dec. 16, 1997, U.S. Pat. No. 5,710,140, issued Jan. 20, 1998, WO 94/15932, published Jul. 21, 1994, U.S. Pat. No. 5,344,991, issued Jun. 6, 1994, U.S. Pat. No. 5,134,142, issued Jul. 28, 1992, U.S. Pat. No. 5,380,738, issued Jan. 10, 1995, U.S. Pat. No. 5,393,790, issued Feb. 20, 1995, U.S. Pat. No. 5,466,823, issued Nov. 14, 1995, U.S. Pat. No. 5,633,272, issued May 27, 1997, and U.S. Pat. No. 5,932,598, issued Aug. 3, 1999, all of which are hereby incorporated by reference. Other examples of specific inhibitors of COX-2 include those disclosed in U.S. Pat. No. 6,313,138 the disclosure of which is incorporated herein by reference in its entirety.
- General and specific synthetic procedures for the preparation of the COX-2 inhibitor compounds described above are found in U.S. Pat. No. 5,474,995, issued Dec. 12, 1995, U.S. Pat. No. 5,861,419, issued Jan. 19, 1999, and U.S. Pat. No. 6,001,843, issued Dec. 14, 1999, all of which are herein incorporated by reference.
-
- Compounds which are described as specific inhibitors of COX-2 and are therefore useful in the present invention, and methods of synthesis thereof, can be found in the following patents, pending applications and publications, which are herein incorporated by reference: WO 94/15932, published Jul. 21, 1994, U.S. Pat. No. 5,344,991, issued Jun. 6, 1994, U.S. Pat. No. 5,134,142, issued Jul. 28, 1992, U.S. Pat. No. 5,380,738, issued Jan. 10, 1995, U.S. Pat. No. 5,393,790, issued Feb. 20, 1995, U.S. Pat. No. 5,466,823, issued Nov. 14, 1995, U.S. Pat. No. 5,633,272, issued May 27, 1997, and U.S. Pat. No. 5,932,598, issued Aug. 3, 1999.
- Compounds which are specific inhibitors of COX-2 and are therefore useful in the present invention, and methods of synthesis thereof, can be found in the following patents, pending applications and publications, which are herein incorporated by reference: U.S. Pat. No. 5,474,995, issued Dec. 12, 1995, U.S. Pat. No. 5,861,419, issued Jan. 19, 1999, U.S. Pat. No. 6,001,843, issued Dec. 14, 1999, U.S. Pat. No. 6,020,343, issued Feb. 1, 2000, U.S. Pat. No. 5,409,944, issued Apr. 25, 1995, U.S. Pat. No. 5,436,265, issued Jul. 25, 1995, U.S. Pat. No. 5,536,752, issued Jul. 16, 1996, U.S. Pat. No. 5,550,142, issued Aug. 27, 1996, U.S. Pat. No. 5,604,260, issued Feb. 18, 1997, U.S. Pat. No. 5,698,584, issued Dec. 16, 1997, and U.S. Pat. No. 5,710,140, issued Jan. 20, 1998.
- Other examples of angiogenesis inhibitors include, but are not limited to, endostatin, ukrain, ranpimase, IM862, 5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2,5]oct-6-yl(chloroacetyl)carbamate, acetyldinanaline, 5-amino-1-[[3,5-dichloro4-(4-chlorobenzoyl)phenyl]-methyl]-1H-1,2,3-triazo le-4-carboxamide, CM101, squalamine, combretastatin, RP14610, NX31838, sulfated mannopentose phosphate, 7,7-(carbonyl-bis[imino-N-methyl4,2-pyrrolocarbonyi-imino[N-methyl4,2-pyrrole]-carbonylimino]-bis-(1,3-naphthalene disulfonate), and 3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone (SU5416).
- As used above, “integrin blockers” refers to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the αvβ3 integrin, to compounds which selectively antagonize, inhibit or counter-act binding of a physiological ligand to the αvβ5 integrin, to compounds which antagonize, inhibit or counteract binding of a physiological ligand to both the αvβ3 integrin and the αvβ5 integrin, and to compounds which antagonize, inhibit or counteract the activity of the particular integrin(s) expressed on capillary endothelial cells. The term also refers to antagonists of the αvβ6; αvβ8, α1β1, α5β1, α6β1 and α6β4 integrins. The term also refers to antagonists of any combination of αvβ3, αvβ5, αvβ6, αvβ8, α1β1, α2β1, α5β1, α6β1 and α5β4 integrins.
- Some specific examples of tyrosine kinase inhibitors include N-(trifluoromethylphenyl)-5-methylisoxazol4-carboxamide, 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl)indolin-2-one, 17-(allylamino)-17-demethoxygeldanamycin, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxyl]quinazoline, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine, BIBX1382, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-hydroxy-9-methyl-9,12-epoxy -1H-diindolo[1,2,3-fg:3′,2′,1′-k1]pyrrolo[3,4-1,6]benzodiazocin-1-one, SH268, genistein, ST1571, CEP2563, 4-(3-chlorophenylamino)-5,6-dimethyl-7H-pyrrolo [2,3-d]pyrimidinemethane sulfonate, 4-(3-bromo4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, 4-(4′-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, SU6668, SU11248, STI571A, N-4-chlorophenyl-4-(4-pyridylmethyl)-1-phthalazinamine, and EMD121974.
- The instant compounds are also useful, alone or in combination with platelet fibrinogen receptor (GP Iib/IIIa) antagonists, such as tirofiban, to inhibit metastasis of cancerous cells. Tumor cells can activate platelets largely via thrombin generation. This activation is associated with the release of VEGF. The release of VEGF enhances metastasis by increasing extravasation at points of adhesion to vascular endothelium (Amirkhosravi, Platelets 10, 285-292, 1999). Therefore, the present compounds can serve to inhibit metastasis, alone or in combination with GP Iib/IIIa) antagonists. Examples of other fibrinogen receptor antagonists include abciximab, eptifibatide, sibrafiban, lamifiban, lotrafiban, cromofiban, and CT50352.
- “DNA methyltransferase inhibitor” refers to compounds which inhibit the methylation of the DNA base cytosine at the C-5 position of that base by the DNA methyltransferase enzyme. Examples of such DNA methyltransferase inhibitor include compounds disclosed in U.S. Pat. Nos. 6,329,412 and 6,268,137. Specific DNA methyltransferase inhibitors include 5-azacytosine and zebularine®.
- If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described above and the other pharmaceutically active agent(s) within its approved dosage range. Compounds of the instant invention may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when a combination formulation is inappropriate.
- The term administration and variants thereof (erg., “administering” a compound) in reference to a compound of the invention means introducing the compound or a prodrug of the compound into the system of the animal in need of treatment. When a compound of the invention or prodrug thereof is provided in combination with one or more other active agents (e.g., a cytotoxic agent, etc.), “administration” and its variants are each understood to include concurrent and sequential introduction of the compound or prodrug thereof and other agents.
- As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- The compounds of the instant invention may also be co-administered with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated. For example, the compounds of the instant invention may also be co-administered with other well known cancer therapeutic agents that are selected for their particular usefulness against the condition that is being treated. Included in such combinations of therapeutic agents are combinations of the farnesyl-protein transferase inhibitors disclosed in U.S. Pat. No. 6,313,138 and an antineoplastic agent. It is also understood that such a combination of antineoplastic agent and inhibitor of farnesyl-protein transferase may be used in conjunction with other methods of treating cancer and/or tumors, including radiation therapy and surgery.
- Examples of an antineoplastic agent include, in general, microtubule-stabilizing agents (such as paclitaxel (also known as Taxol®, docetaxel (also known as Taxotere®, epothilone A, epothilone B, desoxyepothilone A, desoxyepothilone B or their derivatives); microtubule-disruptor agents; alkylating agents, anti-metabolites; epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes; biological response modifiers and growth inhibitors; hormonal/anti-hormonal therapeutic agents and haematopoietic growth factors.
- Example classes of antineoplastic agents include, for example, the anthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, the taxanes, the epothilones, discodermolide, the pteridine family of drugs, diynenes and the podophyllotoxins. Particularly useful members of those classes include, for example, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloro-methotrexate, mitomycin C, porfiromycin, Herceptin®, Rituxan®, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin or podo-phyllotoxin derivatives such as colchicines, etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosidine, vindesine, leurosine, paclitaxel and the like. Other useful antineoplastic agents include estramustine, cisplatin, carboplatin, cyclophosphamide, bleomycin, tamoxifen, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT-11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons and interleukins. The preferred class of antineoplastic agents is the taxanes and the preferred antineoplastic agent is paclitaxel.
- Radiation therapy, including x-rays or gamma rays that are delivered from either an externally applied beam or by implantation of tiny radioactive sources, may also be used in combination with the compounds of this invention alone to treat cancer.
- The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.
-
- Step 1
- To a solution of 2-aminoethanol (3.1 g, 50 mmol) in THF (10 ml) was added tert-butyloxycarbonyl anhydride (10.9 g, 50 mmol) in THF (150 ml). The reaction mixture was stirred for 3 h, then diluted with ethyl acetate, washed with 0.5 M aqueous HCl, and brine. The organic layer was dried (MgSO4), filtered and concentrated in vacuo to give 2-N-Boc-aminoethanol which was directly used in the next step.
- Step 2
- To a solution of triphenylphosphine (17.7 g, 67.5 mmol) in anhydrous THF (135 ml) was added DIAD (13.6 g, 67.5 mmol). The solution was stirred until a white precipitate was formed (2 to 10 min). After additional 60 min., a solution of 2-N-Boc amino-ethanol (7.2 g, 45 mmol) and methyl 4-hydroxybenzoate (6.8 g, 45 mmol) in THF (25 ml) was added and stirring was continued for 5 h. The reaction mixture was concentrated in vacuo and purified by flash chromatography to give methyl 4-(2-N-Boc aminoethoxy)benzoate. Alternatively, the crude material can directly be used in the next step.
- Step 3
- To a solution of crude methyl 4-(2-N-Boc aminoethoxy)benzoate in methanol (20 ml) was added 4M HCl/dioxane (180 ml). After stirring for 3 h, diethyl ether (300 ml) was added providing a white precipitate. The solid was collected, suspended in ethyl acetate and stirred for 15-20 min. The solid was collected again and dried under high vacuo providing methyl 4-(2-aminoethoxy)benzoate hydrochloride 6.3 g (60% over 2 steps).
- Step 4
- To a suspension of methyl 4-(2-amino-ethoxy)benzoate hydrochloride (0.232 g, 1 mmol) in THF (6 ml) was added benzoyl chloride (0.140 g, 1 mmol) followed by triethylamine (0.121 g, 1.2 mmol). The reaction mixture was stirred for 1 h and then diluted with ethyl acetate. The organic layer was washed with 0.5 M aqueous HCl, saturated sodium bicarbonate solution, and brine. The organic layer was concentrated in vacuo to give methyl 4-(2-benzenecarbonylamino-ethoxy)benzoate which was directly used in the next step.
- Step 5
- To a solution of crude methyl 4-(2-benzenecarbonylamino-ethoxy)benzoate (0.5 mmol) in a 1:1 mixture of THF/methanol (20 ml) was added 50 wt. % aqueous hydroxylamine (3 ml) followed by 1M aqueous NaOH (1 ml) adjusting the pH between 10-11. The reaction mixture was stirred for 14 h, neutralized to pH=7-8 with 6 M aqueous HCl and concentrated in vacuo. The precipitate was collected and purified by HPLC providing the title compound as a white solid. 1H NMR (DMSO-d6):δ8.69 (t, J=5.8 Hz, 1H), 7.83 (d, J=7.5 Hz, 2H), 7.69 (d, J=9.1 Hz, 2H), 7.46 (m, 3H), 6.99 (d, J=9.1 Hz, 2H), 4.16 (t, J=5.8 Hz, 211), 3.63 (q, J=5.8 Hz, 2H). EM (calc.): 300.1; MS (ESI) m/e: 301.1 (M−1)+, 299.0 (M+1)−.
- Proceeding as described in Example 1, Steps 1-4 above, but substituting 2-aminoethanol with (S)-(+)-2-amino-1-butanol provided methyl 4-(2S-aminobutoxy)benzoate hydrochloride.
-
- Step 1
- A mixture of benzofuran-2-carboxylic acid (0.162 g, 1 mmol), EDC-HCl (0.268 g, 1.4 mmol) and HOBT-H2O (0.203 g, 1.5 mmol) in DMF (6 ml) was stirred for 2 h. Methyl 4-(2-aminoethoxy)benzoate hydrochloride (0.232 g, 1 mmol) was added followed by triethylamine (0.121 g, 1.2 mmol). The reaction mixture was stirred for 2 h and then diluted with ethyl acetate, washed with saturated sodium bicarbonate solution, and brine. The organic layer was concentrated in vacuo and the crude 4-[2-(benzofuran-2-ylcarbonylamino)ethoxy]-benzoate was converted to the title compound as described in Example 1, Step 5 above. 1H NMR (DMSO-d6)δ11.05 (s, 1H), 8.92 (t, J=5.6 Hz, 11H), 8.88 (s, 1H), 7.76 (d, J=8.0 Hz, 1H), 7.70 (d, J=9.2 Hz, 2H), 7.64 (d, J=8.0 Hz, 1H), 7.55 (s, 1H), 7.46 (t, J=6.8 Hz, 1H), 7.32 (t, J=8.0 Hz, IH), 7.01 (d, J=8.2 Hz, 21H), 4.18 (t, J=5.6 Hz, 2H), 3.67 (m, 2H). EM (calc.): 340.1; MS (ESI) m/e: (M+1H)+: 341.0, (M−1H)−: 339.1.
-
- To a suspension of methyl 4-(2-aminoethoxy)benzoate hydrochloride (0.232 g, 1 mmol) in THF (6 ml) was added benzothiophene-2-carbonyl chloride (0.150 g, 1 mmol) followed by triethylamine (0.121 g, 1.2 mmol). The reaction mixture was stirred for 1 h and diluted with ethyl acetate (50 ml). The organic layer was washed with 0.5 M aqueous HCl, saturated sodium bicarbonate solution, and brine. The organic layer was concentrated in vacuo and the crude methyl 4-[2-(benzothiophen-2-yl-carbonylamino)etboxy]benzoate was converted to the title compound as described in Example 1, Step 5 above.
- Proceeding as described in Example 3 above, but substituting methyl 4-(2-aminoethoxy)benzoate hydrochloride with methyl 4-(2S-aminobutoxy)benzoate hydrochloride and benzotbiophene-2-carbonyl chloride with cinnamoyl chloride provided N-hydroxy-4-[2S-(trans-cinnamoylamino)butoxy]benzamide.
-
- Step 1
- To a solution of 3-methyl-benzofuran-2-carboxylic acid (0.98 g, 5.6 mmol) and 5 drops of DMF in THF (25 ml) was added oxalyl chloride (0.53 ml, 6.1 mmol). After stirring the solution for 1 h at room temperature, methanol (20 ml) and TEA (7 ml) were added. The slurry was stirred overnight at room temperature, then concentrated and dissolved in ethyl acetate (100 ml) and washed with mild NaHCO3 (100 ml). The organic layer was dried (MgSO4), filtered and concentrated to collect 3-methylbenzofuran-2-carboxylic acid methyl ester (1 g) as a tan solid. The crude methyl ester was used without further purification.
- Step 2
- A solution of 3-methylbenzofuran-2-carboxylic acid methyl ester (1.0 g, 5.3 mmol), NBS (0.95 g, 5.3 mmol) and AIBN (87 mg, 0.53 mmol) was heat to reflux in CC14 (40 ml) for 3 h, then cooled to room temperature and concentrated. The residue was dissolved in ethyl acetate (100 ml) and washed with water (100 ml). The organic layer was dried (MgSO4), filtered and concentrated to collect 3-bromomethylbenzofuran-2-carboxylic acid methyl ester (1.55 g) of a tan/yellow solid which was used in the next step without further purification.
- Step 3
- 3-Bromomethylbenzofuran-2-carboxylic acid methyl ester (269 mg, 1 mmol) was dissolved in anhydrous DMF and added 2M dimethylamine/THF solution (1.5 ml, 3 mmol). After 1-2 h, the reaction was diluted with EtOAc and washed twice with saturated NaHCO3 (aq.) and brine. The organic extract over was dried over Na2SO4 and then concentrated in vacua. The crude was purified on a silica gel column (5% MeOH in dichloromethane) to give 3-dimethylaminomethylbenzofuran-2-carboxylic acid methyl ester (131 mg).
- Step 4
- To a solution of 3-dimethylaminomethylbenzofiuran-2-carboxylic acid methyl ester (131 mg, 0.56 mmol) in MeOH was added 1N NaOH(aq.) till the pH of the solution was 13. The reaction mixture was stirred for 60-90 min. Upon completion, the reaction mixture was acidified to pH 3 with HCl (aq.) and concentrated to dryness to give 3-dimethylaminomethylbenzofiran-2-carboxylic acid as the HCl salt, which was used for next step without further purification.
- Step 5
- To 3-dimethylaminomethylbenzofuran-2-carboxylic acid (140 mg, 0.56 mmol) was added EDC.HCl (150 mg, 0.784 mmol) and HOBt. H2O (114 mg, 0.84 mmol) in anhydrous DMF. The reaction mixture was stiffed for 30-60 min., after which methyl-(4-(2-ethoxyamine))benzoate hydrochloric salt (130 mg, 0.56 mmol) and triethylamine (94 μL, 0.672 mmol) were added and the reaction was stirred overnight. The reaction mixture was diluted with EtOAc and washed twice with saturated NaHCO3 (aq.) and brine. The organic extract was concentrated in vacuo to give methyl 4-[2-(3dimethylaminobenzofuran-2-yl-carbonylamino)ethoxy]benzoate, which was then used without further purification.
- Step 6
- To a solution of crude methyl 4-[2-(3-dimethylaminobenzofuran-2-yl-carbonylamino)-ethoxy]-benzoate in MeOH and THF was added excess aqueous hydroxylamine solution and NaOH(aq.) to give pH 10-11. The reaction mixture was stirred overnight and then neutralized to pH 7-8 with aqueous hydrochloric acid and concentrated in vacuo. The residue was dissolved in acetonitrile and water and purified with prep HPLC to give the title compound (107 mg). 1H NMR (400 MHz, DMSO-d6)δ9.88 (m, 1H), 9.31 (t, J=6.0 Hz, 1H), 8.04 (d, J=7.6 Hz, 1H), 7.70 (m, 3H), 7.57 (t, J=7.6 Hz, 1H), 7.45 (t, J=7.6 Hz, 1H), 6.99 (d, J=9.2 Hz, 2H), 4.76 (d, J=4.8 Hz, 2H), 4.23 (t, J=6.0 Hz, 2H), 3.71 (m, 2H), 2.84 (s, 3H), 2.83 (s, 3H). EM (calc.): 397.2; MS (ESI) m/e (M+1H)+: 398.1, (M−1H)−: 396.2.
-
- Step 1
- Sodium hydride (15 mg, 0.56 mmol) was suspended in anhydrous DMF and stirred under N2(g). 2,2,2-Trifluoroethanol (270 μL, 3.7 mmol) was added and after stirring the reaction mixture for 15-20 min., 3-bromomethylbenzofuran-2-carboxylic acid methyl ester was added. After 8 h, 1N NaOH (aq.) was added and the reaction mixture was stirred for 10-15 min. The reaction mixture was acidified reaction to pH 3 with aqueous hydrochloric acid and the product was extracted with EtOAc. The organic layer was dried organic over Na2SO4 and concentrated in vacuo to give 3-(2,2,2-trifluoroethoxymethyl)benzofuran-2-carboxylic acid (38 mg) which was then used without purification.
- Step 2
- To a solution of 3-(2,2,2-trifluoroethoxymethyl)benzofuran-2-carboxylic acid (38 mg, 0.139 mmol) in anhydrous DMF was added EDC.HCl (37 mg, 0.195 mmol) and HOBt.H2O (26 mg, 0.195 mmol). After 60-90 min., methyl-(4-(2-ethoxyamine))benzoate hydrochloric salt (32 mg, 0.139 mmol) and triethylamine (23 μL, 0.167 mmol) were added and the reaction mixture was stirred for 1-2 h. The reaction mixture was diluted with EtOAc and washed twice with saturated NaHCO3(aq.) and the organic extract was concentrated to give methyl 4-(2-[3-(2,2,2-trifluoroethoxymethyl)benzofuran-2-yl-carbonylamino]ethoxy}-benzoate, which was then used without further purification.
- Step 3
- 4-(2-[3-(2,2,2-Trifluoroethoxymethyl)benzofiuran-2-yl-carbonylamino]-ethoxy}-benzoate was dissolved in MeOH and excess aqueous hydroxylamine solution and NaOH(aq) were added to give pH 10-11. After stirring overnight, the reaction mixture was neutralized reaction to pH 7-8 with aqueous hydrochloric acid. The reaction mixture was concentrated in vacuo to give a solid which was collected and washed with water, then dissolved in acetonitrile and water and purified with prep HPLC to give the title compound (35 mg). 1H NMR (400 MHz, DMSO-d6)δ11.04 (s, 1H), 8.95 (t, 1=5.6 Hz, 1H), 8.89 (s, 1H), 7.81 (d, J=7.6 Hz, 1 H), 7.70 (d, J=8.8 Hz, 2H), 7.63 (d, J=8.8 Hz, 1H), 7.50 (t, J=8.8 Hz, 1H), 7.36 (t, J=8.0 Hz, 1H), 7.00 (d, J=9.2 Hz, 2H), 5.25 (s, 2H), 4.18 (m, 4H), 3.67 (m, 2H). EM (calc.): 452.1; MS (ESI) m/e (M+1H)+: 453.0, (M−1H)+: 451.0.
-
- Step 1
- 5-Methoxybenzofuran-2-carboxylic acid (5.04 g, 26 mmol) was weighed into a 200 ml round bottom flask fitted with a stir bar, septum and nitrogen inlet. Anhydrous MeOH (50 ml) was added under nitrogen atmosphere. The solution was cooled in an ice bath and thionyl chloride (2.3 ml, 32 mmol) was added dropwise with vigorous stirring. After stirring for 72 h at room temperature, the reaction mixture was poured into water (150 ml) and the white solid was collected. The solid was dissolved in toluene (100 ml) and the solution was washed with 1M NaHCO3 and brine and dried over MgSO4. Removal of the organic layer provided 5-methoxybenofuran-2-carboxylic acid methyl ester as a white solid (5.15 g).
- Step 2
- A solution of 5-methoxybenzofuran-2-carboxylic acid methyl ester (5.15 g, 25 mmol) in anhydrous methylene chloride (15 ml) was cooled to −40° under nitrogen atmosphere. Boron tribromide in CH2Cl2 (27 ml of 1.0 M) was added over 1 h using a syringe pump. The reaction mixture was allowed to warm to room temperature. After 16 h, the reaction mixture was cooled in an ice bath and quenched with MeOH (15 ml). The reaction mixture was poured into brine (100 ml) and extracted with EtOAc. The organic extracts were dried over anhydrous MgSO4, and the solvent was removed on rotary evaporator. The residue was triturated with hexane and the yellow solid was filtered and dissolved in anhydrous MeOH (30 ml). The solution was cooled in an ice bath and thionyl chloride (1.9 ml, 26 mmol) was added dropwise. After 72 h, water (100 ml) was added and solid was collected. Purification of the crude product on a 300 cm3 silica gel in a 5×15 cm plug using EtOAc provided 5-hydroxy-benzofuran-2-carboxylic acid methyl ester (4.53 g).
- Step 3
- Anhydrous tetrahydrofuran (15 ml) was added to a mixture of 5-hydroxybenzofuran-2-carboxylic acid methyl ester (1.10 g, 5.7 mmol), triphenylphosphine (1.50 g, 5.7 mmol), and 1-(2-hydroxyethyl)-pyrrolidine (0.66 g, 5.7 mmol) under a nitrogen atmosphere. Diisopropyl azodicarboxylate (1.15 ml, 5.8 mmol) was slowly added to the solution at room temperature. After 2 days, the solvent was removed and the residue was dissolved in a 2:1 mixture of Et2O:EtOAc (150 ml). The solution was washed with 1.0M aqueous NaOH. The product was extracted into 1.0 M hydrochloric acid and the combined acid extracts were washed with Et2O. The extracts were cooled and the pH of the extracts was adjusted to pH 12 with 50% aqueous NaOH. The basic solution was extracted with CH2Cl2 and the organic layer was dried over anhydrous MgSO4, and concentrated to give 5-(2-pyrrolidin-1-yl-ethoxy)benzofuran-2-carboxylic acid methyl ester (0.96 g) as an amber colored solid.
- Step 4
- To an ice-cooled solution of 5-(2-pyrrolidin-1-ylethoxy)benzofuran-2-carboxylic acid methyl ester (960 mg, 3.3 mmol) anhydrous ethylene glycol dimethyl ether (10 ml) was added dropwise degassed aqueous lithium hydroxide solution (2.0 ml, 2.0M). After stirring at room temperature for 4 h, the solution was cooled down and the pH was adjusted to 2 with 4.0 M HCl in dioxane. A gummy tan precipitate formed. The solvent was removed and the gummy residue was frozen and lyophilized. The tan colored solid was dissolved in boiling 2-propanol (90 ml), the solution was filtered hot and then cooled to give 5-(2-pyrrolidin-1-yl-ethoxy)-benzofuran-2-carboxylic acid as beige colored needles (528 mg). Additional 153 mg was obtained from the mother liquor.
- Step 5
- To a solution of 5-(2-pyrrolidin-1-ylethoxy)benzofiuran-2-carboxylic acid (156 mg, 0.50 mmol) and 4-(2-aminoethoxy)benzoic acid methyl ester hydrochloride (129 mg, 0.56 mmol) in DMF (4.5 ml) in a 20 ml vial was added diisopropylethylamine (0.88 ml, 5.1 mmol). A solution of O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (740 μL, 0.82 M, 0.61 mmol) in DMF was added to give a bright yellow solution. The vial was purged with nitrogen and stirred at room temperature for 18 h. The solution was removed and the residue was dissolved in EtOAc (25 ml) and washed with H2O, 1.0M aqueous K2CO3, and brine. The organic layer was dried over anhydrous MgSO4 and solvent was removed on a rotary evaporator. Purification of the residue by column chromatography on a silica gel column using 93:5:2 CH2Cl2:MeOH:TEA eluent provided 4-{2- [5-(2-pyrrolidin-1-ylethoxy)benzofuran-2-carbonylamino]-ethoxy}-benzoic acid methyl ester as a beige solid (174 mg).
- Step 6
- To a solution of 4-{2- [5-(2-pyrrolidin-1-ylethoxy)benzofuran-2-carbonylamino]-ethoxy}-benzoic acid methyl ester (169 mg, 0.37 mmol) in methanol (8 ml) and tetrahydrofuran (4 ml) was added hydroxylamine in water (2.9 ml of a 50 wt. % solution) and 4.0 M aqueous solution of sodium hydroxide (0.65 ml). After stirring for 18 h, the organics were removed and the aqueous solution was cooled in an ice/water bath and the pH was adjusted to −8 with 4.4 ml 1.0 M hydrochloric acid to give precipitates. The heterogeneous solution was warmed to room temperature and acetonitrile was added till the precipitates dissolved. The solution was chromatographed on C-18 reverse phase HPLC. Fractions with absorbance at 214 nm, were collected, frozen, and lyophilize to give the title compound (31 mg). 1H NMR (400 MHz, DMSO-d6)δ: 11.05 (s, 1H), 10.4 (s, 1H), 8.91 (s, 2H), 7.70 (d, 2H, J=7.4), 7.59 (dd, 1H, J=3.7, 9.1Hz), 7.51 (d, 1H, J=3.7 Hz), 7.35 (s, 1H), 7.13 (d, 1H, J=9.0 Hz), 7.00 (d, 2H, J=7.4 Hz), 4.37 (m, 2H), 4.18 (m, 2H), 3.62 (m, 6H), 3.12 (m, 2H), 2.02 (m, 2H), 1.89 (m, 2H). EM (calc.): 453.2; MS (ESI) m/e (M+1H)+: 454.1, (M−1H)−: 452.2.
-
- Step 1
- (2-Hydroxyethyl)carbamic acid tert-butyl ester (152.0 g, 0.942 mol) and 4-hydroxybenzoic acid methyl ester (174.0 g, 1.12 mol) were dissolved in tetrahydrofuran (2000 ml) and cooled to 0-5° C. Triphenylphosphine (292.8 g 1.116 mol) was added to the cooled mixture. A solution of diisopropyl azodicarboxylate (246.0 g, 1.218 mol) in tetrahydrofuran (400 ml) was added dropwise over a period of one to two hours keeping the reaction temperature below 10° C. After addition, the reaction was allowed to warm slowly to ambient temperature and stirred overnight. After completion of reaction, solvent was distilled under reduced pressure and the resulting oil was dissolved in ethanol (500 ml) and ethyl acetate (2000 ml). Acetyl Chloride (222.0 g, 2.826 mol) was added drop wise over fifteen minutes with the temperature allowed to rise to 40° C. The resulting suspension was stirred at 40° C. until completion of reaction. After completion of reaction, the resulting crystals were filtered on a coarse frit and washed with ethyl Acetate (300 mL). The material is dried in vacuo to to give of 4-(2-aminoethoxy)benzoic acid methyl ester hydrochloride (204.1 g) as a white crystalline solid.
- Step 2
- 4-(2-Aminoethoxy)benzoic acid methyl ester hydrochloride (78.90 g, 0.340 mol) and 3-methylbenzofuran-2-carboxylic acid (60.0 g, 0.340 mol) were suspended in acetonitrile (360 ml) and cooled to 0-5° C. Pyridine (137.6 mL, 1.702 mol) was added quickly. A solution of phosphorous oxychloride (52.2 g, 0.340 mol) in acetonitrile (60 ml) was added drop wise over thirty to forty-five minutes with the temperature kept below 20° C. The reaction mixture was allowed to stir for one hour and warm slowly to ambient temperature. After completion of reaction, the solution was added to a rapidly stirred 0-5° C. mixture of chlorobenzene (1000 ml) and 1N hydrochloric acid (1000 ml). The reaction mixture was stirred rapidly and allowed to warm to room temperature. The organic layer was washed with water, 3% potassium hydroxide, and again with water. Chlorobenzene (100 ml) was added to the washed organic layer. Solvent (100 ml) was then distilled at atmospheric pressure until the pot temperature reached 132° C. After cooling to ambient temperature, 4-{2-[(3-methylbenzofuran-2carbonyl)amino]ethoxy}benzoic acid methyl ester was stored in solution for use in the next step.
- Step 3
- A solution of 4-(2-[(3-methylbenzofuran-2-carbonyl)amino]ethoxy}benzoic acid methyl ester (0.340 mol) in chlorobenzene (1000 ml) was treated with 2,2′-azobisisobutyronitrile (5.60 g, 0.017 mol) and N-bromosuccinimide (75.76 g, 0.426 mol). The resulting mixture is heated to 80° C. and stirred for one hour. After completion of reaction, the reaction mixture was cooled to ambient temperature and washed with water, 3% sodium hydrogensulfite, and again with water. Solvent was distilled under reduced pressure and after cooling to ambient temperature, dichloromethane was added and to give 4-{2-[(3-bromomethylbenzofuran-2-carbonyl)amino]ethoxy}benzoic acid methyl ester which was used in the next step.
- Step 4
- A solution of 4-{2-[(3-bromomethylbenzofuran-2-arbonyl)amino]ethoxy}-benzoic acid methyl ester (0.340 mol) in chlorobenzene (200 ml) and dichloromethane (800 ml) was added dropwise to a 0-5° C. solution of 2M dimethylamine in tetrahydrofuran (510 ml, 1.022 mol) over 30 minutes with the temperature below 20° C. The resulting mixture was stirred for one hour and allowed to warm to ambient temperature. After completion of reaction, the reaction mixture was washed with 5% potassium carbonate and water. Solvent was distilled at atmospheric pressure until the pot temperature reached 100° C. After cooling to ˜50° C., acetonitrile (400 ml) and ethyl Acetate (400 ml) were added to the pot. The reaction mixture was heated to reflux until all solids dissolved. The reaction mixture was allowed to cool to give 4-{2-[(3-dimethylaminomethyl-benzofuran-2-arbonyl)amino]ethoxy)benzoic acid methyl ester (76.6 g) as an off white powder.
- Sep 5
- 4-{2-[(3-Dimethylaminomethylbenzofuran-2-carbonyl)amino]ethoxy}benzoic acid methyl ester (70.0 g, 0.177 mol) was suspended in methanol (350 ml). 50% Potassium hydroxide (139.8 g, 1.062 mol) was added and the reaction mixture was heated to 60° C. until completion of reaction. After cooling to room temperature, the resulting crystals were filtered on a coarse frit and washed with methanol. The crystals were dried in vacuo to give 4-{2-[(3-dimethylaminomethylbenzofuran-2-carbonyl)amino]ethoxy}benzoic acid potassium salt (72.0 g) as a white solid.
- Step 6
- 4-{2-[(3-Dimethylaminomethylbenzofuran-2-carbonyl)amino]ethoxy}benzoic acid potassium salt (20.0 g, 0.0476 mol) was suspended in N,N-Dimethylformamide (100 ml). 4 Molar hydrochloric acid in dioxane (11.9 ml, 0.0476 mol) was added to the suspension. After stirring for thirty minutes at ambient temperature, the reaction mixture was filtered through a medium frit. 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (10.94 g, 0.0571 mol) and 1-hydroxybenzotriazole (7.71 g, 0.0571 mol) were added to the solution and the reaction mixture was stirred one hour at ambient temperature. In a separate pot, hydroxylamine hydrochloride (13.2 g, 1.904 mol) was suspended in N,N-dimethylformamide (100 ml) and treated with triethylamine (33.1 ml, 2.380 mol). After stirring the reaction mixture for 1 h, the salt was filtered off and the resulting solution was added to the above activated acid solution and stirred at ambient temperature until completion of reaction. After the product began to crystallize, methanol (150 ml) was added slowly over thirty min. The reaction mixture was stirred for 1 h at ambient temperature then cooled to 0-5° C. and stirred another hour. The crystals were filtered and washed with methanol (40 ml) before being dried in vacuo to give 3-dimethylaminomethylbenzofuran-2-carboxylic acid [2-(4-hydroxy-carbamoylphenoxy)ethyl]amide (11.88 g) as a white solid. The crude material (13.25 g, 0.033 mol) was suspended in N,N-dimethylformamide (80 ml) and heated to 100° C. to give a solution. After cooling, ethanol (80 ml) was added drop-wise over thirty minutes and the resulting suspension was allowed to cool for an hour. The crystals were filtered and washed with ethanol (40 ml) and dried to give pure product (9.82 g) as a white solid.
- Step 7
- N-hydroxy-4-[2-(3-dimethylaminobenzofuran-2-ylcarbonylamino)ethoxy]-benzamide (22.7 g, 0.057 mol) was suspended in 2-propanol (220 ml). 12 M HCl (5.2 ml, 0.063 mol) was added in one portion and the resulting mixture was heated to reflux. Water (44 ml) was added dropwise until a homogenous solution was obtained. The reaction mixture was allowed to cool and crystallize overnight. After cooling below 5° C. for one h, the crystals were filtered and washed with 2-propanol before being dried in vacuo to to give the title compound (22.0 g) as a white solid.
-
- Step 1
- To a solution of diisopropyl azodicarboxylate (DIAD, 4.04 g, 20 mmol) in THF (100 ml) at 0° C. was added triphenylphosphine (5.25 g, 20 mmol). After 1h, a solution of Boc-ethanolamine (3.22 g, 20 mmol) in THF (10 ml) was added. After 20 min., a solution of methyl 4-mercaptobenzoate (3.86 g, 20 mmol) in THF (10 ml) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was concentrated and ethyl acetate (150 ml) was added. The solution was washed with 1M HCl, saturated aqueous NaHCO3, brine, dried over MgSO4, filtered, and evaporated to dryness. The oily yellow residue was eluted through a plug of silica gel (0-20 ethyl acetate in hexane as mobile phase) and the product was then recrystallized from ether and hexane to give methyl 4-(2-tert-butoxycarbonylaminoethylsulfanyl)benzoate (4.00 g).
- Step 2
- A solution of methyl 4-(2-tert-butoxycarbonylaminoethylsulfanyl)benzoate (1.00 g, 3.21 mmol) in dichloromethane (8 ml) was treated with a solution of HCl in dioxane (4M, 8 ml, 10 eq.) at room temperature for 3 h. Ether (100 ml) was added and the mixture was filtered, washed with ether and pumped dry to give methyl 4-(2-aminoethylsulfanyl)benzoate hydrochloride.
- Step 3
- Methyl 4-(2-aminoethylsulfanyl)benzoate hydrochloride (0.248 g, 1.00 mmol), was combined with benzofuran-2-carboxylic acid (0.162 g, 1.00 mmol) and HBTU (0.379 g, 1.00 mmol) in DMF (5 ml) at room temperature. Triethylamine (0.307 ml, 2.2 mmol) was added and the reaction mixture was stirred at room temperature overnight. Saturated aqueous NaHCO3 (15 ml) was added to give precipitates which was broken up by the addition of water (20 ml). The solid was filtered and the cake was dissolved in ethyl acetate. The residual water was removed by pipette and hexane was added to give methyl 4-{2-[(benzofuran-2-yl-carbonyl)-amino]ethylsulfanyl)benzoate (0.138 g) as a gum which was used in the next step without further purification.
- Step 4
- To a solution of methyl 4-{2-[(benzofuran-2-yl-carbonyl)amino]ethylsulfanyl}-benzoate in THF (2 ml) was added a solution of 50% hydroxylamine in water (4 ml). Methanol (2 ml) and 0.1 M NaOH (0.1 ml) were added. The reaction mixture was stirred for three days at room temperature. The solvents were evaporated and the residue was crystallized from dichloromethane/ethyl acetate, to give the title compound (46 mg).
- 1H NMR (DMSO-d6): 3.12 (2H, m); 3.5 (2H, m); 7.33 (1H, t); 7.42 (2H, d); 7.45 (1H, m*); 7.53 (1H, s); 7.62 (1H, d); 7.7 (2H, d); 7.78 (1H, d); 8.96 (1H, t); 8.99 (1H, br. s). MS (M+1): 357.
-
- Step 1
- To a solution of methyl 4-(2-tert-butoxycarbonylaminoethylsulfanyl)-benzoate (3.00 g, 9.63 mmol) in methanol/water (1:1, 100 ml) was added Oxone® (13.03 g, 21.19 mmol). After 48 h, methanol was removed under reduced pressure, and the residue was partitioned between ethyl acetate (150 ml) and saturated aqueous NaHCO3 (150 ml). The organic phase was washed with brine (100 ml), dried over MgSO4, filtered, concentrated in vacuo, and the residue was recrystallized from ethyl acetate/hexane to give methyl 4-2-tert-butoxycarbonylamino-ethanesulfonyl)benzoate (2.86 g) of the product.
- Step 2
- A solution of methyl 4-(2-tert-butoxycarbonylaminoethanesulfonyl)benzoate (2.86 g, 8.33 mmol) in dichloromethane (20 ml) was treated with 4M HCl in dioxane (20 ml) for 2 h. Ether (200 ml) was added and the suspension was filtered, washed with ether (2×50 ml), hexane (50 ml) and pumped dry to give methyl 4-(2-aminoethylsulfonyl)benzoate hydrochloride (2.23 g) which was coupled with benzofuran 2-carboxylic acid as described above to afford the title compound. MS (M+1): 388.
- Proceeding as described in Example 1-3 above but using appropriate commercially available starting materials the following compounds of Table I-IV were prepared.
TABLE 1 Cpd. 1 1H NMR (400 MHz, DMSO-d6) δ 8.69 (t, J = 5.8 Hz, 1H), 7.83 (d, J = 7.5 Hz, 2H), 7.69 (d, J = 9.1 Hz, 2H), 7.46 (m, 3H), 6.99 (d, J = 9.1 Hz, 2H), 4.16 (t, J = 5.8 Hz, 2H), 3.63 (q, J = 5.8 Hz, 2H). EM (calc.): 300.1; MS (ESI) m/e: 301.1 (M − 1)+, 299.0 (M + 1)−. Cpd. 2 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 8.92 (s, 1H), 8.41 (t, J = 6 Hz, 1H), 7.74 (d, J = 8.8 Hz, 2H), 7.58 (d, J = 6.8 Hz, 2H), 7.46 (d, J = 15.6 Hz, 1H), 7.45-7.37 (m, 3H), 7.03 (d, J = 8.8 Hz, 2H0, 6.72 (d, J = 15.6 Hz, 1H), 4.13 (t, J = 5.2 Hz, 2H), 3.60 (q, J = 5.6 Hz, 2H). EM (calc.): 326.1; MS (ESI) m/e (M + 1H)+: 327.1, (M − 1H)−: 325.2. Cpd. 3 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.91 (s, 1H), 8.42 (t, J = 4.8 Hz, 1H), 7.72 (d, J = 8.4 Hz, 2H), 7.27 (t, J = 7.2 Hz, 2.0 Hz), 7.18 (t, J = 7.2 Hz, 1H), 7.13 (d, J = 7.2 Hz, 2H), 7.01 (d, J = 8.8 Hz, 2H), 4.07 (t, J = 5.6 Hz, 2H), 3.49 (dq, J1 = 5.6 Hz, J2 = 1.6 Hz, 2H), 2.28 (ddd, J1 = 4.0 Hz, J2 = 5.6 Hz, J3 = 9.6 Hz, 1H), 1.95 (ddd, J1 = 4.1 Hz, J2 = 5.2 Hz, J3 = 8.4 Hz, 1H), 1.39 (ddd, J1 = 4.0 Hz, J2 = 5.2 Hz, J3 = 9.2 Hz, 1H), 1.24 (ddd, J1 = 4.0 Hz, J2 = 6.4 Hz, J3 = 10.4 Hz, 1H). EM (calc.): 340.1; MS (ESI) m/e (M + 1H)+: 341.2, (M − 1H)−: 339.2. Cpd. 4 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 8.92 (s, 1H), 8.31 (t, J = 5.6 Hz, 1H), 7.73 (d, J = 9.2 Hz, 2H), 7.52 (d, J = 9.2 Hz, 2H), 7.41 (d, J = 15.6 Hz, 1H), 7.03 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 8.8 Hz, 2H), 6.55 (d, J = 15.6 Hz, 1H), 4.12 (t, J = 5.6 Hz, 2H), 3.81 (s, 3H), 3.58 (q, J = 5.6 Hz, 2H). EM (calc.): 356.1; MS (ESI) m/e (M + 1H)+: 357.2, (M − 1H)−: 355.2. Cpd. 5 1H NMR (400 MHz, DMSO-d6) δ 10.96 (s, 1H), 8.80 (s, 1H), 8.01 (t, J = 4.8 Hz, 1H), 7.61 (d, J = 8.8 Hz, 2H), 7.14-7.02 (m, 5H), 6.86 (d, J = 8.8 Hz, 2H), 3.32 (q, J = 5.6 Hz, 2H), 2.71 (t, J = 7.2, 2H), 2.30 (t, J = 7.6 Hz, 2H). EM (calc.): 328.1; MS (ESI) m/e (M + 1H)+: 329.2, (M − 1H)−: 327.0. Cpd. 6 1H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 10.89 (s, 1H), 8.95 (br s, 1H), 8.22 (t, J = 5.6 Hz, 1H), 7.76 (d, J = 8.8 Hz, 2H), 7.56 (d, J = 8.0 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.22 (d, J = 2.0 Hz, 1H), 7.08 (t, J = 7.6 Hz, 1H), 7.02 (d, J = 8.4 Hz, 2H), 6.93 (t, J = 8.4 Hz, 1H), 4.09 (pseudo t, J = 6.0 Hz, 2H), 3.58 (s, 2H), 3.50 (pseudo q, J = 5.6 Hz, 2H). EM (calc.): 353.1; MS (ESI) m/e (M + 1H)+: 353.9, (M − 1H)−: 252.0. Cpd. 7 1H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 8.80 (t, J = 5.6 Hz, 1H), 7.82 (d, J = 7.6 Hz, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.76 (d, J = 8.4 Hz, 2H), 7.19 (t, J1 = 5.2 Hz, 1H), 7.06 (d, J = 8.8 Hz, 2H), 4.21 (pseudo t, J = 6.0 Hz, 2H), 3.67 (pseudo q, J = 5.6 Hz, 2H). EM (calc.): 306.1; MS (ESI) m/e (M + 1H)+: 307.0, (M − 1H)−: 304.9. Cpd. 8 1H NMR (400 MHz, DMSO-d6) δ 8.98 (s, 1H), 8.9 (t, J = 5.4 Hz, 1H), 8.67 (d, J = 4.6 Hz, 1H), 8.16 (d, J = 8.1 Hz, 1H), 7.69 (d, J = 8.9 Hz, 2H), 7.48 (m, 1H), 6.99 (d, J = 8.9 Hz, 2H), 4.17 (t, J = 5.4 Hz, 2H), 3.65 (m, 2H). EM (calc.): 301.11; MS (ESI) m/e (M − 1H)−: 300.0. Cpd. 9 1H NMR (400 MHz, DMSO-d6) δ 11.03 (1H, s), 8.87 (1H, bs), 8.74 (1H, t, J = 5.6 Hz), 7.93 (2H, d, J = 8.0 Hz), 7.75 (2H, d, J = 8.0 Hz), 7.69 (3H, m), 7.47 (1H, t, J = 8.0 Hz), 7.39 (2H, m), 6.99 (2H, d, J = 8.9 Hz), 4.18 (2H, t, J = 5.6 Hz), 3.66 (2H, m). EM (calc.): 376.41; MS (ESI) m/e (M + 1H)+: 377.1, (M − 1H)−: 375.0. Cpd. 10 EM (calc.): 376.1; MS (ESI) m/e (M + 1)+: 376.9, (M − 1)−: 375.1. Cpd. 11 1H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H0, 8.95 (s, 1H), 8.84 (t, J = 6.0 Hz, 1H), 7.83 (d, J = 4.0 Hz, 1H), 7.77 (d, J = 9.2 Hz, 2H), 7.75 (d, J = 7.2 Hz, 2H), 7.59 (d, J = 4.0 Hz, 1H), 7.49 (pseudo t, J = 7.2 Hz, 2H), 7.41 (pseudo t, J = 7.6 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 4.22 (pseudo t, J = 5.6 Hz, 2H), 3.69 (pseudo q, J = 5.2 Hz, 2H). EM (calc.): 382.1; MS (ESI) m/e (M + 1H)+: 383.1, (M − 1H)−: 381.0. Cpd. 12 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 10.15 (s, 1H), 8.36 (t, J = 5.6 Hz, 1H), 7.70 (d, J = 8.8 Hz, 2H), 7.32 (m, 1H), 6.97 (d, J = 8.8 Hz, 2H), 6.92 (m, 1H), 6.88 (m, 1H), 4.04 (t, J = 5.6 Hz, 2H), 3.66 (s, 2H), 3.45 (m, 2H). EM (calc.): 320.1; MS (ESI) m/e (M + 1H)+: 320.9, (M − 1H)−: 319.0. Cpd. 13 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.87 (m, 2H), 8.45 (s, 1H), 7.97 (m, 4H), 7.71 (d, J = 8.8 Hz, 2H), 7.59 (m, 2H), 7.02 (d, J = 8.8 Hz, 2H), 4.21 (t, J = 5.6 Hz, 2H), 3.71 (m, 2H). EM (calc.): 350.1; MS (ESI) m/e (M + 1H)+: 350.9, (M − 1H)−: 349.1. Cpd. 14 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.98 (m, 2H), 8.52 (m, 2H), 8.19 (d, J = 8.8 Hz, 1H), 8.08 (d, J = 8.8 Hz, 1H), 7.71 (d, J = 8.8 Hz, 2H), 7.62 (m, 1H), 7.02 (d, J = 8.8 Hz, 2H), 4.22 (t, J = 5.6 Hz, 2H), 3.72 (m, 2H). EM (calc.): 351.1; MS (ESI) m/e (M + 1H)+: 351.8, (M − 1H)−: 349.9. Cpd. 15 EM (calc.): 383.1; MS (ESI) m/e (M + 1)+: 383.9, (M − 1)−: 382.2. Cpd. 16 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.88 (s, 1H), 8.61 (t, J = 4.8 Hz, 1H), 7.78 (d, J = 8.4 Hz, 2H), 7.70 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 8.6 Hz, 2H), 4.15 (t, J = 5.6 Hz, 2H), 3.62 (m, 2H), 1.29 (s, 9H). EM (calc.): 356.2; MS (ESI) m/e (M + 1H)+: 357.0, (M − 1H)−: 355.1. Cpd. 17 1H NMR (400 MHz, DMSO-d6) δ 11.06 (s, 1H), 8.95 (s, 1H), 8.72 (d, J = 5.2 Hz, 1H), 8.56 (t, J = 4.8 Hz, 1H), 8.40 (d, J = 7.6 Hz, 1H), 7.80 (m, 1H), 7.71 (d, J = 8.8 Hz, 2H), 7.55 (d, J = 16.0 Hz, 1H), 7.00 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 16.0 Hz, 1H), 4.12 (t, J = 5.6 Hz, 2H), 3.59 (m, 2H). EM (calc.): 327.1; MS (ESI) m/e (M + 1H)+: 328.1, (M − 1H)−: 326.1. Cpd. 18 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.88 (s, 1H), 8.73 (t, J = 5.6 Hz, 1H), 7.93 (d, J = 9.2 Hz, 2H), 7.69 (m, 4H), 7.47 (t, J = 2.4 Hz, 2H), 7.01 (d, J = 9.2 Hz, 2H), 6.29 (t, J = 2.4 Hz, 2H), 4.18 (t, J = 5.6 Hz, 2H), 3.66 (m, 2H). EM (calc.): 365.1; MS (ESI) m/e (M + 1H)+: 366.0, (M − 1H)−: 364.2. Cpd. 19 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.53 (t, J = 5.6 Hz, 1H), 7.80 (d, J = 9.2 Hz, 2H), 7.70 (d, J = 9.2 Hz, 2H), 6.99 (m, 4H), 5.95 (m, 1H), 5.80 (m, 1H), 4.96 (s, 1H), 4.14 (t, J = 5.6 Hz, 2H), 3.60 (m, 2H), 2.00 (m, 3H), 1.72 (m, 3H). EM (calc.): 396.2; MS (ESI) m/e (M + 1H)+: 397.1, (M − 1H)−: 395.2. Cpd. 20 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 9.35 (t, J = 5.6 Hz, 1H), 8.25 (d, J = 7.6 Hz, 1H), 8.15 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.68-7.58 (m, 2H), 7.03 (d, J = 9.2 Hz, 2H), 4.23 (pseudo t, J = 6.4 Hz, 2H), 3.74 (pseudo q, J = 6.0 Hz, 2H). EM (calc.): 357.1; MS (ESI) m/e (M + 1H)+: 358.1, (M − 1H)−: 356.0. Cpd. 21 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 9.47 (t, J = 5.6Ha, 1H), 7.90 (pseudo t, J = 9.2 Hz, 2H), 7.73 (d, J = 8.8 Hz, 2H), 4.59 (td, J1 = 7.6 Hz, J2 = 0.8 Hz, 1H), 7.52 (td, J2 = 8.0 Hz, J2 = 1.2 Hz, 1H), 7.03 (d, J = 8.8 Hz, 2H), 4.24 (t, J = 6.0 Hz, 2H), 3.72 (pseudo q, J = 6.0 Hz, 2H). EM (calc.): 341.1; MS (ESI) m/e (M + 1H)+: 342.1, (M − 1H)−: 340.2. Cpd. 22 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 9.70 (s, 1H), 8.91, (t, J = 5.6 Hz, 1H), 7.72 (d, J = 8.4 Hz, 2H), 6.97 (d, J = 8.4 Hz, 2H), 4.10 (m, 2H), 3.93 (m, 2H), 3.54 (m, 2H), 3.27 (m, 2H), 3.08 (m, 2H), 2.21 (m, 1H), 2.01 (m, 1H), 1.51 (m, 10H). EM (calc.): 375.2; MS (ESI) m/e (M + 1H)+: 376.1, (M − 1H)−: 374.1. Cpd. 23 1H NMR (400 MHz, DMSO-d6) δ 11.09 (s, 1H), 8.35 (d, J = 6.8 Hz, 2H), 7.72 (d, J = 9.2 Hz, 2H), 7.25 (d, J = 6.8 Hz, 2H), 6.98 (d, J = 9.2 Hz, 2H), 4.10 (t, J = 5.6 Hz, 2H), 3.97 (m, 2H), 3.54 (m, 10H). EM (calc.): 399.2; MS (ESI) m/e (M + 1H)+: 400.1, (M − 1H)−: 398.1. Cpd. 24 EM (calc.): 290.1; MS (ESI) m/e (M + 1)+: 291.1, (M − 1)−: 289.2. Cpd. 25 EM (calc.): 377.1; MS (ESI) m/e (M + 1)+: 377.9, (M − 1)−: 376.0. Cpd. 26 EM (calc.): 377.1; MS (ESI) m/e (M + 1)+: 378.0, (M − 1)−: 375.9. Cpd. 27 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 9.11 (t, J = 5.6 Hz, 1H), 7.70 (d, J = 9.2 Hz, 2H), 7.62 (m, 2H), 7.29 (m, 2H), 7.01 (d, J = 9.2 Hz, 2H), 4.21 (t, J = 5.6 Hz, 2H), 3.71 (m, 2H). EM (calc.): 340.1; MS (ESI) m/e (M + 1H)+: 341.0, (M − 1H)−: 339.1. Cpd. 28 EM (calc.): 289.1; MS (ESI) m/e (M + 1H)+: 290.0, (M − 1H)−: 287.8. Cpd. 29 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s 1H), 10.43 (s, 1H), 8.62 (t, J = 6.0 Hz, 1H), 7.94 (d, J = 6.4 Hz, 2H), 7.853 (m, 4H), 7.70 (d, J = 9.2 Hz, 2H), 7.60 (m, 1H), 7.52 (m, 2H), 7.00 (d, J = 9.2 Hz, 2H), 4.16 (t, J = 6.0 Hz, 2H), 3.63 (dt, J1 = 5.6 Hz, J2 = 6.0 Hz, 2H). EM (calc.): 419.2; MS (ESI) m/e (M + 1H)+: 420.2, (M − 1H)−: 418.3. Cpd. 30 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 9.23 (t, J = 6.0 Hz, 1H), 9.01 (s, 1H), 8.89 (d, J = 6.8 Hz, 2H), 8.38 (d, J = 6.4 Hz, 2H), 7.70 (d, J = 9.2 Hz, 2H), 7.00 (d, J = 9.2 Hz, 2H), 4.22 (t, J = 5.6 Hz, 2H), 3.71 (m, 2H). EM (calc.): 384.1; MS (ESI) m/e (M + 1H)+: 384.9, (M − 1H)−: 382.9. Cpd. 31 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.56 (t, J = 5.6 Hz, 1H), 7.01 (d, J = 8.8 Hz, 2H), 4.01 (t, J = 5.6 Hz, 2H), 3.40 (m, 2H), 1.95 (m, 3H), 1.69 (m, 12H). EM (calc.): 358.2; MS (ESI) m/e (M + 1H)+: 358.9, (M − 1H)−: 357.2. Cpd. 32 EM (calc.): 336.09; MS (ESI) m/e (M − 1H)−: 335.3. Cpd. 33 EM (calc.): 370.12; MS (ESI) m/e (M − 1H)−: 369.0. Cpd. 34 EM (calc.): 344.10; MS (ESI) m/e (M + 1H)+: 345.0, (M − 1H)−: 343.1. Cpd. 35 EM (calc.): 360.13; MS (ESI) m/e (M − 1H)−: 359.1. Cpd. 36 EM (calc.): 344.10; MS (ESI) m/e (M − 1H)−: 358.8. Cpd. 37 EM (calc.): 336.09; MS (ESI) m/e (M + 1H)+: 337.2, (M − 1H)−: 335.0. Cpd. 38 EM (calc.): 328.14; MS (ESI) m/e (M + 1H)+: 329.2, (M − 1H)−: 327.2. Cpd. 39 EM (calc.): 368.03; MS (ESI) m/e (M − 1H)−: 367.0. Cpd. 40 EM (calc.): 328.14; MS (ESI) m/e (M + 1H)+: 328.8, (M − 1H)−: 327.2. Cpd. 41 EM (calc.): 364.08; MS (ESI) m/e (M + 1H)+: 365.1, (M − 1H)−: 363.2. Cpd. 42 EM (calc.): 344.14; MS (ESI) m/e (M + 1H)+: 345.1, (M − 1H)−: 343.1. Cpd. 43 EM (calc.): 344.14; MS (ESI) m/e (M + 1H)+: 345.0, (M − 1H)−: 343.2. Cpd. 44 EM (calc.): 348.11; MS (ESI) m/e (M + 1H)+: 348.8, (M − 1H)−: 346.9. Cpd. 45 EM (calc.): 412.11; MS (ESI) m/e (M + 1H)+: 413.3, (M − 1H)−: 411.0. Cpd. 46 EM (calc.): 412.11; MS (ESI) m/e (M + 1H)+: 413.2, (M − 1H)−: 411.1. Cpd. 47 EM (calc.): 376.14; MS (ESI) m/e (M + 1H)+: 377.0, (M − 1H)−: 375.2. Cpd. 48 EM (calc.): 339.12; MS (ESI) m/e (M + 1H)+: 340.1, (M − 1H)−: 338.3. Cpd. 49 1H NMR (400 MHz, DMSO-d6) δ 11.53 (s, 1H), 11.04 (s, 1H), 8.12 (d, J = 7.6 Hz, 2H), 8.01 (s, 1H), 7.70 (d, J = 9.2 Hz, 2H), 7.40 (d, J = 8.0, Hz, 1H), 7.10 (m, 2H), 7.017 (d, J = 8.8 Hz, 2H), 4.16 (t, J = 5.6 Hz, 2H), 3.64 (m, 2H). EM (calc.): 339.1; MS (ESI) m/e (M + 1H)+: 340.0, (M − 1H)−: 338.1. Cpd. 50 1H NMR (400 MHz, DMSO-d6) δ 9.37 (s, 1H), 9.21 (t, J = 5.2 Hz, 1H), 9.02 (s, 1H), 8.15 (t, J = 9.2 Hz, 2H), 7.94 (m, 1H), 7.74 (m, 3H), 7.02 (d, J = 8.8 Hz, 2H), 4.24 (t, J = 5.6 Hz, 2H), 3.75 (m, 2H). EM (calc.): 351.1; MS (ESI) m/e (M + 1H)+: 352.0, (M − 1H)−: 349.9. Cpd. 51 1H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H) 9.09 (d, J = 4.4 Hz, 1H), 8.70 (d, J = 7.6 Hz, 1H), 8.65 (d, J = 7.6 Hz, 1H), 8.29 (d, J = 8.0 Hz, 1H), 7.79 (m, 4H), 7.10 (d, J = 8.8 Hz, 2H), 4.30 (t, J = 5.6 Hz, 2H), 3.89 (m, 2H). EM (calc.): 351.1; MS (ESI) m/e (M + 1H)+: 352.0, (M − 1H)−: 349.9. Cpd. 52 1H NMR (400 MHz, DMSO-d6) δ 13.57 (s, 1H), 11.04 (s, 1H), 8.88 (s, 1H), 8.53 (t, J = 5.6 Hz, 1H), 8.16 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.8 Hz, 2H), 7.60 (d, J = 8.4 Hz, 1H), 7.40 (t, J = 8.0 Hz, 1H), 7.23 (t, J = 8.0 Hz, 1H), 7.01 (d, J = 8.8 Hz, 2H), 4.19 (t, J = 6.0 Hz, 2H), 3.68 (m, 2H). EM (calc.): 340.1; MS (ESI) m/e (M + 1H)+: 341.1, (M − 1H)−: 339.2. Cpd. 53 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.89 (m, 2H), 8.45 (s, 1H), 7.93 (s, 2H), 7.70 (d, J = 8.4 Hz, 2H), 7.01 (d, J = 8.8 Hz, 2H), 4.20 (t, J = 5.6 Hz, 2H), 3.69 (m, 2H). EM (calc.): 341.1; MS (ESI) m/e (M + 1H)+: 341.8, (M − 1H)−: 340.0. Cpd. 54 1H NMR (400 MHz, DMSO-d6) δ 9.07 (s, 1H), 9.24 (d, J = 8.0 Hz, 1H), 8.53 (m 1H), 8.03 (m, 2H), 7.82 (t, J = 6.8 Hz, 1H), 7.71 (m, 3H), 7.03 (d, J = 8.4 Hz, 2H), 4.24 (t, J = 4.8 Hz, 2H), 3.76 (m, 2H). EM (calc.): 351.1; MS (ESI) m/e (M + 1H)+: 351.9, (M − 1H)−: 350.1. Cpd. 55 1H NMR (400 MHz, DMSO-d6) δ 9.39 (s, 1H), 9.11 (s, 1H), 8.59 (s, 1H), 8.25 (m, 1H), 7.87 (m, 2H), 7.70 (m, 2H), 7.02 (m, 2H), 4.23 (s, 2H), 3.76 (s, 2H). EM (calc.): 351.1; MS (ESI) m/e (M + 1H)+: 351.8, (M − 1H)−: 349.9. Cpd. 56 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 9.47 (m, 1H), 9.23 (m, 1H), 8.19 (m, 2H), 7.98 (m, 2H), 7.70 (d, J = 8.8 Hz, 2H), 7.02 (d, J = 8.4 Hz, 2H), 4.25 (t, J = 5.2 Hz, 2H), 3.78 (m, 2H). EM (calc.): 352.1; MS (ESI) m/e (M + 1H)+: 352.8, (M − 1H)−: 350.9. Cpd. 57 EM (calc.): 350.11; MS (ESI) m/e (M + 1H)+: 351.1, (M − 1H)−: 349.1. Cpd. 58 EM (calc.): 351.12; MS (ESI) m/e (M + 1H)+: 352.2, (M − 1H)−: 350.0. Cpd. 59 EM (calc.): 365.14; MS (ESI) m/e (M + 1H)+: 366.0, (M − 1H)−: 364.2. Cpd. 60 EM (calc.): 368.12; MS (ESI) m/e (M + 1H)+: 369.0, (M − 1H)−: 367.1. Cpd. 61 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.88 (s, 1H), 8.68 (t, J = 5.6 Hz, 1H), 8.34 (s, 1H), 8.14 (s, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.0 Hz, 1H), 7.01 (d, J = 8.8 Hz, 2H), 4.18 (t, J = 6.0 Hz, 2H), 3.66 (m, 2H). EM (calc.): 340.1; MS (ESI) m/e (M + 1H)+: 341.0, (M − 1H)−: 339.2. Cpd. 62 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.11 (m, 2H), 7.98 (s, 1H), 7.70 (d, J = 9.2 Hz, 2H), 7.47 (d, J = 7.6 Hz, 1H), 7.20 (t, J = 8.4 Hz, 1H), 7.13 (t, J = 6.8 Hz, 1H), 7.01 (d, J = 9.2 Hz, 2H), 4.15 (t, J = 6.0 Hz, 2H), 3.82 (s, 3H), 3.62 (m, 2H). EM (calc.): 353.1; MS (ESI) m/e (M + 1H)+: 354.0, (M − 1H)−: 351.9. Cpd. 63 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 9.14 (t, J = 5.6 Hz, 1H), 8.19 (d, J = 8.4 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.85 (t, J = 8.4 Hz, 1H), 7.69 (m, 4H), 7.03 (d, J = 8.8 Hz, 2H), 4.24 (t, J = 6.0 Hz, 2H), 4.15 (s, 3H), 3.78 (m, 2H). EM (calc.): 381.1; MS (ESI) m/e (M + 1H)+: 381.9, (M − 1H)−: 380.1. Cpd. 64 EM (calc.): 380.14; MS (ESI) m/e (M + 1H)+: 381.0, (M − 1H)−: 379.0. Cpd. 65 EM (calc.): 380.14; MS (ESI) m/e (M + 1H)+: 381.2, (M − 1H)−: 378.9. Cpd. 66 EM (calc.): 351.12; MS (ESI) m/e (M + 1H)+: 352.0, (M − 1H)−: 350.0. Cpd. 67 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 8.26 (t, J = 5.6 Hz, 1H), 7.70 (d, J = 8.8 Hz, 2H), 7.41-7.35 (m, 4H), 7.29 (m, 1H), 7.21 (s, 1H), 7.00 (d, J = 9.2, 2H), 4.12 (t, J = 6.0 Hz, 2H), 3.54 (pseudo q, J = 6.0 Hz, 2H), 2.01 (s, 3H). EM (calc.): 340.1; MS (ESI) m/e M + 1H)+: 340.9, (M − 1H)−: 339.2. Cpd. 68 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 10.72 (br s, 1H), 8.81 (t, J = 5.2 Hz, 1H), 7.94 (dd, J1 = 8.4 Hz, J2 = 2.0 Hz, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.32 (s, 1H), 7.03 (d, J = 9.2 Hz, 2H), 4.60 (s, 2H), 4.13 (pseudo t, J = 5.6 Hz, 2H), 3.70 (pseudo q, J = 5.2 Hz, 2H), 2.83 (s, 6H). EM (calc.): 397.2; MS (ESI) m/e (M + 1H)+: 398.1, (M − 1H)−: 396.0. Cpd. 71 1H NMR (DMSO-d6): 0.92 (3H, t, 7 Hz); 1.53 (1H, m); 1.72 (1H, m); 2.48 (3H, s); 3.94 (1H, m); 4.03 (2H, m); 6.62 (1H, s); 6.78 (1H, dd); 6.92 (1H, d); 7.01 (2H, d); 7.08 (1H, s); 7.31 (1H, d); 7.7 (2H, d); 8.27 (2H, d, 7 Hz); 9.25 (1H, s). MS (M + 1): 425. Cpd. 72 1H NMR (DMSO-d6): 0.90 (2H, dd); 0.91 (3H, t, 7 Hz); 1.1 (2H, br. S); 1.52 (1H, m); 1.68 (1H, m); 1.92 (1H, m); 2.0-2.1 (3H, m*); 2.25 (1H, m); 2.48 (3H, s); 3.24 (1H, m); 3.37 (4H, m); 3.54 (1H, m); 3.95 (1H, m); 4.03 (2H, m); 6.66 (1H, s); 6.97 (1H, m); 6.99 (2H, d, 9 Hz); 7.07 (1H, dd, 9, 2 Hz); 7.12 (1H, d, 6 Hz): 7.28 (1H, dd, 20, 2 Hz); 7.45 (1H, t, 9 Hz), 7.7 (2H, d, 9 Hz); 8.29 (1H, d, 8 Hz). MS (M + 1): 548. Cpd. 73 1H NMR (DMSO-d6): 2.00 (2H, m); 2.64 (1H, m); 2.75 (1H, m); 4.1 (1H, m); 4.18 (1H, m); 4.39 (1H, m); 6.98 (2H, d, 9 Hz); 7.14 (1H, m); 7.19-7.28 (5H, m); 7.32 (1H, t, 8 Hz); 7.45 (1H, m); 7.58 (1H, s); 7.65 (1H, d, 7 Hz); 7.68 (2H, d, 9 Hz); 7.76 (1H, d, J = 7 Hz) 8.74 (1H, d, 7 Hz). MS (M − 1): 443. Cpd. 78 1H NMR (DMSO-d6): 3.56 (2H, m); 4.15 (1H, m); 4.23 (1H, m); 4.57 (2H, s); 4.94 (1H, m); 6.99 (2H, d, 9 Hz); 7.33 (1H, t, 7 Hz); 7.38 (5H, s); 7.47 (1H, t, 7 Hz) 7.58 (1H, s); 7.65 (1H, d, 8 Hz); 7.70 (2H, d, 9 Hz); 7.77 (1H, d, 8 Hz); 8.90 (1H, s); 9.0 (1H, d, 8 Hz). MS (M + 1): 509. Cpd. 79 1H NMR (DMSO-d6): 2.7-2.81 (2H, m); 3.78 (2H, s); 4.12 (1H, dd, 10.5 Hz); 4.22 (1H, dd, 10.7 Hz); 4.51 (1H, m); 6.97 (2H, d, 9 Hz); 7.22 (1H, m); 7.28 (2H, m); 7.29 (2H, s); 7.33 (1H, t, 7 Hz); 7.46 (1H, td, 7.1 Hz); 7.58 (1H, s); 7.65 (1H, d, 8 Hz); 7.70 (2H, d, 9 Hz); 7.77 (2H, d, 8 Hz); 8.79 (1H, d, 8 Hz). MS (M + 1): 475. Cpd. 80 1H NMR (DMSO-d6): 2.47 (3H, d, 1 Hz); 3.57-3.62 (3H, m); 3.77 (3H, s); 4.08 (1H, t, 6 Hz); 6.64 (1H, s); 6.92 (1H, dd, 9, 3 Hz); 6.99 (2H, d, 9 Hz); 7.12-7.15 (2H, s + d); 7.42 (1H, d, 9 Hz); 7.7 (2H, d, 9 Hz); 8.49 (1H, t, 6 Hz); 8.88 (1H, s). MS (M + 1): 411. Cpd. 91 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.91 (s, 1H), 8.24 (t, J = 5.6 Hz, 1H), 7.73 (d, J = 9.2 Hz, 2H), 7.57 (d, J = 6.8 Hz, 2H), 7.44 (d, J = 16.0 Hz, 1H, buried under m at 7.41), 7.41 (m, 3H), 7.00 (4, J = 8.8 Hz, 2H), 6.63 (d, J = 16.0 Hz, 1H), 4.10 (pseudo t, J = 6.0 Hz, 2H), 3.37 (pseudo q, J = 6.4 Hz, 2H), 1.96 (pseudo p, J = 6.4 Hz, 2H). EM (calc.): 340.1; MS (ESI) m/e (M + 1H)+: 341.2, (M − 1H)−: 339.3. Cpd. 92 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.15 (s, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 15.6 Hz, 1H), 6.99 (m, 4H), 6.48 (d, J = 15.6 Hz, 1H), 4.09 (pseudo t, J = 6.0 Hz, 2H), 3.80 (s, 3H), 3.35 (pseudo q, J = 5.2 Hz, 2H), 1.94 (pseudo q, J = 6.0 Hz, 2H). EM (calc.): 370.2; MS (ESI) m/e (M + 1H)+: 371.0, (M − 1H)−: 368.9. Cpd. 93 1H NMR (400 MHz, DMSO-d6) δ 10.96 (s, 1H), 8.90 (t, J = 5.6 Hz, 1H), 8.31 (s, 1H), 7.98 (dd, J1 = 7.2 Hz, J2 = 1.6 Hz, 2H), 7.62 (d, J = 8.4 Hz, 2H), 7.40 (pseudo t, J = 7.2 Hz, 2H), 7.31 (pseudo tt, J1 = 7.2 Hz, J2 = 2.0 Hz, 1H), 6.90 (d, J = 9.2 Hz, 2H), 4.03 (t, J = 5.6 Hz, 2H), 3.42 (pseudo q, J = 6.0 Hz, 2H), 1.98 (pseudo p, J = 6.0 Hz, 2H). EM (calc.): 397.1; MS (ESI) m/e (M + 1H)+: 397.9, (M − 1H)−: 396.0. Cpd. 94 1H NMR (400 MHz, DMSO-d6) δ 11.09 (s, 1H), 8.26 (d, J = 7.2 Hz, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 7.2 Hz, 2H), 7.44 (m, 4H), 7.05 (d, J = 8.8 Hz, 2H), 6.68 (d, J = 16.4 Hz, 1H), 4.27 (m, 1H), 4.07 (m, 1H), 3.96 (m, 1H), 1.25 (d, J = 6.8 Hz, 3H). EM (calc.): 340.1; MS (ESI) m/e (M + 1H)+: 341.1, (M − 1H)−: 339.1. Cpd. 95 1H NMR (400 MHz, DMSO-d6) δ 11.09 (s, 1H), 8.27 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.8 Hz, 2H), 7.58 (d, J = 7.2 Hz, 2H), 7.46 (d, J = 16.0 Hz, 1H), 7.42 (m, 3H), 7.04 (d, J = 9.2 Hz, 2H), 6.68 (d, J = 16.4 Hz, 1H), 4.27 (pseudo p, J = 6.8 Hz, 1H) 4.07 (dd, J1 = 5.6 Hz, J2 = 10.0 Hz, 1H), 3.96 (dd, J1 = 5.6 Hz, J2 = 9.6 Hz, 1H), 1.25 (d, J = 7.2 Hz, 3H). EM (calc.): 340.1; MS (ESI) m/e (M + 1H)+: 341.1, (M − 1H)−: 339.1. Cpd. 96 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 8.87 (s, 1H), 8.12 (d J = 8.0 Hz, 1H), 7.67 (dt, J1 = 8.8 Hz, J2 = 2.0 Hz, 1H), 7.54 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 2H), 7.43-7.33 (m, 4H), 6.99 (dt J1 = 9.2 Hz, J2 = 2 Hz, 2H), 6.65 (d, J = 15.6 Hz, 1H), 4.26 (m, 1H), 4.01 (dd, J1 = 9.6 Hz, J2 = 4.8 Hz, 1H), 3.94 (dd J1 = 9.6 Hz, J2 = 5.6 Hz, 1H), 1.66 (m, 1H), 1.49 (m, 2H), 0.91 (d J = 6.8 Hz, 3H), 0.87 (d, J = 6.4 Hz, 3H). EM (calc.): 382.2; MS (ESI) m/e (M + 1H)+: 383.0, (M − 1H)−: 381.1. Cpd. 97 1H NMR (400 MHz, DMSO-d6) δ 10.95 (s, 1H), 8.81 (s, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 8.8 Hz, 2H), 7.47 (d, J = 6.8 Hz, 2H), 7.37-7.28 (m, 4H), 6.92 (dt, J1 = 8.4 Hz, J2 = 1.6 Hz, 2H), 6.61 (d, J = 16 Hz, 1H), 4.21 (m, 1H), 3.94 (m, 1H), 3.86 (m, 1H), 1.69 (d. J = 12.4 Hz, 1H), 1.59-1.52 (m, 4H), 1.42 (t, J = 7.2 Hz, 2H), 1.28 (m, 1H), 1.15-1.05 (m, 3H), 090 (m, 1H), 0.77 (m, 1H). EM (calc.): 422.2; MS (ESI) m/e (M + 1H)+: 423.2, (M − 1H)−: 421.2. Cpd. 98 1H NMR (400 MHz, DMSO-d6) δ 11.03 (s, 1H), 8.88 (s, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.69 (dt, J1 = 8.8 Hz, J2 = 2.8 Hz, 2H), 7.432-7.32 (series m, 4H), 6.99 (dt, J1 = 9.2 Hz, J2 = 2.4 Hz, 2H), 6.73 (d, J = 15.6 Hz, 1H), 4.05 (s, 3H), 1.98 (m, 1H), 0.95 (d, J = 2.4 Hz, 3H), 0.93 (d, J = 2.4 Hz, 3H). EM (calc.): 368.2; MS (ESI) m/e (M + 1H)+: 368.7, (M − 1H)−: 367.1. Cpd. 99 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.32 (d, J = 8 Hz, 1H), 7.69 (d, J = 9.2 Hz, 2H), 7.53 (m, 2H), 7.43-7.34 (m, 4H), 7.28-7.22 (m, 3H), 7.18 (m, 2H), 6.99 (d, J = 9.2 Hz, 2H), 6.63 (d, J = 16 Hz, 1H), 4.38 (m, 1H), 4.02 (d, J = 6.4 Hz, 2H), 2.99 (m, 1H), 2.88 (m, 1H). Missing OH or NH. EM (calc.): 416.2; MS (ESI) m/e (M + 1H)+: 417.3, (M − 1H)−: 415.2. Cpd. 100 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.78 (s, 1H), 8.32 (d, J = 8 Hz, 1H), 7.69 (d, J = 8.8 Hz, 2H), 7.52 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 2H), 7.41-7.34 (m, 4H), 7.28-7.23 (m, 4H), 7.19-7.15 (m, 1H), 6.99 (d, J = 9.2 Hz, 2H), 6.63 (d, J = 15.6 Hz, 1H), 4.38 (m, 1H), 4.01 (d, J = 4.4 Hz, 2H), 2.99 (dd, J1 = 13.6 Hz, J2 = 6 Hz, 1H), 2.88 (dd, J1 = 14 Hz, J2 = 8 Hz, 1H). EM (calc.): 416.2; MS (ESI) m/e (M + 1H)+: 417.2, (M − 1H)−: 415.2. Cpd. 101 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 8.87 (s, 1H), 8.12 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 7.2 Hz, 2H), 7.43-7.33 (m, 4H), 6.99 (d, J = 9.2 Hz, 2H), 6.65 (d, J = 15.6 Hz, 1H), 4.25 (m, 1H), 4.01 (dd, J = 9.6 Hz, 4.8 Hz, 1H), 3.94 (dd J1 = 9.6 Hz, J2 = 5.6 Hz, 1H), 1.66 (m, 1H), 11.48 (m, 2H), 0.91 (d J = 6.8 Hz, 3H), 0.87 (d, J = 6.4 Hz, 3H). EM (calc.): 382.2; MS (ESI) m/e (M + 1H)+: 383.2, (M − 1H)−: 381.2. Cpd. 102 1H NMR (400 MHz, DMSO-d6) δ 11.03 (s, 1H), 8.87 (s, 1H), 8.08 (d, J = 8 Hz, 1H), 7.69 (d, J = 8.8 Hz, 2H), 7.55 (d, J = 1.2 Hz, 2H), 7.43-7.32 (m, 4H), 6.99 (d, J = 9.2 Hz, 2H), 6.73 (d, J = 16 Hz, 1H), 4.05 (s, 3H), 1.98 (m, 1H), 0.946 (d, J = 2 Hz, 3H), 0.93 (d, J = 2.4 Hz, 3H). EM (calc.): 368.2; MS (ESI) m/e (M + 1H)+: 369.1, (M − 1H)−: 367.1. Cpd. 103 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.14 (d, J = 8.4 Hz, 1H), 7.69 (dt, J1 = 8.8 Hz, J2 = 2.8 Hz, 2H), 7.54 (dd, J1 = 6.8, J2 = 1.2 Hz, 2H), 7.43-7.32 (m, 4H), 6.99 (dt, J1 = 8.8 Hz, J2 = 3.2 Hz, 2H), 6.66 (d, J = 15.6 Hz, 1H), 4.16 (m, 1H), 4.03 (dd, J1 = 10 Hz, J2 = 5.6 Hz, 1H), 3.96 (dd, J1 = 10 Hz, J2 = 5.2 Hz, 1H), 1.67 (m, 1H), 1.53 (m, 1H), 1.36-1.27 (m, 4H), 0.87 (t, J = 6.4 Hz, 3H). Missing 1H, NH or OH. EM (calc.): 382.2; MS (ESI) m/e (M + 1H)+: 383.1, (M − 1H)−: 381.1. Cpd. 104 1H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.25 (d, J = 8.4 Hz, 1H), 7.64 (dt, J1 = 8.8 Hz, J2 = 2 Hz, 2H), 7.46 (dd, J1 = 7.6 Hz, J2 = 2 Hz, 2H), 7.34-7.18 (series m, 6H), 6.93 (dt, J1 = 9.2 Hz, J2 = 2.8 Hz, 2H), 6.54 (d, J = 15.6 Hz, 1H), 4.31 (m, 1H), 3.95 (d, J = 4.8 Hz, 2H), 2.93 (dd, J1 = 13.6 Hz, J2 = 5.6 Hz, 1H), 2.79 (dd, J1 = 13.6 Hz, J2 = 8.4 Hz, 1H). EM (calc.): 450.1; MS (ESI) m/e (M + 1H)+: 451.2; (M − 1H)−: 449.2. Cpd. 105 1H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.07 (d, J = 8 Hz, 1H), 7.62 (dt, J1 = 8.8 Hz, J2 = 2.8 Hz, 2H), 7.47 (dd, J1 = 8.8 Hz, J2 = 1.6 Hz, 2H), 7.34-7.26 (series m, 4H), 6.93 (dt, J1 = 8.8 Hz, J2 = 2.8 Hz, 2H), 6.61 (d, J = 15.6 Hz, 1H), 4.04 (m, 1H), 3.98 (dd, J1 = 15.6 Hz, J2 = 5.6 Hz, 1H), 3.90 (dd, J1 = 9.2, J2 = 5.6 Hz, 1H), 1.64 (m, 1H), 1.46 (m, 1H), 0.85 (t, J = 6.8 Hz, 3H). EM (calc.): 354.2; MS (ESI) m/e (M + 1H)+: 354.6, (M − 1H)−: 353.2. Cpd. 106 1H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.07 (d, J = 8 Hz, 1H), 7.62 (d J = 8.8 Hz, 2H), 7.47 (dd, J1 = 6.8 Hz, J2 = 1.6 Hz, 2H), 7.35-7.62 (series m, 4H), 6.93 (dt, J1 = 9.2, J2 = 2 Hz, 2H), 6.61 (d, J = 15.6 Hz, 1H), 3.98 (dd, J1 = 9.6 Hz, J2 = 5.6 Hz, 1H), 3.90 (dd, J1 = 9.6, J2 = 4.8 Hz, 1H), 1.65 (m, 1H), 1.49 (m, 1H), 0.85 (t, J = 7.2 Hz, 3H). EM (calc.): 354.2; MS (ESI) m/e (M + 1H)+: 354.8, (M − 1H)−: 353.1. Cpd. 107 EM (calc.): 400.49; MS (ESI) m/e (M + 1): 401.0, (M − 1H): 399.0. Cpd. 108 EM (calc.): 400.49; MS (ESI) m/e (M + 1): 401.1, (M − 1): 399.2. Cpd. 109 1H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.80 (br s, 1H), 8.73 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 9.2 Hz, 2H), 7.48 (d, J = 6.8 Hz, 2H), 7.38-7.27 (series m, 8H), 7.21 (t, J = 7.2 Hz, 1H), 6.93 (d, J = 8.8, 2H), 6.69 (d, J = 15.6 Hz, 1H), 5.30 (dd, J1 = 13.6 Hz, J2 = 7.6 Hz, 1H), 4.19 (d, J = 6.4 Hz, 2H). EM (calc.): 402.2; MS (ESI) m/e (M + 1H)+: 403.2, (M − 1H)−: 400.9. Cpd. 110 1H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.80 (br s, 1H), 8.74 (d, J = 8 Hz, 1H), 7.62 (dt, J1 = 8.8 Hz, J2 = 2 Hz, 2H), 7.48 (dd, J1 = 6.4 Hz, J2 = 1.6 Hz, 2H), 7.39-7.27 (series m, 8H), 7.21 (tt, J1 = 7.6 Hz, J2 = 1.2 Hz, 1H), 6.93 (dt, J1 = 9.2 Hz, J2 = 2.4 Hz, 2H), 6.69 (d, J = 15.6, 1H), 5.29 (dd, J1 = 8 Hz, J2 = 6.4 Hz, 1H), 4.18 (d, J = 6.4 Hz, 2H). EM (calc.): 402.2; MS (ESI) m/e (M + 1H)+: 402.9, (M − H)−: 401.2. Cpd. 111 1H NMR (400 MHz, DMSO-d6) δ 8.25 (d, J = 8 Hz, 1H), 7.83 (d, J = 8.8 Hz, 2H), 7.48 (d, J = 6.4 Hz, 2H), 7.39-7.27 (series m, 4H), 7.01 (d, J = 8.8 Hz, 2H), 6.58 (d, J = 16.4 Hz, 1H), 4.25 (m, 1H), 4.03 (m, 2H), 3.73 (s, 3H), 3.12 (m, 2H), 2.06 (m, 1H), 1.93 (m, 1H). EM (calc.): 432.1; MS (ESI) m/e (M + 1H)+: 433.2, (M − 1H)−: 430.0. Cpd. 112 1H NMR (400 MHz, DMSO-d6) δ 8.24 (d, J = 8 Hz, 1H), 7.82 (d, J = 8.8 Hz, 2H), 7.48 (d, J = 8.8 Hz, 2H), 7.84-7.29 (series m, 4H), 7.01 (d, J = 8.8 Hz, 2H), 6.58 (d, J = 16.4 Hz, 1H), 4.35 (m, 1H), 4.03 (m, 2H), 3.70 (s, 3H), 3.13 (m, 2H), 2.06 (m, 1H), 1.93 (m 1H). EM (calc.): 432.1; MS (ESI) m/e (M + 1H)+: 432.2, (M − 1H)−: 430.2. Cpd. 113 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, J = 8.0 Hz, 1H), 7.83 (dt, J1 = 9.2 Hz, J2 = 2.8 Hz, 2H), 7.48 (dd, J1 = 6 Hz, J2 = 1.6 Hz, 2H), 7.39 (d, J = 16 Hz, 1H), 7.31 (m, 9H), 6.97 (dt, J1 = 9.2 Hz, J2 = 2.4 Hz, 2H), 6.57 (d, J = 16 Hz, 1H), 4.72 (m, 1H), 4.50 (s, 1H), 4.16 (dd, J1 = 9.6 Hz, J2 = 5.2 Hz), 1H, 4.08 (dd, J1 = 10 Hz, J2 = 4.8 Hz, 1H), 3.45 (dd, J1 = 14.4 Hz, J2 = 5.6 Hz, 1H), 3.36 (dd, J1 = 14.4 Hz, J2 = 6.8 Hz, 1H). EM (calc.): 492.2; MS (ESI) m/e (M + 1H)+: 494.3, (M − 1H)−: 492.2. Cpd. 114 1H NMR (400 MHz, DMSO) δ 11.07 (br s, 1H), 8.38 (d, J = 7.6 Hz, 2H), 7.84 (dd, J1 = 3.6 Hz, J2 = 1.2 Hz, 1H), 7.77 (dd, J1 = 4.8 Hz, J2 = 1.2 Hz, 1H), 7.72 (d, J = 8.4 Hz, 2H), 7.16 (dd, J1 = 3.6 Hz, J2 = 5.2 Hz, 1H), 7.02 (d, J1 = 8.4 Hz, 2H), 4.20 (m, 1H), 4.13 (dd, J1 = 6.4 Hz, J2 = 9.6 Hz, 1H), 4.04 (dd, J1 = 5.2 Hz, J2 = 9.2 Hz, 2H) 1.77 (m 1H), 1.63 (m, 1H), 1.21 (d, J = 6.4 Hz, 1H), 0.96 (t, J = 7.2 Hz, 3H). EM (calc.): 334.1; MS (ESI) m/e (M + 1H)+: 335.0, (M − 1H)−: 333.0. Cpd. 115 1H NMR (400 MHz, DMSO-d6) δ 11.03 (s, 1H), 8.37 (d, J = 8.0 Hz, 1H), 7.94 (d, J = 8.4 Hz, 2H), 7.72 (m, 6H), 7.48 (m, 2H), 7.39 (m, 1H), 7.00 (d, J = 8.4 Hz, 2H), 4.24 (m, 1H), 4.06 (m, 2H), 1.74 (m, 2H), 0.95 (t, J = 7.2 Hz, 3H). EM (calc.): 404.2; MS (ESI) m/e (M + 1H)+: 405.2, (M − 1H)−: 403.2. Cpd. 116 1H NMR (400 MHz, DMSO-d6) δ 11.03 (s, 1H), 8.87 (s, 1H), 8.50 (d, J = 8.4 Hz, 1H), 8.44 (s, 1H), 7.97 (m, 4H), 7.70 (d, J = 8.8 Hz, 2H), 7.59 (m, 2H), 7.02 (d, J = 8.8 Hz, 2H), 4.29 (m, 1H), 4.14 (m, 2H), 1.68 (m, 2H), 0.98 (t, J = 7.2 Hz, 3H). EM (calc.): 378.2; MS (ESI) m/e (M + 1H)+: 378.9, (M − 1H)−: 377.0. Cpd. 117 1H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 8.82 (s, 1H), 8.27 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 9.2 Hz, 2H), 7.48 (dd, J1 = 6.4 Hz, J2 = 1.6 Hz, 2H), 7.38 (d, J = 15.6 Hz, 1H), 7.36-7.27 (m, 3H), 7.23-7.19 (m, 4H), 7.14 (m, 1H), 6.92 (d, J = 8.8 Hz, 2H), 6.61 (d, J = 15.6 Hz, 1H), 4.29 (m, 1H), 4.08 (dd, J1 = 9.6 Hz, J2 = 5.6 Hz, 1H), 3.98 (dd, J1 = 9.6 Hz, J2 = 4.4 Hz, 1H), 3.70 (d, J = 2.4 Hz, 2H), 2.67 (dd, J1 = 6.8 Hz, J2 = 13.6 Hz, 1H), 2.58 (dd, J1 = 13.2 Hz, J2 = 7.2 Hz, 1H). EM (calc.): 460.2; MS (ESI) m/e (M − 1H)−: 460.8. Cpd. 118 1H NMR (400 MHz, DMSO-d6) δ 11.02 (s, 1H), 8.31 (d, J = 8.4 Hz, 1H), 7.83 (d, J = 7.2 Hz, 2H), 7.68 (d, J = 8.8 Hz, 2H), 7.52-7.42 (m, 3H), 6.99 (d, J = 9.2 Hz, 2H), 4.22 (m, 1H), 4.11 (dd, J1 = 6.4 Hz, J2 = 10.0 Hz, 1H), 4.01 (dd, J1 = 6.0 Hz, J2 = 9.6 Hz, 1H), 1.73 (m 1H0, 1.62 (m, 1H), 0.93 (t, J = 7.6 Hz, 3H). EM (calc.): 328.1; MS (ESI) m/e (M + 1H)+: 329.1. (M − 1H)−: 327.0. Cpd. 119 1H NMR (400 MHz, DMSO-d6) δ 11.03 (s, 1H), 8.08 (d, J = 7.2 Hz, 1H), 7.69 (d, J = 8.8 Hz, 2H), 7.24 (m, 5H), 6.96 (d, J = 9.2 Hz, 2H), 3.94 (m 3H), 3.43 (s, 2H), 1.64 (m, 1H), 1.47 (m, 1H), 0.86 (t, 7.2 Hz, 3H). EM (calc.): 342.2; MS (ESI) m/e (M + 1H)+: 343.0, (M − 1H)−: 341.1. Cpd. 120 1H NMR (400 MHz, DMSO-d6) δ 11.03 (s, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.23-7.10 (m, 5H), 6.94 (d, J = 9.2 Hz, 2H), 3.94 (m, 2H), 3.84 (m, 1H), 2.81 (t, J = 7.2 Hz, 2H), 2.40 (t, J = 7.6 Hz, 2H), 1.61 (ddd, J1 = 4.4 Hz, J2 = 7.6 Hz, J3 = 18.4 Hz, 1H), 1.41 (m, 1H), 0.81 (t, J = 6.8 Hz, 3H). EM (calc.): 356.2; MS (ESI) m/e (M + 1H)+: 357.1, (M − 1H)−: 355.1. Cpd. 121 EM (calc.): 356.38; MS (ESI) m/e (M + 1): 357.0, (M − 1): 355.1. Cpd. 122 1H NMR (400 MHz, DMSO-d6) δ 10.96 (s, 1H), 8.65 (d, J = 8.8 Hz, 1H), 8.33 (s, 1H), 8.00 (d, J = 7.2 Hz, 2H), 7.62 (d, J = 8.4 Hz, 2H), 7.39 (pseudo t, J = 7.2 Hz, 2H), 7.30 (pseudo t, J = 7.6 Hz, 1H), 6.93 (d, J = 9.2 Hz, 2H), 4.20 (m, 1H), 4.23 (dd partially buried under peak at 4.20,, J1 = 9.2 Hz, J2 = 16.8 Hz, 1H), 4.05 (dd, J1 = 10.0 Hz, J2 = 4.8 Hz, 1H), 1.69 (m 1H), 1.62 (m, 1H), 0.88 (t, J = 7.2 Hz, 3H). EM (calc.): 411.1; MS (ESI) m/e (M − 1H)−: 410.1. Cpd. 123 1H NMR (400 MHz, DMSO-d6) δ 11.03 (s, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.69 (d, J = 8.8 Hz, 2H), 7.48 (d, J = 9.2 Hz, 2H), 7.36 (d, J = 15.6 Hz, 1H), 6.99 (d, J = 9.2 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 6.52 (d, J = 15.6 Hz, 1H), 4.09 (m, 1H), 4.04 (dd, J1 = 5.2 Hz, J2 = 9.6 Hz, 1H), 3.95 (dd, J1 = 5.2 Hz, J2 = 9.6 Hz, 1H), 3.77 (s, 3H), 1.71 (m, 1H), 1.52 (m, 1H), 0.91 (t, J = 6.8 Hz, 3H). EM (calc.): 384.2; MS (ESI) m/e (M + 1H)+: 385.0, (M − 1H)−: 383.2. Cpd. 124 1H NMR (400 MHz, DMSO-d6 δ 11.07 (s, 1H), 10.62 (br s, 1H), 8.43 (d, J = 8.0 Hz, 1H), 8.28 (d, J = 1.6 Hz, 1H), 7.94 (dd, J1 = 8.4 Hz, J2 = 2.0 Hz, 1H), 7.23 (d, J = 8.4 Hz, 2H), 7.32 (s, 1H), 7.03 (d, J = 8.8 Hz, 2H), 4.60 (s, 2H), 4.28 (m, 1H), 4.17 (dd, J1 = 10.0 Hz, J2 = 6.8 Hz, 1H), 4.08 (dd, J1 = 10.4 Hz, J2 = 6.0 Hz, 1H), 2.84 (s, 6H), 1.80 (m, 1H), 1.65 (m, 1H), 0.98 (t, J = 7.6 Hz, 3H). EM (calc.): 425.2; MS (ESI) m/e (M + 1H)+: 426.2, (M − 1H)−: 424.1. Cpd. 125 1H NMR (400 MHz, DMSO-d6) δ 10.96 (s, 1H), 8.80 (s, 1H), 8.27 (t, J = 5.2 Hz, 1H), 7.62 (J = 8.8 Hz, 2H), 7.46 (d, J = 6.8 Hz, 2H), 7.36 (d, J = 12.8 Hz, 1H), 7.33-7.28 (m, 3H), 6.95 (d, J = 8.4 Hz, 2H0, 6.60 (d, J = 12.8 Hz, 1H), 4.53 (ddd, J = 5.6 Hz, 1H), 3.40 (m, 1H), 3.29 (m, 1H, buried under water peak), 1.19 (d, J = 6.4 Hz, 3H). EM (calc.): 340.1. Cpd. 126 1H NMR (400 MHz, DMSO-d6) δ 11.02 (s, 1H), 8.87 (s, 1H), 8.34 (t, J = 5.6 Hz, 1H), 7.68 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 8.8 Hz, 2H), 7.43 (d, J = 13.2 Hz, 1H), 7.40-7.35 (m, 3H), 7.02 (d, J = 8.8 Hz, 2H), 6.67 (d, J = 16 Hz, 1H), 4.60 (ddd, J1 = 6.0 Hz, J2 = 11.6 Hz, J3 = 17.6 Hz, 1H), 3.47 (m, 1H), 3.36 (m 1H, buried under water peak), 1.26 (d, J = 6.0 Hz, 3H). EM (calc.): 340.1; MS (ESI) m/e (M + 1H)+: 341.0, (M − 1H)−: 339.2. Cpd. 127 EM (calc.): 397.1; MS (ESI) m/e (M − 1H)−: 396.1. Cpd. 128 EM (calc.): 397.1; MS (ESI) m/e (M + 1H)+: 398.2, (M − 1H)−: 396.2. Cpd. 129 1H NMR (400 MHz, DMSO-d6) δ 10.96 (s, 1H), 8.69 (t, J = 5.6 Hz, 1H), 7.84 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.4 Hz, 1H), 7.63 (m, 4H), 7.40 (t, J = 7.6 Hz, 2H), 7.32 (m, 1H), 6.98 (d, J = 12.0 Hz, 2H), 4.62 (ddd, J1 = 6.0 Hz, J2 = 12.0 Hz, J3 = 18.0 Hz, 1H), 3.52 (ddd, J1 = 6.4 Hz, J2 = 13.6 Hz, J3 = 19.6 Hz, 1H), 3.31 (m, 1H, buried under water peak), 1.23 (d, J = 6.0 Hz, 3H). EM (calc.): 390.2; MS (ESI) m/e (M + 1H)+: 391.3, (M − 1H)−: 389.0. Cpd. 130 1H NMR (400 MHz, DMSO-d6) δ 11.03 (s, 1H), 8.24 (t, J = 5.2 Hz, 1H), 7.68 (d, J = 8.8 Hz, 2H), 7.48 (d, J = 8.8 Hz, 2H), 7.37 (d, J = 15.6 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 6.51 (d, J = 15.6 Hz, 1H0), 4.58 (pseudo q, J = 5.6 Hz, 1H), 3.77 (s, 3H), 3.46 (ddd, J1 = 4.8 Hz, J2 = 13.2 Hz, J3 = 19.2 Hz, 1H), 3.32 (ddd, J1 = 5.2 Hz, J2 = 10.8 Hz, J3 = 13.2 Hz, 1H), 1.25 (d, J = 6.0 Hz, 3H). EM (calc.): 370.2; MS (ESI) m/e (M + 1H)+: 371.0, (M − 1H)−: 369.1. Cpd. 131 1HNMR (DMSO-d6): 3.67 (q, 2H), 4.18 (t, 2H), 7.01 (d, 2H), 7.7 (d, 2H), 7.98 (d, 2H), 8.12 (d, 2H), 8.17 (d, 2H), 8.55 (s, 1H), 8.79 (m, 3H), 11.05 (s, 1H). LC\MS: (M + 1)+1 461.2, (M − 1)−1 459.0. Cpd. 132 1H NMR (400 MHz, DMSO-d6) δ: 11.08 (s, 1H), 8.94 (m, 2H), 7.75 (m, 3H), 7.47 (d, 1H, J = 8.1 Hz), 7.16 (d, 1H, J = 8.1 Hz), 7.04 (d, 2H, J = 9.6 Hz), 4.22 (t, 2H, J = 5.5 Hz), 3.71 (t, 2H, J = 5.5 Hz), 3.36 (s, 3H). EM (calc.): 388.08; MS (ESI) m/e (M + 1H)+: 388.9, (M − 1H)−: 387.1. Cpd. 133 1HNMR (DMSO-d6): 2.85 (s, 3H), 3.4 (s, 8H), 3.65 (q, 2H), 4.17 (t, 2H), 7.00 (d, 2H), 7.54 (s, 1H), 7.7 (d, 2H), 7.9 (dd, 4H), 8.74 (t, 1H), 8.9 (s, 1H), 10.2 (s, 1H), 11.05 (s, 1H). LC\MS: (M + 1)+1 482.0, (M − 1)−1 480.2. Cpd. 134 1HNMR (DMSO-d6): 3.66 (q, 2H), 4.18 (t, 2H), 7.01 (d, 2H), 7.69 (m, 4H), 7.91 (d, 2H), 8.02 (d, 3H), 8.33 (dd, 2H), 8.75 (t, 1H), 9.16 (s, 1H), 10.99 (s, 1H), 11.05 (s, 1H). LC\MS: (M + 1)+1 476.1, (M − 1)−1 474.2. Cpd. 135 1HNMR (DMSO-d6): 2.85 (s, 3H), 3.01 (m, 4H), 3.51 (d, 2H), 3.60 (q, 2H), 4.00 (d, 2H), 4.13 (t, 2H), 6.98 (dd, 4H), 7.74 (dd, 4H), 8.48 (t, 1H), 9.97 (s, 1H), 11.05 (s, 1H). LC\MS: (M + 1)+1 399.3, (M − 1)−1 397.2. Cpd. 136 1HNMR (DMSO-d6): 1.4 (m, 2H), 1.8 (m, 2H), 2.95 (m, 2H), 3.6 (m, 5H), 4.12 (t, 2H), 4.69 (s, 1H), 6.91 (d, 2H), 6.99 (d, 2H), 7.7 (dd, 4H), 8.36 (t, 1H), 8.87 (s, 1H), 11.03 (s, 1H). LC\MS: (M + 1)+1 400.2, (M − 1)−1 398.3. Cpd. 138 1H NMR (400 MHz, DMSO-d6) δ: 9.02 (t, 2H, J = 5.3 Hz), 7.77-7.72 (m, 3H), 7.27 (m, 1H), 7.11 (m, 1H), 7.03 (d, 2H, J = 8.8 Hz), 4.22 (t, 2H, J = 5.3 Hz), 3.70 (t, 2H, J = 5.3 Hz), 2.51 (s, 3H). EM (calc.): 372; MS (ESI) m/e (M + 1H)+: 373.0, (M − 1H)−: 371.0. Cpd. 139 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (s, 1H), 10.04 (s, 1H), 9.02 (t, 1H, J = 5.7 Hz), 7.74 (d, 1H, J = 2.7 Hz), 7.70 (d, 2H, J = 8.5 Hz), 7.32 (m, 1H), 7.25 (m, 1H), 7.00 (d, 2H, J = 8.5 Hz), 4.72 (s, 2H), 4.19 (t, 2H, J = 5.7 Hz), 3.67 (m, 2H), 3.59 (m, 2H), 3.48 (m, 2H), 3.24 (s, 3H). EM (calc.): 446.15; MS (ESI) m/e (M + 1H)+: 447.4, (M − 1H)−: 445.3. Cpd. 140 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (br s, 1H), 9.25 (t, 1H, J = 5.9 Hz), 8.07 (d, 1H, J = 8.6 Hz), 7.96 (d, 1H, J = 8.6 Hz), 7.70 (m, 3H), 7.39 (t, 1H, J = 7.6 Hz), 7.01 (d, 2H, J = 9.1 Hz), 6.88 (br s, 1H), 4.21 (t, 2H, J = 5.9 Hz), 3.70 (q, 2H, J = 5.9 Hz). EM (calc.): 367; MS (ESI) m/e (M + 1H)+: 368.0, (M − 1H)−: 366.2. Cpd. 141 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (br s, 1H), 9.04 (t, 1H, J = 5.9 Hz), 7.80 (d, 1H, J = 2.6 Hz), 7.70 (d, 1H, J = 8.7 Hz), 7.40 (m, 2H), 7.28 (t, 1H, J = 8.1 Hz), 7.05-6.92 (m, 5H), 5.35 (s, 2H), 4.18 (t, 2H, J = 5.9 Hz), 3.66 (q, 2H, J = 5.9 Hz). EM (calc.): 464; MS (ESI) m/e (M + 1H)+: 465.3, (M − 1H)−: 463.1. Cpd. 143 1HNMR (DMSO-d6): 2.55 (t, 3H), 2.80 (s, 3H), 3.07 (d, 3H), 3.4 (d, 2H), 3.65 (q, 2H), 4.02 (s, 2H), 4.17 (t, 2H), 6.99 (d, 2H), 7.69 (d, 2H), 7.91 (d, 2H), 8.01 (d, 2H), 8.23 (s, 1H), 8.75 (t, 1H), 9.6 (s, 1H), 11.05 (s, 1H). LC\MS: (M + 1)+1 496.3, (M − 1)−1 494.4 Cpd. 144 MS (ESI) m/e: (M + 1H)+: 302.0, (M − 1H)−: 300.2. Cpd. 145 MS (ESI) m/e: (M + 1H)+: 318.1, (M − 1H)−: 316.1. Cpd. 146 MS (ESI) m/e: (M + 1H)+: 318.1, (M − 1H)−: 316.2. Cpd. 147 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.28 (m, 2H), 8.15 (m, 1H), 7.94 (m, 2H), 7.66 (m, 2H), 7.41 (m, 3H), 6.89 (m, 2H), 4.10 (m, 2H), 3.63 (m, 2H). MS (ESI) m/e: (M + 1H)+: 439.2, (M − 1H)−: 437.2. Cpd. 148 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 9.10 (t, J = 8.0 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.06 (d, J = 8.0 Hz, 1H), 7.85 (t, J = 8.0 Hz, 1H), 7.67 (m, 4H), 7.04 (d, J = 8.0 Hz, 2H), 4.45 (m, 2H), 4.23 (t, J = 8.0 Hz, 2H), 3.84 (m, 2H), 3.76 (m, 2H). MS (ESI) m/e: (M + 1H)+: 426.3, (M − 1H)−: 424.2. Cpd. 149 1H NMR (400 MHz, DMSO-d6) δ 11.06 (s, 1H), 10.31 (s, 1H), 9.10 (t, J = 8.0 Hz, 1H), 8.40 (d, J = 8.0 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.86 (t, J = 8.0 Hz, 1H), 7.69 (m, 4H), 7.02 (d, J = 8.0 Hz, 2H), 4.74 (m, 2H), 4.23 (t, J = 8.0 Hz, 2H), 3.77 (m, 2H), 3.70 (m, 2H). MS (ESI) m/e: (M + 1H)+: 439.3, (M − 1H)−: 437.3. Cpd. 150 MS (ESI) m/e: (M + 1H)+: 379.9, (M − 1H)−: 379.9. Cpd. 151 MS (ESI) m/e: (M + 1H)+: 379.9, (M − 1H)−: 379.9. Cpd. 152 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (br s, 1H), 8.85 (d, 1H, J = 9.0 Hz), 8.20 (d, 1H, J = 1.2 Hz), 8.18 (d, 1H, J = 1.2 Hz), 7.85 (m, 1H), 7.70-7.65 (m, 4H), 7.01 (t, 2H, J = 8.7 Hz), 4.32 (m, 1H), 4.25 (m, 1H), 4.15 (s, 3H), 4.13 (m, 1H), 1.77 (m, 2H), 0.95 (t, 3H, J = 7.0). EM (calc.): 409; MS (ESI) m/e (M + 1H)+: 410.2, (M − 1H)−: 408.2. Cpd. 153 1H NMR (400 MHz, DMSO-d6) δ: 11.05 (s, 1H), 10.17 (s, 1H), 8.65 (m, 1H), 8.14 (m, 1H), 7.95 (m, 1H), 7.88 (d, 1H, J = 8.2 Hz), 7.73-7.66 (m, 3H), 7.62-7.59 (m, 2H), 7.05 (m, 2H), 4.24 (m, 2H), 3.89 (s, 3H), 3.73 (m, 2H). EM (calc.): 380; MS (ESI) m/e (M + 1H)+: 381.0, (M − 1H)−: 379.1. Cpd. 154 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (s, 1H), 9.14 (t, 1H, J = 6.0 Hz), 8.18 (d, 1H, J = 7.7 Hz), 8.07 (d, 1H, J = 8.2 Hz), 7.85 (t, 1H, J = 7.7 Hz), 7.72-7.64 (m, 4H), 7.08 (d, 2H, J = 9.1 Hz), 4.78 (m, 1H), 4.14 (s, 3H), 3.66 (m, 1H), 3.55 (m, 1H), 1.31 (d, 3H, J = 6.1 Hz). EM (calc.): 395; MS (ESI) m/e (M + 1H)+: 396.1, (M − 1H)−: 394.2. Cpd. 155 MS (ESI) m/e: (M + 1H)+: 377.9, (M − 1H)−: 376.1. Cpd. 156 MS (ESI) m/e: (M + 1H)+: 408.3, (M − 1H)−: 406.2. Cpd. 157 MS (ESI) m/e: (M + 1H)+: 373.9, (M − 1H)−: 372.1. Cpd. 158 MS (ESI) m/e: (M + 1H)+: 422.3, (M − 1H)−: 420.3. Cpd. 159 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (s, 1H), 9.10 (t, 1H, J = 5.9 Hz), 8.16 (d, 1H, J = 8.4 Hz), 8.07 (d, 1H, J = 8.4 Hz), 7.85 (t, 1H, J = 7.9 Hz), 7.71-7.65 (m, 4H), 7.03 (d, 2H, J = 8.9 Hz), 4.60 (t, 2H, J = 5.9 Hz), 4.23 (t, 2H, J = 5.1 Hz), 3.75 (q, 2H, J = 5.9 Hz), 3.00 (m, 2H). EM (calc.): 463; MS (ESI) m/e (M + 1H)+: 464.3, (M − 1H)−: 462.2. Cpd. 160 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (s, 1H), 8.78 (d, 1H, J = 9.0 Hz), 8.15 (d, 1H, J = 8.3 Hz), 8.09 (d, 1H, J = 8.5 Hz), 7.85 (t, 1H, J = 6.7 Hz), 7.68 (m, 4H), 7.00 (d, 2H, J = 9.0 Hz), 4.61 (t, 2H, J = 5.9 Hz), 4.32 (m, 1H), 4.24 (m, 1H), 4.14 (m, 1H), 3.00 (m, 2H), 1.76 (m, 2H), 0.95 (t, 3H, J = 7.0 Hz). EM (calc.): 491; MS (ESI) m/e (M + 1H)+: 492.1, (M − 1H)−: 490.1. Cpd. 161 1H NMR (400 MHz, DMSO-d6) δ: 9.13 (t, 1H, J = 6.1 Hz), 8.15 (d, 1H, J = 8.1 Hz), 8.07 (d, 1H, J = 8.3 Hz), 7.86 (t, 1H, J = 6.7 Hz), 7.71-7.67 (m, 4H), 7.08 (d, 2H, J = 8.7 Hz), 4.78 (m, 1H), 4.61 (t, 1H, J = 5.5 Hz), 3.65 (m, 1H), 3.55 (m, 1H), 3.00 (m, 2H), 1.31 (d, 3H, J = 6.0 Hz). EM (calc.): 477; MS (ESI) m/e (M + 1H)+: 477.9, (M − 1H)−: 476.1. Cpd. 162 1HNMR (DMSO-d6): 3.56 (s, 2H), 4.09 (t, 2H), 6.57 (d, 1H), 6.77 (d, 1H), 6.95 (m, 3H), 7.18 (t, 1H), 7.32 (d, 2H), 7.69 (d, 2H), 8.38 (t, 1H), 9.6 (s, 1H), 11.05 (s, 1H). LC\MS: (M + 1)+1 343.2, (M − 1)−1 341.3. Cpd. 163 1HNMR (DMSO-d6): 3.55 (s, 2H), 4.08 (t, 2H), 6.4 (d, 1H), 6.8 (d, 2H), 7.0 (d, 2H), 7.35 (d, 1H), 7.4 (d, 2H), 7.69 (d, 2H), 8.25 (t, 1H), 9.85 (s, 1H), 11.05 (s, 1H). LC\MS: (M + 1)+1 343.1, (M − 1)−1 341.1. Cpd. 164 EM (calc.): 420.17; MS (ESI) m/e (M + 1H)+: 421.2, (M − 1H)−: 419.5. Cpd. 165 EM (calc.): 420.17; MS (ESI) m/e (M + 1H)+: 421.3, (M − 1H)−: 419.3. Cpd. 166 EM (calc.): 420.17; MS (ESI) m/e (M + 1H)+: 421.3, (M − 1H)−: 419.3. Cpd. 167 1HNMR (DMSO-d6):δ 8.89 (1H, s), 8.58 (1H, m), 7.71 (2H, m), 7.65 (1H, d), 7.56 (1H, d), 7.41 (1H, d), 7.36 (1H, t), 7.25 (1H, t), 7.21 (1H, s), 7.00 (2H, d), 6.74 (1H, dd), 4.11 (2H, t), 3.58 (2H, q). Cpd. 168 EM (calc.): 420.17; MS (ESI) m/e (M + 1H)+: 421.2, (M − 1H)−: 419.3. Cpd. 169 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 9.14 (s, 1H), 9.11 (t, J = 8.0 Hz, 1H), 8.93 (s, 1H), 8.63 (t, J = 4.0 Hz, 1H), 8.17 (m, 1H), 7.72 (m, 4H), 7.00 (d, J = 8.0 Hz, 2H), 4.20 (t, J = 8.0 Hz, 2H), 3.71 (m, 2H). MS (ESI) m/e: (M + 1H)+: 384.1, (M − 1H)−: 382.0. Cpd. 170 MS (ESI) m/e: (M + 1H)+: 451.0, (M − 1H)−: 449.2. Cpd. 171 MS (ESI) m/e: (M + 1H)+: 409.3, (M − 1H)−: 407.2. Cpd. 172 1HNMR (DMSO-d6): 3.54 (q, 2H), 3.84 (s, 3H), 4.08 (t, 2H), 6.6 (d, 1H), 6.98 (m, 4H), 7.35 (t, 1H), 7.5 (d, 1H), 7.65 (d, 1H), 7.69 (d, 2H), 8.36 (t, 1H), 8.9 (s, 1H), 11.04 (s, 1H). LC\MS: (M + 1)+1 356.9, (M − 1)−1 355.2. Cpd. 173 1HNMR (DMSO-d6): 3.56 (q, 2H), 3.77 (s, 3H), 4.09 (t, 2H), 6.66 (d, 1H), 6.93 (m, 2H), 6.99 (d, 2H), 7.1 (d, 2H), 7.29 (t, 1H), 7.39 (d, 1H), 7.70 (d, 2H), 7.87 (d, 1H), 8.36 (t, 1H), 8.9 (s, 1H), 11.05 (s, 1H). LC\MS: (M + 1)+1 357.1, (M − 1)−1 355.1. Cpd. 174 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 9.21 (t, J = 8.0 Hz, 1H), 9.07 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 7.70 (m, 4H), 7.01 (d, J = 8.0 Hz, 2H), 6.92 (m, 1H), 4.21 (t, J = 8.0 Hz, 2H), 3.71 (m, 2H). MS (ESI) m/e: (M + 1H)+: 421.2, (M − 1H)−: 419.4. Cpd. 175 1HNMR (DMSO-d6):δ 8.91 (1H, s), 8.44 (1H, t), 7.73 (2H, d), 7.72 (1H, s), 7.57 (1H, d), 7.44 (1H, d), 7.02 (2H, d), 6.50 (1H, d), 4.11 (2H, t), 3.58 (2H, q). LC/MS, M + 1: 413.1. Cpd. 176 1HNMR (DMSO-d6): 3.54 (q, 2H), 4.07 (t, 2H), 6.36 (d, 1H), 6.68 (s, 1H), 6.98 (d, 2H), 7.32 (d, 1H), 7.69 (m, 3H), 7.98 (s, 1H), 8.27 (t, 1H), 8.9 (s, 1H), 11.04 (s, 1H). LC\MS: (M + 1)+1 316.9, (M − 1)−1 315.3. Cpd. 177 1HNMR (DMSO-d6): 3.55 (q, 2H), 4.08 (t, 2H), 6.47 (d, 1H), 6.98 (d, 2H), 7.31 (d, 1H), 7.42 (d, 1H), 7.58 (m, 1H), 7.69 (d, 2H), 7.78 (s, 1H), 8.30 (t, 1H), 8.9 (s, 1H), 11.04 (s, 1H). LC\MS: (M + 1)+1 333.0, (M − 1)−1 331.0. Cpd. 178 1HNMR (DMSO-d6):δ 8.91 (1H, s), 8.40 (1H, t), 7.73 (2H, d), 7.61 (2H, m), 7.38 (1H, d), 7.11 (1H, dd), 7.01 (2H, d), 6.43 (1H, d), 4.11 (2H, t), 3.57 (2H, q). LC/MS, M + 1: 333.0. Cpd. 179 1HNMR (DMSO-d6): 2.31 (s, 3H), 3.55 (q, 2H), 4.09 (t, 2H), 6.6 (d, 1H), 6.99 (d, 2H), 7.2-7.4 (m, 6H), 7.70 (d, 2H), 8.33 (t, 1H), 8.9 (s, 1H), 11.04 (s, 1H). LC\MS: (M + 1)+ 1 341.1, (M − 1)−1 339.1. Cpd. 180 1HNMR (DMSO-d6): 2.31 (s, 3H), 3.55 (q, 2H), 4.09 (t, 2H), 6.6 (d, 1H), 6.99 (d, 2H), 7.2 (d, 2H), 7.38 (d, 1H), 7.42 (d, 2H), 7.69 (d, 2H), 8.33 (t, 1H), 8.9 (s, 1H), 11.04 (s, 1H). LC\MS: (M + 1)+1 341.2, (M − 1)−1 339.2. Cpd. 181 1HNMR (DMSO-d6):δ 8.87 (1H, s), 8.52 (1H, t), 7.70 (2H, d), 7.64 (1H, d), 7.52 (1H, d), 7.34 (1H, m), 7.24 (1H, t), 7.22 (1H, s), 6.99 (2H, d), 6.67 (1H, m), 4.09 (2H, t), 3.52 (2H, q), 2.48 (3H, m). LC/MS, M + 1: 381.0. Cpd. 182 1HNMR (DMSO-d6):δ 8.88 (1H, s), 8.33 (1H, t), 7.68 (2H, d), 7.54 (1H, m), 7.41 (1H, d), 7.28 (1H, s), 7.24 (1H, m), 7.19 (1H, m), 6.95 (2H, d), 6.07 (1H, m), 4.11 (2H, t), 3.52 (2H, q), 2.15 (3H, m). LC/MS, M + 1: 381.1. Cpd. 183 1HNMR (DMSO-d6): 2.94 (s, 6H), 3.54 (q, 2H), 4.07 (t, 2H), 6.38 (d, 1H), 6.69 (d, 2H), 6.98 (d, 2H), 7.29 (d, 1H), 7.35 (d, 2H), 7.69 (d, 2H), 8.15 (t, 1H), 8.87 (s, 1H), 11.04 (s, 1H). LC\MS: (M + 1)+1 370.1, (M − 1)−1 368.3. Cpd. 184 1HNMR (DMSO-d6): 3.57 (q, 2H), 4.10 (t, 2H), 6.65 (d, 1H), 7.0 (d, 2H), 7.14 (m, 2H), 7.42 (m, 1H), 7.6 (d, 1H), 7.72 (m, 3H), 7.87 (d, 1H), 8.149 (t, 1H), 8.87 (s, 1H), 11.04 (s, 1H), 11.52 (s, 1H). LC\MS: (M + 1)+1 366.2, (M − 1)−1 364.4. Cpd. 185 1HNMR (DMSO-d6): 2.36 (s, 3H), 3.56 (q, 2H), 4.10 (t, 2H), 6.56 (d, 1H), 7.00 (d, 2H), 7.23 (m, 3H), 7.5 (d, 1H), 7.65 (d, 1H), 7.7 (d, 2H), 8.4 (t, 1H), 8.87 (s, 1H), 11.04 (s, 1H). LC\MS: (M + 1)+1 341.2, (M − 1)−1 339.3. Cpd. 186 1HNMR (DMSO-d6): 3.55 (q, 2H), 3.93 (s, 3H), 4.08 (t, 2H), 6.66 (d, 1H), 6.79 (t, 1H), 6.86 (d, 1H), 6.98 (d, 2H), 7.15 (m, 1H), 7.4 (d, 1H), 7.65 (d, 1H), 7.7 (d, 2H), 8.31 (t, 1H), 10.0 (s, 1H), 11.04 (s, 1H). LC\MS: (M + 1)+1 343.1, (M − 1)−1 340.9. Cpd. 187 1HNMR (DMSO-d6): 3.57 (q, 2H), 3.93 (s, 3H), 4.09 (t, 2H), 6.75 (d, 1H), 6.98 (m, 3H), 7.18 (m, 3H), 7.38 (d, 1H), 7.7 (d, 2H), 8.5 (t, 1H), 8.87 (s, 1H), 11.04 (s, 1H). LC\MS: (M + 1)+1 396.7, (M − 1)−1 395.0. Cpd. 188 1HNMR (DMSO-d6): 0.922 (t, 3H), 1.5-1.8 (m, 2H), 3.93 (s, 3H), 3.95-4.07 (m, 3H), 6.8 (d, 1H), 6.98 (m, 3H), 7.19 (m, 3H), 7.36 (d, 1H), 7.69 (d, 2H), 8.3 (d, 1H), 11.03 (s, 1H). LC\MS: (M + 1)+1 425.2, (M − 1)−1 423.2. Cpd. 189 1H NMR (DMSO-d6): 0.95 (3H, t, 7 Hz); 1.53 (1H, m); 1.72 (1H, m); 2.52 (3H, s); 3.79 (3H, s); 3.94 (1H, m); 4.06 (2H, m); 6.66 (1H, s); 6.93 (1H, dd); 7.02 (2H, d); 7.15 (2H, m); 7.42 (1H, d); 7.7 (2H, d); 8.27 (2H, d, 7 Hz); 8.87 (1H, d, 2 Hz). MS (M + 1): 439. Cpd. 190 1HNMR (DMSO-d6): 3.54 (q, 2H), 4.08 (t, 2H), 6.44 (d, 1H), 6.56 (s, 1H), 6.75 (s, 1H), 6.98 (d, 2H), 7.23 (d, 1H), 7.70 (d, 2H), 7.75 (s, 1H), 8.41 (t, 1H), 8.9 (s, 1H), 11.04 (s, 1H). LC\MS: (M + 1)+1 317.0, (M − 1)−1 315.2. Cpd. 191 1HNMR (DMSO-d6): 3.5-4.05 (m, 14H), 4.18 (t, 2H), 6.99 (d, 2H), 7.69 (d, 2H), 7.93 (d, 2H), 8.02 (d, 2H), 8.2 (s, 1H), 8.76 (t, 1H), 8.97 (s, 1H), 11.05 (s, 1H). LC\MS: (M + 1)+ 1 497.4, (M − 1)−1 495.4. -
TABLE 2 Cpd. 1 EM (calc.): 370.2; MS (ESI) m/e (M + 1)+: 371.1, (M − 1)−: 369.2. Cpd. 2 1H NMR (400 MHz, DMSO-d6) δ 11.03 (s, 1H), 8.88 (s, 1H), 7.67 (d, J = 9.2 Hz, 2H), 7.51 (m, 3H), 7.36 (m, 8H), 6.92 (d, J = 9.2 Hz, 2H), 6.27 (d, J = 15.2 Hz, 1H), 4.16 (m, 4H). EM (calc.): 402.2; MS (ESI) m/e (M + 1H)+: 403.1, (M − 1H)−: 401.1. Cpd. 3 EM (calc.): 340.1; MS (ESI) m/e (M + 1H)+: 341.0, (M − 1H)−: 339.4. Cpd. 4 EM (calc.): 398.13; MS (ESI) m/e (M + 1H)+: 399.0, (M − 1H)−: 397.1. Cpd. 5 EM (calc.): 368.17; MS (ESI) m/e (M + 1H)+: 368.8, (M − 1H)−: 367.2. Cpd. 6 EM (calc.): 354.1; MS (ESI) m/e (M + 1H)+: 354.8, (M − 1H)−: 353.2. -
TABLE 3 Cpd. 1 1H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 9.07 (t, J = 5.2 Hz, 1H), 8.94 (s, 1H), 8.16 (s, 1H), 8.07 (dd, J1 = 2.4 Hz, J2 = 8.4 Hz, 1H), 7.99 (dd, J1 = 2.4 Hz, J2 = 6.8 Hz, 1H), 7.77 (d, J = 9.2 Hz, 2H), 7.50 (m, 2H), 7.08 (d, J = 8.8 Hz, 2H), 4.25 (pseudo t, J = 5.6 Hz, 2H), 3.73 (pseudo q, J = 5.2 Hz, 2H). EM (calc.): 358.1; MS (ESI) m/e (M + 1H)+: 357.0, (M − 1H)−: 355.1. Cpd. 2 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 8.92 (t, J = 5.6 Hz, 1H), 8.88 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 9.2 Hz, 2H), 7.64 (d, J = 8.0 Hz, 1H), 7.55 (s, 1H), 7.46 (t, J = 6.8 Hz, 1H), 7.32 (t, J = 8.0 Hz, 1H), 7.01 (d, J = 8.2 Hz, 2H), 4.18 (t, J = 5.6 Hz, 2H), 3.67 (m, 2H). EM (calc.): 340.1; MS (ESI) m/e: (M + 1H)+: 341.0, (M − 1H)−: 339.1. Cpd. 3 1H NMR (400 MHz, DMSO-d6) δ: 11.57 (s, 1H), 11.04 (s, 1H), 8.71 (t, J = 5.6 Hz, 1H), 7.70 (d, J = 8.8 Hz, 2H), 7.59 (d, J = 8.4 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.16 (t, J = 8.4 Hz, 1H), 7.12 (m, 1H), 7.00 (m, 3H), 4.18 (t, J = 5.6 Hz, 2H), 3.68 (m, 2H). EM (calc.): 339.1; MS (ESI) m/e (M + 1H)+: 340.1, (M − 1H)−: 338.3. Cpd. 4 EM (calc.): 353.1; MS (ESI) m/e (M + 1)+: 354.1, (M − 1)−: 352.2. Cpd. 5 1H NMR (400 MHz, DMSO-d6) δ 8.84 (t, J = 5.6 Hz, 1H), 8.05 (s, 1H), 7.99 (dd, J1 = 6.0 Hz, J2 = 2.0 Hz, 1H), 7.91 (dd, J1 = 6.4 Hz, J2 = 2.0 Hz, 1H), 7.65 (d, J = 8.8 Hz, 2H), 7.42 (m, 2H), 6.88 (d, J = 8.4 Hz, 2H), 4.06 (t, J = 6.0 Hz, 2H), 3.43 (pseudo q, J = 5.6 Hz, 2H), 2.00 (pseudo p, J = 6.0 Hz, 2H). EM (calc.): 370.1; MS (ESI) m/e (M + 1H)+: 371.1, (M − 1H)−: 369.0. Cpd. 6 1H NMR (400 MHz, DMSO-d6) δ 10.96 (s, 1H), 8.74 (t, J = 6.0 Hz, 1H), 7.67 (d, J = 7.6 Hz, 1H), 7.62 (d, J = 8.4 Hz, 2H), 7.44 (s, 1H), 7.55 (dd, J1 = 8.4 Hz, J2 = 0.8 Hz, 1H), 7.43 (d, J = 0.8 Hz, 1H), 7.37 (td, J1 = 7.2 Hz, J2 = 1.2 Hz, 1H), 7.241 (td, J1 = 8.0 Hz, J2 = 0.8 Hz, 1H), 6.89 (d, J = 8.8 Hz, 2H), 4.01 (t, J = 6.4 Hz, 2H), 3.37 (pseudo q, J = 6.0 Hz, 2H), 1.94 (pseudo p, J = 6.0 Hz, 2H). EM (calc.): 354.1; MS (ESI) m/e (M + 1H)+: 355.2, (M − 1H)−: 353.1. Cpd. 7 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.91 (s, 1H), 8.65 (br d, J = 7.2 Hz, 1H), 8.20 (s, 1H), 8.03 (m, 1H), 7.95 (m, 1H), 7.72 (d, J = 8.4 Hz, 2H), 7.46 (m, 2H), 7.03 (d, J = 8.8 Hz, 2H), 4.20 (m, 3H), 2.08 (m, 1H), 1.02 (d, J = 6.8 Hz, 6H). EM (calc.): 398.1; MS (ESI) m/e (M + 1H)+: 399.0, (M − 1H)−: 397.1. Cpd. 8 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.91 (s, 1H), 8.68 (d, J = 8.0 Hz, 1H), 8.17 (s, 1H), 8.03 (dd, J1 = 2.0 Hz, J2 = 6.4 Hz, 1H), 7.96 (dd, J1 = 4.0 Hz, J2 = 6.8 Hz, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.46 (m, 4H), 7.04 (d, J = 9.2 Hz, 2H), 4.24 (m, 1H), 4.18 (dd, J1 = 6.8 Hz, J2 = 10.0 Hz, 1H), 4.09 (dd, J1 = 5.2 Hz, J2 = 9.6 Hz,), 1.81 (m, 1H), 1.67 (m, 1H), 0.99 (t, J = 7.6 Hz, 3H). EM (calc.): 384.1; MS (ESI) m/e (M + 1H)+: 385.0, (M − 1H)−: 383.1. Cpd. 9 1H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 8.95 (br s, 1H), 8.80 (d, J = 8.0 Hz, 1H), 8.19 (s, 1H), 8.06 (dd, J1 = 5.6 Hz, J2 = 1.6 Hz, 1H), 7.98 (dd, J1 = 6.8 Hz, J2 = 1.6 Hz, 1H), 7.76 (d, J = 8.4 Hz, 2H), 7.49 (m, 2H), 7.08 (d, J = 8.8 Hz, 2H), 4.42 (p, J = 6.4 Hz, 1H), 4.20 (dd, J1 = 9.6 Hz, J2 = 6.4 Hz, 1H), 4.07 (dd, J1 = 9.6 Hz, J2 = 5.6 Hz, 1H), 1.36 (d, J = 6.8 Hz, 3H). EM (calc.): 370.1; MS (ESI) m/e (M + 1H)+: 371.0, (M − 1H)−: 368.9. Cpd. 10 1H NMR (400 MHz, DMSO-d6) δ 10.95 (s, 1H0, 8.65 (d, J = 7.6 Hz, 1H), 8.04 (s, 1H), 7.91 (d, J = 7.2 Hz, 1H), 7.83 (d, J = 6.4 Hz, 1H), 7.61 (d, J = 8.8 Hz, 2H), 7.34 (m, 2H), 6.93 (d, J = 8.8 Hz, 2H), 4.27 (p. J = 6.4 Hz, 1H), 4.05 (dd, J1 = 6.8 Hz, J2 = 10.0 Hz, 1H), 3.92 (dd, J1 = 10.0 Hz, J2 = 6.0 Hz, 1H), 1.21 (d, J = 5.2 Hz, 3H). EM (calc.): 370.1; MS (ESI) m/e (M + 1H)+: 370.9, (M − 1H)−: 369.0. Cpd. 11 1H NMR (400 MHz, DMSO-d6) δ 10.96 (s, 1H), 8.54 (d, J = 8.4 Hz, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.61 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 0.8 Hz, 1H), 7.38 (td, J1 = 8.0 Hz, J2 = 0.8 Hz, 1H), 7.25 (td, J1 = 7.2 Hz, J2 = 0.8 Hz, 1H), 6.92 (d, J = 8.8 Hz, 2H), 4.19 (m, 1H), 4.07 (dd, J1 = 10.4 Hz, J2 = 6.4 Hz, 1H), 3.99 (dd, J1 = 10.0 Hz, J2 = 5.6 Hz, 1H), 1.68 (m, 1H), 1.55 (m, 1H), 0.86 (t, J = 7.2 Hz, 3H). EM (calc.): 368.1; MS (ESI) m/e (M − 1H)−: 367.1. Cpd. 12 1H NMR (400 MHz, DMSO-d6) δ 11.06 (s, 1H), 9.03 (t, J = 6.0 Hz, 1H), 8.11 (s, 1H), 8.03 (d, J = 7.2 Hz, 1H), 7.94 (d, J = 6.4 Hz, 1H), 7.72 (d, J = 8.8 Hz, 2H), 7.46 (m, 2H), 7.07 (d, J = 9.2 Hz, 2H), 4.72 (pseudo q, J = 5.6 Hz, 1H), 3.62 (m, 1H), 3.42 (m, 1H), 1.34 (d, J = 6.4 Hz, 3H). EM (calc.): 370.1; MS (ESI) m/e (M + 1H)+: 371.0, (M − 1H)−: 369.1. Cpd. 13 1H NMR (400 MHz, DMSO-d6) δ 11.06 (s, 1H), 9.03, (t, J = 5.6 Hz, 1H), 8.11 (s, 1H), 8.03 (d, J = 6.8 Hz, 1H), 7.94 (d, J = 7.2 Hz, 1H), 7.72 (d, J = 8.4 Hz, 2H), 7.46 (pseudo p, J = 5.6 Hz, 2H), 7.07 (d, J = 8.4 Hz, 2H), 4.74 (pseudo q, J = 5.6 Hz, 1H), 3.63 (m, 1H), 3.42 (m, 1H), 1.34 (d, J 6.0 Hz, 3H). EM (calc.): 370.1; MS (ESI) m/e (M + 1H)+: 371.0, (M − 1H)−: 369.1. Cpd. 14 1H NMR (400 MHz, DMSO-d6) δ 11.02 (s, 1H), 8.92 (t, J = 6.0 Hz, 1H), 7.75 (d, J = 7.6 Hz, 1H), 7.68 (d, J = 8.8 Hz, 2H), 7.54 (d, J = 0.8 Hz, 1H), 7.44 (td, J1 = 7.2 Hz, J2 = 0.8 Hz, 1H), 7.31 (td, J = 7.6 Hz, J2 = 0.8 Hz, 1H), 7.03 (d, J = 9.2 Hz, 2H), 4.69 (pseudo q, J = 6.4 Hz, 1H), 3.59 (ddd, J1 = 6.4 Hz, J2 = 13.6 Hz, J3 = 19.6 Hz, 1H), 3.39 (ddd, J1 = 6.0 Hz, J2 = 12.4 Hz, J3 = 19.6 Hz, 1H), 1.29 (d, J = 6.4 Hz, 3H). EM (calc.): 354.1; MS (ESI) m/e (M + 1H)+: 354.7, (M − 1H)−: 353.1. Cpd. 15 EM (calc.): 386.09; MS (ESI) m/e (M − 1H)−: 384.7. Cpd. 16 EM (calc.): 370.10; MS (ESI) m/e (M − 1H)−: 369.0. Cpd. 17 EM (calc.): 390.0; MS (ESI) m/e (M + 1H)+: 391.2. Cpd. 18 EM (calc.): 354.12; MS (ESI) m/e (M − 1H)−: 353.2. Cpd. 19 EM (calc.): 354.12; MS (ESI) m/e (M − 1H)−: 353.1. Cpd. 20 EM (calc.): 424.07; MS (ESI) m/e (M − 1H)−: 423.9. Cpd. 21 EM (calc.): 374.0; MS (ESI) m/e (M + 1)+: 375.0, (M − 1)−: 373.0. Cpd. 22 EM (calc.): 386.1; MS (ESI) m/e (M + 1)+: 387.1, (M − 1)−: 384.7. Cpd. 23 EM (calc.): 374.1; MS (ESI) m/e (M + 1)+: 374.9, (M − 1)−: 372.9. Cpd. 24 EM (calc.): 370.1; MS (ESI) m/e (M + 1)+: 370.8, (M − 1)−: 369.0. Cpd. 25 EM (calc.): 370.1; MS (ESI) m/e (M + 1)+: 371.0, (M − 1)−: 369.1. Cpd. 26 EM (calc.): 414.14; MS (ESI) m/e (M + 1H)+: 415.2, (M − 1H)−: 413.2. Cpd. 27 EM (calc.): 469.18; MS (ESI) m/e (M + 1H)+: 470.1, (M − 1H)−: 468.4. Cpd. 28 EM (calc.): 447.14; MS (ESI) m/e (M + 1H)+: 448.1, (M − 1H)−: 446.2. Cpd. 29 EM (calc.): 354.1; MS (ESI) m/e (M + 1)+: 355.1, (M − 1)−: 353.1. Cpd. 30 EM (calc.): 370.1; MS (ESI) m/e (M + 1)+: 371.0, (M − 1)−: 368.9. Cpd. 31 EM (calc.): 400.1; MS (ESI) m/e (M + 1H)+: 401.0, (M − 1H)−: 399.2. Cpd. 32 EM (calc.): 427.1; MS (ESI) m/e (M + 1H)+: 428.2, (M − 1H)−: 426.2. Cpd. 33 EM (calc.): 414.1; MS (ESI) m/e (M + 1)+: 415.4, (M − 1)−: 413.2. Cpd. 34 EM (calc.): 469.2; MS (ESI) m/e (M + 1)+: 470.1, (M − 1)−: 468.3. Cpd. 35 EM (calc.): 447.1; MS (ESI) m/e (M + 1)+: 448.2, (M − 1)−: 446.5. Cpd. 36 EM (calc.): 368.1; MS (ESI) m/e (M + 1)+: 369.0, (M − 1)−: 367.2. Cpd. 37 1H NMR (400 MHz, DMSO-d6) δ 11.69 (s, 1H), 11.04 (s, 1H), 8.77 (t, J = 5.6 Hz, 1H), 7.70 (d, J = 8.4 Hz, 2H), 7.39 (m, 2H), 7.11 (s, 1H), 7.05 (m, 1H), 7.01 (d, J = 8.4 Hz, 2H), 4.18 (t, J = 6.0 Hz, 2H), 3.67 (m, 2H). EM (calc.): 357.1; MS (ESI) m/e (M + 1H)+: 357.8, (M − 1H)−: 356.2. Cpd. 38 1H NMR (400 MHz, DMSO-d6) δ 11.42 (s, 1H), 11.05 (s, 1H), 8.66, (t, J = 5.6 Hz, 1H), 7.70 (d, J = 9.2 Hz, 2H), 7.29 (d, J = 8.4 Hz, 1H), 7.03 (m, 4H), 6.81 (m, 1H), 4.17 (t, J = 5.6 Hz, 2H), 3.75 (s, 3H), 3.66 (m, 2H). EM (calc.): 369.1; MS (ESI) m/e (M + 1H)+: 369.9, (M − 1H)−: 368.2. Cpd. 39 EM (calc.): 384.13; MS (ESI) m/e (M + 1H)+: 384.9, (M − 1H)−: 383.2. Cpd. 40 EM (calc.): 446.15; MS (ESI) m/e (M + 1H)+: 447.2, (M − 1H)−: 445.4. Cpd. 41 1H NMR (400 MHz, DMSO-d6) δ 11.28 (s, 1H), 11.04 (s, 1H), 8.53 (t, J = 5.6 Hz, 1H), 7.70 (d, J = 9.2 Hz, 2H), 7.02 (m, 4H), 6.86 (s, 1H), 4.16 (t, J = 5.6 Hz, 2H), 3.76 (s, 3H), 3.75 (s, 3H), 3.63 (m, 2H). EM (calc.): 399.1; MS (ESI) m/e (M + 1H)+: 400.0, (M − 1H)−: 398.1. Cpd. 42 1H NMR (400 MHz, DMSO-d6) δ 11.09 (bs, 1H), 10.60 (bs, 1H), 9.29 (t, J = 6.0 Hz, 1H), 8.08 (d, J = 8.0 Hz, 1H), 7.70 (m, 3H), 7.57 (t, J = 7.2 Hz, 1H), 7.45 (t, J = 7.2 Hz, 1H), 7.00 (d, J = 9.2 Hz, 2H), 4.83 (m, 2H), 4.23 (t, J = 6.0 Hz, 2H), 3.94 (m, 2H), 3.73 (m, 4H), 3.44 (m, 2H), 3.27 (m, 2H). EM (calc.): 439.2; MS (ESI) m/e (M + 1H)+: 439.8, (M − 1H)−: 438.2. Cpd. 44 EM (calc.): 412.16; MS (ESI) m/e (M + 1H)+: 413.1, (M − 1H)−: 411.3. Cpd. 45 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 8.92 (t, J = 5.2 Hz, 1H), 7.74 (d, J = 7.6 Hz, 1H), 7.70 (d, J = 8.8 Hz, 2H), 7.59 (s, 1H), 7.55 (d, J = 6.8 Hz, 1H), 7.32 (m, 3H), 7.06 (d, J = 7.6 Hz, 2H), 7.00 (d, J = 9.2 Hz, 2H), 6.95 (t, J = 7.2 Hz, 1H), 5.44 (s, 2H), 4.19 (t, J = 6.0 Hz, 2H), 3.69 (m, 2H). EM (calc.): 446.2; MS (ESI) m/e (M + 1H)+: 447.2, (M − 1H)−: 445.3. Cpd. 46 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 8.91 (t, J = 5.6 Hz, 1H), 7.71 (m, 3H), 7.58 (s, 1H), 7.44 (d, J = 7.6 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.03 (d, J = 8.8 Hz, 2H), 4.78 (s, 2H), 4.20 (t, J = 6.0 Hz, 2H), 3.69 (m, 2H), 3.36 (s, 3H). EM (calc.): 384.1; MS (ESI) m/e (M + 1H)+: 385.9, (M − 1H)−: 383.2. Cpd. 47 1H NMR (400 MHz, DMSO-d6) δ 11.33 (s, 1H), 11.09 (s, 1H), 9.32 (t, J = 5.6 Hz, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.71 (m, 3H), 7.61 (s, 1H), 7.43 (t, J = 7.6 Hz, 1H), 7.03 (d, J = 8.8 Hz, 1H), 4.68 (s, 2H), 4.23 (t, J = 5.6 Hz, 2H), 3.83 (m, 6H), 3.37 (m, 2H), 3.20 (m, 2H). EM (calc.): 439.2; MS (ESI) m/e (M + 1H)+: 440.2, (M − 1H)−: 438.4. Cpd. 48 1H NMR (400 MHz, DMSO-d6) δ 11.09 (s, 1H) 10.74 (s, 1H), 9.31 (t, J = 5.6 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 8.6 Hz, 2H), 7.65 (d, J = 7.2 Hz, 1H), 7.62 (s, 1H), 7.42 (t, J = 8.0 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H), 4.63 (d, J = 5.2 Hz, 2H), 4.23 (t, J = 6.0 Hz, 2H), 3.70 (m, 2H), 2.78 (s, 3H), 2.770 (s, 3H). EM (calc.): 397.2; MS (ESI) m/e (M + 1H)+: 398.0, (M − 1H)−: 396.1. Cpd. 49 EM (calc.): 384.1; MS (ESI) m/e (M − 1)−: 382.9. Cpd. 50 EM (calc.): 400.1; MS (ESI) m/e (M − 1)−: 398.7. Cpd. 51 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.78 (t, J = 6.0 Hz, 1H), 7.71 (m, 3H), 7.54 (s, 1H), 7.43 (d, J = 7.2 Hz, 1H), 7.32 (d, J = 7.6 Hz, 1H), 6.99 (d, J = 8.4 Hz, 2H), 4.77 (s, 2H), 4.10 (t, J = 6.0 Hz, 2H), 3.47 (m, 2H), 3.36 (s, 3H), 2.02 (m, 2H). EM (calc.): 398.2; MS (ESI) m/e (M + 1H)+: 399.1, (M − 1H)−: 397.1. Cpd. 52 1H NMR (400 MHz, DMSO-d6) δ 8.82 (t, J = 5.6 Hz, 1H), 7.71 (m, 3H), 7.54 (m, 2H), 7.31 (m, 3H), 7.06 (d, J = 8.0 Hz, 2H), 6.95 (m, 3H), 5.43 (s, 2H), 4.09 (t, J = 6.0 Hz, 2H), 3.47 (m, 2H), 2.02 (m, 2H). EM (calc.): 460.2; MS (ESI) m/e (M + 1H)+: 461.0, (M − 1H)−: 459.1. Cpd. 53 EM (calc.): 428.16; MS (ESI) m/e (M + 1H)+: 428.9, (M − 1H)−: 427.1. Cpd. 54 1H NMR (DMSO-d6): 2.11 (3H, s); 2.78 (1H, dd, 14.8 Hz); 2.86 (1H, dd, 14.5 Hz); 4.17 (1H, dd, 10.4 Hz); 4.23 (1H, dd, 10.6 Hz); 4.49 (1H, m); 7.00 (2H, d, 9 Hz); 7.32 (1H, t, 7 Hz); 7.46 (1H, td, 8.1 Hz); 7.56 (1H, s); 7.64 (1H, d, 8 Hz); 7.70 (2H, d, 9 Hz); 7.77 (1H, d, 8 Hz); 8.77 (1H, d, 8 Hz); 8.88 (1H, s). MS (M + 1): 401. Cpd. 55 1H NMR (DMSO-d6): 3.31 (3H, s); 3.53 (1H, dd, 13, 3.5 Hz); 3.66 (1H, dd, 13.8 Hz); 4.16 (1H, dd, 9.6 Hz); 4.24 (1H, dd, 9.8 Hz); 4.87 (1H, m); 7.00 (2H, d, 9 Hz); 7.33 (1H, t, 7 Hz); 7.47 (1H, t, 8 Hz); 7.57 (1H, s); 7.65 (1H, d, 8 Hz); 7.70 (2H, d, 9 Hz); 7.77 (1H, d, 8 Hz); 8.89 (1H, s); 9.0 (1H, d, 8 Hz). MS (M − 1): 431. Cpd. 56 1H NMR (400 MHz, DMSO-d6) δ: 7.92 (br s, 1H), 8.76 (t, 1H, J = 5.9 Hz), 7.75 (m, 3H), 7.60 (d, 1H, J = 7.6 Hz), 7.48 (t, 1H, J = 8.0 Hz), 7.32 (t, 1H, J = 8.0 Hz), 7.27 (m, 5H), 7.17 (m, 1H), 7.04 (m, 2H), 4.21 (t, 2H, J = 5.9 Hz), 3.69 (m, 2H) 3.39 (m, 2H), 2.96 (t, 2H, J = 8.3 Hz). EM (calc.): 444; MS (ESI) m/e (M + 1H)+: 445.3, (M − 1H)−: 443.3. Cpd. 57 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 9.38 (s, 1H), 8.90 (s, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.57 (m, 10H), 6.97 (d, J = 8.0 Hz, 2H), 4.80 (m, 2H), 4.20 (s, 2H), 3.70 (m, 2H), 3.31 (m, 3H), 2.66 (m, 2H). MS (ESI) m/e: (M + 1H)+: 474.4, (M − 1H)−: 472.1. Cpd. 58 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 9.73 (m, 1H), 8.89 (s, 1H), 7.75 (d, J = 8.0 Hz, 2H), 7.70 (t, J = 8.0 Hz, 2H), 7.61 (d, J = 8.0 Hz, 1H), 7.43 (t, 8.0 Hz, 1H), 7.18 (m, 6H), 6.98 (d, J = 8.0 Hz, 2H), 4.13 (t, J = 8.0 Hz, 2H), 3.95 (m, 2H), 3.58 (m, 2H), 2.78 (m, 2H), 2.65 (m, 2H), 1.24 (s, 3H). MS (ESI) m/e: (M + 1H)+: 487.9, (M − 1H)−: 486.1. Cpd. 59 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.88 (s, 1H), 8.84 (t, J = 8.0 Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.59 (d, J = 8.0 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.34 (t, J = 8.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 2H), 4.31 (s, 2H), 4.18 (t, J = 8.0 Hz, 2H), 3.66 (m, 2H), 3.38 (m, 2H), 2.45 (t, J = 8.0 Hz, 2H), 1.65 (m, 2H). MS (ESI) m/e: (M + 1H)+: 445.2, (M − 1H)−: 443.1. Cpd. 60 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 9.04 (t, J = 8.0 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.63 (d, J = 8.0 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 2H), 4.57 (m, 2H), 4.18 (t, J = 8.0 Hz, 2H), 3.65 (m, 2H), 3.46 (t, J = 8.0 Hz, 2H), 2.77 (m, 2H), 1.80 (m, 2H). MS (ESI) m/e: (M + 1H)+: 461.0, (M − 1H)−: 459.1. Cpd. 61 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 9.05 (t, J = 8.0 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.64 (d, J = 8.0 Hz, 1H), 7.51 (t, J = 8.0 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 2H), 5.11 (s, 2H), 4.19 (t, J = 8.0 Hz, 2H), 3.68 (m, 2H), 3.44 (t, J = 8.0 Hz, 2H), 3.13 (m, 2H), 1.83 (m, 2H). MS (ESI) m/e: (M + 1H)+: 477.0, (M − 1H)−: 475.0. Cpd. 62 MS (ESI) m/e: (M + 1H)+: 527.6, (M − 1H)−: 525.5. Cpd. 63 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (s, 1H), 8.88 (br s, 1H), 8.73 (t, 1H, J = 5.9 Hz), 7.75-7.69 (m, 3H), 7.57-7.42 (m, 6H), 7.28 (t, 1H, J = 7.7 Hz), 7.00 (d, 2H, J = 8.7 Hz), 4.17 (t, 2H, J = 5.9 Hz), 3.65 (q, 2H, J = 5.9 Hz) 3.40 (t, 2H, J = 6.9 Hz), 3.04 (t, 2H, J = 6.9 Hz). EM (calc.): 512; MS (ESI) m/e (M + 1H)+: 513.3, (M − 1H)−: 511.2. Cpd. 64 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (s, 1H), 8.87 (br s, 1H), 8.83 (t, 1H, J = 5.9 Hz), 7.70 (m, 3H), 7.55 (d, 1H, J = 8.3 Hz), 7.43 (t, 1H, J = 7.4 Hz), 7.34 (t, 1H, J = 8.0 Hz), 7.28-7.20 (m, 3H), 7.11 (d, 1H, 8.0 Hz), 7.00 (d, 2H, J = 8.6 Hz), 4.17 (t, 2H, J = 5.9 Hz), 3.65 (q, 2H, J = 5.9 Hz) 3.38 (t, 2H, J = 8.3 Hz), 3.00 (t, 2H, J = 8.3 Hz). EM (calc.): 528; MS (ESI) m/e (M + 1H)+: 529.4, (M − 1H)−: 527.5. Cpd. 65 1H NMR (400 MHz, DMSO-d6) δ 11.06 (s, 1H), 10.93 (s, 1H), 9.32 (m, 2H), 9.23 (s, 1H), 8.89 (s, 1H), 7.96 (d, J = 8.0 Hz, 1H), 7.70 (m, 3H), 7.56 (t, J = 8.0 Hz, 1H), 7.44 (t, J = 8.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 2H), 4.64 (s, 2H), 4.23 (t, J = 8.0 Hz, 2H), 3.71 (m, 4H). MS (ESI) m/e: (M + 1H)+: 443.4, (M − 1H)−: 441.4. Cpd. 66 1H NMR (400 MHz, DMSO-d6) δ 11.06 (s, 1H), 9.33 (t, J = 8.0 Hz, 1H), 8.89 (s, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.71 (m, 3H), 7.56 (t, J = 8.0 Hz, 1H), 7.43 (t, J = 8.0 Hz, 3H), 7.00 (d, J = 8.0 Hz, 2H), 4.60 (s, 2H), 4.23 (t, J = 8.0 Hz, 2H), 3.71 (m, 2H), 3.20 (t, J = 8.0 Hz, 2H), 2.72 (t, J = 8.0 Hz, 2H). MS (ESI) m/e: (M + 1H)+: 442.3, (M − 1H)−: 440.1. Cpd. 67 1H NMR (400 MHz, DMSO-d6) δ:, 9.11 (t, 1H, J = 6.0 Hz), 7.82 (d,, 1H, J = 7.7 Hz), 7.76 (d, 2H, J = 8.5 Hz), 7.69 (d, 1H, J = 8.5 Hz), 7.62 (s, 1H), 7.51 (t, 1H, J = 8.5 Hz), 7.40-7.30 (m, 3H), 7.21 (d, 2H, J = 8.5 Hz), 7.00-6.97 (m, 3H), 4.99 (m, 1H), 4.35 (m, 1H), 4.27 (m, 1H), 3.78 (m, 1H), 3.70 (m, 1H). EM (calc.): 446.15; MS (ESI) m/e (M + 1H)+: 447.4, (M − 1H)−: 445.3. Cpd. 68 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.86 (t, J = 4.0 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 8.0 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.33 (t, J = 4.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 2H), 5.02 (s, 2H), 4.18 (t, J = 8.0 Hz, 2H), 3.65 (m, 2H), 3.52 (t, J = 8.0 Hz, 2H), 3.44 (t, J = 8.0 Hz, 2H), 1.68 (m, 2H). MS (ESI) m/e: (M + 1H)+: 429.1, (M − 1H)−: 426.9. Cpd. 69 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (s, 1H), 9.03 (t, 1H, J = 5.9 Hz), 7.86 (d, 1H, J = 9.2 Hz), 7.70 (d, 2H, J = 8.3 Hz), 7.63 (d, 1H, J = 8.3 Hz), 7.49 (t, 1H, J = 8.8 Hz), 7.36 (t, 1H, J = 7.0 Hz), 7.29 (t, 1H, J = 8.8 Hz), 7.18 (m, 1H), 7.07 (t, 1H, J = 7.0 Hz), 7.00 (d, 1H, J = 8.3 Hz), 6.91 (m, 1H), 5.78 (s, 2H), 4.20 (t, 2H, J = 5.9 Hz), 3.68 (q, 2H, J = 5.9 Hz). EM (calc.): 464; MS (ESI) m/e (M + 1H)+: 465.1, (M − 1H)−: 463.1. Cpd. 70 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (s, 1H), 9.04 (t, 1H, J = 5.9 Hz), 9.00 (br s, 1H), 7.84 (d, 1H, J = 7.3 Hz), 7.70 (d, 2H, J = 9.2 Hz), 7.63 (d, 1H, J = 8.1 Hz), 7.49 (t, 1H, J = 8.6 Hz), 7.35 (t, 1H, J = 7.7 Hz), 7.27 (m, 1H), 7.18 (m, 1H), 7.00 (d, 1H, J = 9.2 Hz), 6.95 (m, 1H), 6.87 (m, 1H), 6.74 (m, 1H), 5.71 (s, 2H), 4.21 (t, 2H, J = 5.9 Hz), 3.69 (q, 2H, J = 5.9 Hz). EM (calc.): 464; MS (ESI) m/e (M + 1H)+: 465.0, (M − 1H)−: 463.1. Cpd. 71 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (s, 1H), 9.00 (t, 1H, J = 5.9 Hz), 7.84 (d, 1H, J = 8.4 Hz), 7.70 (d, 2H, J = 9.2 Hz), 7.62 (d, 1H, J = 8.8 Hz), 7.48 (t, 1H, J = 8.4 Hz), 7.34 (t, 1H, J = 7.3 Hz), 7.10-7.00 (m, 6H), 5.67 (s, 2H), 4.20 (t, 2H, J = 5.9 Hz), 3.68 (q, 2H, J = 5.9 Hz). EM (calc.): 464; MS (ESI) m/e (M + 1H)+: 464.9, (M − 1H)−: 463.0. Cpd. 72 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.88 (m, 2H), 7.86 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 8.0HZ, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.33 (t, J = 4.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 2H), 5.05 (s, 2H), 4.19 (t, J = 8.0 Hz, 2H), 3.65 (m, 2H), 3.59 (m, 2H), 3.47 (m, 2H), 3.23 (s, 3H). MS (ESI) m/e: (M + 1H)+: 428.9, (M − 1H)−: 426.9. Cpd. 73 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 9.20 (t, J = 4.0 Hz, 1H), 8.83 (d, J = 8.0 Hz, 2H), 7.86 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.0 Hz, 2H), 7.66 (d, J = 8.0 Hz, 1H), 7.51 (t, J = 8.0 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.25 (d, J = 8.0 Hz, 2H), 6.98 (d, J = 8.0 Hz, 2H), 6.07 (s, 2H), 4.21 (t, J = 8.0 Hz, 2H), 3.70 (m, 2H). MS (ESI) m/e: (M + 1H)+: 448.0, (M − 1H)−: 446.4. Cpd. 74 1H NMR (400 MHz, DMSO-d6) δ: 8.86 (m, 1H), 8.81 (br s, 1H), 7.80 (d, 1H, J = 8.2 Hz), 7.63 (d, 2H, J = 9.4 Hz), 7.57 (d, 1H, J = 8.2 Hz), 7.44 (t, 1H, J = 7.8 Hz), 7.32 (t, 1H, J = 7.0 Hz), 7.12 (t, 1H, J = 9.0 Hz), 6.91 (t, 1H, J = 8.6 Hz), 5.64 (s, 2H), 4.06 (t, 2H, J = 6.0 Hz), 3.54 (t, 2H, J = 6.0 Hz). EM (calc.): 500.13; MS (ESI) m/e (M + 1H)+: 501.5, (M − 1H)−: 499.3. Cpd. 75 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 9.14 (t, J = 4.0 Hz, 1H), 7.89 (m, 1H), 7.70 (m, 3H), 7.61 (d, J = 8.0 Hz, 1H), 7.46 (m, 1H), 7.40 (m, 1H), 7.29 (t, J = 4.0 Hz, 1H), 7.02 (d, J = 8.0 Hz, 2H), 6.43 (d, J = 8.0 Hz, 1H), 6.23 (t, J = 4.0 Hz, 1H), 5.62 (s, 2H), 4.23 (t, J = 4.0 Hz, 2H), 3.72 (m, 2H). MS (ESI) m/e: (M + 1H)+: 448.2, (M − 1H)−: 446.4. Cpd. 76 1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.96 (t, J = 4.0 Hz, 1H), 8.88 (s, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.63 (d, J = 8.0 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 2H), 5.24 (s, 2H), 4.18 (m, 4H), 3.66 (m, 2H). MS (ESI) m/e: (M + 1H)+: 453.3, (M − 1H)−: 451.1. Cpd. 77 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 9.04 (t, J = 4.0 Hz, 1H), 8.89 (s, 1H), 8.09 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.63 (d, J = 8.0 Hz, 1H), 7.89 (m, 1H), 7.50 (m, 3H), 7.35 (t, J = 8.0 Hz, 1H), 7.17 (d, J = 8.0 Hz, 2H), 7.03 (m, 3H), 5.77 (s, 2H), 4.22 (t, J = 8.0 Hz, 2H), 3.70 (m, 2H). MS (ESI) m/e: (M + 1H)+: 513.1, (M − 1H)−: 511.1. Cpd. 78 1H NMR (400 MHz, DMSO-d6) δ: 9.05 (s, 1H), 8.97 (t, 1H, J = 5.9 Hz), 8.81 (s, 1H), 8.08 (s, 1H), 7.80 (d, 1H, J = 7.6 Hz), 7.66-7.62 (m, 4H), 7.56 (d, 1H, J = 8.6 Hz), 7.42 (t, 1H, J = 8.1 Hz), 7.28 (t, 1H, J = 7.6 Hz), 7.15 (m, 2H), 6.94 (d, 2H, J = 8.6 Hz), 5.70 (s, 2H), 4.15 (t, 2H, J = 5.9 Hz), 3.64 (t, 2H, J = 5.9 Hz). EM (calc.): 513.16; MS (ESI) m/e (M + 1H)+: 514.2, (M − 1H)−: 512.2. Cpd. 79 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 10.33 (s, 1H), 9.25 (t, J = 4.0 Hz, 1H), 8.11 (d, J = 8.0 Hz, 1H), 7.70 (m, 3H), 7.53 (t, J = 8.0 Hz, 1H), 7.44 (t, J = 8.0 Hz, 1H), 6.99 (d, J = 8.0 Hz, 2H), 4.84 (d, J = 4.0 Hz, 2H), 4.23 (t, J = 8.0 Hz, 2H), 3.70 (m, 2H), 3.48 (m, 2H), 3.23 (m, 2H), 2.04 (m, 2H), 1.90 (m, 2H). MS (ESI) m/e: (M + 1H)+: 424.1, (M − 1H)−: 422.3. Cpd. 80 1H NMR (400 MHz, DMSO-d6) δ 11.06 (s, 1H), 9.87 (s, 1H), 9.29 (t, J = 4.0 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.71 (m, 3H), 7.57 (t, J = 8.0 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H), 6.99 (d, J = 8.0 Hz, 2H), 4.77 (s, 2H), 4.23 (t, J = 8.0 Hz, 2H), 3.70 (m, 2H), 3.48 (m, 2H), 3.04 (m, 2H), 1.73 (m, 5H), 1.38 (m, 1H). MS (ESI) m/e: (M + 1H)+: 438.0, (M − 1H)−: 436.3. Cpd. 81 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 9.55 (t, J = 4.0 Hz, 1H), 8.89 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 8.0 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H), 7.33 (t, J = 8.0 Hz, 1H), 6.99 (d, J = 8.0 Hz, 2H), 4.19 (t, J = 8.0 Hz, 2H), 3.96 (s, 2H), 3.68 (m, 2H), 2.95 (m, 2H), 2.28 (m, 1H), 2.09 (m, 2H), 1.78 (m, 2H), 1.44 (m, 2H). MS (ESI) m/e: (M + 1H)+: 506.1, (M − 1H)−: 504.2. Cpd. 82 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 9.18 (s, 1H), 8.04 (s, 1H), 7.70 (m, 3H), 7.53 (t, J = 8.0 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 2H), 4.21 (t, J = 8.0 Hz, 2H), 3.70 (m, 12H), 2.76 (s, 3H). MS (ESI) m/e: (M + 1H)+: 453.0, (M − 1H)−: 451.1. Cpd. 83 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 8.90 (m, 2H), 7.83 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 8.0 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.34 (t, J = 8.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 2H), 5.08 (s, 2H), 4.19 (t, J = 8.0 Hz, 2H), 3.68 (m, 4H), 2.58 (m, 2H). MS (ESI) m/e: (M + 1H)+: 467.0, (M − 1H)−: 465.1. Cpd. 84 1H NMR (400 MHz, DMSO-d6) δ: 11.07 (s, 1H), 8.91 (m, 2H), 7.73 (d, 2H, J = 9.0 Hz), 7.66 (s, 1H), 7.47 (d, 1H, J = 8.7 Hz), 7.37 (t, 1H, J = 8.4 Hz), 7.15 (d, 1H, J = 7.4 Hz), 7.04 (d, 2H, J = 9.0 Hz), 4.21 (t, 1H, J = 5.7 Hz), 3.69 (t, 2H, J = 5.7 Hz), 3.36 (s, 3H). EM (calc.): 354.12; MS (ESI) m/e (M + 1H)+: 354.7, (M − 1H)−: 353.1. Cpd. 85 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 8.88 (s, 1H), 8.80 (t, J = 8.0 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.0 Hz, 2H), 7.57 (d, J = 8.0 Hz, 1H), 7.46 (t, J = 8.0 Hz, 1H), 7.32 (m, 3H), 7.03 (m, 4H), 4.76 (s, 2H), 4.15 (t, J = 8.0 Hz, 2H), 3.62 (m, 2H). MS (ESI) m/e: (M + 1H)+: 481.1, (M − 1H)−: 479.0. Cpd. 86 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 8.88 (m, 2H), 7.71 (d, J = 8.0 Hz, 2H), 7.55 (m, 4H), 7.46 (t, J = 8.0 Hz, 1H), 7.28 (m, 3H), 7.00 (d, J = 8.0 Hz, 2H), 4.77 (s, 2H), 4.15 (t, J = 8.0 Hz, 2H), 3.60 (m, 2H). MS (ESI) m/e: (M + 1H)+: 497.3, (M − 1H)−: 495.1. Cpd. 87 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 8.89 (s, 1H), 8.82 (t, J = 8.0 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.0 Hz, 2H), 7.63 (m, 3H), 7.50 (t, J = 8.0 Hz, 1H), 7.34 (m, 3H), 7.00 (d, J = 8.0 Hz, 2H), 5.32 (s, 2H), 4.06 (t, J = 8.0 Hz, 2H), 3.49 (m, 2H). MS (ESI) m/e: (M + 1H)+: 513.2, (M − 1H)−: 511.2. Cpd. 88 1H NMR (400 MHz, DMSO-d6) δ 11.03 (s, 1H), 8.88 (s, 1H), 8.68 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.0 Hz, 2H), 7.64 (d, J = 8.0 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 6.98 (d, J = 8.0 Hz, 2H), 5.25 (s, 2H), 4.18 (m, 5H), 1.72 (m, 2H), 0.94 (t, J = 8.0 Hz, 3H). MS (ESI) m/e: (M + 1H)+: 481.2, (M − 1H)−: 479.2. Cpd. 89 1H NMR (400 MHz, DMSO-d6) δ: 11.94 (s, 1H), 11.04 (m, 1H), 9.36 (m, 1H), 8.88 (br s, 1H), 8.63 (s, 1H), 7.71 (d, 2H, J = 8.5 Hz), 7.22 (t, 1H, J = 8.1 Hz), 7.07 (dd, 1H, J = 8.1, 1.7 Hz), 7.02 (d, 2H, J = 8.5 Hz), 6.65 (dd, 1H, J = 7.6, 1.6 Hz), 4.21 (t, 2H, J = 5.6 Hz), 3.73 (2H, q, J = 5.2 Hz). EM (calc.): 356; MS (ESI) m/e (M + 1H)+: 357.2, (M − 1H)−: 354.9. Cpd. 90 1H NMR (400 MHz, DMSO-d6) δ: 11.03 (s, 1H), 8.69 (d, 1H, J = 8.3 Hz), 7.86 (d, 1H, J = 2.1 Hz), 7.69 (m, 3H), 7.54 (s, 1H), 7.47 (dd, 1H, J = 8.5 Hz, 2.5 Hz), 6.98 (d, 2H, J = 8.6 Hz), 4.24 (m, 1H), 4.13 (m, 1H), 4.06 (m, 1H), 1.75 (m, 1H), 1.62 (m, 1H), 0.93 (t, 3H, J = 7.3 Hz). EM (calc.): 402; MS (ESI) m/e (M + 1H)+: 403.0, (M − 1H)−: 400.9. Cpd. 91 1H NMR (400 MHz, DMSO-d6) δ: 11.02 (s, 1H), 9.00 (t, 1H, J = 5.8 Hz), 7.85 (d, 1H, J = 1.9 Hz), 7.68 (m, 3H), 7.52 (s, 1H), 7.46 (dd, 1H, J = 8.5 Hz, 1.9 Hz), 7.03 (d, 2H, J = 8.5 Hz), 4.69 (m, 1H), 3.57 (m, 1H), 3.40 (m, 1H), 1.32 (d, 3H, J = 5.9 Hz). EM (calc.): 388; MS (ESI) m/e (M + 1H)+: 389.1, (M − 1H)−: 387.0. Cpd. 92 1H NMR (400 MHz, DMSO-d6) δ: 11.05 (br s, 1H), 8.96 (t, 1H, J = 5.6 Hz), 8.80 (d, 1H, J = 2.0 Hz), 8.75 (dd, 1H, J = 5.6, 0.8 Hz), 8.35, (d, 1H, J = 8.0 Hz), 7.87 (dd, 1H, J = 7.6, 5.6 Hz), 7.71 (m, 3H), 7.61 (d, 1H, J = 8.0 Hz), 7.45 (t, 1H, J = 6.8 Hz), 7.34 (d, 1H, J = 7.2 Hz), 7.00 (m, 2H), 4.91 (s, 2H), 4.75 (s, 2H), 4.18 (t, 2H, J = 5.6 Hz), 3.66 (q, 2H, J = 6.0 Hz). EM (calc.): 461; MS (ESI) m/e (M + 1H)+: 462.2, (M − 1H)−: 460.3. Cpd. 93 1H NMR (400 MHz, DMSO-d6) δ: 11.00 (s, 1H), 8.82 (m, 1H), 8.37 (s, 1H), 7.67 (dd, 2H, J = 6.8, 1.6 Hz), 7.32-7.24 (m, 2H), 7.01 (d, 2H, J = 9.6 Hz), 6.90 (d, 1H, J = 8.0 Hz), 4.17 (t, 2H, J = 5.2 Hz), 3.89 (s, 3H), 3.69 (m, 2H). EM (calc.): 370; MS (ESI) m/e (M + 1H)+: 371.2, (M − 1H)−: 369.1. Cpd. 94 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (s, 1H), 8.96 (t, 1H, J = 5.6 Hz), 8.45 (s, 1H), 7.70 (d, 2H, J = 8.4 Hz), 7.37-7.30 (m, 2H), 7.02 (d, 2H, J = 8.4 Hz), 6.98 (dd, 1H, J = 7.6, 0.8 Hz), 4.37 (m, 2H), 4.17 (t, 2H, J = 5.6 Hz), 3.82 (m, 2H), 3.69 (q, 2H, J = 6.0 Hz), 3.34 (s, 3H). EM (calc.): 414; MS (ESI) m/e (M + 1H)+: 415.2, (M − 1H)+: 413.3. Cpd. 95 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (br s, 1H), 8.86 (m, 1H), 8.65 (t, 1H, 5.6 Hz), 8.61 (dd, 1H, J = 4.8, 1.6 Hz), 8.37 (s, 1H), 8.13 (m, 1H), 7.67 (m, 2H), 7.54 (m, 1H), 7.38-7.31 (m, 2H), 7.07 (dd, 1H, J = 7.6, 0.8 Hz), 6.88 (m, 2H), 5.40 (s, 2H), 3.91 (t, 2H, J = 6.0 Hz), 3.40 (m, 2H). EM (calc.): 447; MS (ESI) m/e (M + 1H)+: 448.2, (M − 1H)−: 446.1. Cpd. 96 1H NMR (400 MHz, DMSO-d6) δ: 11.57 (s, 1H), 8.65 (t, 1H, J = 4.5 Hz), 7.69 (d, 2H, J = 8.5 Hz), 7.20 (s, 1H), 7.09-6.98 (m, 4H), 6.48 (d, 1H, J = 7.9 Hz), 4.17 (m, 2H), 3.85 (s, 3H), 3.65 (m, 2H). EM (calc.): 369; MS (ESI) m/e (M + 1H)+: 370.1, (M − 1H)−: 368.2. Cpd. 97 1H NMR (400 MHz, DMSO-d6) δ: 11.06 (s, 1H), 8.62 (d, 1H, J = 8.7 Hz), 7.88 (d, 1H, J = 7.6 Hz), 7.72 (d, 2H, J = 8.5 Hz), 7.65 (d, 1H, J = 8.5 Hz), 7.50 (t, 1H, J = 8.5 Hz), 7.36 (t, 1H, J = 8.5 Hz), 7.02 (d, 2H, J = 8.5 Hz), 5.08 (s, 2H), 4.29 (m, 1H), 4.18 (m, 1H), 4.10 (m, 1H), 3.62 (m, 2H), 3.51 (m, 2H), 3.26 (s, 3H), 1.77 (m, 1H), 1.67 (m, 1H), 0.97 (t, 3H, J = 7.3 Hz). EM (calc.): 456; MS (ESI) m/e (M + 1H)+: 457.1, (M − 1H)−: 455.2. Cpd. 98 1H NMR (400 MHz, DMSO-d6) δ: 11.05 (s, 1H), 8.91 (t, 1H, J = 6.1 Hz), 7.88 (d, 1H, J = 7.5 Hz), 7.72 (d, 2H, J = 8.4 Hz), 7.63 (d, 1H, J = 8.4 Hz), 7.50 (t, 1H, J = 8.5 Hz), 7.36 (t, 1H, J = 8.5 Hz), 7.07 (d, 2H, J = 8.4 Hz), 5.07 (s, 2H), 4.74 (q, 1H, J = 6.0 Hz), 3.60 (m, 2H), 3.50 (m, 2H), 3.45 (m, 2H), 3.26 (s, 3H), 1.32 (d, 3H, J = 6.1 Hz). EM (calc.): 442; MS (ESI) m/e (M + 1H)+: 443.1, (M − 1H)−: 441.5. Cpd. 99 1H NMR (400 MHz, DMSO-d6) δ: 11.09 (s, 1H), 9.54 (s, 1H), 9.40 (t, 1H, J = 5.6 Hz), 8.04 (d, 1H, J = 7.8 Hz), 7.74 (d, 2H, J = 8.3 Hz), 7.61 (t, 1H, J = 7.3 Hz), 7.49 (t, 1H, J = 7.3 Hz), 7.03 (d, 2H, J = 8.5 Hz), 4.82 (s, 2H), 4.26 (t, 2H, J = 5.6 Hz), 3.75 (q, 2H, J = 5.6 Hz), 3.50 (m, 2H), 3.25 (m, 4H), 1.32 (t, 6H, J = 7.4 Hz). EM (calc.): 425; MS (ESI) m/e (M + 1H)+: 426.1, (M − 1H)−: 424.2. Cpd. 109 1H NMR (DMSO-d6): 1.95 (2H, m); 2.05 (3H, s); 2.48-2.62 (2H,.m); 4.08 (1H, dd, 11.6 Hz); 4.16 (1h, dd, 11.7 Hz); 4.45 (1H, m); 6.99 (2H, d, 9 Hz); 7.32 (1H, t, 7 Hz); 7.45 (1H, td, 8.1 Hz); 7.55 (1H, d, 1 Hz); 7.64 (1H, d, 8 Hz); 7.69 (2H, d, 9 Hz); 7.76 (1H, d, 8 Hz); 8.7 (1H, d, 8 Hz); 8.87 (1H, s). MS (M + 1): 415. Cpd. 110 1H NMR (DMSO-d6): 2.03-2.21 (2H, m); 2.99 (1H, s, 3H); 3.22 (2H, t, 7 Hz); 4.12 (1H, dd, 11.6 Hz); 4.19 (1h, dd, 11.7 Hz); 4.46 (1H, m); 7.00 (2H, d, 9 Hz); 7.33 (1H, t, 7 Hz); 7.46 (1H, td, 8.1 Hz); 7.57 (1H, d, 1 Hz); 7.64 (1H, d, 8 Hz); 7.70 (2H, d, 9 Hz); 7.77 (1H, d, 8 Hz); 8.79 (1H, d, 8 Hz); 8.88 (1H, s). MS (M + 1): 447. -
TABLE 4 Cpd. 1 EM (calc.): 381.13; MS (ESI) m/e (M + 1H)+: 382.3, (M − 1H)−: 380.2. Cpd. 2 EM (calc.): 395.15; MS (ESI) m/e (M + 1H)+: 396.1, (M − 1H)−: 394.2. Cpd. 3 EM (calc.): 331.08; MS (ESI) m/e (M + 1H)+: 331.7, (M − 1H)−: 330.1. Cpd. 4 EM (calc.): 317.10; MS (ESI) m/e (M + 1H)+: 318.10, (M − 1H)−: 315.9. Cpd. 5 EM (calc.): 425.2; MS (ESI) m/e (M + 1)+: 426.1, (M − 1)−: 424.1. Cpd. 6 EM (calc.): 381.1; MS (ESI) m/e (M + 1)+: 382.0, (M − 1)−: 380.1. Cpd. 7 EM (calc.): 381.1; MS (ESI) m/e (M + 1)+: 382.0, (M − 1)−: 380.2. Cpd. 8 EM (calc.): 341.1; MS (ESI) m/e (M + 1)+: 341.9, (M − 1)−: 340.1. Cpd. 9 EM (calc.): 381.1; MS (ESI) m/e (M + 1)+: 381.8, (M − 1)−: 380.0. Cpd. 10 EM (calc.): 411.1; MS (ESI) m/e (M + 1)+: 412.0, (M − 1)−: 410.3. Cpd. 11 EM (calc.): 395.2; MS (ESI) m/e (M + 1)+: 396.0, (M − 1)−: 394.2. Cpd. 12 EM (calc.): 388.1; MS (ESI) m/e (M + 1)+: 389.1, (M − 1)−: 387.0. Cpd. 13 EM (calc.): 355.12; MS (ESI) m/e (M + 1)+: 355.9, (M − 1)−: 354.1. Cpd. 14 EM (calc.): 355.1; MS (ESI) m/e (M + 1)+: 355.9, (M − 1)−: 353.8. Cpd. 15 EM (calc.): 409.2; MS (ESI) m/e (M + 1)+: 410.2, (M − 1)−: 408.3. Cpd. 16 EM (calc.): 341.1; MS (ESI) m/e (M + 1)+: 341.8, (M − 1)−: 340.2. Cpd. 17 1H NMR (400 MHz, DMSO-d6) δ 11.64 (s, 1H), 8.66 (d, J = 8.0 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.55 (s, 1H), 7.46 (t, J = 8.4 Hz, 1H), 7.32 (t, J = 8.0 Hz, 1H), 6.72 (s, 1H), 4.30 (m, 3H), 1.67 (m, 2H), 0.92 (t, J = 7.2 Hz, 3H). EM (calc.): 359.1; MS (ESI) m/e: (M + 1H)+: 359.8, (M − 1H)−: 358.1. Cpd. 18 1H NMR (400 MHz, DMSO-d6) δ 11.64 (s, 1H), 9.48 (s, 1H), 8.47 (d, J = 8.0 Hz, 1H), 8.09(m, 1H), 7.82 (m, 2H), 7.71 (m, 2H), 7.55 (t, J = 8.0 Hz, 1H), 7.49 (m, 2H), 7.39 (m, 1H), 4.30 (m, 3H), 1.69 (m, 2H), 0.94 (t, J = 7.2 Hz, 3H). EM (calc.): 395.2; MS (ESI) m/e: (M + 1H)+: 395.8, (M − 1H)−: 394.0. Cpd. 19 1H NMR (400 MHz, DMSO-d6) δ 11.63 (s, 1H), 8.93 (t, J = 5.6 Hz, 1H), 7.75 (d, J = 7.6 Hz, 1H), 7.63 (d, J = 7.6 Hz, 1H), 7.54 (s, 1H), 7.45 (t, J = 7.6 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 6.72 (s, 1H), 4.90 (m, 1H), 3.56 (m, 2H), 0.35 (d, J = 7.2 Hz, 3H). EM (calc.): 345.1; MS (ESI) m/e: (M + 1H)+: 345.8, (M − 1H)−: 344.0. Cpd. 20 1H NMR (400 MHz, DMSO-d6) δ 11.64 (s, 1H), 9.480 (s, 1H), 8.83 (t, J = 5.6 Hz, 1H), 7.07 (m, 1H), 7.80 (d, J = 7.6 Hz, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.48 (m, 2H), 7.39 (m, 1H), 6.72 (s, 1H), 4.91 (m, 1H), 3.58 (m, 2H), 1.36 (d, J = 7.0 Hz, 3H). EM (calc.): 381.1; MS (ESI) m/e: (M + 1H)+: 382.0, (M − 1H)−: 380.0. Cpd. 21 EM (calc.): 367.1; MS (ESI) m/e (M + 1)+: 367.8, (M − 1)−: 366.2. Cpd. 22 EM (calc.): 367.12; MS (ESI) m/e (M + 1H)+: 368.0, (M − 1H)−: 366.1. Cpd. 23 EM (calc.): 374.0; MS (ESI) m/e (M + 1)+: 374.7, (M − 1)−: 372.9. Cpd. 24 EM (calc.): 395.2; MS (ESI) m/e (M + 1)+: 396.1. (M − 1)−: 394.1 Cpd. 25 EM (calc.): 367.1; MS (ESI) m/e (M + 1)+: 368.1, (M − 1)−: 366.2. Cpd. 26 EM (calc.): 381.1; MS (ESI) m/e (M + 1)+: 382.0, (M − 1)−: 380.1. Cpd. 27 1H NMR (400 MHz, DMSO-d6) δ 11.62 (s, 1H), 9.45 (s, 1H), 8.54 (d, J = 7.6 Hz, 1H), 8.43(s, 1H), 7.97 (m, 4H), 7.60 (m, 2H), 6.73 (s, 1H), 4.33 (m, 3H), 1.70 (m, 2H), 0.96 (t, J = 7.6 Hz, 3H). EM (calc.): 369.1; MS (ESI) m/e: (M + 1H)+: 369.9, (M − 1H)−: 368.0. Cpd. 28 1H NMR (400 MHz, DMSO-d6) δ 11.66 (s, 1H), 9.50 (s, 1H), 8.53 (d, J = 7.6 Hz, 1H), 8.11 (m, 1H), 7.96 (m, 2H), 7.55 (m, 4H), 6.78 (s, 1H), 4.33 (m, 3H), 1.68 (m, 2H), 1.01(t, J = 7.2 Hz, 3H). EM (calc.): 369.1; MS (ESI) m/e: (M + 1H)+: 370.0, (M − 1H)−: 368.2. Cpd. 29 1H NMR (400 MHz, DMSO-d6) δ 11.64 (s, 1H), 8.86 (t, J = 5.6 Hz, 1H), 8.40(s, 1H), 7.90 (m, 4H), 7.59 (m, 2H), 6.73 (s, 1H), 4.94 (m, 1H), 3.60 (m, 2H), 1.38 (d, J = 6.0 Hz, 3H). EM (calc.): 355.1; MS (ESI) m/e: (M + 1H)+: 355.9, (M − 1H)−: 353.9. Cpd. 30 1H NMR (400 MHz, DMSO-d6) δ 11.66 (s, 1H), 8.78 (t, J = 5.6 Hz, 1H), 8.09 (d, J = 7.6 Hz, 1H), 7.96 (m, 2H), 7.50 (m, 4H), 6.74 (s, 1H), 4.97 (m, 1H), 3.61 (m, 2H), 1.41 (d, J = 6.4 Hz, 3H). EM (calc.): 355.1; MS (ESI) m/e: (M + 1H)+: 356.1, (M − 1H)−: 353.9. Cpd. 31 EM (calc.): 345.1; MS (ESI) m/e (M + 1)+: 345.8, (M − 1)−: 344.0. Cpd. 32 EM (calc.): 331.1; MS (ESI) m/e (M + 1)+: 331.9, (M − 1)−: 330.2. Cpd. 33 EM (calc.): 437.12; MS (ESI) m/e (M + 1H)+: 438.0, (M − 1H)−: 436.2. - tert-Boc (N-Acetyl-Lys)-AMC (445 mg, 1mmol, purchased from Bachem) was dissolved in 4 M HCL in dioxane to provide H-(N-acetyl-Lys)-AMC as a white solid. To a solution of H-(N-acetyl-Lys)-AMC in DMF (5 ml) was added Ac-Gly-Ala-OH (188 mg, 1 mmol) using PyBOP (520 mg, 1 mmol), HOBt (135 mg, 1 mmol), and NMM (0.296 ml, 2 mmol). The reaction mixture was stirred for 1 h and monitored by MS/LC for the presence of H-(N-acetyl-Lys)-AMC. Additional amounts of PyBOP (260 mg, 0.5 mmol), HOBt (70 mg, 0.5 mmol), and NMM (0.146 ml, 1 mmol) was added and the stirring was continued for additional 4 h after which the product was isolated in quantitative yield.
- The HDAC inhibitory activity of the compounds of this invention in vitro was determined as follows.
- Measurements were performed in a reaction volume of 100 μL using 96-well assay plates. HDAC-1 (200 pM final concentration) in reaction buffer (50 mM HEPES, 100 mM KCl, 0.001% Tween-20, 5% DMSO, pH 7.4) was mixed with inhibitor at various concentrations and allowed to incubate for 30 minutes, after which trypsin and acetyl-Gly-Ala-(N-acetyl-Lys)-AMC were added to final concentrations of 50 nM and 25 μM, respectively, to initiate the reaction. Negative control reactions were performed in the absence of inhibitor in replicates of eight.
- The reactions were monitored in a fluorescence plate reader. After a 30 minute lag time, the fluorescence was measured over a 30 minute time frame using an excitation wavelength of 355 nm and a detection wavelength of 460 nm. The increase in fluorescence with time was used as the measure of the reaction rate. Inhibition constants were obtained using the program BatchKi (Kuzmic et al. Anal. Biochem. 2000, 286, 45-50). Most of the compounds of this invention had a Ki of <40 nm.
- The ability of the compounds of Formula (I) to inhibit growth of tumor cells in vitro was determined as follows.
- Stock cultures of the HCT116 colon carcinoma cell line were maintained in RPMI medium 1640 containing 10%(v/v) fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 units/ml penicillin, and 50 μg/ml streptomycin at 37° C. in 5% CO2 humidified atmosphere. Cells were cultured in 75-cm2 culture flasks and subcultures were established every 3 to 4 days so as not to allow the cells to exceed 90% confluence.
- HCTI 16 cells were harvested for proliferation assays by trypsinization (0.05% trypsin/0.53 mM EDTA), washed twice in culture medium, re-suspended in appropriate volume of medium, and then counted using a hemacytometer. Cells were seeded in wells of flat-bottom 96-well plates at a density of 5,000 cell/well in 100 μl. Cells were allowed to attach for 1.5 to 2 hours at 37° C.
- Compounds were diluted from 10 mM stock solutions in DMSO. Serial 3-fold dilutions were performed in medium containing 0.6% DMSO in wells (in triplicate) of a 96-well U-bottom plates starting with a 60 μM solution. After dilutions were completed, 100 μl of each compound dilution (in triplicate) was transferred to designated triplicate wells of the 96-well plate containing cells in 100 μl of medium. Final concentrations of the dose-response for compounds in assay plates ranged from 0.12 to 30 μM. Control wells (cells with no treatment) received 100 μl of 0.6% DMSO in culture medium. Wells containing medium with no cells served as the background wells. Cells were cultured with the compounds for 48 and 72 hours at 37° C. in a humidified CO2 incubator.
- Cell proliferation was assessed by measuring fluorescence after the addition of the fluorogenic redox indicator, Alamar Blue™ (BioSource International). Ten μl of Alamar Blue™ was added to each well of the 96-well plate(s) 3 to 4 hours prior to the end of the incubation period. Assay plates were read in a fluorescence plate reader (excitation, 530 nM; emission, 620 nM). G150 values (concentration at which the growth of the tumor cells was inhibited by 50%) for compounds were determined by plotting the percent control fluorescence against the logarithm of the compound concentration. The compounds of this invention inhibited the growth of the tumor cells.
- The following are representative pharmaceutical formulations containing a compound of Formula (I)
- The following ingredients are mixed intimately and pressed into single scored tablets.
Quantity per Ingredient tablet, mg compound of this invention 400 cornstarch 50 croscarmellose sodium 25 lactose 120 magnesium stearate 5 - The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.
Quantity per Ingredient capsule, mg compound of this invention 200 lactose, spray-dried 148 magnesium stearate 2 - The following ingredients are mixed to form a suspension for oral administration.
Ingredient Amount compound of this invention 1.0 g fumaric acid 0.5 g sodium chloride 2.0 g methyl paraben 0.15 g propyl paraben 0.05 g granulated sugar 25.5 g sorbitol (70% solution) 12.85 g Veegum K (Vanderbilt Co.) 1.0 g flavoring 0.035 ml colorings 0.5 mg distilled water q.s. to 100 ml - The following ingredients are mixed to form an injectable formulation.
Ingredient Amount compound of this invention 1.2 g lactate buffer solution, 0.1M 10.0 ml HCl (1 N) or NaOH (1 N) q.s. to suitable pH saline (optional) q.s. to suitable osmolarity water (distilled, sterile) q.s. to 20 ml - Compound (1.2 g) is combined with 0.1 M lactate buffer (10 ml) and gently mixed. Sonication can be applied for several minutes if necessary to achieve a solution. Appropriate amount of acid or base is added q.s. to suitable pH (preferable pH 4). A sufficient amount of water is then added q.s. to 20 ml.
- A suppository of total weight 2.5 g is prepared by mixing the compound of the invention with Witepsol™ H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:
compound of the invention 500 mg Witepsol ™ H-15 balance - The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled. All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/830,686 US20070293540A1 (en) | 2003-04-07 | 2007-07-30 | Novel hydroxamates as therapeutic agents |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46128603P | 2003-04-07 | 2003-04-07 | |
US46444803P | 2003-04-21 | 2003-04-21 | |
US10/818,755 US7276612B2 (en) | 2003-04-07 | 2004-04-06 | Hydroxamates as therapeutic agents |
US11/830,686 US20070293540A1 (en) | 2003-04-07 | 2007-07-30 | Novel hydroxamates as therapeutic agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/818,755 Division US7276612B2 (en) | 2003-04-07 | 2004-04-06 | Hydroxamates as therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070293540A1 true US20070293540A1 (en) | 2007-12-20 |
Family
ID=33303040
Family Applications (11)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/818,755 Active 2025-08-20 US7276612B2 (en) | 2003-04-07 | 2004-04-06 | Hydroxamates as therapeutic agents |
US11/830,686 Abandoned US20070293540A1 (en) | 2003-04-07 | 2007-07-30 | Novel hydroxamates as therapeutic agents |
US11/834,558 Expired - Lifetime US7420089B2 (en) | 2003-04-07 | 2007-08-06 | Hydroxamates as therapeutic agents |
US11/940,260 Expired - Lifetime US7482466B2 (en) | 2003-04-07 | 2007-11-14 | Hydroxamates as therapeutic agents |
US11/940,273 Expired - Lifetime US7517988B2 (en) | 2003-04-07 | 2007-11-14 | Hydroxamates as therapeutic agents |
US12/393,923 Expired - Lifetime US7834054B2 (en) | 2003-04-07 | 2009-02-26 | Hydroxamates as therapeutic agents |
US12/896,535 Expired - Lifetime US8026371B2 (en) | 2003-04-07 | 2010-10-01 | Hydroxamates as therapeutic agents |
US13/209,147 Expired - Lifetime US8389570B2 (en) | 2003-04-07 | 2011-08-12 | Hydroxamates as therapeutic agents |
US13/744,265 Expired - Lifetime US8779171B2 (en) | 2003-04-07 | 2013-01-17 | Hydroxamates as therapeutic agents |
US14/311,025 Abandoned US20140301976A1 (en) | 2003-04-07 | 2014-06-20 | Novel hydroxamates as therapeutic agents |
US14/671,384 Expired - Lifetime US9186347B1 (en) | 2003-04-07 | 2015-03-27 | Hydroxamates as therapeutic agents |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/818,755 Active 2025-08-20 US7276612B2 (en) | 2003-04-07 | 2004-04-06 | Hydroxamates as therapeutic agents |
Family Applications After (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/834,558 Expired - Lifetime US7420089B2 (en) | 2003-04-07 | 2007-08-06 | Hydroxamates as therapeutic agents |
US11/940,260 Expired - Lifetime US7482466B2 (en) | 2003-04-07 | 2007-11-14 | Hydroxamates as therapeutic agents |
US11/940,273 Expired - Lifetime US7517988B2 (en) | 2003-04-07 | 2007-11-14 | Hydroxamates as therapeutic agents |
US12/393,923 Expired - Lifetime US7834054B2 (en) | 2003-04-07 | 2009-02-26 | Hydroxamates as therapeutic agents |
US12/896,535 Expired - Lifetime US8026371B2 (en) | 2003-04-07 | 2010-10-01 | Hydroxamates as therapeutic agents |
US13/209,147 Expired - Lifetime US8389570B2 (en) | 2003-04-07 | 2011-08-12 | Hydroxamates as therapeutic agents |
US13/744,265 Expired - Lifetime US8779171B2 (en) | 2003-04-07 | 2013-01-17 | Hydroxamates as therapeutic agents |
US14/311,025 Abandoned US20140301976A1 (en) | 2003-04-07 | 2014-06-20 | Novel hydroxamates as therapeutic agents |
US14/671,384 Expired - Lifetime US9186347B1 (en) | 2003-04-07 | 2015-03-27 | Hydroxamates as therapeutic agents |
Country Status (25)
Country | Link |
---|---|
US (11) | US7276612B2 (en) |
EP (1) | EP1611088B1 (en) |
JP (1) | JP4243628B2 (en) |
KR (2) | KR20100012046A (en) |
CN (2) | CN102304110A (en) |
AT (1) | ATE433954T1 (en) |
AU (1) | AU2004230889B2 (en) |
BR (1) | BRPI0409227C1 (en) |
CA (1) | CA2521647C (en) |
CY (1) | CY1109363T1 (en) |
DE (1) | DE602004021573D1 (en) |
DK (1) | DK1611088T3 (en) |
EA (1) | EA200501570A1 (en) |
ES (1) | ES2328819T3 (en) |
HK (1) | HK1169102A1 (en) |
HR (1) | HRP20090487T1 (en) |
LV (1) | LV13394B (en) |
MX (1) | MXPA05010782A (en) |
NO (1) | NO335889B1 (en) |
NZ (1) | NZ542445A (en) |
PL (1) | PL1611088T3 (en) |
PT (1) | PT1611088E (en) |
SI (1) | SI1611088T1 (en) |
TW (1) | TWI342876B (en) |
WO (1) | WO2004092115A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080004331A1 (en) * | 2003-04-07 | 2008-01-03 | Pharmacyclics, Inc. | Novel hydroxamates as therapeutic agents |
US20080153877A1 (en) * | 2006-12-26 | 2008-06-26 | Pharmacyclics, Inc. | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
US20090270497A1 (en) * | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
US20110053164A1 (en) * | 2007-01-30 | 2011-03-03 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
US20110311624A1 (en) * | 2009-04-17 | 2011-12-22 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
US9421208B2 (en) | 2013-08-02 | 2016-08-23 | Pharmacyclics Llc | Methods for the treatment of solid tumors |
US9492423B2 (en) | 2011-09-13 | 2016-11-15 | Pharmacyclics Llc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE396971T1 (en) | 2002-03-13 | 2008-06-15 | Janssen Pharmaceutica Nv | SULFONYLAMINO DERIVATIVES AS NEW INHIBITORS OF HISTONE DEACETYLASE |
PL205531B1 (en) | 2002-03-13 | 2010-04-30 | Janssen Pharmaceutica Nv | Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
WO2003076438A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
WO2003075929A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
WO2005011598A2 (en) * | 2003-07-31 | 2005-02-10 | University Of South Florida | Leukemia treatment method and composition |
CN100536850C (en) * | 2003-08-08 | 2009-09-09 | 诺瓦提斯公司 | Combinations comprising staurosporines |
GB2427405A (en) * | 2004-04-07 | 2006-12-27 | Pharmacyclics Inc | Novel hydroxamates as therapeutic agents |
ITMI20041347A1 (en) * | 2004-07-05 | 2004-10-05 | Italfarmaco Spa | ALPHA-AMINO ACID DERIVATIVES FOR ANTI-INFLAMMATORY ACTIVITIES |
UA86066C2 (en) | 2004-07-28 | 2009-03-25 | Янссен Фармацевтика Н.В. | Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase |
EA010652B1 (en) | 2004-07-28 | 2008-10-30 | Янссен Фармацевтика Н.В. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
WO2006042035A2 (en) * | 2004-10-07 | 2006-04-20 | Pharmacyclics, Inc. | Method of monitoring anti-tumor activity of an hdac inhibitor |
WO2006054793A1 (en) * | 2004-11-19 | 2006-05-26 | The New Industry Research Organization | Benzofuran compound and pharmaceutical composition containing the same |
EP1855760A2 (en) | 2005-02-03 | 2007-11-21 | TopoTarget UK Limited | Combination therapies using hdac inhibitors |
CA2596015A1 (en) | 2005-02-14 | 2006-08-24 | Sampath K. Anandan | Fused heterocyclic compounds useful as inhibitors of histone deacetylase |
GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
PL1901729T3 (en) | 2005-05-13 | 2012-07-31 | Topotarget Uk Ltd | Pharmaceutical formulations of hdac inhibitors |
DK1885710T3 (en) | 2005-05-18 | 2015-11-23 | Janssen Pharmaceutica Nv | SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE |
US7709516B2 (en) * | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
BRPI0613429A2 (en) | 2005-07-14 | 2009-02-10 | Takeda San Diego Inc | histone deacetylase inhibitors |
EP1940786B1 (en) * | 2005-09-16 | 2010-08-18 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
EP1943232B1 (en) | 2005-10-27 | 2011-05-18 | Janssen Pharmaceutica NV | Squaric acid derivatives as inhibitors of histone deacetylase |
AU2006313517B2 (en) | 2005-11-10 | 2013-06-27 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
CN101374828B (en) | 2006-01-19 | 2012-09-19 | 詹森药业有限公司 | Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase |
SI1981874T1 (en) | 2006-01-19 | 2009-10-31 | Janssen Pharmaceutica Nv | Aminophenyl derivatives as novel inhibitors of histone deacetylase |
DK1981875T3 (en) | 2006-01-19 | 2014-07-14 | Janssen Pharmaceutica Nv | SUBSTITUTED INDOLYLALKYLAMINODE DERIVATIVES AS INHIBITORS OF HISTONDEACETYLASE |
JP5261192B2 (en) | 2006-01-19 | 2013-08-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
WO2007082874A1 (en) | 2006-01-19 | 2007-07-26 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
JP5137848B2 (en) | 2006-01-19 | 2013-02-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
DE602007012247D1 (en) | 2006-06-22 | 2011-03-10 | Anadys Pharmaceuticals Inc | PRODRUGS OF 5-AMINO-3- (3'-DEOXY-BETA-D-RIBOFURANOSYL) -THIAZOLA4,5-DUPRYIDIN-2,7-DION |
GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
BRPI0622100A2 (en) | 2006-10-30 | 2011-12-27 | Chroma Therapeutics Ltd | hydroxamates as histone deacetylase inhibitors |
CA2672192A1 (en) * | 2006-12-19 | 2008-06-26 | Methylgene Inc. | Inhibitors of histone deacetylase and prodrugs thereof |
WO2008083124A1 (en) | 2006-12-28 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
WO2008123395A1 (en) | 2007-03-28 | 2008-10-16 | Santen Pharmaceutical Co., Ltd. | Ocular hypotensive agent comprising compound capable of inhibiting histone deacetylase as active ingredient |
US20100285516A1 (en) * | 2007-04-13 | 2010-11-11 | Pharmacyclics, Inc. | Calcium flux as a pharmacoefficacy biomarker for inhibitors of histone deacetylase |
US20090023798A1 (en) * | 2007-06-15 | 2009-01-22 | Pharmacyclics, Inc. | Thiohydroxamates as inhibitors of histone deacetylase |
US9149463B2 (en) * | 2007-09-18 | 2015-10-06 | The Board Of Trustees Of The Leland Standford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
US8940730B2 (en) | 2007-09-18 | 2015-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
WO2009039248A2 (en) * | 2007-09-18 | 2009-03-26 | Stanford University | Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection |
US9101628B2 (en) * | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
EP2203421B1 (en) | 2007-09-25 | 2014-05-07 | TopoTarget UK Limited | Methods of synthesis of certain n-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide compounds |
CA2708281A1 (en) | 2007-12-11 | 2009-08-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
WO2009079391A1 (en) * | 2007-12-14 | 2009-06-25 | Gilead Colorado, Inc. | Benzofuran anilide histone deacetylase inhibitors |
DK2274301T3 (en) | 2008-03-27 | 2013-01-02 | Janssen Pharmaceutica Nv | AZABICYCLOHEXYL SUBSTITUTED INDOLYLALKYLAMINODE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE |
NZ590283A (en) | 2008-07-14 | 2012-11-30 | Gilead Sciences Inc | Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors |
NZ590320A (en) | 2008-07-14 | 2012-12-21 | Gilead Sciences Inc | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
US8344018B2 (en) | 2008-07-14 | 2013-01-01 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
CN102123987A (en) | 2008-07-28 | 2011-07-13 | 吉里德科学公司 | Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds |
GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
EP2408449A4 (en) | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | Methods and compositions of treating a flaviviridae family viral infection |
WO2010144371A1 (en) | 2009-06-08 | 2010-12-16 | Gilead Colorado, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
JP2012529514A (en) | 2009-06-08 | 2012-11-22 | ギリアード サイエンシーズ, インコーポレイテッド | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compound |
WO2010151441A1 (en) * | 2009-06-23 | 2010-12-29 | Translational Genomics Research Institute | Benzamide derivatives |
EP2464967B1 (en) * | 2009-08-14 | 2013-06-12 | Cellzome Ag | Methods for the identification and characterization of hdac interacting compounds |
US8217079B2 (en) | 2010-03-26 | 2012-07-10 | Italfarmaco Spa | Method for treating Philadelphia-negative myeloproliferative syndromes |
WO2012112447A2 (en) * | 2011-02-14 | 2012-08-23 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase inhibitors and methods of use thereof |
US8948546B2 (en) * | 2011-02-16 | 2015-02-03 | Nippon Telegraph And Telephone Corporation | Optical frequency shifter and optical modulator using the same |
FR2977492B1 (en) | 2011-07-04 | 2013-07-05 | Servier Lab | NOVEL ASSOCIATION BETWEEN N-HYDROXY-4- {2- [3- (N, N-DIMETHYLAMINOMETHYL) BENZOFURAN-2-YLCARBONYLAMINO] ETHOXY} BENZAMIDE AND FOLFOX |
UY34295A (en) * | 2011-09-08 | 2013-04-30 | Servier Lab | NEW N-HYDROXY ADMINISTRATION SCHEME -4- {2- [3- (N, NDIMETILAMINOMETIL) BENZOFURAN -2- ILCARBONILAMINO] ETOXI} BENZAMIDA |
WO2013066833A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
FR2984744B1 (en) | 2011-12-23 | 2014-02-07 | Servier Lab | NOVEL ASSOCIATION BETWEEN N-HYDROXY-4- {2- [3- (N, N-DIMETHYLAMINOMETHYL) BENZOFURAN-2-YLCARBONYLAMINO] ETHOXY} BENZAMIDE AND CISPLATIN IN NASOPHARYNX CARCINOMA |
EP2814493A4 (en) * | 2012-02-17 | 2015-07-22 | Pharmacyclics Inc | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof |
KR102306524B1 (en) * | 2013-03-04 | 2021-10-01 | 파마싸이클릭스 엘엘씨 | Novel abexinostat salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same |
FR3002733B1 (en) * | 2013-03-04 | 2015-08-14 | Servier Lab | NOVEL SALT OF THE ABEXINOSTAT, THE CRYSTALLINE FORM ASSOCIATED WITH THEM, THE PROCESS FOR PREPARING THEM AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
EP3016950B1 (en) | 2013-07-02 | 2017-06-07 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
EP3016951B1 (en) | 2013-07-02 | 2017-05-31 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
KR20160104612A (en) * | 2013-07-26 | 2016-09-05 | 업데이트 파마 인코포레이트 | Compositions to improve the therapeutic benefit of bisantrene |
US10188756B2 (en) * | 2013-10-18 | 2019-01-29 | The General Hospital Corporation | Imaging histone deacetylases with a radiotracer using positron emission tomography |
EP3142652B1 (en) * | 2014-05-14 | 2021-08-25 | The Regents of the University of Colorado, a body corporate | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof |
FR3025196B1 (en) * | 2014-09-03 | 2019-09-06 | Pharmacyclics, Inc. | NOVEL 3 - [(DIMETHYLAMINO) METHYL] -N- {2- [4- (HYDROXYCARBAMOYL) PHENOXY] ETHYL} -1-BENZOFURAN-2-CARBOXAMIDE SALTS, ASSOCIATED CRYSTALLINE FORMS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF CONTAIN |
FR3025197B1 (en) * | 2014-09-03 | 2019-09-06 | Pharmacyclics, Inc. | NOVEL SALT OF 3 - [(DIMETHYLAMINO) METHYL] -N- {2- [4- (HYDROXYCARBAMOYL) PHENOXY] ETHYL} -1-BENZOFURAN-2-CARBOXAMIDE, ASSOCIATED CRYSTALLINE FORMS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF CONTAIN |
SG11201701674RA (en) | 2014-09-03 | 2017-04-27 | Pharmacyclics Llc | Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same |
CN105985335B (en) * | 2015-01-28 | 2018-06-08 | 成都地奥九泓制药厂 | Hydroxamic acid compound, preparation method and its usage |
ITUB20155193A1 (en) | 2015-11-03 | 2017-05-03 | Italfarmaco Spa | Physically and chemically stable oral Givinostat suspensions |
IT201600074606A1 (en) * | 2016-07-18 | 2018-01-18 | Italfarmaco Spa | New benzo-N-hydroxy amide compounds having antitumor activity |
WO2018054960A1 (en) | 2016-09-21 | 2018-03-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and treating resistance to chemotherapy in npm-alk(+) alcl |
GB201918413D0 (en) * | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
EP4351734A1 (en) | 2021-06-10 | 2024-04-17 | Teva Pharmaceuticals International GmbH | Solid state forms of abexinostat and process for preparation thereof |
CN113527237A (en) * | 2021-06-21 | 2021-10-22 | 上海工程技术大学 | Method for preparing abemostat, intermediate and preparation method of intermediate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276612B2 (en) * | 2003-04-07 | 2007-10-02 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE794063A (en) * | 1972-01-17 | 1973-07-16 | Henkel & Cie Gmbh | ANTI-INFLAMMATORY FOR COSMETIC COMPOSITIONS |
EP0084236A3 (en) * | 1981-12-22 | 1983-08-03 | Fbc Limited | Fungicidal heterocyclic compounds and compositions containing them |
DE3889545T2 (en) | 1987-10-20 | 1994-10-13 | Otsuka Pharma Co Ltd | PHENYL CARBONIC ACID COMBINATIONS. |
JPH03215470A (en) * | 1990-01-22 | 1991-09-20 | Suntory Ltd | Propionic acid amide derivative, its production and herbicide containing the derivative as active component |
DE4124345A1 (en) * | 1991-07-23 | 1993-01-28 | Gruenenthal Gmbh | SUBSTITUTED 3,4-DIHYDRONAPHTHALINE, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND METHOD FOR PRODUCING THESE COMPOUNDS AND MEDICINAL PRODUCTS |
JP3215470B2 (en) | 1991-12-03 | 2001-10-09 | 松下冷機株式会社 | Scroll compressor |
DE4327365A1 (en) | 1993-08-14 | 1995-02-16 | Boehringer Mannheim Gmbh | Use of phenols and phenol derivatives as drugs with a fibrinogen-lowering effect |
US5958957A (en) * | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
AU6936500A (en) | 1999-08-24 | 2001-03-19 | Regents Of The University Of California, The | Non-quinoline inhibitors of malaria parasites |
CA2391952C (en) | 1999-11-23 | 2012-01-31 | Methylgene Inc. | Inhibitors of histone deacetylase |
JP4975941B2 (en) * | 2000-09-29 | 2012-07-11 | トポターゲット ユーケー リミテッド | (E) -N-hydroxy-3- (3-sulfamoyl-phenyl) acrylamide compound and therapeutic use thereof |
GB0023983D0 (en) * | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
EP1415987B1 (en) * | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
ITMI20010129A1 (en) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE |
ITMI20011733A1 (en) * | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | HYDROXAMIC ACID DERIVATIVES HISTONE DEHYACETYLASE ENZYM INHIBITORS, WHICH NEW ANTI-INFLAMMATORY DRUGS INHIBIT CITOC SYNTHESIS |
JPWO2003070691A1 (en) | 2002-02-21 | 2005-06-09 | 財団法人大阪産業振興機構 | N-hydroxycarboxamide derivatives |
US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
KR20050034732A (en) | 2002-08-02 | 2005-04-14 | 아젠터 디스커버리 리미티드 | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
US7381825B2 (en) | 2003-03-17 | 2008-06-03 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
GB2427405A (en) | 2004-04-07 | 2006-12-27 | Pharmacyclics Inc | Novel hydroxamates as therapeutic agents |
BRPI0511065A (en) | 2004-06-04 | 2007-12-26 | Pfizer Prod Inc | method to treat abnormal cell growth |
JP2008519047A (en) | 2004-11-05 | 2008-06-05 | セフアロン・インコーポレーテツド | Cancer treatment |
CA2659070C (en) | 2006-09-15 | 2014-10-21 | Janssen Pharmaceutica Nv | Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors |
ES2529147T3 (en) | 2006-12-26 | 2015-02-17 | Pharmacyclics, Inc. | Method for using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
EP2110377A1 (en) | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
UY34295A (en) | 2011-09-08 | 2013-04-30 | Servier Lab | NEW N-HYDROXY ADMINISTRATION SCHEME -4- {2- [3- (N, NDIMETILAMINOMETIL) BENZOFURAN -2- ILCARBONILAMINO] ETOXI} BENZAMIDA |
-
2004
- 2004-04-06 BR BRPI0409227A patent/BRPI0409227C1/en active IP Right Grant
- 2004-04-06 CN CN2011102212773A patent/CN102304110A/en active Pending
- 2004-04-06 CN CN201110221257.6A patent/CN102391222B/en not_active Expired - Lifetime
- 2004-04-06 AT AT04749791T patent/ATE433954T1/en active
- 2004-04-06 EA EA200501570A patent/EA200501570A1/en unknown
- 2004-04-06 US US10/818,755 patent/US7276612B2/en active Active
- 2004-04-06 NZ NZ542445A patent/NZ542445A/en active IP Right Revival
- 2004-04-06 PT PT04749791T patent/PT1611088E/en unknown
- 2004-04-06 DK DK04749791T patent/DK1611088T3/en active
- 2004-04-06 ES ES04749791T patent/ES2328819T3/en not_active Expired - Lifetime
- 2004-04-06 DE DE602004021573T patent/DE602004021573D1/en not_active Expired - Lifetime
- 2004-04-06 KR KR1020097027542A patent/KR20100012046A/en active Search and Examination
- 2004-04-06 CA CA2521647A patent/CA2521647C/en not_active Expired - Lifetime
- 2004-04-06 MX MXPA05010782A patent/MXPA05010782A/en active IP Right Grant
- 2004-04-06 EP EP04749791A patent/EP1611088B1/en not_active Expired - Lifetime
- 2004-04-06 JP JP2006509735A patent/JP4243628B2/en not_active Expired - Lifetime
- 2004-04-06 WO PCT/US2004/010549 patent/WO2004092115A2/en active Application Filing
- 2004-04-06 AU AU2004230889A patent/AU2004230889B2/en not_active Expired
- 2004-04-06 KR KR1020057019120A patent/KR100945959B1/en active IP Right Grant
- 2004-04-06 PL PL04749791T patent/PL1611088T3/en unknown
- 2004-04-06 SI SI200431209T patent/SI1611088T1/en unknown
- 2004-04-07 TW TW093109626A patent/TWI342876B/en not_active IP Right Cessation
-
2005
- 2005-11-03 LV LVP-05-141A patent/LV13394B/en unknown
- 2005-11-04 NO NO20055216A patent/NO335889B1/en unknown
-
2007
- 2007-07-30 US US11/830,686 patent/US20070293540A1/en not_active Abandoned
- 2007-08-06 US US11/834,558 patent/US7420089B2/en not_active Expired - Lifetime
- 2007-11-14 US US11/940,260 patent/US7482466B2/en not_active Expired - Lifetime
- 2007-11-14 US US11/940,273 patent/US7517988B2/en not_active Expired - Lifetime
-
2009
- 2009-02-26 US US12/393,923 patent/US7834054B2/en not_active Expired - Lifetime
- 2009-09-11 CY CY20091100948T patent/CY1109363T1/en unknown
- 2009-09-14 HR HR20090487T patent/HRP20090487T1/en unknown
-
2010
- 2010-10-01 US US12/896,535 patent/US8026371B2/en not_active Expired - Lifetime
-
2011
- 2011-08-12 US US13/209,147 patent/US8389570B2/en not_active Expired - Lifetime
-
2012
- 2012-09-28 HK HK12109635.8A patent/HK1169102A1/en not_active IP Right Cessation
-
2013
- 2013-01-17 US US13/744,265 patent/US8779171B2/en not_active Expired - Lifetime
-
2014
- 2014-06-20 US US14/311,025 patent/US20140301976A1/en not_active Abandoned
-
2015
- 2015-03-27 US US14/671,384 patent/US9186347B1/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276612B2 (en) * | 2003-04-07 | 2007-10-02 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8026371B2 (en) | 2003-04-07 | 2011-09-27 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
US20090220454A1 (en) * | 2003-04-07 | 2009-09-03 | Pharmacyclics, Inc. | Novel hydroxamates as therapeutic agents |
US20080004331A1 (en) * | 2003-04-07 | 2008-01-03 | Pharmacyclics, Inc. | Novel hydroxamates as therapeutic agents |
US20080255214A1 (en) * | 2003-04-07 | 2008-10-16 | Pharmacyclics, Inc. | Novel hydroxamates as therapeutic agents |
US20080255221A1 (en) * | 2003-04-07 | 2008-10-16 | Pharmacyclics, Inc. | Novel hydroxamates as therapeutic agents |
US7482466B2 (en) | 2003-04-07 | 2009-01-27 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
US7517988B2 (en) | 2003-04-07 | 2009-04-14 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
US8779171B2 (en) | 2003-04-07 | 2014-07-15 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
US9186347B1 (en) | 2003-04-07 | 2015-11-17 | Pharmacyclics Llc | Hydroxamates as therapeutic agents |
US7834054B2 (en) | 2003-04-07 | 2010-11-16 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
US20110021528A1 (en) * | 2003-04-07 | 2011-01-27 | Pharmacyclics, Inc. | Novel hydroxamates as therapeutic agents |
US8389570B2 (en) | 2003-04-07 | 2013-03-05 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
US7420089B2 (en) | 2003-04-07 | 2008-09-02 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
US9408816B2 (en) | 2006-12-26 | 2016-08-09 | Pharmacyclics Llc | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
US20080153877A1 (en) * | 2006-12-26 | 2008-06-26 | Pharmacyclics, Inc. | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
US9128096B2 (en) | 2007-01-30 | 2015-09-08 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
US20110053164A1 (en) * | 2007-01-30 | 2011-03-03 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
US20090270497A1 (en) * | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
US20140057862A1 (en) * | 2009-04-17 | 2014-02-27 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses therof |
US8603521B2 (en) * | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
US20150164854A1 (en) * | 2009-04-17 | 2015-06-18 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses therof |
US9403032B2 (en) * | 2009-04-17 | 2016-08-02 | Pharmacyclics Llc | Formulations of histone deacetylase inhibitor and uses therof |
US20190184196A1 (en) * | 2009-04-17 | 2019-06-20 | Pharmacyclics Llc | Formulations of histone deacetylase inhibitor and uses thereof |
US10105552B2 (en) | 2009-04-17 | 2018-10-23 | Pharmacyclics Llc | Formulations of histone deacetylase inhibitor and uses thereof |
US20110311624A1 (en) * | 2009-04-17 | 2011-12-22 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
US9492423B2 (en) | 2011-09-13 | 2016-11-15 | Pharmacyclics Llc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
US9421208B2 (en) | 2013-08-02 | 2016-08-23 | Pharmacyclics Llc | Methods for the treatment of solid tumors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9186347B1 (en) | Hydroxamates as therapeutic agents | |
US7368476B2 (en) | Hydroxamates as therapeutic agents | |
US7368572B2 (en) | Acetylene derivatives as inhibitors of histone deacetylase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: PHARMACYCLICS LLC, CALIFORNIA Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:PHARMACYCLICS, INC.;OXFORD AMHERST LLC;REEL/FRAME:036130/0285 Effective date: 20150526 Owner name: PHARMACYCLICS, INC., CALIFORNIA Free format text: MERGER;ASSIGNOR:OXFORD AMHERST CORPORATION;REEL/FRAME:036130/0254 Effective date: 20150526 |
|
AS | Assignment |
Owner name: PHARMACYCLICS LLC, CALIFORNIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036130 FRAME 0285. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME;ASSIGNORS:PHARMACYCLICS, INC.;OXFORD AMHERST LLC;REEL/FRAME:038742/0673 Effective date: 20150526 Owner name: PHARMACYCLICS, INC., CALIFORNIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036130 FRAME 0254. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER;ASSIGNORS:OXFORD AMHERST CORPORATION;PHARMACYCLICS, INC.;REEL/FRAME:038742/0624 Effective date: 20150526 |